Development and evaluation of non-viral gene delivery vectors and their combination with hydrogel scaffold technology by Villate Beitia, Ane Ilia
DEVELOPMENT AND EVALUATION OF NON-VIRAL GENE 
DELIVERY VECTORS AND THEIR COMBINATION WITH 
HYDROGEL SCAFFOLD TECHNOLOGY 
GENE-GARRAIO EZ-BIRALERAKO BEKTOREEN GARAPENA 
ETA EBALUAZIOA ETA HORIEN KONBINAKETA HIDROGELEN 
TEKNOLOGIAREKIN  
DESARROLLO Y EVALUACIÓN DE VECTORES NO-VIRALES 
PARA TERAPIA GÉNICA Y SU COMBINACIÓN CON LA 
TECNOLOGÍA DE HIDROGELES  
ANE ILIA VILLATE BEITIA 
NanoBioCel Group, Laboratory of Pharmaceutics 
University of the Basque Country (UPV/EHU) 
Vitoria-Gasteiz 
June 2018 






ACKNOWLEDGEMENTS / ESKERRAK / AGRADECIMIENTOS  
 
Badira lau urte Bidarteko kongresu batean nire tesi-zuzendariak izango 
zirenak ezagutu nituela, eta orduan hasitako bidean zehar emandako 
laguntza eta konfiantza eskertu nahi nieke. José Luis, muchas gracias por 
brindarme la oportunidad de formar parte de este grupo de investigación. 
Jon, eskerrik asko zure aholkuengatik eta beti nire formakuntza aberasteko 
jardueretan parte hartzera animatzeagatik. Gustavo, mila esker bide guztian 
zehar nire ondoan egoteagatik eta edozein proiektu aurrera ateratzeko 
erakutsitako indarragatik. Asko ikasi dut hirurongandik eta oso pozgarria izan 
da zuekin lan egitea.  
Jakina, eskerrik asko laborategiko jende guztiari elkarrekin pasatako une 
politengatik. Egindako barreek eta elkarri emandako laguntzak beti aurrera 
egiteko indarra eman didate.   
Eta mila esker baita ere tesian zehar ezagutu ditudan ikertalde guztiei. 
Muchas gracias a los compañeros de la Universidad Miguel Hernández de 
Elche, siempre es un placer trabajar con vosotros. Thank you so much Prof. 
Tatiana Segura for giving me the opportunity to be part of  your research 
group and to all members from Segura Lab for making my stay at UCLA an 
unforgettable experience.  
Azkenik, eskerrik asko bihotzez nire ikerketa-ibilbide guztian zehar hor egon 
zaretenoi. Gurasoei, neure printzipioei eusten erakusteagatik. Kermani, beti 
nigan sinesteagatik. Eta, noski, Javiri, nire lanean eta etorkizunean 




ACKNOWLEDGEMENT FOR THE FINANCIAL SUPPORT 
 
This thesis has been partially supported by the Basque Government 
(Department of Education, University and Research, predoctoral grant 
PRE_2016_2_0302 and Consolidated Groups, IT907-16), the Univeristy of the 
Basque Country (UPV/EHU) (UFI 11/32) and the Spanish Ministry of Education 
(Grant SAF2013-42347-R). Authors wish to thank the intellectual and technical 
assistance from the ICTS “NANBIOSIS”, more specifically by the Drug Formulation 
Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-
BBN) at the University of the Basque Country (UPV/EHU). Ane Ilia Villate Beitia 
gratefully acknowledges the support provided by the Basque Government for the 
fellowship grant.  
 
ACKNOWLEDGMENT TO THE EDITORIALS  
Authors would like to thank the editorials for granting permission to reuse their 



















Have no fear of perfection,  













TABLE OF CONTENTS 
Introduction / Sarrera / Introducción ..................................................... 15 
First Insights into Non-invasive Administration Routes for Non-viral 
Gene Therapy .................................................................................... 17 
Gene-terapia ez-birala eman-bide ez-inbaditzaileak erabiliz .............. 53 
Objectives / Helburuak / Objetivos  ....................................................... 93 
Experimental section / Atal esperimentala / Sección experimental .. 107 
Chapter 1: Non-viral Vectors Based on Magnetoplexes, Lipoplexes and 
Polyplexes for VEGF Gene Delivery into Central Nervous System 
Cells ................................................................................................ 109 
Chapter 2: Polysorbate 20 non-ionic surfactant enhances retinal gene 
delivery of non-viral vectors based on cationic niosomes after 
intravitreal and subretinal administration .......................................... 135 
Chapter 3: Non-viral vectors based on cationic niosomes and minicircle 
DNA technology enhance gene delivery efficiency for biomedical 
applications in retinal disorders ........................................................ 161 
Chapter 4: Hyaluronic acid hydrogels loaded with cationic niosomes for 
efficient non-viral gene delivery ........................................................ 183 
Discussion / Eztabaida/ Discusión  ..................................................... 203 
Conclusions / Ondorioak / Conclusiones ........................................... 327 
 
Note: 
For high quality images refer to the electronic version 
Kalitate altuko irudietarako bertsio elektronikoa kontsultatu 




























First Insights into Non-invasive 
Administration Routes for Non-
viral Gene Therapy 
 
Published in Gene Therapy. Principles and Challenges (InTech) (2015) 
 
Ilia Villate-Beitia, Gustavo Puras, Jon Zarate, Mireia Agirre, Edilberto Ojeda and Jose Luis 
Pedraz (November 26th 2015). First Insights into Non-invasive Administration Routes for 











First Insights into Non-invasive Administration Routes 
for Non-viral Gene Therapy. 
 
Ilia Villatea,b, Gustavo Purasa,b, Jon Zaratea,b, Mireia Agirrea,b, Edilberto Ojedaa,b, 
Jose Luis Pedraza,b,*.  
a NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University 
of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria-
Gasteiz, Spain 
b Biomedical Research Networking Center in Bioengineering, Biomaterials and 
Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain 
 
Abstract: Gene delivery has attracted increasing interest as a highly promising 
therapeutic method to treat various diseases, including both genetic and acquired 
disorders. However, its clinical application is still hampered by the lack of safe and 
effective gene delivery techniques, as well as by the need of non-invasive routes of 
administration in gene delivery platforms. Among the different approaches used to 
transport nucleic acids into target cells, non-viral vectors represent promising and 
safer alternatives to viruses. Non-invasive administration routes are currently being 
studied, such as intranasal administration to target the brain, topical retinal 
administration for ocular diseases and aerosolized formulations for inhalation for the 
treatment of pulmonary diseases. Reasonable evidence suggests that future gene 
delivery systems might be based on effective non-viral vectors administered through 
non-invasive routes, which would constitute a safe, easy to produce, cheap and 
customizable alternative to the current viral gene delivery platforms. In this review, 
after briefly introducing the basis of gene therapy, we discuss the up-to-date and 
possible future strategies to improve DNA transfection efficiency using non-viral 
vectors and focusing on the non-invasive routes of administration. 
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1.1 Concept and historical evolution of gene therapy 
Gene therapy can be broadly defined as the introduction of genetic material into 
target cells in order to modify and control protein expression for therapeutic or 
experimental purposes [1]. Nowadays, the culmination of the Human Genome 
Project along with recent advances on molecular biology have provided a better 
understanding of cellular and pathogenic processes, and several genes have been 
identified as targets for therapeutic approaches. Additionally, the constant advance 
in the development of gene carriers for the delivery of nucleic acids into target cells 
has led to conceiving new therapeutic strategies for the treatment of pathologies by 
genetic and cell-based approaches, collectively known as gene therapy [1]. 
Researchers have been working for decades to bring gene therapy to the clinic, but 
very few patients have received an effective gene-therapy treatment. The potential 
of gene therapy in medical applications was recognized soon after the discovery of 
DNA as genetic material, and the concept of gene therapy arose during the 1960s 
and 1970s [2]. The first success of gene therapy on humans arrived in 1990, it was 
performed by researchers at the National Institute of Health, and the treated disease 
was a form of severe combined immune deficiency (SCID) due to defects in the gene 
encoding adenosine deaminase (ADA) [3]. However, a fatal event in 1991 raised 
serious concerns about gene therapy. An eighteen-year-old boy died as a result of 
his voluntary participation in a gene therapy trial, becoming the first known human 
victim of this technology [4]. The Food and Drug Administration (FDA) investigation 
concluded that the scientists involved in the trial did not foresee serious side effects 
or fatality and that they did not follow the federal rules to ensure the safety of the 
participants [4]. This tragic case caused a severe setback in the research field of 
gene therapy.  
According to data updated to June 2014 and presented by The Journal of Gene 
Medicine [5], since the onset of the first gene therapy clinical trial in 1989, more than 
2000 new clinical trials for gene therapy have been approved globally (Figure 1). As 
shown in Figure 2, these trials address the most challenging diseases of today, that 
is, cancer (64.1% of approved trials), monogenic diseases (9.1%) such as cystic 
fibrosis, infectious diseases (8.2%) and cardiovascular diseases (7.8%). Although in 
a lesser extent, neurological diseases (1.8%) and ocular diseases (1.6%) are also 




during the last few years, at present only 0.1% of all the gene therapy products 
approved for clinical trials have arrived to the phase IV (Figure 3). In 2012, the 
European Medicine Agency approved for the first time a gene therapy product, 
Glybera, an adeno-associated viral vector engineered to express lipoprotein lipase 
in the muscle for the treatment of lipoprotein lipase deficiency [5]. 
 
Figure 1. Number of gene therapy clinical trials approved worldwide 1989-2014.(adapted from 
http://www.wiley.co.uk/genmed/clinical). 
1.2 The need of carriers 
 
One of the main reasons why gene therapy clinical trials are still few in number is 
the lack of suitable and safe approaches to deliver the genetic material to target cells. 
The success of gene therapy critically depends on suitable transfection vectors, 
which should be able to: (i) protect nucleic acids against degradation by blood and 
interstitial nucleases, (ii) promote internalization of the genetic material into target 
cells and (iii) release the nucleic acids once inside the cell to the correct site [1]. 
Furthermore, an ideal gene delivery system should be effective, specific, long 
lasting, safe, easy to use and as inexpensive as possible [6]. Broadly, gene delivery 
vectors are mainly classified into two categories: viral vectors and non-viral vectors. 




Medicine [7], among the over 2,000 clinical trials for gene therapy approved globally 
nowadays, 70% correspond to trials using viral vectors. As shown in Figure 4, there 
is a 17.7% of the gene therapy clinical trials that use naked DNA, and 5.3% of trials 
use lipofection [7]. 
 




Figure 3. Phases of gene therapy clinical trials. (adapted from 
http://www.wiley.co.uk/genmed/clinical). 
  





Despite the still absolute predominance of viral vector based gene delivery platforms 
– which is due to their higher transfection efficiency- in clinical trials, non-viral vectors 
represent promising and safer alternatives to viruses. In addition, non-invasive 
routes of administration for gene delivery systems are currently being studied, such 
as intranasal administration to target the brain, topical administration on the surface 
of the eye to treat retinal inherited diseases and aerosolized formulations for 
inhalation for the treatment of pulmonary diseases. There is reasonable hope to 
suggest that future gene delivery systems might be based on effective non-viral 
vectors administered through non-invasive routes and that they would constitute a 
safe, easy to produce, cheap and customizable alternative to gene delivery 
platforms. Moreover, it is increasingly accepted that future gene delivery platforms 
may be based on multifunctional vectors specifically tailored for different applications 
[1].  
1.2.1 Viral vectors 
In this review we will focus on non-viral vector based strategies for gene delivery 
platforms, but we will briefly discuss the most relevant aspects of viral gene therapy. 
Viruses are highly evolved biological machines that efficiently gain access into host 
cells, deliver their genetic material to cells and exploit the cellular machinery to 
facilitate their replication [8]. Therefore, viruses represent an excellent platform for 
the development of recombinant vectors containing foreign genes for gene delivery 
purposes [1]. However, viral vectors also present many impediments such as the low 
carrying capacity, the expensive and complex production and, most importantly, 
safety issues, since they can induce oncogenesis when randomly integrated in the 
host genome. In addition, the human immune system recognizes and combats 
viruses, shortening their effectiveness [1]. Table 1 summarizes the principal viral 
vectors used in gene therapy, as well as their main utilities and impediments. Viral 
vectors are, therefore, powerful tools but present important drawbacks for clinical 





Table 1. Principal viral vectors used in gene therapy, advantages and drawbacks. Based on 
[8].  
1.2.2. Non-viral vectors 
Non-viral vectors have emerged as a safer, cheaper and easier to produce 
alternative to viral vectors. In fact, non-viral vectors can be produced on a large scale 
with high reproducibility and acceptable costs, they are relatively stable to storage, 
they can be administered repeatedly with no or little immune response and the 
dimension of the genetic material they can carry is practically unlimited [1,9]. 
Nevertheless, the employment of non-viral gene delivery vectors still strongly limited 
by their lower transfection efficiency as compared to viral vectors [1].  
Non-viral vectors can be classified into two main categories depending on whether 
they are based on physical methods or on chemical methods. We will briefly review 
the most commonly employed non-viral DNA delivery systems for each category.  
1.2.1.1 Physical methods 
 
Physical methods for gene delivery purposes usually employ physical force to create 




[6,10]. No particulate system is used to introduce the genetic material into the target 
cells [6]. Needle injection, ballistic DNA injection, electroporation, sonoporation, 
photoporation, magnetofection and hydroporation are the most utilized physical 
methods at present [6,11].  
 
1.2.1.2 Chemical methods 
 
Depending on the chemical feature, those methods can be classified into three 
groups: cationic lipids, cationic polymers and inorganic nanoparticles. Chemical 
vectors based on cationic lipids and cationic polymers form condensed complexes 
with negatively charged DNA through electrostatic interactions [10]. The complexes 
protect DNA and facilitate cell uptake intracellular delivery [10]. The principal 
characteristics of the non-viral chemical vectors are the following:  
 
• Vectors based on cationic lipids 
 
As shown in Figure 4, cationic lipid-mediated gene transfer or lipofection represents 
the most commonly used non-viral gene delivery system. Cationic lipids share four 
common functional domains: (i)a hydrophilic head-group – which is responsible for 
the interaction with the DNA-, (ii) a hydrophobic domain – which is usually derived 
from aliphatic hydrocarbon chains-, (iii) a linker structure – which influences the 
flexibility, stability and biodegradability of the cationic lipid- and (iv) a backbone 
domain – which separates the polar head-group from the hydrophobic domain and 
it is usually a serinol or a glycerol group- [12]. Changes in those domains can vary 
the transfection efficiency of different vectors elaborated with cationic lipids. The 
most employed cationic lipid formulations for gene delivery platforms are (i) 
liposomes –vesicles made up of phospholipids-, (ii) niosomes –non-ionic 
surfactant vesicles, with greater physic-chemical and storage stability than 
liposomes- and (iii) solid lipid nanoparticles (SLN) –particles with a solid lipid core, 
stabilized with surfactants- [13].  
 
• Vectors based on cationic polymers 
 
Vectors based on cationic polymers are mostly spherical particles ranging in the size 
of 1-1000nm and they condense DNA into polyplexes preventing DNA from 
degradation [6]. The DNA can be entrapped into the polymeric matrix or can be 




cationic polymers employed for DNA delivery purposes are: (i) poly(ethylene imine) 
- PEI, which has an excellent buffering capacity-, (ii) chitosan – a linear 
polysaccharide derived from the deacetylation of the natural chitin-, (iii) cyclodextrins 
– a series of natural cyclic oligosaccharids-,(iv) dendrimers – tree-shaped synthetic 
molecules up to a few nanometers in diameter that are formed with a regular 
branching structure- and (vi) Poly(L-lysine) – PLL, which can form nanometer size 
complexes with polynucleotides thanks to the presence of protonable amine groups 
on the lysine moiety- [6,13,14].  
 
• Vectors based on inorganic nanoparticles 
 
Inorganic nanoparticles are nanostructures varying in size, shape and porosity, and 
calcium phosphate, silica, gold, and several magnetic compounds are the most 
studied [6,15]. Inorganic particles can be easily prepared and surface-functionalized. 
They exhibit good storage stability and are not subject to microbial attack [6,16].  
 
In summary, non-viral vectors for gene delivery represent a safer alternative to 
conventional viral vectors. However, although tremendous progress has been made 
in this field in recent years, the clinical application of non-viral vector based gene 
therapy is still hampered by the lack of effective gene delivery techniques. In the 
present review, we will discuss the up-to-date and possible future strategies to 
improve DNA transfer efficacy using non-viral vectors and focusing on non-invasive 
routes of administration. First, the intracellular barriers that non-viral vectors have to 
overcome and the strategies to improve the transfection efficiency in this regard will 
be described. Second, we will review the extracellular barriers that hamper an 
efficient gene delivery, as well as the invasive and the alternative non-invasive routes 
of administration that elude those barriers. Finally, challenges for non-viral vectors 
to reach clinical trials will be discussed, focusing on the transfection efficiency, the 
targeting and the duration of the transfected gene expression.  
2. INTRACELLULAR BARRIERS AND STRATEGIES TO IMPROVE 
TRANSFECTION EFFICIENCY 
A key factor conditioning transfection efficiency is the ability of the gene delivery 
system to overcome the intracellular and extracellular barriers. In this section we will 
describe the main intracellular barriers that gene delivery systems must overcome 
to reach an efficient transfection and the different strategies used for this purpose. 




overcome from cell surface association to nuclear entry in target cells. The 
knowledge of the molecular features that command all these processes for the non-
viral vectors and the overcoming of these hurdles are mandatory issues that need to 
be deeply considered in order to design efficient gene delivery methods. In this 
section, we will review the cellular uptake pathways and intracellular trafficking of 
non-viral vectors and we will discuss the existing methods to enhance the endosomal 
escape and the nuclear entry, which are the principal strategies to achieve an 
efficient transfection.  
2.1. Cellular uptake pathways 
Cell surface association is the first intracellular barrier that non-viral gene delivery 
platforms need to overcome and it can directly influence the next intracellular fates 
of the non-viral complexes [17]. Cell binding interactions of non-viral vectors can be 
receptor independent or receptor mediated. Receptor independent cell surface 
association occurs by electrophilic attraction between the positively charged non-
viral complexes (i.e. cationic lipoplexes and cationic polyplexes) and the negatively 
charged cell surface proteoglycans [18]. This binding method can efficiently transfect 
many cell types in vitro, but therapeutic potential in vivo requires additional 
refinement. In fact, in order to specifically deliver a gene into a target tissue in vivo, 
non-specific cell binding would require very high and potentially toxic doses of the 
non-viral vector. The addition of cell-specific ligands or antibodies to the vectors 
reduces this problem, allowing the use of lower and safer vector doses and 
promoting tissue targeting [18]. For instance, transferrin (Tf), which is an iron 
transporting protein, has been used to achieve brain delivery in view that the Tf 
receptor is expressed in neurons and in the capillary endothelial cells of the brain-
blood-barrier (BBB) [19]. Ligand choice not only depends on the cell type being 
targeted, but it is also important to consider the type of cell entry pathway that will 
be induced after ligation. As discussed in the following section, the endocytic 
pathway used by the vector can depend on the targeting ligand.  
Once bound to the cell surface, non-viral vectors need to cross the plasma 
membrane to enter the cell and initiate the intracellular trafficking to enter the 
nucleus. The cellular uptake of macromolecules and solutes into membrane-bound 
vesicles derived by the invagination and pinching off of pieces of the plasma 
membrane is known as endocytosis [20]. There are four principal endocytic 




(CvME), phagocytosis, and macropinocytosis [17,21]. These endocytic pathways 
are described below.   
2.1.1 Clathrin-Mediated Endocytosis 
Clathrin-mediated endocytosis (CME) is a highly regulated and energy-dependent 
process, and it constitutes the major and best characterized endocytic pathway [20]. 
The first step in CME is the strong binding of a ligand to a specific cell surface 
receptor. This triggers the localized accumulation of clathrin structures on the 
cytoplasmic surface of the plasma membrane, which helps to deform the membrane 
into a coated pit with a size about 100-150 nm [22]. As the clathrin lattice formation 
continues, the coated pits become deeply invaginated and they finally pinch off from 
the plasma membrane to form intracellular clathrin-coated vesicles (CCVs) [20]. The 
clathrin coats then depolymerize, resulting in early endosomes. A kind of GTPase 
named dynamin is necessary for the vesicle fission from the plasma membrane [23]. 
Cholesterol seems to be also important for CCV formation because its depletion 
impedes the coated pits to pinch off from the plasma membrane [24].  
 
In the next step of the CME pathway, the endocyted vesicles internalized from the 
plasma membrane are integrated into late endosomes and those then deliver their 
cargos to lysosomes [25]. During maturation from early to late endosomes, proton 
pumps located on the endosome membrane produce the acidification of the 
compartment, and there is a further reduction to pH 5 in the progression from late 
endosomes to lysosomes [20]. The acid pH in endosomes seems to cause the 
dissociation of the ligands from their receptors. Most authors state that, in absence 
of an endosomal escape mechanism, non-viral vector/DNA complexes are retained 
and degraded in the lysosomes due to the acid environment and the enzymatic 
activity in these compartments. The final result is that DNA molecules have little or 
almost no access to the nucleus [20].  
 
Some authors suggest that in some cases, depending on the formulation of the non-
viral vector, the CME pathway might be the most suitable to achieve a high 
transfection efficiency because the lysosomal activity facilitates the cytosolic release 
of nanoparticles and enhances the nuclear entry of DNA [26]. Depending on the 
composition of the vector, the most appropriate internalization mechanism may be 
modulated [26]. Therefore, it is crucial to have a comprehensive understanding of 





2.1.2 Caveolae-Mediated Endocytosis 
Caveolae-mediated endocytosis (CvME) begins in membrane microdomains called 
caveolae, which are small, hydrophobic, and cholesterol- and sphingolipid-rich 
smooth invaginations [17,20]. As well as CME, CvME is a type of receptor-mediated 
and dynamin-dependent pathway in which cholesterol also plays an important role 
[27]. The main difference between the clathrin- and the caveolae-mediated pathways 
is that in CvME there are no endosomes. Instead, internalized molecules go into 
intracellular vesicles called caveosomes, which do not fuse with lysosomes and, 
therefore, the potential degradation process of the DNA is avoided in this pathway 
[17]. In fact, CvME is generally considered a non-acidic and non-digestive 
internalization pathway, meaning that the internalized molecules can be directly 
transported into their intracellular target sites without being degraded in lysosomes 
[17,28]. Nevertheless, this issue is still under debate because some authors have 
recently reported that sometimes caveosomes join the classical endocytic pathway, 
in which they eventually fuse with lysosomes [29]. Therefore, in this regard further 
evidence is needed in order to understand the relationship between caveosomes 
and lysosomes.  
 
2.1.3 Phagocytosis 
Phagocytosis is a special type of endocytic pathway that is primarily used by 
professional phagocytes such as macrophages, monocytes, neutrophils and 
dendritic cells, although other cells might use it too [17]. Cup-like membrane 
extensions larger than 1µm mediate the phagocytic pathway, and it is usually 
employed by cells to internalize large particles such as bacteria or dead cells, 
although large lipoplexes and polyplexes can also be internalized trough this 
pathway [17].  
 
Phagocytosis usually involves three steps that are common for all molecules 
internalized through this pathway, including non-viral vectors. First, non-viral 
vector/DNA complexes are recognized by opsonins and, therefore, opsonized, in the 
bloodstream. Second, the opsonized complexes bind to the surface of macrophages 
through the interaction between macrophage receptors and the constant fragment 
of particle-adsorbed immunoglobulins [17]. Antibodies lacking the constant fragment 
can be employed in non-viral gene delivery systems to prevent their recognition and 





Finally, the union of the molecule or non-viral/DNA complex to the macrophage 
receptors activates Rho-family GTPases, which trigger actin assembly and cell 
surface extension formation [17]. The complexes are ingested by the macrophages 
when the surface extension zippers up around them [20]. The vesicles internalized 
in the cells though the phagocytic pathway are called phagosomes and the usually 
have a diameter of 0.5 – 1.0 µm [20]. The phagosomes carrying the internalized 
complexes form mature phagolysosomes when they fuse with lysosomes, where the 
complexes undergo an acidification process [20]. In view that the intracellular fate of 
the phagocytic pathway is the fusion with lysosomes, the nucleic acids carried in the 
non-viral vector complexes will probably be degraded in this internalization pathway 
[31].  
2.1.4 Macropinocytosis 
Macropinocytosis is an internalization pathway based on fluid-phase endocytosis, 
since it non-specifically takes up a large amount of fluid-phase contents [17]. 
Similarly to the phagocytic pathway, macropinocytosis also happens through the 
formation of actin-directed membrane protuberances. Nevertheless, here the 
protrusions do not zipper up the ligand-coated particle. Alternatively, as shown in 
Figure 5, in the macropinocytic pathway the protuberances fuse with the plasma 
membrane. Macropinosomes are also different from clathrin-coated vesicles (CCVs) 
and caveosomes, since macropinosomes have no coat structures and, even if they 
are heterogeneous in size, they use to be larger than 0.2 µm in diameter [32]. As 
well as the other endocytic pathways, macropinocytosis also depends on small 
GTPase proteins since they are necessary for the vesicle fission from the plasma 
membrane [17].  
The connection between macropinosomes and lysosomes remains still unknown. In 
some studies, early macropinosomes have been reported to show the same markers 
as early endosomes, and late macropinosomes have been reported to present 
lysosome markers [17]. However, macropinosomes have been shown to present 
different intracellular fates depending on the cell type, even if the explanation of this 
event remains unclear, and they do not always fuse with lysosomes [17].  
2.2. Endosomal escape mechanisms 
As mentioned before, most non-viral vectors are internalized in the cells mainly 
through the clathrin-mediated endocytic pathway. The major problem here is the 




lead to the degradation of the nucleic acids. In order to avoid this effect, while taking 
advantage of the CME pathway for cellular uptake, several attempts have been 
made to promote the early endosomal escape of non-viral gene delivery systems.  
Many pathogens, mainly viruses and bacteria, have evolved different mechanisms 
to promote endosomal escape when internalized in cells. Several endosomal escape 
agents derive for virus (i.e. haemagglutinin protein of influenza virus) and bacteria 
(i.e. diphtheria toxin), and some derive from plants (i.e, ricin), human (i.e. fibroblast 
growth factors) or animals (i.e. melittin form bee venom) too [33]. The understanding 
of the mechanism used by pathogens allows to design and to ameliorate endosomal 
escape strategies applicable to non-viral gene delivery systems.  Nowadays several 
synthetic peptides with specific sequences and length are designed (i.e. the 
amphiphatic Sweet Arrow Peptide), as well as specific chemical agents (i.e. the 
polymer polyethylenimine PEI) for endosomal escape induction [33]. In the following 
paragraphs the principal endosomal escape mechanisms are described.  
2.2.1 Pore formation in the endosomal membrane 
Pore formation is based on the interplay between a membrane tension that enlarges 
the pore and a line tension that closes the pore. Some peptides have a high affinity 
for the edge of the pore, and binding of those peptides to the edge of the pore 
produces a reduction of the line tension [33].  
Some studies have reported that the union of cationic amphiphilic peptides to the 
lipid bilayer produces a strong internal membrane tension able to create pores in the 
lipid membrane [33].  
2.2.2 pH-buffering effect (the proton sponge effect) 
In this endosomal escape mechanism, the low pH of the endosomal environment 
leads to the protonation of the entrapped agents with a high buffering capacity. 
Protonation causes an influx of ions (H+ and Cl-) and water into endosomes, resulting 
in osmotic swelling and endosome rupture [33].  
The proton-sponge effect has been observed in certain cationic polymers with a high 
H+ buffering capacity over a wide pH range [34]. These polymers usually contain 
protonable secondary or tertiary amine groups with pKa close to 
endosomal/lysosomal pH. As explained before, during the maturation of endosomes, 
the membrane-bound ATPase proton pumps actively translocate protons from the 




At this point, cationic polymers with high buffering capacity become protonated and 
resist the acidification of endosomes, which results in more protons pumped into the 
endosome in an attempt to decrease the pH [34]. The proton pumping action is 
followed by passive chloride ions entry, increasing ionic concentration and, 
consequently, water influx [34]. The high osmotic pressure produces the swelling 
and the rupture of endosomes, releasing their contents to the cytosol [34]. Histidine-
rich molecules show a buffering effect upon protonation [33] and histidine can be 
included in non-viral vectors to enhance transfection efficiency by facilitating 
endosomal escape.  
2.2.3 The flip-flop mechanism 
This endosomal escape mechanism can be useful for endocytosed lipoplexes. 
Lipoplexes are endocytosed and become entrapped inside the early endosomes. 
There is an electrostatic interaction between the cationic lipoplexes and the anionic 
lipids of the endosomal membrane [34]. The anionic lipids of the endosomal 
membrane laterally diffuse into the lipoplexes and form charge-neutralized ion pair 
with cationic lipids of the lipoplexes, resulting in the nucleic acids being displaced 
from the lipoplexes and released in the cytoplasm [34].  
2.2.4 Fusion in the endosomal membrane  
This mechanism of endosomal escape is based on the destabilization of the 
endosomal membrane by water soluble and partly hydrophobic, and/or polybasic 
peptides known as cell-penetration peptides or CPPs. CPPs were originally derived 
from viruses, and they are constituted by short sequences of amino acids (10-30 
residues) that use to be cationic and/or amphiphatic [34]. The main features of CPPs 
are their abilities to penetrate the cell membrane at low molecular concentrations 
without causing significant membrane damage and to internalize electrostatically or 
covalently bound biologically active cargoes (including proteins, peptides and nucleic 
acids) with high efficiency and low toxicity [35]. CPPs either form complexes with 
nucleic acids, through electrostatic interaction, or can be incorporated into polymeric 
and lipidic delivery systems [34]. To date, the internalization mechanism of CPPs 
still remains controversial, since there is evidence for both energy-idependent and 
endocytic processes for cellular uptake of CPPs. Nowadays, it is generally accepted 
that endocytosis is the major internalization mechanism for most CPPs. However, it 
seems plausible that that several CPPs utilize two or more cellular uptake pathways 
depending on the experimental conditions [35]. Further research would be needed 
in order to elucidate the exact uptake mechanisms and to identify the precise factors 




There are different criteria to categorize CPPs into different families. In general, 
CPPs can be classified into two categories [36]: (i) Cationic peptides that usually 
contain arginine and lysine residues; and (ii) amphiphatic peptides that consist of 
both hydrophobic and hydrophilic segments. Two examples of CPPs currently used 
to improve transfection efficiency of non-viral gene delivery platforms are the 
transcriptional activator protein or TAT (which belongs to the first category and was 
the first CPP identified, derived from the transcription activating factor of human 
immunodeficiency virus 1 (HIV-1)) [33,37] and the Sweet Arrow Peptide or SAP 
(which belongs to the second category and is a proline-rich amphipathic peptide of 
synthetic origin) [38].  
2.2.5 Photochemical disruption of the endosomal membrane 
Photochemical internalization (PCI) is a light-directed delivery technology that 
utilizes photosensitizers to facilitate the transport of membrane impermeable 
macromolecules from endocytic vesicles into the cytoplasm [34]. Photosensitizers 
that are used in PCI use to be amphiphilic compounds that can bind and localize in 
the plasma membrane. In this mechanism, photosensitizers bind to and localize in 
the plasma membrane, and they can be taken up by endocytosis together with the 
non-viral gene delivery systems. Photosensitizers are confined to the endosomal 
membrane and remain inactive until they are triggered by light with specific 
wavelengths matching their absorption spectra [39]. Once activated, they induce the 
formation of highly reactive oxygen species, causing the rupture of endosomes and 
lysosomes membrane. As a result, macromolecules that are trapped inside the 
endosomes/lysosomes can be liberated into the cytosol [34].  
In general, the enhancement of endosomal escape is believed to be a crucial factor 
in non-viral vector based DNA delivery platforms. Different strategies for endosomal 
escape have different characteristics. A safe endosomal escape agent applicable in 
the clinic should have low immunogenicity and toxicity, high efficiency, ease of use 
and production, modular attachment of targeting ligands and the potential for cost-
effective large-scale manufacture [33].  
2.3 Nuclear import 
In the previous section we have seen several strategies suitable for non-viral gene 
delivery to avoid endosomal degradation of the DNA and to enhance its release to 




molecules have to enter the nucleus. Here, we will discuss the principal strategies to 
transport DNA to the nucleus once released in the cytoplasm.  
To enter the nucleus, molecules must pass through nuclear pore complexes (NPCs), 
which are multimeric structures with a central channel of 9 nm that prevents 
molecules with a molecular weight higher than 45 kDa from passively diffusing into 
the nucleus [40]. In the case of naked DNA, molecules smaller than 300 bp can 
passively diffuse into the nucleus, but larger DNA molecules, even when condensed 
by a non-viral vector, are excluded from the nucleus except when cells are 
undergoing mitosis [40-42]. During cell division, the integrity of the nuclear 
membrane is lost, which allows the nuclear entry of DNA-vector complexes within 
the daughter cells [21,40]. This is the case in the in vitro transfection with dividing 
cells, but in vivo transfection often targets slow dividing or terminally differentiated 
cells [21,40]. Therefore, the nuclear envelope cannot be neglected in in vivo 
situations, and there is considerable interest in improving the nuclear import 
efficiency of non-viral vectors [21,40].  
Classically, proteins that are destined for the nucleus contain a nuclear localization 
signal (NLS), which is abundant in basic amino acids and it can be recognized by 
cytoplasmic proteins known as importins [17], that mediate energy-dependent 
transport through the NPC [40,43]. The same approach can be used to enhance 
non-viral gene delivery to the nucleus [21]. A NLS containing vector can be added 
to the DNA-vector formulation or a NLS sequence can be directly bound to the DNA 
in order to promote its transport to the nucleus by the importins [40]. In addition, 
highly polymers such as polylysine and protamine, the highly basic sequence of 
which resemble typical NLS sequences, have been used as potential agents to 
enhance nuclear targeting when complexed with DNA [40].  
Finally, it should be considered that, once inside the nucleus, the non-viral vector 
itself may constitute a barrier to transgene expression. In fact, the agent used to 
condense the DNA could potentially interfere with the access of the cellular 
transcription machinery to the transgene promoter, thereby reducing or preventing 
its expression [40]. Still, premature release of DNA from the vector may expose the 
DNA to enzymatic degradation before expression can occur [40,44]. For liposomal-
based vectors, DNA displacement from the vector seems to be connected to 
endosomal escape, driven by the anionic lipids of the endosomal membrane that 
neutralize the charge of the cationic lipids in the liposomal formulation [40,45,46]. In 




nucleus through exchange of the polycations in the complexes with the protein 
components of the surrounding proteins [40,47,48]. However, it seems plausible that 
additional mechanisms other than competitive charge interactions may be involved 
in the dissociation of DNA from polycations, and a deeper understanding of 
chromatin remodelling mechanisms may shed further light on this issue.  
In summary, non-viral vectors for DNA delivery systems must overcome several 
intracellular barriers from cell-surface association to nuclear entry and DNA release. 
Depending on the cell type and on the cellular internalization pathway, some 
intracellular barriers may differ. Most non-viral vectors are taken up in cells through 
the CME pathway, which presents some problems such as the acid environment of 
endosomal and lysosomal compartments and the risk of DNA degradation. 
Therefore, several endosomal escape agents and mechanisms are currently being 
studied to avoid DNA degradation and to enhance its cytosolic release. In addition, 
DNA molecules have to enter the nucleus for the transgene expression. The most 
employed strategy for this purpose is the incorporation of a NLS in the vector-DNA 
complex. Finally, once inside the nucleus or earlier during the endocytic pathway, 
the vector-DNA complex needs to dissociate in order to allow the transcriptional 
machinery of the cell to access the transgene promoter.  Thus, Figure 5 summarizes 
the most relevant aspects described in this section.  
Figure 5. Cell entry pathways and intracellular trafficking of non-viral gene delivery systems. 
A) Phagocytosis. B) Clathrin-mediated endocytosis (CME). C) Caveolae-mediated 
endocytosis. D) Macropinocytosis. Internalized vector/DNA complexes following the CME 
pathway escape from endosomes and can be transported into the nucleus by the importins if 




expressed in the target cells. Yellow filaments represent actin; red chain represents clathrin 
coat; green filaments represent caveolin dimers; orange little circles represent the small 
GTPase dynein; blue filaments represent opsonins. Adapted from [23; 24].  
3. EXTRACELLULAR BARRIERS TO OVERCOME. NON-INVASIVE ROUTES 
OF ADMINISTRATION.  
Depending on the administration route and the target organ, gene delivery systems 
must overcome several extracellular barriers in vivo before reaching the target cells. 
As mentioned earlier, cancer diseases represent 60% of all clinical trials in gene 
therapy; yet other pathologies such as infectious, neurodegenerative, ocular and 
pulmonary diseases merit special attention, which, in sum, represent 10% of clinical 
trials in gene therapy. The principal and most studied route of administration of non-
viral gene delivery systems for those diseases is the intravenous administration. 
Here, vectors need to be properly designed in order to overcome all the hurdles this 
route presents. Moreover, when specific tissues need to be targeted, such as the 
brain, the eye or the lungs, additional extracellular barriers appear and vectors have 
to be able to surpass them too. In this section, we will review the principal systemic 
barriers following the intravenous administration of non-viral gene delivery systems, 
as well as the additional tissue-specific barriers DNA/vector complexes have to 
overcome. We will also describe several attempts that have been made in order to 
overcome those barriers using invasive and alternative non-invasive routes of 
administration. Many efforts are being conducted to achieve effective strategies for 
safe non-viral gene delivery platforms based on non-invasive administration routes.  
3.1 Intravenous administration 
For many cancer forms, and specially disseminated cancer diseases, treatment 
needs to be administered systemically. Thus, intravenously administered current 
gene delivery systems to treat cancer should be able to transport and deliver the 
genetic cargo into cancerous cells.  
The principal challenge of systemically administered DNA is to resist the extracellular 
enzymatic degradation, since DNA is subject to enzymatic degradation from the 
point of entry. However, it is possible to considerably dominate this hurdle by 





Secondly, other major extracellular barrier in the systemic route is the non-specific 
binding of the non-viral vector/DNA complex –which has a net positive charge- with 
blood cells and serum proteins such as albumin, complements, immunoglobulins 
and fibronectin –which have a negative surface charge- [49]. These interactions 
could potentially end in aggregation or dissociation of vector/DNA complexes, 
resulting in their rapid clearance and elimination by the reticuloendothelial systems 
[49].  
A third obstacle in systemic delivery might be the colloidal instability of non-viral 
vector/DNA complex formulations in the extracellular environment, which can also 
result in the aggregation of the complexes [49]. Fourth, vascular system is an 
extracellular barrier to be considered since it limits the size of the nanoparticles that 
can pass through the endothelial cells, which are relatively small and have tight 
junctions [49].  
Finally, the activation of the immune system by the foreign vector/DNA complexes is 
an extracellular issue to be taken into consideration as well. In fact, foreign synthetic 
vectors can also induce an inflammatory response and/or complement activation, 
and hydrophobic particles can be eliminated by mononuclear phagocytic system 
through opsonisation [49].  
In order to overcome all these systemic barriers, non-viral vectors should be 
structurally modified. Formulation of gene delivery vectors is a key factor in 
determining their bioavailability and transfection efficiency in vivo [49]. Some of the 
strategies that are being developed to improve the properties of nanoparticles in the 
extracellular environment are discussed below.   
The most employed strategy to increase the stability of vector/DNA complexes is 
shielding the outer surface of complexes with poly(ethylene glycol) or PEG [50]. 
Because of its highly hydrophobic nature, PEG produces a steric barrier against 
nuclease degradation and aggregation of nanoparticles in blood circulation [49]. 
However, despite the promising results, some difficulties exist in conjugation of PEG 
to gene delivery systems. PEGylation could decrease binding ability of non-viral 
vectors to DNA causing instability of lipo- or polyplexes in blood circulation. It may 
also affect the binding of vector/DNA complexes to receptors on the cell membrane 
[51]. Moreover, PEGylation can induce accelerated blood clearance due to activation 
of splenic synthesis of anti-PEG IgM antibody after first injection, resulting in the 
opsonisation of the subsequent doses [49]. The length and the degree of PEGylation 




in vivo, and the optimal PEG length and content depends on gene carrier systems 
[52].  
Consequently, considerable research has been made with the aim of compensating 
the negative effect of PEGylation in non-viral gene delivery systems. As reported in 
a recent study, one possible solution is to replace PEG by some hydrophilic polymers 
such as poly(N-vinyl-2-pyrrolidone) (PVP), poly(4-acryloylmorpholine), or poly(N,N-
dimethylacrylamide) [53]. Coating of nanoparticles with these polymers led to 
extended residence of the nanoparticles in blood circulation in rats, although they 
had a shorter half-life than the PEG-coated nanoparticles [53].  Other strategies 
include providing stability against serum compounds and enzymatic digestion using 
copolymers of poly(L-lysine) and poly(2-methyl-2-oxazoline) [54], the pH-sensitive 
shielding of DNA polyplexes or lipoplexes (e.g. with PEG-acetal-MAL or maleimide 
moiety) [55], the use of enzymatically cleavable PEG linkers (e.g. PEG-peptide-
DOPE or PPD that is cleaved in a matrix metalloproteinase-rich environment) [56], 
or the production of reducible PEG nanoparticles (e.g. PEG and chitosan bound 
through disulphide bridges) [57].  
Besides from PEGylation, other chemical and structural modifications can be applied 
to gene delivery agents in order to overcome the systemic barriers. In the case of 
cationic lipid-based non-viral vectors, incorporation of cholesterol can stabilize 
lipoplexes against binding to red blood cells [49]. In the case of cationic polymer-
based non-viral vectors, conjugation of lactose to chitosan polyplexes has shown 
excellent DNA binding ability, good protection of DNA from nuclease, and the 
suppression of self-aggregation and serum-induced aggregation [58]. Therefore, 
current research has focused on multifunctional and diverse non-viral gene carriers 
that can be adjusted for each particular condition.  
3.2 Targeting specific tissues: additional extracellular barriers 
When targeting specific tissues, vectors have to be able to surpass additional 
barriers as well. Here, we will focus on specific extracellular barriers present in gene 
delivery to the central nervous system (CNS), to the eye and to the lungs. The 
invasive and alternative non-invasive routes of administration that avoid those 
barriers will also be discussed.  
3.2.1. Gene delivery to CNS 
The CNS possesses particular anatomical and physiological properties that make 




barrier (BBB), which consists of tightly joined capillary endothelial cells [19], and it is 
considered to be impermeable for almost 100% of the macromolecular drugs and 
over 98% of small molecule drugs [59]. The spinal cord is part of the CNS and it is 
protected by the blood-cerebrospinal fluid barrier (BCSFB), which is constituted of 
choroid plexus epithelial cells and restricts the free diffusion of molecules into the 
cerebrospinal fluid (CSF) [19]. Transport into the CNS of essential nutrients, such as 
glucose and amino acids, occurs through specific receptors present in the BBB and 
the BSCFB [19]. Within the CNS, distinct cell types exist including neurons and 
different types of glial cells; neurons are particularly challenging to transfect and it is 
thought this is attributable to their post-mitotic nature, their complex structure and 
the complexity of neuronal networking [19].  
Most of the strategies to cross the BBB upon systemic administration of non-viral 
vector/DNA complexes exploit receptor-mediated uptake of molecules such as 
transferrin (Tf), lactoferrin and insulin, since receptors of those molecules are 
expressed on many cell types, including neurons and the capillary endothelial cells 
of the BBB [19]. By attaching a ligand for those receptors to the non-viral delivery 
system, one can enhance the transport of the vector/DNA complex towards the CNS. 
Other strategy known as “Molecular Trojan Horse” uses peptidomimetic monoclonal 
antibodies that are designed to target specific receptors on the BBB and induce 
receptor-mediated transcytosis of the non-viral delivery system into the CNS [60]. 
Other approaches investigated for CNS delivery of conventional pharmaceutics upon 
systemic administration include transient mechanical disruption of the BBB and 
RNAi-mediated knockdown of tight junction proteins [19].  
The ultimate goal for CNS gene therapeutics is delivery by systemic route, which is 
the most acceptable for clinical use. Nevertheless, in view of the high amount of 
extracellular barriers vectors must overcome, many studies have attempted different 
routes of administration. To date, several pre-clinical studies have essayed local 
administration to the brain, either by injection or by infusion. However, even if local 
administration to the brain eludes the extracellular barriers to access the CNS, the 
need for brain surgery to infuse a gene therapy vector clearly limits the clinical 
applicability for this approach.  
Intranasal delivery offers a novel and non-invasive means by which non-viral gene 
delivery systems can gain access to the brain. The mechanisms by which 
intranasally delivered substances enter the CNS have not been fully elucidated, but 




through a combination of perineuronal, perivascular and lymphatic transport 
pathways. In addition, the prevailing nose-to-brain pathway will largely depend on 
the region where the delivered agent is placed within the nasal cavity and the 
physicochemical properties of the therapeutic being administered [61]. It is currently 
accepted that the intranasally administered substance can reach the CNS by three 
main pathways: (i) direct paracellular or transcellular transport via the olfactory 
neurons or olfactory epithelial cells (“olfactory neural pathway”), (ii) transport via the 
trigeminal nerves (“trigeminal pathway”) or (iii) indirectly, via blood vasculature 
and/or lymphatic system (“systemic pathway”) [62]. The nasal mucosa is highly 
vascularized, and the blood vessels allow passage of drugs following nasal 
administration in nano-drug delivery systems; however, the substance that has been 
absorbed into the systemic circulation has to cross the BBB in order to reach the 
CNS [61]. Following olfactory and trigeminal nerve pathways, drug is delivered to the 
olfactory bulbs and to more caudal brain areas, respectively [63]. Within the brain, 
pulsatile flow in perivascular spaces has been postulated to allow for widespread 
transport of molecules within interstitial fluid to sites deep in parenchyma [63,64]. 
Advantages of intransal administration include ease of administration (non-invasive), 
rapid dose absorption via highly vascularized mucosa, large nasal mucosa surface 
area for dose absorption, avoidance of the gastrointestinal tract and first-pass 
metabolism and lower side effects among others [65]. Moreover, intranasal 
administration confers improved convenience and compliance compared to other 
more invasive routes and it allows self-administration [65]. Disadvantages of this 
route include that nasal congestion could interfere with dose absorption, that the 
amount of dose that reaches the CNS varies with each agent and that the frequent 
use of this route leads to mucosal damage [65]. In addition, the administered 
formulation can undergo rapid clearance from nasal cavity by the mucociliary system 
[59,66]. This latter drawback can be overcome by adding a mucoadhesive substance 
to the formulations. For non-viral vector based gene delivery systems, chistosan is 
an attractive excipient that can confer both bioadhesion and absorption properties, 
and it is the most widely investigated absorption enhancer material both in terms of 
efficiency and safety [63]. Chitosan is able to interact through its positively charged 
amino groups with the anionic counterpart present in the mucus layers, mainly sialic 
acid, and to affect permeability of the epithelial membrane by the transient opening 
of the tight junctions in the epithelial cells [67]. In a recent study, another substance, 
the non-ionic surfactant laureate sucrose ester has been also reported to be an 




Recently, the first report that intranasal delivery of DNA nanoparticles can bypass 
the BBB and transfect and express the encoded protein in rat brain has been 
published, thereby affording a non-invasive approach for gene therapy CNS 
disorders [63]. Authors demonstrated that intranasal delivery of unimolecularly 
compacted DNA nanoparticles, which consist of single molecules of plasmid DNA 
encoding enhanced green fluorescent protein (eGFP) compacted with 10kDa 
commercial peptide (PEG-substituted lysine 30mers or CK30PEG10k) successfully 
transfect cells and leads to the expression of the eGFP in the rat brain [63]. The 
results further suggest that the cells transfected within the brain are likely to be 
pericytes, and that the distribution of nasally administered substances occurs via 
perivascular transport [63]. Additionally, another recent study has reported brain 
(cortex and hippocampus) transfection upon intranasal administration of chitosan 
and polyethyleneimine (PEI)-coated magnetic micelles [69]. Even if those 
nanoparticles were able to reach the brain presumably because of a transient 
disruption of the BBB following mild traumatic brain injury, the results show that the 
intranasal route might be useful for targeting the brain. Although further optimization 
of the dose, dosing regimen and dose interval is needed to achieve appropriate 
levels of transgene expression [63], the promising results will certainly encourage 
the research in the field of intranasal administration of non-viral vector based gene 
delivery systems, which has clinical importance due to its non-invasive nature.  
3.2.2 Gene delivery to the eye 
The eye is an attractive target organ for gene therapy because of its unique 
characteristics. The tissue volume to be treated is small, the therapeutic 
concentration to be administered is relatively low and the diffusion of active products 
from the eye to the circulation is minimal [70]. In addition, the eye benefits from a 
relative immune privilege, minimizing the potential immune and inflammatory 
reactions that may follow the intraocular injections of foreign agents [70].  
In general, gene delivery systems for eye diseases range from simple eye drops and 
ointments to more advanced bio- and nanotechnology-based systems such as 
muco-adhesive systems, polymers, liposomes and ocular inserts. Most of these 
technologies were developed for front-of-the-eye ophthalmic therapies and are not 
applicable as back-of-the-eye delivery systems [71].  
When the systemic administration is used to target the eye, non-viral vector/DNA 




constitutes a real challenge, since the BOB is composed of tight epithelial junctions. 
Two principal strategies to overcome this barrier are the use of vectors smaller than 
100 nm to allow intracellular passage across the BOB [72] and the use of ligand-
equipped vectors that recognize specific receptors in the BOB [73]. Therefore, even 
if the intravenous route permits the delivery of larger volumes of the formulations as 
well as repeated administrations, the therapeutic effect achieved by this method is 
often limited by the factors restricting the access to the eye.  
Invasive methods such as intravitreal injection, subconjuntival injection and 
subretinal injection can bypass some of those barriers, and intravitreal and subretinal 
injections are currently considered as the most effective and common methods of 
gene delivery to retinal ganglion cells and to inner layers of the retina, respectively. 
However, these methods are very invasive and repeated gene delivery to the eye 
using such methods can cause further damage of the eye like retinal detachment, 
haemorrhages, and sub- or pre-retinal fibrosis [71]. Therefore, non-invasive and 
effective methods for ocular gene delivery are needed. In this regard, topical 
administration in the form of eye drops is a non-invasive delivery method that can be 
performed repeatedly with minimal side effects [71].  
However, the non-invasive route of administration is perhaps the most ambitious 
goal because the barriers associated with topical gene delivery to the posterior 
ocular tissue are the most challenging. First, vector/DNA complexes have to surpass 
the tear film, which is an aqueous layer covered by lipids and underlined by mucin 
that covers the corneal and conjuctival layers [71]. This tear film restricts the 
bioavailability of applied formulations because of the tear turnover rate and the 
lacrimal and nasolacrimal drainage [85]. Strategies to overcome this barrier include 
addition of viscosity enhancers –such as cellulose derivatives or thermoreversible 
poloxamer gels- [71] and, most importantly, the incorporation of muco-adhesive 
polymers –such as  chitosan and hyaluronic acid derivatives- in gene delivery 
systems [74].  Second, ocular tissue barriers such as the cornea, conjunctiva, sclera 
and choroid, contain epithelial tight junctions, proteoglycan matrices and fibril 
collagen networks within their structures, which contribute to restrict the passage of 
vector/DNA complexes to the neuroretina [71]. Finally, the vitreous is an aqueous 
biogel composed of collagen, hyaluronan and proteoglycans that hinders 
transfection of the retinal cells [71]. Strategies to overcome those barriers include all 
the above-mentioned methods from the use of vectors of suitable dimensions to the 




The majority of success in ocular gene therapy research thus far was accomplished 
for applications involving the anterior part of the eye, using mainly viral-based 
delivery systems and invasive delivery methods. Interestingly, effective gene 
delivery to the retina and retinal pigment epithelium using non-viral vectors has been 
recently reported; however, in this study magnetic nanoparticles were administered 
invasively, through intravitreal and subretinal injections [75]. Rather than in gene 
delivery, significant advances have been made in drug delivery systems to target the 
posterior part of the eye using non-invasive administration routes. For instance, in a 
recent study, it was reported that surface-modified submicron-sized lipid emulsions 
could be promising vehicles of hydrophobic drug delivery to the ocular posterior 
segment [76]. In that study, researchers performed surface modification of the lipid 
emulsions using a positive charge inducer and the functional polymers chitosan and 
poloxamer 407. Authors suggested that poloxamer 407 increased the lipid emulsion 
retention time on the eye surface by its adhesive properties, therefore enhancing 
gene delivery to the ocular posterior segment. Additionally, another study has 
reported successful drug delivery to the posterior segment of the eye of rats and 
rabbits using annexin A5-associated liposomes [77]. Here, authors suggested that 
annexin A5 mediated endocytosis can enhance the delivery of associated lipidic drug 
delivery vehicles across biological barriers. Moreover, a novel study has reported 
the topical drug delivery to retinal pigment epithelium with microfluidizer produced 
small liposomes, which might be an attractive option for drug delivery to the posterior 
segment tissues of the eye [78]. It may be reasonable that some of the advances in 
drug delivery will be applicable for gene delivery systems as well, and they will 
probably inspire further strategies for non-invasive, non-viral gene therapy platforms 
aimed at targeting the posterior segment of the eye.  
3.2.3 Gene delivery to the lungs 
Pulmonary gene therapy is considered for the treatment of a variety of lung diseases 
like cystic fibrosis, asthma, emphysema and lung cancer [79]. Depending on the 
respiratory disease to be treated, the target cells in the lung can vary from epithelial 
cells, alveolar cells, macrophages, respiratory stem cells or endothelial cells [79]. 
Besides, the nucleic acid cargo needs to be delivered to cells in the target region of 
the lung. Nevertheless, this is severely limited by the pulmonary architecture, the 
presence of mucus, the clearance mechanisms and the activation of the immune 
system [79]. Inhalation, intranasal instillation, intratracheal instillation, and 
intratracheal intubation are techniques that can be used to administer materials of 




for clinical applications, aerosolized non-viral vector/DNA complexes for inhalation 
would be the ideal choice for lung gene therapy. There are many advantages to 
administering medications to the lungs as an aerosol, such as the high local 
concentration by delivery directly to the airways, and the pain- and needle-free 
delivery.  
Respiratory secretions, which include mucus and alveolar fluid, are the most 
important extracellular barriers for lung gene delivery. Respiratory mucus is one of 
the most important defence mechanisms and it is mainly composed by a three-
dimensional network of cross-linked mucin chains, which gives the mucus 
viscoelastic properties [79]. The major proteins in respiratory mucus are albumin, 
proteases, anti-proteases, immunoglobulins, lysozyme and lactoferrin, and the 
respiratory secretions of patients with cystic fibrosis or respiratory infections also 
contain huge amounts of DNA and actin [79]. The alveolar fluid is a thin continuous 
layer of pulmonary surfactant that covers the alveolar epithelium and it comprises 
phospholipids and specific surfactant-associated proteins [79].  
Respiratory mucus can act as a barrier towards pulmonary gene delivery in several 
ways. The biopolymer network of mucus limits the diffusion of complexes by sterical 
obstruction or by binding the complexes [79]. Also, negatively charged and non-
cross-linked macromolecules of mucus, as well as other components present in the 
mucus such as antibodies, can bind to the surface of vector/DNA complexes. These 
interactions may cause: (i) entrapment of the vector/DNA complexes in the mucus, 
(ii) aggregation of the complexes due to neutralization of their surface charges, (iii) 
release of the DNA cargo from the vector, and (iv) an inefficient cell binding of the 
complex due to shielding of their positive charges or their receptor binding ligands 
[79].  Finally, the mucus blanket is continuously removed via mucociliary transport 
or coughing. Therefore, the vector/DNA complex should be able to cross the mucus 
before they are cleared from the respiratory tract. The diffusion coefficient of the 
complexes in the mucus, the thickness of the mucus layer and the rate of mucus 
clearance will determine whether the vector/DNA complexes will reach the epithelial 
cells [79].  
Regarding the alveolar fluid as a barrier towards pulmonary gene therapy, the 
presence of this surfactant layer can inhibit transfection of cationic lipid based 
vector/DNA complexes [79]. It has been suggested that this inhibitory effect results 
from disintegration of the lipoplexes by the negatively charged lipids present in the 




degradation and loss of function [80]. On the other hand, non-viral vectors based on 
cationic polymers such as PEI might be more resistant to detrimental effects by 
pulmonary surfactant [79].  
Several strategies have been developed in order to overcome the extracellular 
barriers of lung gene delivery. Size and surface properties of non-viral vector/DNA 
complexes have a pivotal role in determining their behaviour in respiratory 
secretions. Most efforts have been conducted to increase the mobility of vector/DNA 
complexes in respiratory mucus and to avoid interactions of complexes with 
respiratory secretions.  
There are different methods to increase non-viral vector/DNA complex mobility 
through the respiratory mucus. One straightforward mechanism consists of adding 
mucolytic agents that hydrolyze mucins present in the mucus [79]. Also, it has been 
demonstrated that N-acetylcysteine and its derivatives lower the viscosity and 
elasticity of mucus by reducing the disulphide bridges between the subunits of 
mucins [81]. As future directions, research is focusing on functionalized 
nanoparticles with mucolytic agents able to cut a way through the mucus, enhancing 
their transport across the extracellular matrix [79].  
On the other hand, the principal strategy to avoid interactions between vector/DNA 
complexes and components of biological fluids is the shielding of the complexes by 
modification with biocompatible hydrophilic but biologically inert polymers [79]. 
Shielding of vector/DNA complexes may not only be important to reduce interaction 
with mucus and alveolar fluid components but also diminish clearance by alveolar 
macrophages. For instance, shielding the positive surface charges of vector/DNA 
complexes with neutral hydrophilic polymers such as polyethylene glycol (PEG) 
favours their physicochemical stability and their gene transfer capacity [79].  
A number of challenges must be overcome before pulmonary gene therapy becomes 
a reality, such as the development of gene vectors that can more efficiently penetrate 
the mucus barrier [82]. However, real advances have been made in recent years, 
novel aerosol therapeutic modalities are currently being investigated for lung cancer, 
and inhaled gene therapy has already presented safety and effectiveness in cystic 




As summarized in Figure 6, non-viral vector/DNA complexes have to overcome 
several extracellular barriers before binding the target cells and initiate the 
intracellular trafficking towards the nucleus, where transgene expression will occur. 
Intravenous injection is the most widely used administration route but it presents 
many hurdles that hamper effective gene delivery. Local administration routes are 
being explored in order to directly target the tissue of interest and avoid systemic 
barriers, but they often implicate invasive procedures (e.g. brain surgery). Many 
efforts are currently focused on the study of non-invasive routes of administration 
that can equally avoid the systemic barriers (e.g. intranasal administration). Besides, 
local administration into specific tissues such as the eye or the lungs, involve 
additional barriers that gene delivery systems have to elude. Surface modifications 
of the vector/DNA formulations are the most employed strategies to overcome both 
systemic and tissue-specific barriers. It is expected that future non-viral gene 
delivery systems will be based on multifunctional vectors and that they will allow a 
non-invasive administration of therapeutic genes into target tissues.  
Figure 6. Overview of the systemic and tissue-specific (SNC, eye, lungs) extracellular barriers 
in non-viral gene therapy.  
4. CHALLENGES OF NON-VIRAL GENE THERAPY AND FUTURE 
PROSPECTS 
Non-viral gene therapy has emerged as a promising therapeutic approach for gene 
delivery. Even if this field is still far from clinical practice, much progress has been 
made in the last few years regarding both the optimization of the non-viral vector 




transgene expression to occur, optimal non-viral vectors should not elicit an immune 
response and should be able, among other aspects, to protect the DNA cargo from 
degradation in circulation, to enable extravasation from the bloodstream, to traverse 
cellular membranes, to enhance endosomal escape and to facilitate DNA transport 
to the nucleus [84]. The comprehensive understanding of the extracellular and 
intracellular barriers vector/DNA complexes have to overcome in order to achieve 
an efficient transfection, has allowed the development of several strategies to 
surpass all those barriers, most of them based on formulation modifications of the 
complexes and on the use of local routes of administration. Regarding this latter 
aspect, considerable evidence suggests that the optimization of non-invasive routes 
of administration may provide safer and more effective gene delivery platforms in the 
future; therefore, it might be relevant to guide some efforts in this direction.  
The major limitation of non-viral gene delivery, as mentioned repeatedly, is the low 
transfection efficiency. Several strategies discussed along the chapter increase 
transfection efficiency by providing to the nanoparticles the ability to overcome extra- 
and intracellular barriers. However, there are two other aspects that are also 
essential for developing optimal gene delivery platforms; those are targeting and 
long-term expression of the transgene.  Both are crucial to bring non-viral gene 
delivery systems into the clinic, since they provide specificity and sustained effect of 
the treatment, respectively. Many efforts have been made in this regard; however, 
further research is still required. In addition, other aspects such as the toxicity of the 
nanoparticles and the manufacturing and regulatory issues have to be carefully 
considered. Here, we will briefly discuss the current strategies for targeting the 
desired cells or tissues and for achieving a long-term expression of the transgene. 
We will also highlight the importance of considering the toxicity, manufacturing and 
regulatory issues of the nanoparticle formulations.  
4.1 Targeting 
Targeting to the desired cells or tissue can be achieved by modifying either the 
vehicle (the non-viral vector) or the cargo (the plasmid DNA). The most employed 
strategy is the attachment to the non-viral vector specific ligands (such as transferrin 
for targeting the SNC) that recognize particular receptors present in the target cells 
or tissues. As discussed earlier, this approach has proved effective in several 
studies. Also, in cancer gene therapy, some strategies are based on the exploitation 
of the tumour-specific physiological changes (the tumour microenvironment) to 




On the other hand, another possibility is to introduce modifications in the DNA cargo 
(instead of the vector) to achieve targeted expression of the transgene, this approach 
is known as “transcriptional targeting”. This strategy is based on the use of DNA 
expression cassettes that contain regulatory regions that are recognized by 
transcription factors specifically present or selectively expressed by the target cell 
population [85]. In this strategy the DNA would, in theory, be delivered to all tissues, 
but the expression of the transgene would only occur in the cell populations where 
the particular transcription factors are present, that is, in the target cell populations 
[84]. The success of this method of targeting needs prior knowledge of a difference 
in transcription factor expression between the target and normal tissue [84].  
Targeting is an essential requirement in gene delivery systems. Beneficial aspects 
of targeted gene delivery include, among others, increased bioavailability of the 
therapeutic product in the diseased tissue; reduced accumulation in healthy tissues 
and, hence, reduced side effects; reduction of drug dosage and reduced dosing 
frequency, which enhances patient compliance. All those aspects help to increase 
the therapeutic efficacy and permit to reduce treatment costs [86].  
4.2 Duration of gene expression 
Long-term or sustained expression of the transgene delivery constitutes a real 
challenge in non-viral gene therapy, and it is a considerable limiting factor, since 
transient expression requires repeated dosing and makes the therapeutic effect 
unsustained. Transgene expression can decrease in time due to several factors, 
including destruction by nucleases, loss by recombination, distribution to non-
nuclear compartments and/or recognition and subsequent silencing of foreign DNA 
[85]. In addition, in dividing cells the percentage of transfected cells decreases at 
each division, because while cells replicate, plasmids do not.  
Strategies to increase duration of transgene expression have focused on plasmid 
DNA modifications rather than on vector modifications. Some of those strategies are 
aimed to integrating the transgenes into the host genome using viral integrases, site-
specific recombinases and transposases, which are enzymes with capacity of 
inserting foreign DNA into the host genome [85]. However, this approach cannot be 
clinically applicable in humans because of its associated risks, such as the induction 
of insertional mutagenesis in the host cells.  
A different strategy to achieve sustained transgene expression is the use of 




in the host genome and, hence, avoids insertional mutagenesis risks [85]. In 
addition, episomally replicating plasmids usually yield high levels of transgene 
expression. These strategies incorporate genes that encode necessary cofactors for 
transcription of the plasmid to the therapeutic plasmid DNA, making the transgene 
expression less dependent on host factors. Incorporation of viral DNA that allows the 
plasmid to replicate extrachromosomally is an efficient approach, but it presents a 
major drawback, since those replication-inducing viral DNA elements are associated 
with induction of immune response and risk of transformation and oncogenicity [85]. 
Alternatively, mammalian scaffold/matrix attachment regions (S/MARs) have been 
identified that can be incorporated to plasmid DNA instead of the aforementioned 
viral sequences. These sequences can also enhance episomal replication of the 
plasmids, probably by bringing the plasmids into contact with the host replication 
machinery [73]. Episomally replicating plasmids are especially important in cancer 
gene therapy, where maintenance and vertical transfer of the therapeutic plasmid 
will be essential because of the presence of dividing tumour cells [85].  
Some other strategies for achieving sustained expression focus on the prevention of 
transgene silencing, since cellular gene silencing mechanisms can impede 
transgene expression [85].  
Further modifications can be also applied to the therapeutic plasmid DNA in order to 
increase the strength or the specificity of the therapeutic transgene expression. For 
instance, positive feedback loops can be incorporated. To do this, a promoter that 
drives the expression of both the transgene and of a strong artificial transcriptional 
activator is used. This transcriptional activator is capable of interacting with 
appropriate binding sites within the promoter and, that way, upregulating transgene 
expression, as well as its own expression [85]. Technologies incorporating positive 
feedback loops are estimated to increase strength of weak but highly specific 
regulatory elements [85].  
4.3 Toxicity, Manufacturing and Regulatory issues 
Besides from increasing transfection efficiency through targeting and other 
strategies, careful consideration of toxicity, manufacturing and regulatory issues of 
non-viral delivery systems is mandatory. Scalability and long-term storage 
requirements are essential factors to be taken into serious consideration when 
developing non-viral formulations for potential commercial application and 
introduction in clinical practice [19]. A generally accepted advantage of non-viral 




complex as formulations increase in complexity, incorporating stabilising 
components and bioactive targeting ligands. 
Regarding toxicity of non-viral vectors, characteristics such as size, charge, surface 
functionalization, shape and architecture may contribute to the toxicity profile of 
nanoparticles. Non-viral vectors are thought to cause toxicity through different 
mechanisms, including membrane destabilisation and lysis, inducing oxidative 
stress, initiating inflammatory response, inducing global changes in gene expression 
profiles among others [85]. Also, the properties of the biomaterials used can 
influence toxicity, depending on the rate of degradation and persistence in organs 
[19]. Persisting and accumulating biomaterials are more likely to induce an 
inflammatory response; also, products of the degradation of nanoparticles could 
potentially cause toxicity. However, knowledge about how non-viral vectors are 
disassembled and metabolically processed is still very scarce and further research 
is necessary in this regard [19].  
To conclude, the concept of a unique universal non-viral vector is nowadays 
abandoned, and it is increasingly accepted that future non-viral gene delivery 
platforms will be based on multifunctional vectors specifically tailored for different 
applications [1]. However, there are some generally assumed features that all non-
viral vectors should accomplish for efficient gene delivery. In short, three main 
factors should be taken into consideration when developing non-viral gene delivery 
platforms: (i) formulation components (of both the vector and the DNA) – the 
nanoparticle should be able to protect DNA over extra- and intracellular barriers and 
deliver the cargo into the nucleus of target cells; once inside the nucleus, the 
plasmids can be addressed to the nuclear matrix for episomal replication and 
sustained expression–; (ii) manufacturing issues – non-viral vector formulations 
should have potential for scale up–; and (iii) safety and regulatory issues – 
formulations should be non-toxic, non-immunogenic and should have suitable 
storage conditions–. Although non-viral vectors are still far from clinical practice, they 
represent a safer alternative to conventional viral vectors. Several formulations and 
strategies are under investigation with the aim of overcoming extra- and intracellular 
barriers, enhancing targeted transfection and, in general, increasing transfection 
efficiency. In addition, those formulations would ideally be suitable for administration 
through non-invasive routes, such as the intranasal administration to target the brain, 
topical ocular administration for the retina and aerosols for pulmonary diseases. 
Finally, the inclusion of novel functional modules within both the carrier and the DNA 




including the safe and long-term expression of therapeutic genes in humans [40]. 
Therefore, reasonable hope suggests that next generation gene delivery systems 
may be based on non-viral vector systems tailored for specific applications and 
suitable for non-invasive administration routes, representing an ideal platform to 
effectively shuttle the genetic material to target cells in a safe and controlled way.  
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Laburpena: Gene-terapiak interes handia piztu du azken aldian gaixotasun 
ezberdinei, genetikoak zein ez-genetikoak, aurre egiteko tratamendu itxaropentsu 
gisa. Hala ere, bektoreen eraginkortasun faltak eta eman-bide ez-inbaditzaileen 
beharrak gene-terapiaren erabilera klinikoa oztopatzen dute oraindik ere. Material 
genetikoa garraiatzeko erabili daitezkeen molekulen artean, bektore ez-biralak 
birusak baino seguruagoak dira eta alternatiba egokia izan litezke. Eman-bide ez-
inbaditzaileen ikerketek ere aurrera egin dute, esate baterako, sudur-barneko bidea 
garunera iristeko, eman-bide topiko okularra erretinara iristeko edota inhalazioz 
hartzeko aerosol erako formulazioak biriketara iristeko. Gaur egungo zantzuen 
arabera, datorren belaunaldiko gene-garraiorako sistemak bektore ez-biraletan 
oinarrituta egongo dira eta eman-bide ez-inbaditzaileetatik emateko egokiak eta 
seguruak izango dira. Errebisio-lan honetan, gene-terapiaren kontzeptua labur 
berrikusi ondoren, gene-transferentziaren eraginkortasuna hobetzeko gaur egungo 
eta etorkizuneko estrategiak deskribatuko ditugu.  
Hitz gakoak: gene-terapia, bektore ez-birala, zelulaz kanpoko eta barneko hesiak, 






1.1. Gene-terapiaren kontzeptua eta eboluzio historikoa 
Orohar, gene-terapia gisa ezagutzen da material genetiko arrotza zeluletan 
txertatzea horien proteina-espresioa aldatzeko edota kontrolatzeko, eta helburu 
esperimentalak zein terapeutikoak izan ditzake1. Gaur egun, Giza Genomaren 
Proiektuari eta biologia molekularrean egindako aurrerapenei esker, hobeto ulertzen 
dira prozesu zelularrak nahiz patologikoak, eta estrategia terapeutikoen jomuga izan 
litezkeen hainbat gene identifikatu ahal izan dira. Gainera, azido nukleikoen 
garraiatzaile gisa jarduten duten molekulak edo bektoreak etengabe garatzen eta 
hobetzen ari dira, eta horrek gene terapeutikoak modu eraginkorrean jomuga diren 
zeluletara garraiatzea ahalbidetzen du, gene-terapian oinarritutako estrategiak 
errealitate klinikora gero eta gehiago gerturatuz.  
Hala ere, oraindik gutxi dira entsegu klinikoetara edota merkatura iritsi diren gene-
terapian oinarritutako produktuak. Metodo honen potentziala DNAren egitura 
deskribatu eta denbora gutxira plazaratu zen eta gene-terapia kontzeptua 1960 eta 
1970 hamarkaden artean sortu zen2. Gene-terapian oinarritutako lehen entsegu 
arrakastatsua 1990. urtean iritsi zen, National Institute of Health erakundearen 
eskutik. Entsegu hartan, adenosina desaminasa (ADA) genearen mutazioak 
eragiten duen immunodefizientzia konbinatu larria (ingelesez SCID siglaz ezaguna) 
sendatzea lortu zen3. Zoritxarrez, 1991. urtean jazotako gertaera larri batek gene-
terapiaren segurtasuna kolokan jarri zuen. Izan ere, hemezortzi urteko mutil bat hil 
egin zen gene-terapiaren entsegu kliniko batean boluntario gisa parte hartu eta 
gero4. Food and Drug Administration (FDA) erakundearen ikerketen arabera, 
entsegu kliniko hura aurrera eraman zuten ikertzaileek ez zituzten aurreikusi albo-
ondorio larriak eta ez zituzten bete parte-hartzaileen segurtasuna bermatzeko 
neurriak4. Kasu tragiko horrek atzerapauso handia eragin zuen gene-terapiaren 
arloko ikerketan.  
Gaur egun, The Journal of Gene Medicine aldizkariak 2014ko ekainean 
eguneratutako datuen arabera5, 1989. urtean lehen gene-terapiako entsegu klinikoa 
egin zenetik, beste 2.000 entsegu kliniko baino gehiago baimendu dira mundu-
mailan (1. irudia). Entsegu horiek batez ere ondorengo gaixotasunen sendabideak 
lortzera zuzenduta daude (2. irudia): minbizia (baimendutako entseguen %64,1), 
eritasun monogenikoak (%9,1), gaixotasun infekziosoak (%8,2) eta bihotzeko 
gaitzak (%7,8). Neurri txikiagoan bada ere, gaixotasun neurologikoak (%1,8) eta 




eta guztiz ere, gutxi dira oraindik merkatura edota entsegu klinikoen laugarren fasera 
iritsi diren produktuak (3. irudia). 2012. urtean, Europako Medikutza Agentziak 
(EMA) lehenbiziko aldiz gene-terapian oinarritutako medikamentu bat merkaturatzea 
baimendu zuen Europan. Produktu horrek, Glybera® izenekoak, birus adeno-
asoziatua darama bektore gisa eta ingeniaritza genetikoaren bidez lipoproteina 
lipasa entzimaren genea garraiatzeko diseinatua izan zen5.  
1.Irudia: Mundu-mailan 1989-2014 urteen artean baimendutako gene-terapia bidezko 
entsegu klinikoak. (Ondorengo estekatik moldatua: http://www.wiley.co.uk/genmed/clinical).  
1.2. Gene-garraiatzaileen beharra 
Gene-terapiaren erabilera mugatzen duen faktore nagusia gene-garraiatzaile 
eraginkor eta seguruen eskasia da. Gene terapeutikoak zeluletara garraiatzen 
dituzten molekulak bektoreak dira, eta honako funtzio hauek betetzeko gai izan 
behar dira: (i) azido nukleikoak odoleko nukleasengandik babestea, (ii) material 
genetikoa zeluletan barneratzea eta (iii) azido nukleikoak zelula-barneko gune 
egokian askatzea1. Horrez gain, gene-garraio sistema idealak efizienteak, 
espezifikoak, iraunkorrak, seguruak, erabilerrazak eta merkeak izan beharko lirateke 
[6]. Orokorrean, bektoreak bi multzo nagusitan sailkatzen dira: biralak eta ez-biralak. 
The Journal of Gene Medicine aldizkariak 2014an argitaratutako datuen arabera7, 
gaur egun baimendutako gene-terapia bidezko 2.000 entsegu klinikoen artean, 
%70ak bektore biralak erabiltzen ditu (4. irudia). Beste %17,7ak DNA biluzia edo 





2. Irudia. Gene-terapiako entsegu klinikoetan sendatu nahi diren gaixotasunak. 
(Ondorengo estekatik moldatua: http://www.wiley.co.uk/genmed/clinical). 
 
 









Beraz, gaur egun oraindik ere bektore biralak dira nagusi gene-terapia entseguetan, 
batez ere eraginkortasun handiena dutenak direlako. Hala ere, bektore ez-biralak 
alternatiba seguru eta merkeago gisa sortu dira, eta gero eta ikerketa talde gehiagok 
horien aldeko apustua egin dute. Horrez gain, eman-bide ez-inbaditzaileen ikerketak 
ere pisu handia hartu du azken urteotan, adibidez, sudur-barneko administrazioa 
garunera iristeko, topikoa erretinarako edota aerosol erako formulazioak 
biriketarako. Zantzu askoren arabera, etorkizunean gene-garraioa eman-bide ez-
inbaditzailetatik administratu daitezkeen bektore ez-biralen bidez egingo da, eta 
plataforma terapeutiko seguruak, eraginkorrak, erabilerrazak eta indibidualizatuak 
eskainiko dituzte. Bestalde, bektore ez-biralak multifuntzionalak eta aplikazio 
bakoitzerako modu espezifikoan moldatuak izan beharko dira1.  
1.2.1. Bektore biralak 
Errebisio honetan bektore ez-biralen gainean jardungo dugu, baina komeni da 
birusen ezaugarri nagusiak labur aipatzea ere. Birusak sistema biologiko konplexuak 
dira eta euren eboluzio-prozesua material genetikoa zeluletan ahalik eta modu 
eraginkorrenean txertatzera zuzenduta egon da, horretan oinarritzen baita euren 
ugaltzeko gaitasuna8. Beraz, alde horretatik, birusak erreminta ezin hobeak dira 
material genetiko terapeutikoa zeluletara bideratzeko gene-terapian1. Hala ere, 
bektore biralek hainbat desabantaila ere badituzte, adibidez, ezin dituzte tamaina 
handiko DNA molekulak garraiatu, euren produkzioa oso konplexua eta garestia da 
eta, gainera, ez dira guztiz seguruak giza-genoman modu aleatorioan txertatu 
ezkero mutagenesia eragin dezakete eta. Horrez gain, gizakion sistema 
immunologikoak birusak identifikatu eta erasotu egiten ditu eta, horrek, bektore 
biralen eraginkortasuna gutxitu dezake1. Honenbestez, birusak erreminta sendoak 
izan daitezke geneen garraiorako, baina erabilera klinikorako mugak ere badituzte. 
Ondorengo taulan gehien erabiltzen diren bektore biralen ezaugarri nagusiak 








































1.Taula. Gene-terapian gehien erabiliak diren bektore biralak, abantailak eta desabantailak. 
(8. erreferentzian oinarrituta).  
 
1.2.2. Bektore ez-biralak 
Bektore ez-biralak birusak ordezkatu ditzaketen alternatiba seguruagoak, 
merkeagoak eta errazago ekoiztu daitezkeenak dira. Izan ere, bektore ez-biralak 
eskala industrialetan produzitu daitezke erreprodukzio handiarekin eta kostu 
onargarriekin, egonkorrak dira biltegiratzean, behin eta berriro hartu daitezke 
erantzun immunerik eragiteko arriskurik gabe eta garraiatu dezaketen material 
genetikoaren tamaina mugagabea da1, 9. Hala ere, ez dira birusak bezain 
eraginkorrak dira eta horrek bektore ez-biralen erabilera mugatzen du1.  
Bektore ez-biralak bi kategoria nagusitan sailkatu daitezke, metodo fisikoetan ala 
kimikoetan oinarritzen diren kontuan hartuta. Jarraian, bektore ez-biral nagusiak 
aipatuko ditugu.  
1.2.2.1. Metodo fisikoak 
Gene-terapiarako metodo fisiko gehienek indar fisikoa erabiltzen dute zelula-
mintzetan aldi baterako poroak sortzeko eta bertatik material genetiko arrotza 
zeluletan barneratzeko6, 10. Metodo hauetan, ez dira partikula-sistema erabiltzen 




transferentzia6. Horren adibide dira orratz bidezko injekzioa, injekzio balistikoa, 
elektroporazioa, fotoporazioa, magnetofekzioa eta hidroporazioa6, 11.  
1.2.2.2. Metodo kimikoak 
Ezaugarri kimikoaren arabera, metodo hauek hiru multzotan sailkatzen dira: lipido 
kationikoak, polimero kationikoak eta partikula inorganikoak. Lipido eta polimero 
kationikoetan oinarritutako bektore ez-biralek partikula kondentsatuak eratzen 
dituzte karga negatiboa duten DNA molekulekin indar elektrostatikoen bitartez10. 
Elkarrekintza horien ondorioz eratzen diren partikulek DNA molekulak babesten 
dituzte nukleasen eraginetik eta zeluletan barneratzea ahalbidetzen dute10. 
Ondorengoak dira bektore ez-biral kimiko ezberdinen ezaugarri nagusiak:  
• Lipido kationikoetan oinarritutako bektoreak 
Lipofekzioa edo lipido kationiko bidezko transfekzioa da gene-garraio ez-biral 
nagusia (4. irudia). Lipido kationiko guztiek lau domeinu funtzional dituzte: (i) buru 
hidrofilikoa –DNA molekulekin elkarrekintza elektrostatikoak ahalbidetzen dituena-, 
(ii) domeinu hidrofobikoa –normalean hidrokarburo kate alifatikoen eratorria-, (iii) 
egitura lotailua –lipido kationikoaren malgutasuna, egonkortasuna eta 
biodegradagarritasuna baldintzatzen dituena- eta (iv) bizkarrezur deritzon domeinua 
–buru hidrofilikoaren eta domeinu hidrofobikoaren artean kokatua, orokorrean 
glizerol edo serinol talde batez osatuta egoten da-12. Domeinu horietan egindako 
aldaketek bektoreen transfekzio eraginkortasuna aldatu dezakete. Gene-terapian 
erabiltzen diren eta lipido kationikoetan oinarritutako formulazio nagusiak 
ondorengoak dira: (i) liposomak –fosfolipidoz osatutako besikulak-, (ii) niosomak –
tentsoaktibo ez-ionikoz osatutako besikulak, liposomak baino egonkorragoak- eta 
(iii) nanopartikula lipidiko solidoak (SLN) –nukleo solidoa duten eta surfaktantez 
egonkortutako partikulak-.  
• Polimero kationikoetan oinarritutako bektoreak 
Orokorrean, polimero kationikoetan oinarritutako partikulak esferikoak izaten dira eta 
1-1000 nm arteko tamaina izaten dute. DNA molekulak matrize polimerikoan 
txertatzen dira edota partikulen gainazalean konjugatzen dira, poliplexoak eratuz. 
Egitura horiek material genetikoa nukleasen degradaziotik babesten dute6. DNA 
garraiatzeko gehien erabiltzen diren polimero kationikoak ondokoak dira: (i) 
poli(etileno imina) edo PEI –tanpoi gaitasun handikoa-, (ii) kitosanoa –polisakarido 




oligosakarido zikliko naturalak-, (iv) dendrimeroak –zuhaitz itxurako molekula 
sintetikoak, adarkatze egitura erregularrak dituztenak- eta (v) poli(L-lisina) edo PLL 
–polinukleotidoekin nanometro tamainako egiturak osatu ditzakeena amina 
protonagarriei esker-6, 13, 14.  
• Nanopartikula inorganikoetan oinarritutako bektoreak 
Nanopartikula inorganikoak tamaina, forma eta porositate ezberdineko nano-
egiturak dira, eta erabilienak kaltzio fosfatoa, silizea, urrea eta hainbat elementu 
magnetiko dira6, 15. Partikula inorganikoak erraz prestatu eta funtzionalizatu daitezke 
eta ez dute mikrobio-erasorik jasaten6, 16.  
Beraz, gene-garraiorako bektore ez-biralak birusak baino alternatiba seguruagoa 
dira. Hala ere, nahiz eta arlo horretan asko aurreratu den azken urteotan, bektore 
ez-biralen erabilera klinikoa oraindik ere mugatuta dago eraginkortasun falta dela 
eta. Errebisio honetan, gene-transferentzia hobetzeko gaurko eta etorkizuneko 
estrategiak eztabaidatuko ditugu, betiere bektore ez-biralak eta eman-bide ez-
inbaditzaileak oinarri hartuta. Lehenengo, bektore ez-biralek gainditu beharreko 
zelula-barneko hesiak deskribatuko ditugu. Jarraian, zelulaz kanpoko hesiak 
aipatuko ditugu, eta hesi horiek gainditzeko eman-bide inbaditzaile eta ez-
inbaditzaileen gainean jardungo dugu. Azkenik, bektore ez-biralek klinikara iristeko 
dituzten erronkak eztabaidatuko ditugu, batez ere, transfekzio eraginkortasunari, 
jomugara zuzentzeari eta gene-espresioaren iraunkortasunari dagokionean.  
2. ZELULA-BARNEKO HESIAK ETA TRANSFEKZIO ERAGINKORTASUNA 
HOBETZEKO ESTRATEGIAK 
Transfekzio eraginkortasuna baldintzatzen duen faktore nagusia sistema ez-biralak 
zelula-barneko zein kanpoko hesiak gainditzeko duen gaitasuna da. Atal honetan, 
bektore ez-biralek gene-transferentzia eraginkorra lortzeko gainditu beharreko 
zelula-barneko hesi nagusiak eta horretarako estrategiak deskribatuko ditugu. 
Zelula-barneko hesiak dira zelula-mintzetik nukleorainoko bidean bektore ez-biralek 
gainditu beharreko oztopoak. Hesi horien ezaugarri molekularrak ezagutzea 
ezinbestekoa da horiek gainditzeko gai izango diren bektoreak diseinatu ahal 
izateko. Beraz, atal honetan zelulan barneratzeko eta nukleoraino iristeko bide 
ezberdinak deskribatuko ditugu, eta endosomatik ihesa zein nukleorako sarrera 
areagotzeko hainbat estrategia aipatuko ditugu, horiek baitira gene-




2.1. Zelulan barneratzeko bideak 
Zelula-mintzarekiko asoziazioa da lehen hesia, eta bektore ez-biralak DNA 
molekularekin osatzen duten partikulek jarraian hartuko duten zelula-barneko 
ibilbidea baldintzatuko duen faktore nagusia da17. Zelula-mintzarekin bertako 
errezeptoreen bitartez edota modu independentean lotu daitezke bektore ez-biralak. 
Errezeptoreekiko modu independentean gertatzen diren asoziazioak erakarpen 
elektrofilikoaren bitartez gauzatzen dira, karga positiboa duten partikulen (adibidez, 
poliplexo edota lipoplexo kationikoak) eta karga negatiboa duten zelula-mintzeko 
proteoglikanoen artean18. Lotura-modu horren bitartez zelula-mota ugariren 
transfekzioa gauzatu daiteke in vitro, baina in vivo egin ahal izateko prozesuak 
optimizazio handiagoa eskatzen du. Izan ere, gene terapeutiko bat ehun jakin batera 
transferitzeko, zelula-lotze ez-espezifikoak direla eta dosi oso altuak eta, ziurrenik, 
toxikoak beharko lirateke. Hori ekiditeko, estekatzaile zehatzak edota antigorputzak 
gehitu dakizkieke bektore ez-biralei ehun- edo zelula-espezifikotasuna lortzeko18. 
Esate baterako, transferrina (Tf) izeneko proteina burdin-garraiatzailea erabili 
daiteke bektore ez-biralak garunera bideratzeko, proteina horren errezeptorea 
neuronek eta hesi hematoentzefalikoko zelula endotelialek agertzen baitute19. 
Erabilitako estekatzailearen aukeraketa ez da soilik iritsi nahi den zelula-motaren 
araberakoa, baizik eta baita behin zelulari lotuta abiaraziko duen zelula-barneko 
ibilbidearen araberakoa ere. Hurrengo atalean aipatuko den bezala, bektore ez-
biralak jarraituko duen ibilbide endozitikoa honi gehitutako estekatzaileak 
baldintzatuta egon daiteke.  
Behin zelula-gainazalean lotuta, bektore ez-biralek mintz plasmatikoa zeharkatu 
behar dute zelulan sartzeko, trafiko intrazelularra abian jartzeko eta nukleoraino iritsi 
ahal izateko. Endozitosi deritzo partikulak zeluletan zelula-mintzaren 
inbaginazioaren bidez barneratzeari eta zelula barneko ibilbidea inbaginazio 
horretatik sortutako besikulen baitan egiteari20. Hori izaten da bektore ez-biralek 
jarraitzen duten bidea. Lau endozitosi mota nagusi daude: klatrina bidezko 
endozitosia (CME), kabeola bidezko endozitosia (CvME), fagozitosia eta 
makropinozitosia17, 21. Ibilbide endozitiko horiek jarraian azaltzen dira.  
2.1.1. Klatrina bidezko endozitosia 
Klatrina bidezko endozitosia (CME) oso prozesu erregulatua eta energia-
dependentea da eta, gainera, hobekien ezagutzen den ibilbide endozitikoa da20. 
Lehen pausua CME ibilbidean partikuletako estekatzaile baten eta zelula-mintzeko 




lokalizatua abiarazten du zelula-mintzaren alde zitoplasmatikoan, mintz 
plasmatikoaren deformazioa eraginez eta 100-150 nm arteko inbaginazio bat 
eratuz22. Klatrina pilaketak jarraitu ahala, inbaginazio horiek gero eta gehiago 
barneratzen dira zitoplasman, azkenean mintz plasmatikotik askatu arte eta klatrinaz 
bildutako besikula zitoplasmatikoak sortu arte20. Jarraian, klatrina desegin egiten da 
eta besikulak endosoma goiztiar bilakatzen dira. Besikula mintz plasmatikotik 
askatzeko beharrezkoa da GTPasa mota bat, dinamina izenekoa23. Horrez gain, 
dirudienez kolesterolak ere paper garrantzitsua jokatzen du besikularen eraketan, 
kolesterolik gabe besikulak ez baitira gai zelula-mintzetik askatzeko24.  
Ibilbide honetako hurrengo pausuan, endosoma goiztiarrak heldu eta endosoma 
berantiar bilakatzen dira eta, jarraian, horiek lisosomekin bat egiten dute25. 
Endosoma goiztiarretatik endosoma berantiarretarako heltze prozesuan, protoi 
bonbek konpartimentuko azidifikazioa eragiten dute eta endosometatik 
lisosometarako trantsizioan pH-aren balioa are gehiago jaisten da 5era iritsi arte20. 
Endosometako pH azidoak, dirudienez, estekatzaile eta errezeptoreen arteko 
disoziazioa eragiten du. Autore gehienen esanetan, endosomatik ihes egiteko 
mekanismorik ez badago, bektore ez-biralek eta DNA molekulek osatutako 
partikulak harrapatuta geratzen dira lisosometan eta bertan degradatzen dira 
azidotasunaren eta aktibitate entzimatikoaren eraginez, nukleora iristeko aukerarik 
gabe20.  
Beste autore batzuen arabera, berriz, bektore ez-biralaren konposizioaren arabera, 
kasu batzuetan CME ibilbidea egokiena litzateke transfekzio eraginkortasun altua 
lortzeko, lisosometako giroak bektore ez-biralen eta DNA molekulen arteko lotura 
askatzea ahalbidetzen duelako, DNA molekulak aske utzi nukleoraino iristeko26. 
Bektorearen ezaugarrien arabera, zelula barneko ibilbide bat edo bestea jarraitu 
dezake26 eta beharrezkoa da bektore ez-biralek bide ezberdinak ezagutzea bektore 
eraginkorragoak diseinatu ahal izateko.  
2.1.2. Kabeola bidezko endozitosia 
Kabeola bidezko endozitosia (CvME) kabeola izeneko zelula-mintzeko mikro-
domeinuetan hasten da. Horiek zelula-mintzaren inbaginazio txikiak eta 
hidrofobikoak dira, kolesterol eta esfingolipido ugari dituztenak17, 20. Aurreko ibilbidea 
bezala, CvME ere estekatzaile bidezko eta dinamina proteinaren akzioa behar duen 
ibilbide endozitikoa da, kolesterolak ere paper garrantzitsua jokatzen duelarik27. 
Klatrina bidezko endozitosiarekin alderatuta, ezberdintasun nagusia da kabeola 




sortzen dira eta horiek, autore gehienen arabea, ez dira lisosomekin elkartzen17. 
Beraz, lisosoma barruko DNA molekulen degradaziorik ez da espero ibilbide 
honetan. Orokorrean, CvME ibilbide ez-azidiko eta ez-digestibotzat hartzen da, 
alegia, degradaziorik gabeko ibilbidetzat17, 28. Hala ere, kontu hori ez dago erabat 
argi eta debatea zabalik dago, ikertzaile batzuek argitaratu baitute kasu batzuetan 
kabeosomek lisosomekin bat egiteko joera dutela29. Beraz, ikerketa sakonagoak 
beharrezkoak izango dira auzi hori argitzeko.  
2.1.3. Fagozitosia 
Fagozitosia endozitosi mota berezia da, gehienbat horretan espezializatutako zelula 
taldeek burutzen dutena, hala nola, makrofagoek, monozitoek, neutrofiloek eta 
zelula dendritikoek, nahiz eta beste zelula talde batzuk ere burutu dezaketen17. 
Zelula-mintzaren luzapenen bitartez (normalean 1 µm ingurukoak edo luzeagoak) 
bideratzen da fagozitosia eta batez ere partikula handiak irensteko balio du, besteak 
beste, bakterioak eta zelula hilak, eta baita tamaina handiko lipoplexo eta 
poliplexoak irensteko ere17.  
Fagozitosiak normalean hiru fase izaten ditu, molekula guztientzat –bektore ez-
biralak barne- berdinak direnak. Lehenbizi, opsoninek bektore ez-biralak eta DNA 
molekulak osatutako partikulak antzematen dituzte eta opsonizatu egiten dituzte 
odolean. Jarraian, partikula opsonizatuak makrofagoen gainazalari lotzen zaizkio 
antigorputzen atal konstantearen eta makrofagoen zelula-mintzeko errezeptoreen 
arteko interakzioaren bidez17. Atal konstanterik gabeko antigorputzak bektore ez-
biralei txerta dakizkieke in vivo makrofagoek antzeman ez ditzaten eta beste zelula 
batzuetara iritsi daitezen30.  
Azkenik, makrofagoen errezeptoreen aktibazioak Rho familiako GTPasak aktibatzen 
ditu, eta horiek aktinaren antolaketa eta zelula-mintzaren luzapenen eraketa 
abiarazten ditu17. Horrela, makrofagoek bektore ez-biralak eta DNA molekulak 
osatutako partikulak irensten dituzte20. Zelulan fagozitosi bidez barneratzen diren 
besikulei fagosoma deritze eta 0,5 – 1,0 µm arteko diametroa izaten dute20. 
Fagosomek, heltzean, lisosomekin bat egiten dute eta, beraz, azidifikazio prozesua 
jasaten dute20. Horrenbestez, litekeena da bide endozitiko honen bitartez zelulan 







Makropinozitosia fase fluidoko endozitosi-mota da, eta era ez-espezifikoan 
elementu fluidoak barneratzen ditu zeluletan17. Fagozitosian bezala, 
makropinozitosian ere aktina filamentuek sortutako mintz-luzapenek hartzen dute 
parte. Hala ere, kasu honetan protuberantziek mintz plasmatikoarekin bat egiten 
dute azkenean (5. irudia). Makropinozitosian sortzen diren besikulei 
makropinosomak deritze eta, nahiz eta tamaina heterogeneoak ager ditzaketen, 
normalean 0,2 µm inguruko diametroa izaten dute32. Gainontzeko endozitosi-motak 
bezala, makropinozitosia ere GTPasa proteinen menpeko prozesua da eta proteina 
horiek beharrezkoak dira besikulak zelulen barnean mintz plasmatikotik askatzeko17.  
Makropinosomen eta lisosomen arteko konexioa ez da oraindik ezagutzen. Ikerketa 
batzuek diotenez, makropinosoma goiztiarrek eta endosoma goiztiarrek markatzaile 
berdinak aurkezten dituzte eta gauza bera gertatzen omen da makropinosoma 
berantiarren ete lisosomen artean ere17. Hala ere, hainbat ikerketak erakutsi dute 
makropinosomek patu ezberdinak izan ditzaketela zelula motaren arabera eta ez 
dutela beti lisosomekin bat egiten, nahiz eta oraindik asko dagoen ikertzeko arlo 
horretan ere17.  
2.2. Endosomatik ihes egiteko mekanismoak 
Esan bezala, bektore ez-biral gehienak klatrina bidezko endozitosiz barneratzen dira 
zeluletan. Horren arazoa da endosomatik ihes egin ezean, lisosomara iritsiko direla 
eta bertan degradatuak izango direla. Hori ekiditeko, bektore ez-biralek endosomatik 
ihes egiteko hainbat estrategia garatu dira.  
Patogeno askok, batez ere birusek eta bakterioek, endosomatik ihes egiteko 
mekanismoak garatu dituzte eboluzioan zehar. Endosomatik ihes egiteko gaitasuna 
duten molekula asko birusetan (adib. influenza birusaren hemaglutinina), 
bakterioetan (adib. difteria toxina), landareetan (adib. errizinoa), gizakian (adib. 
fibroblastoen hazkuntza faktorea) edota animalietan (adib. erleen pozoitik ateratako 
melitina) aurki daitezke33. Molekula horien funtzionamendua ulertzeak ahalbidetzen 
du bektore ez-biralentzako endosomatik ihes egiteko estrategia berriak sortzea. 
Gaur egun, sekuentzia eta luzera jakineko peptido sintetikoak (adib. Sweet Arrow 
Peptide edo SAP anfipatikoa) eta agente kimiko espezifikoak (adib. poli(etileno 
imina) edo PEI polimeroa) erabiltzen dira endosomatik ihesa bultzatzeko33. Datozen 
paragrafoetan endosomatik ihes egiteko erabiltzen diren estrategia nagusiak 




2.2.1. Endosoma-mintzean poroak eratzea 
Poro-eraketa mintzaren tentsioaren eta tentsio linealaren arteko erlazioan 
oinarritzen da. Zenbait peptidok afinitate handia dute poroen ertzarekiko eta tentsio 
linearraren jaitsiera eragiten dute33. Hainbat ikerketaren arabera, peptido kationiko 
anfifilikoak mintz plasmatikora lotzeak barne-tentsio handia eragiten du, poroak 
sortzeko gai dena33.  
2.2.2. pH indargetzaile efektua (protoi-esponja efektua) 
Endosomatik ihes egiteko mekanismo honetan, endosomako pH baxuak bertako 
elementuen protonazioa eragiten du, gaitasun indargetzaile handia izango dutenak. 
Protonazioak ioien (H+ eta Cl-) eta uraren barne-fluxua eragiten du, endosomaren 
hantura eta haustura eragiten dituena33.  
Mekanismo hori protoiak indargetzeko gaitasuna duten hainbat polimero 
kationikorekin ikusi da pH tarte zabalean34. Polimero horiek protonatu daitezkeen 
amina binarioak edo tertziarioak izan ohi dituzte, pKa balioa endosomaren pH 
mailatik gertu dutenak. Esan bezala, endosomen heltze prozesuan ATPasa protoi 
bonbek protoiak barneratzen dituzte zitosoletik endosomara, barneko azidifikazioa 
eraginez. Une horretan, polimero kationikoak protonatu egiten dira endosomako pH-
a mantentzeko, baina horrek protoi gehiagoren sarrera eragiten du, konpartimentua 
are gehiago azidotuz34. Presio osmotiko altuak endosomen hantura eta apurketa 
eragiten du, barruko elementuak zitoplasmara jaurtiz34. Histidina daukaten 
molekulek efektu indargetzailea dute33 eta, beraz, bektore ez-biraletan txertatu 
daitezke hauek ere endosomatik ihes egiteko gai izan daitezen.  
2.2.3. Flip-flop mekanismoa 
Edozitosi bidez barneratutako lipoplexoentzat erabilgarria izan daitekeen 
mekanismoa da hau. Endosoma barruko lipoplexoetako lipido kationikoen eta 
endosomako mintzeko lipido anionikoen artean elkarrekintza elektrostatikoak 
sortzen dira, bi mintzen arteko interakzioa eta fusioa sortuz eta, horrela, material 
genetikoa zitoplasmara askatuz34.  
2.2.4. Endosoma-mintzarekin fusioa 
Mekanismo hau zeluletan barneratzeko peptido edo CPP (cell penetrating peptides) 
izeneko molekulen erabileran oinarritzen da. CPP-ak uretan disolbagarriak eta 




mintz plasmatikoan kalterik sortu gabe zeluletan barneratzeko gaitasuna da, eta 
elektrostatikoki edo kobalenteki lotutako molekulak barneratu ditzakete eurekin 
batera (proteinak, peptidoak eta azido nukleikoak) eraginkortasun handiarekin eta 
toxikotasun baxuarekin35. Hala ere, ez da oraindik ezagutzen CPP-ek zelulan 
barneratzeko erabiltzen duten mekanismo zehatza. Izan ere, ikerketa batzuen 
arabera, energiaren menpeko prozesua da eta, beste batzuen arabera, mekanismo 
energia-independentea da. Gaur egun uste da batez ere endozitosi bidez 
barneratzen direla zeluletan, baina baldintza esperimentalen arabera bide bat edo 
gehiago har ditzakete. Beraz, ikerketa sakonagoak behar dira prozesu horiek 
argitzeko.  
Irizpide ezberdinak daude CPP-ak sailkatzeko, baina, orokorrean, bi multzotan 
sailkatzen dira36: (i) arginina eta lisina aminoazidoak dituzten peptido kationikoak eta 
(ii) peptido anfipatikoak. Adibidez, bektore ez-biralen endosomatik ihes egiteko 
gaitasuna handitzeko birusetatik eratorritako TAT izeneko transkripzio aktibatzailea 
erabiltzen da33, 37. Bestalde, bigarren kategoriari dagokion SAP peptidoa ere 
erabiltzen da38.  
2.2.5. Endosoma-mintzaren haustura fotokimikoa 
Barneratze fotokimikoa argiaren bitartez gauzatzen den mekanismoa da eta 
elementu fotosentsibilizatzaileak erabiltzen ditu molekulek mintza zeharkatu ahal 
izateko [34]. Fotosentsibilizatzaileak elementu anfifilikoak dira eta mintz 
plasmatikoan txertatu daitezke. Elementu horiek endozitosi bidez barneratzen dira 
bektore ez-biralekin batera eta egoera inaktiboan jarraitzen dute beren absortzio 
espektroko argi uhinek aktibatzen dituzten arte39. Orduan, oxigeno erreaktibo 
espezieak eratzen dituzte, endosomen haustura eraginez. Horrela, endosomako 
molekulak zitoplasmara askatzen dira34.  
Orohar, uste da endosomatik ihes egiteko gaitasuna faktore oso garrantzitsua dela 
gene-transferentzia eraginkortasunez gauzatzeko. Hala ere, endosomatik ihes 
egiteko ahalmena duten molekula seguruak eta erabilerrazak behar dira klinikan 
erabiliko diren bektore ez-biraletan txertatzeko.  
2.3. Nukleora sarrera 
Aurreko atalean aipatu dugu zer mekanismoren bitartez egin dezaketen ihes bektore 
ez-biralek endosomatik transfekzio eraginkortasuna handiagotzeko. Hala ere, beste 




nukleoan sartzea. Horretarako ere hainbat estrategia daude eta atal honetan 
deskribatuko ditugu.  
Nukleoan sartzeko, molekulek nukleo-poro konplexuak (NPC) zeharkatu behar 
dituzte. Horiek egitura multimerikoak dira eta 9 nm-ko kanal bat daukate erdian, 45 
kDa baino gutxiago duten molekulei difusio pasiboz nukleoan sartzen uzten diena40. 
DNA molekula biluzien kasuan, 300 bp baino gutxiagoko molekulak ere difusio 
pasiboz pasatu daitezke, baina molekula handiagoak ezin dira sartu zelulak ez 
badira zatiketa mitotikoa egiten ari40-42. Zelularen zatiketa prozesuan edo mitosian, 
nukleo mintza desegiten da eta horrek bektore ez-biralak eta DNA molekulak 
osatutako partikulak barneratzea ahalbidetzen du21, 40. Hori da hain zuzen zelulak in 
vitro transfektatzean gertatzen dena, baina in vivo kasuetan prozesua zailagoa da 
zelula batzuk ez direlako inoiz edo ia inoiz zatitzen21, 40. Beraz, nukleo-mintza ere 
kontuan hartu beharra dago bektore ez-biralak diseinatzeko orduan, DNA molekulak 
nukleora iritsiko badira.  
Orohar, nukleora joan behar duten proteinek nukleora bideratzeko sekuentzia bat 
izaten dute, NLS (nuclear localization signal) izenekoa eta aminoazido basiko ugari 
dituena17. Sekuentzia hori inportina izeneko zitoplasmako proteina batzuek 
antzematen dute eta nukleora bidaltzen dute seinale hori daraman proteina oro 
NPC-an barrena, energiaren menpeko garraioaren bitartez40, 43. Estrategia bera 
erabili daiteke bektore ez-biralak ere nukleora bideratzeko. Hau da, bektore ez-
biralei NLS sekuentzia txertatuta, inportinek ezagutu eta nukleora bidaliko lituzkete 
NPC-an zehar. Aminoazido basiko ugari dituzten beste sekuentzia batzuk ere erabili 
izan dira molekula ezberdinak nukleora bideratzeko, besteak beste, poli-lisina eta 
protamina40.  
Azkenik, kontuan hartu behar da behin nukleoan egonda, bektore ez-biralak gai izan 
behar direla material genetikoa bertan askatzeko transkripzioa gertatu dadin. Halere, 
ez da komenigarria ere DNA azkarregi askatzea, degradazio entzimatikoa jasan 
lezake eta40,44. Liposometan oinarritutako bektore ez-biraletan, DNAren garraioa 
endosomatik ihes egiteko flip flop mekanismoari lotuta dagoela dirudi eta, beraz, 
DNA molekulak bakarrik iritsiko lirateke zitoplasmatik nukleora, bektoreei lotuta 
heldu beharrean40, 45, 46. Aldiz, bektore polimerikoetan, DNA nukleoan askatzen da 
bektoretik nukleoko proteinen interakzioaren eta oraindik guztiz argitu gabeko beste 
prozesu batzuen bitartez40, 47, 48.  
Beraz, bektore ez-biralek hainbat zelula-barneko hesi zeharkatu behar dituzte 




motaren arabera eta endozitosi motaren arabera, hesi intrazelularrak ezberdinak 
izan daitezke. Bektore ez-biral gehienak klatrina bidezko endozitosiz barneratzen 
dira zeluletan eta endosomatik ihes egin beharra izaten dute lisosometan 
degradaziorik ez jasateko. Gainera, DNA molekulak nukleoan sartu behar dira 
transgenearen espresioa gertatu ahal izateko eta horretarako NLS seinalea gehitu 
dakioke bektoreak eta material genetikoak osatutako partikulari. Behin nukleoan, 
DNA molekulak bektoretik askatu behar dira transkripzio prozesuan parte hartu ahal 
izateko. Prozesu hori guztia 5. irudian laburbilduta ageri da.  
5. Irudia. Bektore ez-biralen zelulan barneratzeko eta zelula barneko ibilbide endozitikoak. A) 
Fagozitosia. B) Klatrina bidezko endozitosia (CME). C) Kabeola bidezko endozitosia (CvME). 
D) Makropinozitosia. Zelulan barneratutako bektore ez-birala/DNA partikulak klatrina bidezko 
bidea jarraituz, endosomatik ihes egin eta nukleora garraiatuak dira inportinek NLS sekuentzia 
antzeman ostean. Horiz, aktina; gorriz, klatrina; berdez, kabeolina dimeroak; laranjaz, dineina 
GTPasa txikia; urdinez, opsoninak. (23 eta 24 erreferentzietatik moldatua).  
3. ZELULAZ KANPOKO HESIAK. EMAN-BIDE EZ-INBADITZAILEAK.  
Eman-bidearen eta iritsi nahi den ehunaren arabera, gene-garraiorako sistemek 
hainbat zelulaz kanpoko hesi gainditu behar dituzte zeluletara iritsi eta gene 
transferentzia egin ahal izateko. Lehenago aipatu bezala, gene-terapian 
oinarritutako entsegu klinikoen %60 inguru minbiziaren aurkako sendagaien 
ikerketari dagokio. Beste gaixotasun batzuk ere, hala nola infekziosoak, 
neurodegeneratiboak, ala begiari zein birikei eragiten dietenak, interes berezia piztu 
dute azken aldian eta entsegu klinikoen %10a osatzen dute. Bektore ez-biralen 




Horretarako, bektore ez-biralak era egokian diseinatu behar dira eman-bide horretan 
zehar topatuko dituzten zelulaz kanpoko hesiak gainditu ahal izateko. Gainera, ehun 
zehatzetara iritsi nahi denean, esate baterako, garunera, begietara edo biriketara, 
beste hainbat zelulaz kanpoko hesi ere zeharkatu beharko dituzte bektoreek. Atal 
honetan, zain barneko eman-bidean ageri diren hesi sistemiko nagusiak aipatuko 
ditugu, eta baita garunean, begietan edota biriketan ageri diren hesi espezifikoak 
ere. Horrez gain, zelulaz kanpoko hesi horiek gainditzeko garatu diren estrategiak 
berrikusiko ditugu, eman-bide inbaditzaile zein ez-inbaditzaileetan oinarritutakoak. 
Gaur egun, komunitate zientifikoa gogor ari da lanean bektore ez-biralak modu 
seguruan eta eman-bide ez-inbaditzaileen bitartez ehun espezifikoetara 
helarazteko.  
3.1. Zain barneko eman-bidea 
Minbizi mota askotan eta, batez ere, minbizi hedatuetan, tratamendua odolaren 
bidez administratu beharra dago. Beraz, minbiziari aurre egiteko diseinatutako 
bektore ez-biralak gai izan behar zain barneko eman-bidean aurkituko dituzten 
oztopoei aurre egin eta minbizi-zeluletaraino iristeko.  
Zain barnetik emandako DNA molekulentzat, erronka nagusia da zelulaz kanpoko 
degradazioa ekiditea, odolean azido nukleikoak erasotzen dituzten nukleasa ugari 
baitaude. Horretan laguntzen dute hain zuzen ere bektore ez-biralek, DNA 
molekulak kondentsatuz eta, horrela, aktibitate entzimatikotik babestuz13.  
Odoleko nukleasez gain, bertako proteinek ere –albumina, immunoglobulinak, etab.- 
gainditu beharreko hesi bat osatzen dute. Izan ere, bektore ez-biralek eta DNA 
molekulek osatutako partikulak era ez-espezifikoan odoleko proteinekin elkartu 
daitezke, agregatuak sortuz eta jomuga diren minbizi zeluletara iristea oztopatuz49.  
Hirugarren oztopoa zain barneko eman-bidean bektore ez-biralek eta DNA 
molekulak osatutako partikulen ezegonkortasun koloidala litzateke. Ezegonkortasun 
horrek ere partikulen agregazioa eta helmugara ez iristea eragin ditzake49. Gainera, 
odol-hodien sistema bera ere hesi garrantzitsua da, endotelio-zeluletan barrena 
igaro daitezkeen partikulen tamaina baldintzatzen baitu49.  
Azkenik, sistema immunologikoaren aktibazioa ere kontuan hartu beharreko 
faktorea da. Izan ere, bektore ez-biralek zein DNA molekula arrotzek hantura 




Hesi sistemiko guzti horiei aurre egiteko, bektore ez-biralen egitura hobetu beharra 
dago. Bektoreen formulaziok baldintzatuko du in vivo horien bioerabilgarritasuna49. 
Ondorengo paragrafoetan, formulazioa optimizatzeko garatzen ari diren hainbat 
estrategia deskribatuko ditugu.  
Bektore ez-biralek eta azido nukleikoek osatutako partikulak egonkortzeko, gehien 
erabiltzen den metodoa partikulen gainazala polietileno glikolez (PEG) estaltzea 
da50. Molekula hori oso hidrofobikoa denez, hesi moduko bat osatzen du bektore ez-
birala/DNA partikularen inguruan, odoleko proteinekin interakzioak saihestuz eta, 
beraz, agregazioak ekidinez49. Hala ere, nahiz eta emaitza itxaropentsuak lortu diren 
estrategia hori erabilita, zenbait zailtasun ere badira PEG-aren erabileran. Izan ere, 
molekula horrek bektore ez-biralen eta DNAren arteko elkarrekintza ahuldu dezake, 
partikulen barne-ezegonkortasuna areagotuz. Gainera, erantzun immunea ere piztu 
dezake, antigorputzen produkzioa eraginez eta, beraz, bektore ez-birala/DNA 
partikulak zirkulaziotik kanporatuz51. PEG molekulen luzerak eta kantitateak 
baldintzatuko dute in vivo estrategia horren egokitasuna eta parametro horiek 
bektore ez-biralaren ezaugarrietara egokitu beharko dira52.  
Horren ondorioz, komunitate zientifikoa lanean ari da PEG molekulen desabantailak 
nola edo hala orekatzeko. Ikerketa berri baten arabera, soluzioa izan daiteke PEG 
molekulen ordez polimero hidrofilikoak erabiltzea, adibidez poli(N-binil-2-pirrolidona) 
(PVP), poli(4-akriloilmorfolina) edo poli(N,N-dimetilakrilamida)53. Partikulen 
egonkortasuna handitzeko beste estrategia batzuk ko-polimeroen erabileran 
oinarritzen dira, adibidez, PLL54. Bestalde, pH-arekiko sentsibilitatea duten 
partikulak ere erabili izan dira55, baita entzimatikoki ebaki daitezkeen PEG 
molekulak56 edota erreduzitu daitezkeenak57 ere.  
Gainera, beste aldaera kimiko eta estruktural batzuk ere egin daitezke bektore ez-
biraletan zelulaz kanpoko hesiak gainditzen laguntzeko. Lipido kationikoak dituzten 
bektore ez-biraletan, esaterako, kolesterola gehitzeak odoleko globulu gorriekin 
elkartzea ekidin dezake49. Aldiz, polimero kationikoak dituzten bektore ez-biralen 
kasuan, esaterako, kitosanoa laktosarekin konjugatuz agregazioa ekiditea lortu da 
odol-hodietan58. Beraz, bektore ez-biralaren ezaugarrien arabera, estrategia 
ezberdinak erabil daitezke bektore ez-biralak eta DNA molekulak osatutako 





3.2. Ehun zehatzetara bideratzea: zelulaz kanpoko hesi gehigarriak 
Ehun espezifikoetara iritsi nahi denean, bektoreak gai izan behar dira ehun 
bakoitzari dagozkion hesi gehigarriak ere zeharkatzeko. Atal honetan, hiru ehunetan 
jarriko dugu arreta: garuna, begia eta birikak. Ehun horietara iristeko erabiltzen diren 
eman-bide inbaditzaileak eta ez-inbaditzaileak ere berrikusiko ditugu.  
3.2.1. Gene-garraioa garunera 
Nerbio-sistema zentralak (NSZ) ezaugarri anatomiko eta fisiologiko bereziak ditu, 
garuneko gene-garraioa asko zailtzen dutenak. Hesi hematoentzefalikoak (HHE) 
babesten du NSZ, elkarri estu lotutako endotelio zelulez osatutakoak19, eta uste da 
farmako makromolekularren %100i sarrera galarazten diola, baita farmako txikien 
%98ri ere59. Bizkarrezur-muina ere NSZren parte da eta beste hesi batek babesten 
du, likido zefalorrakideoaren hesiak hain zuzen, epitelio-zelulez osatua eta molekula 
arrotzak likido zefalorrakideora hedatzea galarazten duena19. Nutrienteen garraioa 
NSZra, glukosa eta aminoazidoena kasu, HHEn ageri diren errezeptore espezifikoen 
bidez egiten da19. Zelula-mota ezberdinak daude NSZn, neuronak eta glia-zelulak 
barne, eta gehienbat neuronak oso zailak dira transfektatzen post-mitotikoak 
direlako eta euren egitura zein osatzen duten sarea oso konplexuak direlako19.  
Bektore ez-biralak eta DNA molekulak osatutako konplexuek HHE zeharkatzeko 
hainbat estrategia garatu dira. Gehienak HHEko errezeptoreetan lotuko diren 
estekatzaileen erabileran oinarritzen dira, adibidez, transferrina, laktoferrina eta 
intsulina, horien errezeptore ugari baitaude bai HHEko zeluletan eta baita 
neuronetan ere19. Estekatzaile horietako bat bektore ez-biralari lotuta, bektore ez-
birala/DNA konplexua HHEn barrena garraiatu ahal izango da NSZra iritsi arte. 
Beste estrategia bat “Troiako zaldia” gisa ezagutzen dena da eta antigorputz 
monoklonal peptido-mimetikoen erabileran du oinarria. Antigorputz horiek HHEko 
errezeptoreak aktibatzeko gai dira eta bektore ez-birala/DNA konplexuaren garraioa 
ahalbidetzen dute NSZra60. Beste ildo batzuk HHEren aldi baterako ezegonkortze 
mekanikoa eragitea edota HHE osatzen duten endotelio-zelulen arteko loturak modu 
iragankorrean haustea dira19.  
Garunera helarazi nahi diren farmakoentzat eman-bide sistemikoa da egokiena eta 
onargarriena erabilera klinikorako. Hala ere, kontuan izanda horrek zelulaz kanpoko 
hesi ugari igaro behar izatea dakarrela eta ez dela beti posible izaten, hainbat 
ikerketak beste eman-bide batzuk aztertu dituzte. Entsegu aurre-kliniko batzuetan 




administratzen saiatu dira, baina nahiz eta eman-bide horien bidez HHE eta beste 
zelulaz kanpoko hesiak gainditzen diren, askotan inbaditzaileegiak izaten dira eta 
bide horretatik eman beharreko farmakoek aukera gutxi dituzte erabilera klinikora 
iristeko.  
Sudur-barneko eman-bidea ez-inbaditzailea eta itxaropentsua izan daiteke 
farmakoak garunera modu seguruan eta zelulaz kanpoko hesiak ekidinez iritsi ahal 
izateko. Oraindik ez dago erabat argi farmakoak sudurretik garunera zer 
mekanismoren bidez iristen diren, baina, dirudienez, garraio perineuronal, 
peribaskular eta linfatikoen bitartez gertatzen da. Dena dela, garraio horietako bata 
edo bestea gailenduko da bektore ez-biralaren ezaugarrien arabera61. Gaur egun, 
uste da sudur barnetik emandako substantzia bat hiru bide ezberdinetatik heldu 
daitekeela NSZra: (i) garraio parazelular edo transzelular zuzena usaimen 
neuronetan edo zelula epitelialetan barrena (“usaimen neurona bidea”), (ii) nerbio 
trigeminoan barrena (“trigeminoko bidea”) edo (iii) zeharka, odol-hodietan edo 
sistema linfatikoan barrena (“bide sistemikoa”)62. Sudurreko mukosak odol-kapilar 
ugari ditu eta horiek nano-farmakoei igarotzen uzten diete, baina zirkulazio 
sistemikora pasatzen diren farmakoek HHE zeharkatu beharko dute NSZra 
iristeko61. Nerbio trigeminoa jarraituz, farmakoak usaimen erraboiletan eta garuneko 
alde kaudaletan askatzen dira63. Behin garunean, espazio peribaskularretako 
fluxuak farmakoak garuneko eremu ezberdinetara iristea ahalbidetzen duela uste 
da63, 64.  
Sudur-barneko eman-bideak hainbat abantaila ditu, besteak beste, administrazio 
erraza eta ez-inbaditzailea, dosiaren absortzio azkarra sudurreko mukosan barrena, 
azalera egokia dosia xurgatzeko eta albo-efektu gastrointestinalak zein lehen 
pausuko metabolismoa ekiditea65. Gainera, norberak har dezake farmakoa eman-
bide honetatik eta beste bide inbaditzaile batzuk baino onargarriagoa da65. 
Desabantailen artean, aipagarrienak dira sudurreko kongestioa dagoenean dosia ez 
dela behar bezala xurgatuko eta eman-bide hau behin eta berriro erabiliko balitz 
sudurreko mukosa kaltetu egingo litzatekeela65. Gainera, sistema mukoziliarrak 
farmakoa mukosatik bizkor kanporatu dezake59, 66, baina oztopo hori erraz gainditu 
daiteke farmakoari molekula muko-adesiboak gehituta. Bektore ez-biralentzat, 
kitosanoa eszipiente erakargarria da sudur-barneko eman-bidean erabiltzeko. Izan 
ere, absortzioa errazten du eta mukosako azido sialikoarekin elkarrekintzak 
mantentzeko gai da, zelula epitelialen arteko lotura estuetan zabaluneak sortuz eta, 




laureato sukrosa tentsoaktibo ez-ionikoa erabili dute sudur-barneko absortzioa 
areagotzeko68.  
Azken aldian, HHE zeharkatu dezaketen lehen DNA nanopartikulak erabiltzea lortu 
da eta, gainera, arratoien garunean in vivo egindako entseguetan, transgenea 
garuneko zeluletan espresatzea lortu da63. Ikerketa horren egileek erakutsi dutenez, 
proteina berde fluoreszentearen (eGFP) genea daraman DNA molekula 10 kDa-ko 
peptido komertzial batean kondentsatzean, zelulen transfekzioa egitea lortzen da 
eta eGFP proteinaren espresioa modu egokian ematen da. Emaitza horien arabera, 
garunean transfektatutako zelulak perizitoak dira, eta bektore ez-birala/DNA 
konplexuak garraio peribaskularra jasan du63. Gainera, duela gutxiko beste ikerketa 
batean lortu dute kortexa eta hipokanpoa transfekatzea sudur-barneko eman-bidea 
eta kitosanoz eta PEG molekulaz osatutako mizelak bektore ez-biral gisa erabilita69. 
Nahiz eta ematen duen partikula horiek HHEren behin behineko ezegonkortzearen 
bidez lortu zutela garunera iristea, sudur-barneko bidea egokia izan daitekeela 
iradokitzen dute emaitza horiek. Hala ere, oraindik dosia eta dosi-erregimena hobetu 
behar dira transgene espresio maila egokiak lortu ahal izateko63.  
3.2.2. Gene-garraioa begietara 
Begia oso ehun erakargarria gene-terapian bere ezaugarri bereziak direla eta. Izan 
ere, ehunaren tamaina txikia da, eman beharreko kontzentrazio terapeutikoa baxua 
da eta begian ematen diren farmakoak ez dira odol zirkulazio sistemikora 
igarotzen70. Gainera, begiak nolabaiteko immunitate-pribilegioa dauka eta, beraz, 
molekula arrotzak begian injektatzean gerta daitezkeen erantzun immune eta 
hanturazkoak ez dira horren larriak izaten70.  
Orokorrean, begirako gene-garraio sistemek espektro zabala hartzen dute, 
begietako tanta arruntetatik hasita bio- eta nanoteknologian oinarritutako farmako 
aurreratuetaraino, adibidez, sistema muko-adesiboak, polimeroak, liposomak eta 
begiko inplanteak. Teknologia horiek gehienak begiaren aurreko atalerako terapia 
oftalmikoei zuzenduta daude eta ezin dira begiaren atzealdean aplikatu71.  
Eman-bide sistemikoa erabiltzen denean farmakoak begira garraiatzeko, horiek hesi 
odol-okularra zeharkatu behar dute begiaren atzeko aldera helduko badira. Hesi 
odol-okularra ere elkarren artean estu lotutako zelula epitelialez osatuta dago, eta 
hori zeharkatzea erronka handia da bektore ez-biralak eta DNA molekulak osatutako 
partikulentzat. Bi estrategia nagusi erabiltzen dira hesi hori gainditzeko: 100 nm 




bektore ez-biralak erabiltzea, hesiko errezeptore espezifikoak ezagutzen 
dituztenak73. Beraz, eman-bide sistemikoaren bidez bolumen handiak eta 
errepikatuak administratu badaitezke ere, horien begiko bioerabilgarritasuna hesi 
odol-okularrak baldintzatuko du.  
Metodo inbaditzaileak ere badira begiaren atzeko aldera iristeko, adibidez, bitreo-
barneko injekzioa, konjuntiba-azpikoa eta erretina-azpikoa. Horiek hesi odol-
okularra gainditzea eta erretinako geruza ezberdinetara iristea ahalbidetzen dute. 
Hala ere, metodo horiek oso inbaditzaileak dira eta administrazio errepikatuek 
begiko kalte larriak eragingo lituzkete, esate baterako, erretina-askatzea, odol-
jarioak eta azpi- edo aurre-erretinako fibrosia71. Beraz, beharrezkoak dira begiaren 
atzeko aldera bektore ez-biralak garraiatzeko eman-bide ez-inbaditzaile eraginkor 
eta seguruak. Horri dagokionez, begiko tantak lirateke aukerarik onena eta albo-
efektu gutxien sortuko lituzketenak71.  
Dena dela, begiko atzeko aldera iristeko eman-bide ez-inbaditzaile eraginkorrak 
lortzea erronka handia da, bektore ez-biralek begi barneko hesi ugari zeharkatu 
beharko lituzketelako haraino iristeko. Lehenik eta behin, malko-hesia gainditu behar 
dute, lipidoz estalitako geruza urtsua eta konjuntibako zein korneako geruzak 
estaltzen dituen muzinaz inguratua71. Malko-hesiak formulazioen 
bioerabilgarritasuna mugatzen du, malko jarioa eta drainatze lakrimala eta 
nasolakrimala direla eta85. Hesi hori gainditzeko estrategien artean, bektore ez-
biralei biskositatea areagotzeko elementuak –zelulosa edo poloxamer gelak, kasu-
71 eta polimero muko-adesiboak –kitosanoa edota azido hialuronikoaren eratorriak, 
esate baterako-74 gehitzea ditugu. Bigarren, ehun okularreko hesiak daude, besteak 
beste, kornea, konjuntiba, esklera eta koroidea, eta egitura horiek zelula epitelialen 
arteko lotura estuak, proteoglikano matrizeak eta kolageno sareak dituzte, bektoreak 
igarotzea oztopatzen dutenak71. Azkenik, humore beirakara biogel urtsua da eta 
bertako kolageno, azido hialuroniko eta proteoglikanoek erretinako zelulen 
transfekzioa oztopatzen dute71. Hesi horiek gainditzeko ere, aurretik aipatutako 
estrategiak erabiltzen dira, alegia, tamaina egokiko partikulak eta polimero muko-
adesiboak71.  
Begiko gene-terapian, arrakastarik handiena begiko aurreko aldearen transfekzioan 
lortu da, batez ere bektore biralak eta eman-bide inbaditzaileak erabilita. Duela gutxi, 
erretinako zelulak bektore ez-biralen bidez transfektatzea lortu da, baina kasu 
horretan ere partikula magnetikoak era inbaditzailean eman ziren, bitreo-barneko 




garrantzitsuagoak egin dira farmakoen garraioan begiaren atzealdera eman-bide ez-
inbaditzaileen bidez iristeko. Adibidez, ikerketa berri batean erakutsi dutenez, 
emultsio lipidikoak erabilita posible da farmako hidrofobikoak ehun okularraren 
atzeko aldera bideratzea eman-bide ez-inbaditzaileen bitartez76. Lan horretan, 
ikertzaileek emultsio lipidikoen gainazalean aldaketa batzuk egin zituzten kitosanoa 
eta poloxamer 407 bezalako polimero funtzionalak gehituz. Egileen esanetan, 
poloxamer 407 elementuak emultsioaren atxikipen denbora luzatu zuen begiaren 
gainazalean bere propietate adesiboei esker. Gainera, beste ikerketa batean ere 
lortu dute farmakoak begiaren atzeko aldera bideratzea eman-bide ez-inbaditzaileak 
erabilita, A5 anexina daramaten liposomen bitartez77. Kasu horretan, egileen 
arabera, A5 anexinak partikulen endozitosia sustatzen du, gene-transferentziaren 
eraginkortasuna handituz. Azkenik, beste ikerlan batek erakutsi du mikrofluidika 
bidez eratutako liposoma txikiak era topikoan eman daitezkeela ehun okularrean eta 
erretinako geruzetara iritsi daitekeela horrela78. Pentsatzekoa da farmako-garraioan 
egindako ekarpenak eta aurrerapenak baliagarriak izatea gene-garraiorako bektore 
ez-biral egokien diseinuan ere aurrera egiteko.  
3.2.3. Gene-garraioa biriketara 
Biriketako gene-terapia egokia izan daiteke arnas-bideetako hainbat gaixotasunen 
tratamendurako, besteak beste, fibrosi kistikoa, asma, enfisema edota biriketako 
minbizia79. Gaixotasunaren arabera, biriketako zelula-mota ezberdinak izan daitezke 
jomuga gene-terapian, adibidez, albeolo zelulak, epitelialak, makrofagoak, 
endotelialak edota biriketako zelula-amak79. Bestalde, material genetikoa biriketako 
toki egokian askatu beharko da iritsi nahi den zelula-motaren arabera. Zoritxarrez, 
biriketako hainbat eremutara iristea oso zaila da ehun horren arkitektura, mukiaren 
presentzia, garbiketa mekanismoak eta sistema immunearen aktibazioa direla 
medio79. Inhalazioa, sudur-barneko instilazioa eta trakea-barneko intubazioa dira 
teknika erabilienak bektoreak biriketara bideratzeko. Erabilera klinikorako, 
inhalazioz har daitezkeen aerosoletan formulatutako bektore ez-biral/DNA partikulak 
izango lirateke egokienak, izan ere, horrek abantaila ugari eskainiko lituzke, besteak 
beste, eman-bide ez-inbaditzailea erabiltzea, arnas bideetan zuzenean eta lokalki 
kontzentrazio altuak lortzea eta albo-efektuak gutxitzea.  
Arnas-bideko jariakinak, alegia, mukia eta albeolo-fluidoa, dira bektore ez-biralek 
biriketan gainditu beharreko hesi garrantzitsuenak. Arnas-bideko mukia defentsa 
mekanismo eraginkorra da eta batez ere muzinazko hiru dimentsioko sareek 




diren proteina nagusiak albumina, proteasak, anti-proteasak, antigorputzak, lisozima 
eta laktoferrina dira, eta fibrosi kistikoak jotako edo infekzioak dituzten gaixoen 
mukiak DNA eta aktina kantitate handiak ere izaten ditu bere konposizioan79. 
Albeolo-fluidoa fosfolipidoz eta beste proteina batzuez osatutako geruza surfaktante 
fina eta jarraia da eta albeolo-epitelioa biltzen du79.  
Arnas-bideko mukiak hesi gisa jardun dezake era ezberdinetan biriketako gene-
terapian. Mukiko biopolimero sareak konplexuen difusioa oztopatzen du, bai modu 
esterikoan eta baita konplexuekin elkartuz ere79. Gainera, karga negatiboa duten eta 
elkarri lotuta ez dauden mukiko makromolekulak eta antigorputzak ere bektore ez-
biralek eta DNA molekulek osatutako konplexuekin lotu daitezke. Interakzio horiek 
ondorio ezberdinak izan ditzakete: (i) konplexuak mukian harrapatuta geratzea, (ii) 
partikulen agregazioa gainazaleko kargen neutralizazioa dela eta, (iii) DNA 
konplexutik denbora baino lehen askatzea edota (iv) partikulak era ez-eraginkorrean 
lotzea zeluletan, karga positiboak partzialki neutralizatuta geratu direlako79. Azkenik, 
mukia etengabe garbitzen da garraio mukoziliarraren bitartez. Beraz, bektore ez-
biralek mukia kanporatu baino lehen zeharkatu behar dute zeluletara garaiz iristeko. 
Partikulen difusio koefizienteak, mukiaren lodierak eta muki-garbiketa abiadurak 
baldintzatuko dute partikulak zeluletaraino iritsi ahal izatea79.  
Albeolo-fluidoari dagokionez, geruza surfaktante honek transfekzio eraginkortasuna 
kaltetzen du79. Uste da lipoplexoak degradatu egin daitezkeela geruza 
surfaktantearen eraginez eta horrek DNA babesgabe uzten duela nukleasen 
aurrean80. Bektore polimerikoei dagokienez, bektore lipidikoak baino sendoagoak 
lirateke albeolo-fluidoaren aurrean eta ez lieke kalte handirik eragingo79.  
Estrategia ezberdinak garatu dira biriketako zelulaz kanpoko hesiak gainditzeko. 
Bektore ez-biralek eta DNA molekulek osatutako partikulen tamaina faktore 
garrantzitsua da, baina saiakera gehienak mukian zehar partikulen bizkortasuna 
areagotzera zuzenduta daude.  
Metodo ezberdinak erabil daitezke partikulek mukia azkarrago zeharkatu dezaten. 
Errazena bektoreei agente mukolitikoak gehitzea da, horrela, inguruko mukia 
hidrolizatzeko eta bizkorrago mugitzeko gaitasuna izan dezaten79. Baita, erakutsi da 
N-azetil zisteina eta eratorriek mukiaren biskositatea eta elastikotasuna gutxitzen 
dituztela, muzinen arteko disulfuro zubiak hausten dituztelako81. Etorkizunera 
begira, ikerketa-lerro gehienak saiatzen ari dira nanopartikulak elementu 




Bestalde, partikulen eta fluido biologikoetako proteinen arteko interakzioak 
ekiditeko, estrategia nagusia da partikulak biologikoki inerteak diren polimero 
biobateragarriekin estaltzea79. Horrek, interakzioak gutxitzeaz gain, makrofagoen 
garbiketa ere ekiditen du. Adibidez, polietileno glikola edo PEG aukera egokia izan 
liteke bektore ez-biralen egonkortasun fisiko-kimikoa eta gene-transferentzia 
gaitasuna hobetzeko79.  
Erronka ugari gainditu behar dira oraindik biriketako gene-terapia klinikara iristeko 
eta, beharbada, garrantzitsuena bektoreak mukian zehar azkar eta era 
eraginkorrean igarotzea lortzea litzateke82. Hala ere, aurrerapen handiak egin dira 
alor horretan eta aerosol bidezko formulazioak ikertzen ari dira dagoeneko biriketako 
minbiziari aurre egiteko, besteak beste. Gainera, inhalazio bidezko gene-terapiak 
lehen emaitza onak lortu ditu fibrosi kistikoarekin egindako entseguetan, eraginkorra 
eta segurua dela erakutsiz83.  
Beraz, aurreko guztia kontuan hartuta, bektore ez-biralek eta DNA molekulek 
osatutako partikulak gai izan behar dira zelulaz kanpoko hesiak gainditzeko jomuga 
diren zelula eta ehunetara iritsi ahal izateko (6. irudia). Injekzio sistemikoa da eman-
bide erabiliena, baina zenbait oztopo ditu gene-terapiaren eraginkortasuna 
baldintzatzen dutenak. Eman-bide lokalak eraginkorrak dira zelulaz kanpoko hesi 
gehienak gainditzeko, baina askotan inbaditzaileak dira eta ezin dira praktika 
klinikoan erabili. Gaur egun, ikerketa lerro askok eman-bide ez-inbaditzaileetan jarri 
dute arreta eta, horien bitartez, zelulaz kanpoko hesiak gainditzeko estrategiak 
garatzen ari dira. Izan ere, ehun zehatzetara bideratzean, hesi gehigarriak agertzen 
dira, esate baterako, HHE garunean edota hesi odol-okularra begian. Beraz, 
administrazio lokal eta ez-inbaditzaileak ehun horietan zailtasun gehiago dakartza 
eta kontuan hartu behar dira bektore ez-biral eraginkorrak diseinatu ahal izateko. 
Espero da etorkizuneko gene-garraio sistema ez-biralak eman-bide lokal eta ez-








6. irudia. Zelulaz kanpoko hesi orokorrak (eman-bide sistemikoa) eta ehun-espezifikoak 
(garuna, begia, birikak) gene-terapia ez-biralean.  
4. GENE-TERAPIA EZ-BIRALAREN ERRONKAK ETA ETORKIZUNERAKO 
PERSPEKTIBAK 
Bektore ez-biralak gene-terapiarako estrategia itxaropentsuak dira. Nahiz eta 
oraindik ere erabilera klinikotik urrun egon, aurrerapauso handiak egin dira azken 
urteetan bai bektoreen diseinuari dagokionean eta baita eman-bide ez-inbaditzaileei 
dagokienean ere. Transgenearen espresioa modu egokian eman dadin, hainbat 
baldintza bete behar dira. Horien artean, garrantzitsuenak erantzun immunerik ez 
eragitea, DNA degradazio entzimatikotik babestea, zelulaz kanpoko zein barneko 
hesiak gainditzea eta DNA molekulak nukleoraino helaraztea dira84. Zelulaz kanpoko 
zein barruko hesien ezagutza molekularrak oztopo horiek gainditzen lagunduko 
duten estrategiak garatzea ahalbidetu du eta metodo gehienak formulazioaren 
diseinuaren aldaketetan edota eman-bide lokalen erabileran oinarritzen dira. Azken 
honi dagokionez, ematen du eman-bide ez-inbaditzaileen bitartez ere iritsi 
daitekeela jomuga diren ehun eta zeluletara, eta etorkizuneko gene-terapiarako 
bektore ez-biralen garapena norabide horretan doa.  
Gene-terapia ez-biralaren oztopo nagusia, behin eta berriro errepikatu dugun 
bezala, transfekzio-eraginkortasun baxua da. Metodologia ezberdinak erabili dira 
horri aurre egiteko, batik bat, bektoreei gorputzeko hesiak gainditzeko ahalmena 
emanez. Halere, beste estrategia batzuk ere garrantzizkoak dira transfekzio 
eraginkortasuna handitu ahal izateko: bektoreen bideratzea edo targeting-a eta 
transgenearen espresio iraunkorra lortzea. Biak ala biak ere nahitaezkoak dira 
bektore ez-biralak erabilera klinikora iristeko, espezifikotasuna eta epe luzerako 




garatzeko, baina oraindik ikerketa sakonagoak falta dira zentzu horretan. Bestalde, 
erabilera klinikora iristeko beste faktore batzuk ere kontuan hartu behar dira, besteak 
beste, bektoreen toxikotasuna eta produkzioari zein produktuen erregulazioari 
lotutako auziak. Atal honetan, bektoreak ehun espezifikoetara bideratzeko eta 
transgene espresio iraunkorra lortzeko gaur egun existitzen diren estrategia 
nagusiak aipatuko ditugu. Halaber, bektoreen toxikotasunari, produkzioari eta 
erregulazioari dagozkien datuak ere berrikusiko ditugu.  
4.1. Ehun espezifikoetara bideratzea edo targeting-a 
Bektore ez-biralak ehun zehatzetara bideratzea bektorean bertan edota horiek 
garraiatzen duten DNA molekuletan aldaketak eginez lortu daiteke. Estrategia 
erabiliena bektore ez-biralari estekatzaile espezifikoak txertatzea da, jomuga diren 
organoetako zeluletako errezeptoreak ezagutuko dituztenak. Lehenago aipatu 
bezala, metodo horren eraginkortasuna frogatua izan da hainbat ikerketatan. 
Gainera, minbiziaren aurkako gene-terapian, minbizi-zelulen ezaugarri fisiologiko 
bereziak baliatzen dira bektoreak modu espezifikoan zelula horietara helarazteko85.  
Bestalde, DNA molekulan ere aldaketak egin daitezke transfekzio espezifikoagoa 
lortze aldera. Estrategia horri “transcriptional targeting” edo bideratze 
transkripzionala deritzo, eta soilik jomuga den zelula-populazioak dituen transkripzio 
faktoreek ezagutuko dituzten DNA sekuentzien erabileran oinarritzen da85. Metodo 
honetan DNA molekula ehun guztietara iritsi arren, soilik tratatu nahi den zelula-
populazioan gertatuko litzateke transgenearen edo gene terapeutikoaren 
espresioa84. Metodo hori arrakastaz gauzatzeko ezinbestekoa da zelula-
populazioen transkripzio faktoreen arteko ezberdintasunak ondo ezagutzea84.  
Gene-garraio sistemetan, partikulak ehun zehatzetara bideratzea oso onuragarria 
da. Besteak beste, produktu terapeutikoaren bioerabilgarritasuna igo egiten da, 
tratamendurik behar ez duten ehunetan ez da transgenearen espresiorik ematen 
eta, beraz, albo-efektuak gutxitu egiten dira eta eman beharreko dosiak ere 
baxuagoak dira. Aspektu guzti horiek eraginkortasun terapeutikoa areagotzen dute 
eta tratamenduaren kostua jaisten laguntzen dute86.  
4.2. Gene-espresioaren iraupena 
Epe luzeko transgenearen espresioa lortzea erronka zaila da gene-terapia ez-
biralarentzat eta klinikarako jauzia mugatzen duen faktore garrantzitsua da. 




jaitsiera, esate baterako, nukleasek eragindako degradazioak, errekonbinazioaren 
ondoriozko galerak, konpartimentu ez-nuklearretara lekualdatzeak edota DNA 
arrotza zeluletan isilarazteak85. Gainera, zatitzen diren zeluletan transfektatutako 
zelula-kopurua belaunaldi bakoitzean murriztu egiten da, zelulak ugaldu arren, 
plasmidoak ez direlako bikoizten.  
Transgenearen espresioa denboran luzatzeko estrategia gehienek DNA molekulen 
aldaketetan jarri dute arreta guztia, eta ez bektorearen hobekuntzan. Metodo 
horietako batzuk integrasak erabiltzen dituzte material genetiko arrotza zeluletako 
genometan txertatzeko eta, horrela, transgenea belaunaldiz belaunaldi 
transmititzeko zelula-populazioetan85. Halabaina, metodo hori ezingo litzateke 
klinikan erabili arrisku handiak dakartzalako, horien artean larriena, mutagenesia 
sortzea transgenea modu aleatorioan zelulen genoman txertatzean.  
Beste estrategia bat modu autonomoan bikoizten diren DNA plasmidoak erabiltzea 
da. Horiek ez dute zelulen genoman txertatzeko beharrik bikoizteko eta hurrengo 
zelula-belaunaldietara igarotzeko eta, beraz, mutagenesi arriskua ekiditen dute85. 
Gainera, mota horretako plasmidoek transfekzio maila altuak lortu ohi dituzte. 
Metodo horretan, plasmidoa bikoizteko beharrezkoak diren transkripzio ko-faktoreak 
gehitzen dira DNA sekuentzian, zelularen transkripzio makinariarekiko 
independenteago eginez. Horrez gain, hainbat birus sekuentzia ere gehitu daitezke 
are modu autonomoagoan bikoiztu dadin DNA molekula, baina horrek, besteak 
beste, immune-sistemaren aktibazioa eragin dezake85. Beste aukera bat da 
sekuentzia biralen ordez ugaztunen genomako S/MAR sekuentziak txertatzea. 
Sekuentzia horiek ere gai dira plasmidoen bikoizketa episomala abiarazteko 
zeluletako transkripzio makinaria DNA molekuletara hurbilduz73. Modu episomalean 
bikoizten diren plasmidoak bereziki garrantzitsuak dira minbiziaren aurkako gene-
terapian, bertan ezinbestekoa baita produktu terapeutikoa zelula-belaunaldi batetik 
hurrengora igarotzea85. Transgenearen espresio iraunkorra lortzeko beste 
estrategia batzuk zeluletan DNA molekula arrotzen isilaraztea saihesten saiatzen 
dira, hori delako transgeneen espresioa oztopatzen duen faktore nagusietako bat85.  
Gainera, aldaketa gehiago ere egin daitezke DNA molekuletan transgenearen 
espresioaren indarra edota espezifikotasuna handitzeko. Horretarako, 
transgenearen zein transkripzioaren aktibatzaile gisa jarduten duen genearen 
espresioa abiarazten dituen promotorea erabili behar da. Transkripzioaren 
aktibatzaile hori gai da promotorearen gune zehatzetan lotu eta promotorearen 




eta berriro abian jartzeko85. Atzeraelikatze positiboko mekanismo horiek egokiak 
izan daitezke oso espezifikoak baina espresio ahulekoak diren elementu 
erregulatzaileak kontrolatzeko85.  
4.3. Toxikotasuna, produkzioa eta erregulazioa 
Gene-transferentziaren eraginkortasuna handitzeaz gain, gene-terapiarako 
produktuak merkatura iristeko beste aspektu batzuk ere kontuan hartu behar dira. 
Horien artean, bektoreen toxikotasuna zehaztasun handiz ikertu beharreko atala da, 
eta baita bektoreen produkzioari eta erregulazioari dagozkien auziak ere. Produktua 
kantitate industrialetan ekoiztu ahal izatea eta epe luzera biltegiratu ahal izatea 
ezinbesteko baldintzak dira merkatura iritsi nahi bada19. Bektore ez-biralen kasuan, 
orokorrean onartuta dago horien abantaila nagusietako bat eskala industrialen 
ekoizteko erraztasuna dela. Halere, gaur egun hori gero eta zailagoa bihurtzen ari 
da, bektoreen konplexutasun-maila handituz doan heinean.  
Toxikotasunari dagokionez, nanopartikulen tamainak, kargak, gainazaleko 
funtzionalizazioak, morfologiak eta arkitekturak segurtasun profilean eragina izan 
dezakete. Uste da bektore ez-biralek modu ezberdinetan sortu dezaketela 
toxikotasuna, adibidez, zelula-mintzaren ezegonkortzearen, estres oxidatzailearen 
edota hantura-erantzunen bidez, baita gene-espresioan aldaketa globalak eraginez 
ere85. Metatzeko joera duten biomaterialek errazago sortzen dituzte hantura-
erantzunak eta partikulen degradazioan sortutako molekulak ere toxikoak izan 
daitezke. Hala ere, oraindik ez dago argi zer prozesuk hartzen duten parte bektore 
ez-biralen metabolizazioan eta ikerketa sakonagoak beharrezkoak dira auzi horiek 
argitzeko19.  
Amaitzeko, esan dezakegu bektore ez-biral bakar eta unibertsalaren kontzeptua 
gaur egun baztertuta dagoela eta gero eta onartuago dagoela komunitate 
zientifikoan bektore ez-biralak anitzak eta aplikazio bakoitzerako espezifikoki 
egokituak izan behar direla1. Dena den, badira bektore ez-biral guztiek bete behar 
dituzten gutxieneko baldintza baztuk gene-transferentzia modu seguru eta 
eraginkorrean gauzatu ahal izateko. Laburbilduz, hiru faktore nagusi hartu behar dira 
kontuan bektore ez-biraletan oinarritutako gene-garraiorako sistemak diseinatzean: 
(i) formulazioaren osagaiak, bai bektoreari eta baita DNA molekulari dagokionean –
partikula gai izan behar da DNA babesteko, zelulaz kanpoko zein barneko hesiak 
gainditzeko eta, behin nukleoan, DNA modu autonomoan bikoiztea komeni da epe 
luzeko transgene espresioa lortzeko-, (ii) ekoizpenari dagokionez, maila 




lotutako neurriak, hau da, formulazioak ez-toxikoak, ez-immunogenikoak eta 
biltegiratze egonkorrekoak izan behar dira. Nahiz eta oraindik aplikazio klinikotik 
urrun egon, bektore ez-biralak birusak baino seguruagoak dira. Formulazio eta 
estrategia ezberdinak ikertzen ari dira gene-transferentziaren eraginkortasuna 
igotzeko, hala nola, bektore ez-biralei zelulaz kanpoko zein barneko hesiak 
gainditzeko gaitasuna emanez, ehun espezifikoetara bideratuz eta gene-espresio 
iraunkorragoak bilatuz. Gainera, formulazio horitako asko eman-bide ez-
inbaditzaileetatik emateko diseinatzen dira, esate baterako, sudur-barnetik garunera 
iristeko, administrazio topiko okularra erretinara iristeko edota inhalazioz hartzeko 
aerosolak biriketara iristeko. Azkenik, modulu funtzional berriak txertatzeak, bai 
bektorean eta baita DNA molekuletan ere, espezifikotasuna eta gene terapeutikoen 
iraunkortasuna bermatu ahal izango dute40. Beraz, zantzu horien arabera, 
etorkizuneko gene-terapia sistemak aplikazio bakoitzera egokitutako eta eman-bide 
ez-inbaditzaileetatik hartu ahal izango diren bektore ez-biraletan oinarrituta egongo 
dira, gene terapeutikoak ehun zehatzetara modu seguru eta eraginkorrean 
helarazteko.  
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Nanotechnology-based non-viral vectors have emerged as promising alternatives to 
viruses to carry genetic material into target cells due to their ability to overcome many 
limitations of viral vectors. Although very efficient, viruses present low carrying 
capacity, expensive and complex production and safety issues related to 
immunogenic responses and even oncogenesis when randomly integrated in the 
host genome. In this regard, non-viral vectors present lower immunogenicity, higher 
nucleic acid packing capacity and ease of fabrication compared to their viral 
counterparts. In addition, continuous advances in the fields of material science and 
nano-engineering as well as the diversity of available nanosized material allows the 
design of multifunctional vectors specifically tailored for different applications. 
Although most conventional gene therapy strategies based on gene addition use 
viral vectors, nowadays non-viral vectors are predominant in new investigations 
based on gene editing due to their favorable characteristics. To date, a wide variety 
of nanosized non-viral gene delivery vectors have been developed, including cationic 
lipids, polymers and magnetic nanoparticles. These molecules can be 
nanoengineered to pass over several extracellular and intracellular barriers and to 
transport therapeutic genes into specific organs or cell types, including cells in the 
central nervous system (CNS), one of the most challenging organs for both viral and 
non-viral gene delivery systems.  
Among the wide plethora of non-viral vectors, recently emerged niosomes are 
biocompatible, synthetic, non-ionic surfactant vesicles with a closed bilayer 
structure. Niosomes have been demonstrated to be effective for retinal gene 
transfer, an important target organ in many gene therapy strategies due to the 
existence of several well characterized monogenic retinal disorders. Niosome 
formulations are based on three principal components -cationic lipids, helper lipids, 
and non-ionic surfactants. The global chemical properties of these components 
influence on the physicochemical characteristics of niosomes, such as size, surface 
charge and morphology, which in turn determine their ability to enter the cells, follow 
a particular endocytic pathway, deliver the DNA cargo into the nucleus and, 
therefore, their transfection efficiency. Although the roles of cationic lipids and helper 
lipids in the transfection process and efficiency mediated by niosomes have been 
thoroughly studied in rat retina and brain, there is still an important margin for 
transfection efficiency improvement. Thus, the influence of the non-ionic surfactant 
component also needs to be well characterized in order to optimize the design of 
niosome formulations for retinal gene delivery and be able to achieve persistent and 




Until recently, most efforts have focused on improving nucleic acid delivery 
strategies either by modifying non-viral vectors or by employing physical methods 
such as electroporation. However, successful gene transfer not only depends on the 
carrier, but the properties of the vectored genetic material are also important. With 
respect to the enhancement of transfection efficiency it can also be achieved by 
modifying the composition and conformation of the genetic material in order to 
improve its bioavailability, biocompatibility, durability and safety. In this regard, 
minimized expression units devoid of bacterial backbone and that only contain the 
gene of interest and regulatory sequences such as minicircle (MC) DNA vectors 
emerge as an attractive alternative to conventional plasmid DNA vectors. In fact, MC 
DNA vectors offer several advantages over their larger parental plasmid DNA 
vectors, including enhanced transfection efficiency with sustained transgene 
expression as well as improved immunocompatibility and safety profiles. High levels 
of transgene expression mediated by MC DNA vectors have been demonstrated in 
a variety of organ systems in vivo including the liver, heart and skeletal muscle, but 
MC DNA technology has not yet been assessed for retinal gene delivery in complex 
with niosome formulations.  
Finally, in addition to the optimization of the carrier and the genetic material, a new 
trend in non-viral gene therapy is to explore novel combined strategies between 
delivery systems and tissue-engineered scaffolds or matrix design. In fact, these 
combined approaches may offer relevant advantages such as enhanced stability and 
reduced toxicity. Moreover, complementing gene transfer with matrix design would 
allow for an effective, targeted and local DNA delivery, which would promote the 
applicability of gene therapy in many therapeutic fields such as tissue regeneration. 
Hyaluronic acid (HA) hydrogels have been widely studied for their biocompatibility 
as well as their ability to incorporate a wide variety of molecules, including nucleic 
acids. In addition, polymeric non-viral vectors based poly(ethylene imine) (PEI) have 
been encapsulated into HA hydrogels with successful local transgene expression, 
but the biomedical application of PEI derivatives is often restricted due to 
immunogenicity and cytotoxicity issues. In this regard, niosomes offer several 
advantages due to their high compatibility with biological systems and low toxicity, 
but the combination between niosome gene delivery systems and HA hydrogel 
scaffolds has not yet been explored.  
In view of these considerations, the main objective of the present work is to evaluate 
key factors that determine the transfection process and efficiency of non-viral 




vectors, the composition and conformation of the genetic material and the 
combination of delivery systems with other technologies such as matrix design. To 
accomplish that purpose, four specific objectives are considered:  
1. To evaluate and compare the transfection efficiency of different commercial 
non-viral vectors based on cationic lipids, polymers and magnetic 
nanoparticles carrying a therapeutic plasmid containing the vascular 
endothelial growth factor gene into central nervous system cells.  
 
2. To understand the role of the non-ionic tensioactive component of niosome 
formulations in the transfection process and efficiency in retinal cells in vitro 
and in vivo.  
 
3. To analyze the interaction between DNA and niosome formulations and to 
study the influence of the genetic material of nioplexes in retinal gene 
delivery in vitro and in vivo comparing plasmid DNA vectors of different sizes 
and minicircle DNA vectors.  
 
4. To explore new combinations between niosome-based gene delivery 
systems and hyaluronic acid hydrogel scaffolds for 3D transfection and local 










Nanoteknologian oinarritutako bektore ez-biralak birusen alternatiba itxaropentsu 
gisa sortu dira material genetikoa zeluletara garraiatzeko, bektore biralek dituzten 
desabantaila ugari gainditu ditzaketelako. Nahiz eta oso eraginkorrak diren, birusak 
ez dira gai DNA molekula handiak garraiatzeko, euren ekoizpena oso konplexua eta 
garestia da eta, gainera, segurtasun arazoak dituzte, hantura erantzuna eta 
mutagenesia eragin ditzaketelako, besteak beste. Zentzu horretan, bektore ez-
biralek ez dute erantzun immunerik sortzen, garraiatu ditzaketen DNA molekulen 
tamainan ez daukate mugarik, eta birusekin alderatuta, ekoizpen errazagoa eta 
merkeagoa daukate. Gainera, materialen zientzian zein nano-ingeniaritzan egiten 
diren etengabeko aurrerapenek, eskuragarri dugun biomaterialen aukera 
zabalarekin batera, aplikazio bakoitzera espezifikoki egokitutako bektore ez-biralak 
diseinatzea ahalbidetzen du. Nahiz eta entsegu klinikoetara iritsi diren gene-terapian 
oinarritutako ikerketa gehienetan birusak erabiltzen diren, gene-edizioan 
oinarritutako entsegu berrietan ohikoagoa da jada bektore ez-biralak erabiltzea 
beren ezaugarri onuragarriei esker. Gaur egun, nano-eskalako bektore ez-biral 
ezberdinak garatu dira eta material ezberdinez osatuta egon daitezke, ohikoenak 
lipido kationikoak, polimero kationikoak edota partikula  magnetikoak direlarik. 
Molekula horiei nano-ingeniaritza aplikatuta, zelulaz kanpoko zein barneko hesiak 
gainditzeko gaitasuna eman dakieke, horrela, material genetikoa zelulen 
nukloetaraino garraiatzeko gai izan daitezen.  
Bektore ez-biralen aukera zabalaren artean, niosoma izenekoak lipido kationikoz eta 
surfaktante ez-ionikoz osatutako besikula biobateragarriak dira. Niosomak gai dira 
erretinako zelulak modu eraginkorrean transfektatzeko eta ehun horri eragiten 
gaixotasun monogenikoen tratamendurako potentziala erakutsi dute. Niosoma 
formulazioek hiru osagai nagusi dituzte: lipido kationikoa, lipido laguntzailea eta 
tentsoaktibo ez-ionikoa. Osagai horien ezaugarri kimikoek niosomen ezaugarri 
fisiko-kimikoak –tamaina, karga, morfologia, etab.- baldintzatzen dituzte eta horiek, 
aldi berean, zeluletan barneratzeko eta DNA molekulak nukleoraino garraiatzeko 
gaitasuna baldintzatzen dute, gene-transferentziaren eraginkortasunean eraginez. 
Niosoma formulazioetan lipido kationikoek eta lipido laguntzaileek jokatzen dituzten 
rolak sakonki aztertu dira arratoi erretinan eta garunean eginiko transfekzio 
entseguetan. Hala ere, oraindik aukera handiak daude formulazioak are gehiago 
optimizatzeko. Beraz, tentsoaktibo ez-ionikoak transfekzio prozesuan eta 
eraginkortasunean jokatzen duen papera aztertzea ezinbestekoa da niosoma 




Dena dela, gene-transferentziaren arrakasta ez dago soilik bektorearen ezaugarrien 
menpe. Izan ere, bektoreek garraiatzen dituzten DNA molekulen ezaugarriak ere 
oso garrantzitsuak dira transfekzio prozesuan eta orain arte estrategia gehienek 
bektoreetan arreta jarri badute ere, gaur egun funtsezkoa da material genetikoaren 
propietateak ere ikertzea. Material genetikoaren osaerak eta konformazioak eragina 
dauka bere bioerabilgarritasunean, biobateragarritasunean, segurtasunean eta 
transgene-espresioaren iraupenean. Zentzu horretan, plasmido konbentzionalen 
alternatiba gisa sortu dira minicircle (MC) izeneko DNA egitura berriak, alegia, 
espresio unitate minimoak, soilik transgenea eta sekuentzia erregulatzaileak 
dituztenak eta bakterioetatik eratorritako sekuentziak ezabatu zaizkienak. Izan ere, 
MC egiturek abantaila ugari aurkezten dituzte plasmido konbentzionalekin 
alderatuta, esate baterako, transfekzio-maila altuagoak, denboran gehiago irauten 
duten transgene-espresioak, immunobateragarritasun hobea eta segurtasun profil 
egokiagoak. DNA egitura berri horiekin transfekzio-maila altuak lortu dira hainbat 
ehunetan, besteak beste, gibelean, ehun kardiakoan eta muskuluetan, baina MC 
teknologiaren eraginkortasuna ez da oraindik ikertu erretinako zeluletan eta bektore 
ez-biral gisa niosomak erabilita.  
Azkenik, bektorearen eta material genetikoaren hobekuntzez gain, gaur egun joera 
berriak sortu dira, adibidez, gene-garraio sistemak ehun-ingeniaritzarekin uztartzea. 
Izan ere, konbinaketa horiek zenbait onura ekar ditzakete, esate baterako, sistemen 
egonkortasuna hobetzea eta toxikotasuna jaistea. Gainera, gene-garraioa jomuga 
diren ehun edota zeluletan modu lokal, espezifiko eta eraginkorrean egitea 
ahalbidetuko luke eta horrek, aldi berean, klinikarako jauzia erraztuko luke. Azido 
hialuronikoz (HA) osatutako hidrogelak asko ikertu dira dituzten propietate 
biobateragarriak direla eta, baita molekula ezberdinak barneratzeko gai direlako ere. 
Gainera, polimeroz osatutako bektore ez-biralak eta HAz osatutako hidrogelak 
konbinatu dira gene-garraioa bideratzeko eta emaitza onak lortu dira. Dena dela, 
entsegu horiek ez dute aplikazio klinikorik izan, erabilitako polimeroek zelula-
toxikotasuna eta erantzun immuneak eragiten zituztelako. Zentzu horretan, 
interesgarria litzateke polimero horien ordez niosomak erabiltzea, sistema 
biologikoekin bateragarritasun handia dutelako eta ez dutelako ia erantzun 
immunerik sortzen. Gainera, oraindik ez da ikertu HA hidrogelen eta niosomen 
arteko elkarrekintzak zer ondorio izango lituzkeen gene-garraio lokala egiteko.  
Aurreko guztia kontuan hartuta, tesi honen helburu nagusia da bektore ez-biralen 
bidezko transfekzio prozesua eta eraginkortasuna baldintzatzen dituzten faktore 




kontuan hartuz eta bektore ez-biralen eta hidrogelen teknologiaren arteko uztartzea 
bilatuz. Helburu hori betetzeko, honako helburu espezifiko hauek mahaigaineratu 
ditugu:  
1. Lipido kationikoz, polimero kationikoz eta partikula magnetikoz osatutako 
bektore ez-biral komertzialen transfekzio eraginkortasuna ebaluatzea eta 
konparaketa egitea, material genetiko gisa endotelio baskularraren 
hazkuntza faktorea daraman DNA plasmidoa eta entseguetarako nerbio 
sistema zentraleko zelulak erabilita.  
 
2. Niosoma formulazioen osagai diren tentsoaktibo ez-ionikoek transfekzio 
eraginkortasunean eta prozesuan jokatzen duten papera ulertzea, 
horretarako proteina berde fluoreszentearen genea daraman DNA 
plasmidoa erabilita erretinako zeluletan, in vitro zein in vivo.  
 
3. Material genetikoaren eta bektore ez-biralen arteko elkarrekintza aztertzea 
eta material genetikoaren ezaugarriek erretinako zelulen transfekzio 
eraginkortasunean jokatzen duten rola aztertzea, plasmido konbentzionalen 
eta minicircle egituren arteko konparaketa eginez eta bektore ez-biral gisa 
niosomak erabilita.  
 
4. Niosoma bektore ez-biralen eta HA hidrogelen teknologiak uztartzea gene-
garraio lokala bideratzeko, transfekzio eraginkortasunaren ebaluazioa hiru 









Los vectores no-virales basados en la nanotecnología han surgido en los últimos 
años como alternativa a los virus para transportar genes terapéuticos a células 
diana, debido a su gran capacidad para superar varias limitaciones de los vectores 
virales. Aunque son capaces de llevar a cabo la transfección de manera eficiente, 
los virus presentan una baja capacidad de carga, una producción compleja y 
costosa y, además, conllevan problemas de seguridad relacionados con respuestas 
inmunes en el huésped y mutagénesis insercional. En este sentido, los vectores no-
virales son menos inmunogénicos, tienen alta capacidad de carga y presentan una 
fabricación sencilla en comparación con los virus. Además, los continuos avances 
en los campos de la ciencia de materiales y la nano-ingeniería han propiciado el 
diseño de vectores no-virales multifuncionales específicos para cada aplicación. A 
pesar de que hoy en día la mayoría de estrategias de terapia génica convencional 
utilizan vectores virales, en las nuevas estrategias de terapia génica de edición o 
corrección genómica, el uso de sistemas no-virales predomina frente a los virales. 
Hasta la fecha, se han desarrollado vectores no-virales compuestos de diversos 
materiales, entre los que destacan los lípidos catiónicos, los polímeros o las 
nanopartículas magnéticas. Estas moléculas pueden ser diseñadas de modo que 
puedan atravesar barreras extra- e intracelulares para poder llevar a cabo la 
transfección en células u órganos diana, incluyendo las células del sistema nervioso 
central (NSC) que a día de hoy siguen siendo de las más difíciles de transfectar 
tanto para los vectores no-virales como los virales.  
Entre la amplia variedad de vectores no-virales, los niosomas son vesículas de 
surfactante no-iónico sintéticas y biocompatibles, y forman una bicapa lipídica 
cerrada. Se ha demostrado que los niosomas son eficaces en la transferencia 
génica en retina, un órgano diana relevante en varias estrategias de terapia génica 
debido a la existencia de un gran número de enfermedades monógenicas bien 
caracterizadas que afectan a este tejido. Las formulaciones de niosomas se basan 
en tres componentes: el lípido catiónico, el lípido helper y el tensioactivo no-iónico. 
Las características químicas y moleculares de esos compuestos determinan en gran 
medida las propiedades físico-químicas de las formulaciones, como el tamaño de 
las partículas, la morfología o la carga superficial. A su vez, esas características 
determinan la habilidad de los niosomas de ser captados por las células diana, de 
seguir una particular ruta de tráfico intracelular y de liberar el ADN terapéutico en el 
compartimento intracelular correcto. En última instancia, todo ello condiciona la 
eficiencia de transfección de las formulaciones de niosomas. El rol del lípido 
catiónico y del lípido helper en el proceso y eficiencia de transfección en cerebro y 




mejora en la eficiencia de transfección de los niosomas. Es por ello que es 
importante determinar también el papel que desempeña el tensioactivo no-iónico en 
el proceso de transfección de los niosomas, ya que esto permitiría diseñar 
formulaciones más eficientes y mejor adaptadas a cada aplicación terapéutica.  
El éxito de la transferencia génica no solo depende del vector, sino que las 
características del material genético transportado son también relevantes. Hasta 
hace poco, la mayoría de estrategias para incrementar la eficiencia de transfección 
se basaban en las modificaciones del vector no-viral o en el uso de métodos físicos 
como la electroporación. Sin embargo, se puede mejorar la eficiencia de 
transfección a través de la modificación de la composición y la conformación del 
material genético con el fin de incrementar su biodisponibilidad, biocompatibilidad, 
duración de la expresión génica y seguridad. En este sentido, las unidades 
minimizadas de expresión génica como la tecnología minicircle (MC) constituyen 
una alternativa atractiva a los plásmidos convencionales. Las estructuras MC son 
secuencias de ADN a las que se les han eliminado los elementos bacterianos como 
los orígenes de replicación o los genes de resistencia a antibióticos, y que 
únicamente contienen el gen de interés y las secuencias reguladoras. Estas 
estructuras ofrecen ventajas importantes frente a los plásmidos convencionales, ya 
que consiguen mayor eficiencia de transfección y expresión génica prolongada, así 
como una mejora en el perfil de seguridad y mayor biocompatibilidad. El incremento 
en la expresión génica a través del uso de la tecnología MC se ha demostrado en 
varios órganos in vivo, incluyendo el hígado, el corazón o el músculo esquelético. 
Sin embargo, aún no se ha estudiado su eficiencia en terapia génica ocular y 
utilizando los niosomas para su vehiculización.  
Por último, además de la optimización del vector y del material genético, una nueva 
tendencia en terapia génica no-viral es buscar sinergias complementarias con otras 
tecnologías como, por ejemplo, la ingeniería tisular. Estas estrategias combinadas 
pueden ofrecer ciertas ventajas, entre otras, proporcionan una mayor estabilidad al 
sistema no-viral de liberación génica y producen menos toxicidad. Además, la 
combinación de transferencia génica con el diseño de matrices tridimensionales 
ofrecería la posibilidad de liberar el ADN de manera local, prolongada y efectiva de 
manera específica en los tejidos diana, lo cual facilitaría su aplicabilidad en 
estrategias terapéuticas dirigidas al tratamiento del cáncer o la regeneración tisular. 
Los hidrogeles de ácido hialurónico (HA) son de gran interés en ese campo debido 
a su bicompatibilidad y a su capacidad para incorporar diferentes moléculas, 




derivados de la poli(etileno imina) o PEI han sido incorporados en hidrogeles de HA 
de manera exitosa, consiguiendo altas eficiencias de transfección. Sin embargo, la 
aplicabilidad clínica de los derivados de PEI está limitada por su elevada 
citotoxicidad. En este sentido, los niosomas pueden constituir una alternativa 
interesante, ya que ofrecen ventajas importantes como una elevada compatibilidad 
con sistemas biológicos y baja toxicidad, aunque su combinación los hidrogeles de 
HA no se ha estudiado aún para terapia génica no-viral.  
Tomando en cuenta las consideraciones anteriores, el principal objetivo de esta 
tesis doctoral es evaluar los factores clave que determinan la eficiencia de 
transfección de los sistemas no-virales de liberación génica, incluyendo la 
composición y las propiedades físico-químicas de los vectores no-virales, la 
composición y conformación del material genético y la combinación de la liberación 
génica no-viral con otras tecnologías como el diseño de matrices tridimensionales. 
Para ello, planteamos cuatro objetivos específicos:  
1. Evaluar y comparar la eficiencia de transfección de distintos vectores no-
virales basados en lípidos catiónicos, polímeros y nanopartículas 
magnéticas que vehiculizan un plásmido terapéutico que codifica el factor 
de crecimiento del endotelio vascular a células del sistema nervioso central.  
 
2. Comprender el rol del tensioactivo no-iónico de las formulaciones de 
niosomas en el proceso y la eficiencia de transfección en retina tanto in vitro 
como in vivo.  
 
3. Analizar la interacción entre el ADN y las formulaciones de niosomas y 
evaluar la influencia de la composición del material genético en la eficiencia 
de transfección en retina in vitro e in vivo.  
 
4. Explorar nuevas combinaciones entre sistemas de liberación génica no-viral 
basadas en niosomas e hidrogeles de ácido hialurónico para transfectar 
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Nanoteknologian oinarritutako bektore ez-biralek itxaropen handia piztu dute gene 
terapeutikoak nerbio sistema zentralera (NSZ) modu seguru eta kontrolatuan garraiatzeko. 
Endotelio baskularraren hazkuntza faktorea (VEGF) hautagai terapeutiko egokia izan liteke 
NSZri eragiten dioten gaitzen tratamendurako, angiogenesian eta neuro-babesean jokatzen 
dituen rol garrantzitsuak kontuan hartuta. Lan honetan, hiru bektore ez-biral ezberdin prestatu 
genituen, partikula magnetikoak, lipido kationikoak edo polimero kationikoak erabiliz. 
Formulazio horiei phVEGF165aIRESGFP plasmidoa gehitu genien, VEGF proteina –zelulaz 
kanpokoa- eta GFP proteina –zelula barnekoa- kodifikatzen dituena. Nanopartikulak eta 
dagozkien nanoplexoak –magnetoplexoak, lipoplexoak eta poliplexoak- fisiko-kimikoki 
karakterizatu ziren, tamainari, zeta potentzialari, polidispertsio indizeari, morfologiari eta DNA 
eusteko, babesteko eta askatzeko gaitasunari dagokionez. Nanoplexoen transfekzio 
eraginkortasuna neurtzeko, hainbat parametro aztertu ziren: GFP proteina espresatzen zuen 
zelulen ehunekoa, batezbesteko fluoreszentzia intentsitatea (MFI) eta VEGF proteinaren 
ekoizpena (ng/ml-tan) HEK293, C6 eta neurona kultibo primarioetako zeluletan. 
Magnetoplexoekin lortu ziren transfekzio-mailarik altuenak, lipoplexoak atzetik zituztela C6 
zeluletan eta, aldiz, poliplexoak atzetik zituztela neurona kultibo primarioetan. Lipoplexoak 
izan ziren HEK293 zelulen transfekzioan eraginkorrenak, atzetik magnetoplexoak zituztela. 
VEGF proteinaren aktibitate biologikoa HUVEC zeluletan neurtu zen, horiengan eragiten zuen 
ugaltze-efektuaren arabera. Orohar, emaitza horiek ikuspegi berriak zabaltzen dituzte VEGF 
faktore terapeutikoa bektore ez-biralak erabilita garunera bideratzeko 
. 
Los vectores no-virales basados en la nanotecnología poseen gran potencial para 
vehiculizar genes terapéuticos al sistema nervioso central (SNC) de manera segura y 
controlada. El factor de crecimiento del endotelio vascular (VEGF) es un prometedor gen 
terapéutico candidato para alteraciones del SNC debido a su rol específico en agiogénesis 
cerebral y neuroprotección. En este trabajo, elaboramos tres vectores no-virales distintos 
basados en nanopartículas magnéticas, lipídicas y poliméricas unidos al plásmido 
phVEGF165aIRESGFP, que codifica la proteína VEGF –extracelular- y la proteína verde 
fluorescente (GFP) –intracelular-. Las nanopartículas y los correspondientes nanoplexos –
magnetoplexos, lipoplexos y poliplexos- fueron caracterizados según su tamaño de partícula, 
potencial zeta, índice de polidispersión (PDI), morfología y habilidad para condensar, proteger 
y liberar el ADN. Las eficiencias de transfección de los nanoplexos se determinaron a través 
de tres parámetros: el porcentaje de células que expresa GFP, la intensidad de fluorescencia 
media (MFI) y la producción de VEFG (ng/ml) en células HEK293, C6 y cultivo primario de 
neuronas. Los magnetoplexos presentaron la mayor eficiencia de transfección en C6, 
seguidos de los lipoplexos, y en células de cultivo primario de neurona, seguidos de los 
poliplexos. Los lipoplexos fueron los más eficaces en células HEK293, seguidos por los 
magnetoplexos. La actividad biológica de la proteína VEGF se confirmó por su efecto 
proliferativo en células HUVEC. En general, estos resultados proporcionan nuevo 
conocimiento para la vehiculización del gen VEGF a células del SNC mediante vectores no-
virales. 
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Abstract  
Nanotechnology based non-viral vectors hold great promise to deliver therapeutic 
genes into the central nervous system (CNS) in a safe and controlled way. Vascular 
endothelial growth factor (VEGF) is a potential therapeutic gene candidate for CNS 
disorders due to its specific roles in brain angiogenesis and neuroprotection. In this 
work, we elaborated three different non-viral vectors based on magnetic, cationic 
lipid and polymeric nanoparticles complexed to the phVEGF165aIRESGFP plasmid, 
which codifies the VEGF protein –extracellular- and the green fluorescent protein 
(GFP) –intracellular-. Nanoparticles and their corresponding nanoplexes –
magnetoplexes, lipoplexes and polyplexes- were characterized in terms of size, zeta 
potential, PDI, morphology and ability to bind, release and protect DNA. Transfection 
efficiencies of nanoplexes were measured in terms of percentage of GFP expressing 
cells, mean fluorescent intensity (MFI) and VEGF (ng/ml) production in HEK293, C6 
and primary neuronal culture cells. Magnetoplexes showed the highest transfection 
efficiencies in C6, followed by lipoplexes, and in primary neuronal culture cells, 
followed by polyplexes. Lipoplexes were the most efficient in HEK293 cells, followed 
by magnetoplexes. The biological activity of VEGF was confirmed by its proliferative 
effect in HUVEC cells. Overall, these results provide new insights for VEGF gene 
delivery into CNS cells using non-viral vectors. 
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Nanotechnology-based gene delivery has gained interest in recent years. 
Continuous advances in the fields of material science and nano-engineering - along 
with a better understanding of the multiple possibilities for genome editing - have 
motivated the synthesis, characterization, and functionalization of biocompatible 
nanomaterials for gene delivery purposes (Keles et al., 2016). In addition, the 
diversity of available nanosized material allows the design of multifunctional vectors 
specifically tailored for different applications (Srikanth and Kessler, 2012; Pezzoli et 
al., 2012).   
Non-viral vectors are characterized by their potential to overcome many of the 
limitations of viral vectors, especially those related to safety and vector production. 
Although viral vector based gene delivery platforms are still predominant in clinical 
trials due to their higher transfection efficiencies (Yin et al., 2014), non-viral vectors 
have emerged as a promising alternative because of their lower immunogenicity, 
higher nucleic acid packing capacity and ease of fabrication (Jin et al., 2014). 
Additionally, non-viral formulations can be produced on a large scale with high 
reproducibility and acceptable costs, and they are relatively stable to storage 
(Pezzoli et al., 2012). To date, a wide variety of nanosized non-viral gene delivery 
vectors have been developed, including cationic lipids (Yin et al., 2014; Ojeda et al., 
2015; Jubeli et al., 2016), polymers (Pack et al., 2005; Agirre et al., 2015a) and 
magnetic nanoparticles (Soto-Sanchez et al., 2015). These molecules can be 
nanoengineered to transport therapeutic genes into specific organs or cell types and 
to pass over several extracellular and intracellular barriers.  
Central nervous system (CNS) cells are one of the most challenging to transfect for 
both viral and non-viral gene delivery systems, due to the numerous protective 
barriers enclosing the CNS and its complex cellular organization. Therefore, the 
discovery of an effective approach to afford the wide range of neurodegenerative 
disorders remains a huge dare, where nanotechnologies are expected to play an 
important role. Most neurodegenerative disorders, although presenting diverse 
clinical manifestations, share some common traits such as vast neuronal loss, 
synaptic failures and aggregates of misfolded proteins (Spuch et al., 2012). 
Additionally, accumulating evidence suggests that aging-related vascular alterations 
of the brain make it vulnerable to cognitive dysfunction, leading to 
neurodegeneration and dementia (Kalaria, 2010). In Alzheimer’s disease (AD) – the 
most prevalent adult-onset dementia –reductions in the cerebral blood flow and 
dysfunction of the blood-brain barrier (BBB) have been related to amyloid-beta (Aβ) 




accumulation in brain (Zlokovic, 2011). In this regard, vascular endothelial growth 
factor (VEGF) is a physiological regulator mainly involved in brain angiogenesis and 
BBB integrity, and it also plays specific roles in neuroprotection (Carmeliet and Ruiz 
de Almodovar, 2013a). Recently, it has been shown that administration of VEGF 
encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanospheres to animal models 
of AD increases vascularisation and reduces neuronal loss and Aβ deposits in brain 
(Herran et al., 2013a). Also, it has been reported that, in a mouse model of AD, 
administration of encapsulated VEGF-secreting cells enhances proliferation of 
neuronal progenitor cells in the hippocampus (Antequera et al., 2012). 
Based on these considerations, we present a nanoformulation based approach for 
VEGF gene delivery into CNS cells. For that purpose, three different 
nanoformulations –ultrapure oligochitosan (UOC), Lipofectamine cationic lipid and 
NeuroMag magnetic nanoparticles– were complexed to the phVEGF165aIRESGFP 
plasmid, which codifies for the human VEGF165a protein and for the green 
fluorescent protein (GFP).  Nanoformulations and resulting nanoplexes –
nanoformulations complexed to DNA– were physicochemically characterized in 
terms of size, superficial charge, polydispersity index (PDI), morphology and 
capacity to condense, release and protect DNA. In vitro transfection studies were 
carried out in C6 glial cells and in primary neuronal culture cells as CNS cell models, 
and in HEK293 cells, as a general transfection model. Transfection efficiencies were 
evaluated in terms of percentage of GFP expressing cells, mean fluorescent intensity 
(MFI) and VEGF protein expression. Cell viability upon exposition to nanoplexes was 
also evaluated. Bioactivity of the VEGF protein secreted by transfected primary 
neuronal culture cells was assessed by a proliferation assay in human umbilical vein 
endothelial cells (HUVEC).  
2. MATERIALS AND METHODS 
2.1. Materials 
Ultrapure Oligochitosan (UOC) O15 (MWs of 5.7, DDA ≥97% and endotoxin levels 
≤0.05 EU/mg) was purchased from NovaMatrix/FMC (Sandvika, Norway). Human 
embryonic kidney 293 (HEK293) cells, Rattus Norvegicus glial cells (C6), human 
umbilical vein endothelial cells (HUVEC), Eagles’s Minimal Essential Medium with 
Earle’s BSS and 2mM 1-glutamine (EMEM, ATCC 30-2003) and Kaighn's 
Modification of Ham's F-12 Medium (F-12K, ATCC 30-2004) were obtained from the 
American Type Culture Collection (ATCC, Teddington, UK). Endothelial Cell Growth 
Medium (EGM-2 Bullekit, CC-3162) was purchased from Lonza Group Ltd. (Basel, 




Switzerland). Opti-MEM I reduced medium, Antibiotic/Antimicotic solution, 
Penicillin/Streptomycin solution and Lipofectamine 2000 were purchased from 
Invitrogen (Life Technologies, Paisley, UK). The phVEGF165aIRESEGFP plasmid 
was purchased from PlasmidFactory (Bielefeld, Germany). The Human VEGF 
ELISA Development Kit and the recombinant hVEGF165 protein were provided by 
Peprotech EC Ltd. (London, UK). Phosphate buffer saline (PBS), fetal bovine serum 
(FBS), horse serum (HS), Cell Counting Kit-8 (CCK-8), DNase I, sodium dodecyl 
sulfate (SDS) and propidium iodide were acquired from Sigma-Aldrich (Madrid, 
Spain). Gel electrophoresis materials were obtained from Bio-Rad (Madrid, Spain). 
NeuroMag Transfection Reagent was acquired from OZ Biosciences (Marseille, 
France). TECAN infiniteM200 spectrophotometer was acquired from TECAN Ibérica 
Instrumentación S.L., Madrid, Spain. 
2.2. Preparation of nanoplexes 
Lipoplexes were prepared at a Lipofectamine/DNA ratio of 2:1 (w/w) by mixing gently 
Lipofectamine 2000 solution (1mg/mL) and the plasmid solution (1 mg/mL) at 
appropriate volumes. Magnetoplexes were prepared at a NeuroMag/DNA ratio of 2:1 
(w/w) by mixing gently NeuroMag solution (1mg/mL) and plasmid solution (1 mg/mL) 
at appropriate volumes. Polyplexes based on UOC were prepared by the self-
assembly method. Briefly, a determined value of plasmid solution (1 mg/ml) was 
added under vortex agitation to a stock solution of UOC (2 mg/ml) to obtain a final 
UOC/DNA ratio of 13:1 (w/w). In all cases, the formulations were incubated for 25 
min at room temperature to allow the correct formation of the complexes. 
2.3. Nanoformulation characterization: size, zeta potential, PDI, morphology  
The hydrodynamic diameter and the zeta potential of nanoparticles and their 
corresponding nanoplexes were determined by Dynamic Light Scattering (DLS) and 
by Lasser Doppler Velocimetry (LDV), respectively, using a Zetasizer Nano ZS 
(Malvern Instrument, UK) as previously described (Ojeda et al., 2015). Briefly, 50 µl 
of the formulations were resuspended into 950 µl of 0.1 mM NaCl solution. All 
measurements were carried out in triplicate. The particle size reported as 
hydrodynamic diameter was obtained by cumulative analysis. The Smoluchowski 
approximation was used to support the calculation of the zeta potential from the 
electrophoretic mobility.  
The morphologies of cationic lipid and magnetic nanoparticles were characterized 
by transmission electron microscopy (TEM) and Cryo-TEM was used to characterize 




the morphology of UOC polymeric nanoparticles as previously described (Ojeda et 
al., 2015). 
2.4. Agarose gel electrophoresis assay 
For DNA release assay, 12 μl of a 7% SDS solution were added to the samples. For 
DNA protection assay, 3 µl of DNase I enzyme and 12 μl of a 7% SDS solution were 
added to the samples. For DNA binding assay, no SDS neither DNase I enzyme 
were added to the samples. The amount of DNA per well was 100 ng in all cases. 
Samples with DNase I were incubated at 37°C for 30 min. 4 µl of loading buffer were 
added to all samples before running the gel. Agarose gel (0.8% w/w) was immersed 
in a Tris-acetate-EDTA buffer and exposed for 30 min to 120 V. GelRed was used 
to stain the DNA bands and images were obtained with a ChemiDocTM MP Imaging 
System and analyzed by Image LabTM Software (BioRad, USA). Naked DNA was 
used as control at each condition.  
2.5. Cell culture and in vitro transfection 
HEK293 and C6 cells were maintained in complete medium. For HEK293 cells, 
Eagles’s Minimal Essential medium with Earle’s BSS and 2mM 1-glutamine (EMEM, 
ATCC 30-2003) supplemented with 10% FBS and Antibiotic/Antimycotic solution 
was used. For C6 cells, Kaighn's Modification of Ham's F-12 Medium (F-12K, ATCC 
30-2004) supplemented with 2.5% FBS, 15% HS and Penicillin/Streptomycin 
solution was used. Both cell cultures were kept at 37°C under a humidified 
atmosphere containing 5% CO2. Before transfection, HEK293 and C6 cells were 
seeded in 24-well plates at an initial density of 1.2 x 105 cells per well with 250 µl of 
complete medium and without the corresponding antibiotic solutions. All cells were 
incubated overnight to achieve 70-90% of confluence at the time of transfection.  
Experimental procedures for in vitro primary neuronal cultures were carried out 
conformed to the directive 2010/63/EU of the European Parliament and of the 
Council, and the RD 53/2013 Spanish regulation on the protection of animals use for 
scientific purposes and was approved by the Miguel Hernandez University 
Committee for Animal use in Laboratory. Dissociated cultures from cortical tissue 
were obtained from E17-E18 rat embryos (Sprague Dawley) and preserved in 
DMEM (32430-027, GIBCO®, Thermo Fisher Scientific, MA, USA) containing 10% 
FBS, during extraction. Subsequently cells were transferred to FBS-free DMEM and 
trypsin was added and incubated at 37°C for chemical dissociation. The cell density 
was determined using a hemocytometer and seeded at an initial density of 




approximately 3x105 cells per well in a 12-well plates on glass coverslips in 
Neurobasal (12348-017, GIBCO®) / FBS (S181B-500, Biowest, Nuaillé, France) 
medium supplemented with B27 (17504-044, GIBCO®), Glutamax (35050-038, 
GIBCO®) and Penicillin-Streptomycin (15-40-122, GIBCO®) and maintained in an 
incubator at 37 °C and 5% CO2 
For transfection, antibiotic free complete mediums were replaced with serum-free 
Opti-MEM medium, and cells were exposed to nanoplexes resuspended in Opti-
MEM at their corresponding nanoparticle/DNA ratios (w/w). The amount of plasmid 
per well was 1.25 µg, each formulation was tested in triplicate. Additionally, in the 
case of polyplexes, Opti-MEM containing 270 mM mannitol was used to obtain a 
final isotonic medium and pH was adjusted to 7.0 using HCl 0.1 M (Agirre et al., 
2015b). After 3h of incubation at 37°C, nanoplexes were removed from wells and 
250 µl of complete medium were added. HEK293, C6 and primary neuronal culture 
cells were allowed to grow 48 h at 37 °C under a humidified atmosphere containing 
5% CO2 for analysis of cell viability and transfection efficiencies.  
2.6. Flow cytometry assay 
Flow cytometry analysis was conducted using a FACSCalibur system flow cytometer 
(Becton Dickinson Bioscience, San Jose, USA). The supernatant mediums of the 
plated cell samples were removed and kept at -80°C for later analysis of VEGF 
production. Plated cells were washed twice with PBS and detached from the 
microplate with 200 μl of trypsin/EDTA. 400 μl of complete growth mediums were 
added and cells were transferred to specific flow cytometer tubes. Cell viability was 
evaluated using 5 μL of propidium iodide (dilution 1:10) reagent in each sample, and 
dead cells were excluded from the GFP expression analysis. The fluorescent signal 
corresponding to dead cells was measured at 650 nm (FL3). Transfection efficiency 
was expressed as the percentage of live GFP positive cells at 525 nm (FL1). MFI 
data were obtained from live positive cells at 525 nm (FL1). Control samples (non-
transfected cells) were displayed on a forward scatter (FSC) versus side scatter 
(SSC) dot plot to establish a collection gate and exclude cells debris. For each 
sample 10,000 events were collected. Each formulation was analyzed in triplicate.  
2.7. Immunocytochemistry assay 
For analysis of GFP expression, primary neuronal cultures seeded onto coated 
coverslips were fixed with 4% paraformaldehyde (in 0.1M PBS) for 20 min at room 
temperature and incubated in blocking buffer (10% normal donkey serum, PBS, 




0.5% Triton X-100) for 1 hour. Then incubated with primary antibody chicken anti-
GFP (Invitrogen, 1:100, diluted in PBS, 0.5% Triton X-100) overnight at room 
temperature. Subsequently, cells were washed in PBS and incubated in secondary 
antibody Alexa Fluor 555-conjugated goat anti-chicken IgG (Invitrogen, 1:100, 
diluted in PBS, 0.5% Triton X-100) for 1 hour. Hoechst 33342 was used to label all 
the nuclei. The cells were finally washed in PBS and the coverslips mounted in 
fluoromount Vectashield (Vector Laboratories) for viewing by laser-confocal 
microscopy (Leica TCS SPE Microsystems GmbH, Germany). Alexa Fluor 555 was 
pseudocolored in green to visualize GFP expression. Immunocytochemistry controls 
were performed by omission of antibodies (data not shown). 
2.8. VEGF production assay 
VEGF concentration (ng/ml) of transfected cell supernatants was analyzed using 
Human VEGF Standard ABTS ELISA Development Kit according to the 
manufacturer’s instructions at 48 h post-transfection. Each measurement was 
performed in triplicate. The absorbance was measured at 405 nm with wavelength 
correction set at 650 nm using the Tecan i-Control 1.7 software and the TECAN 
spectrophotometer.  
2.9. VEGF bioactivity assay 
HUVEC cells were maintained in Endothelial Cell Growth Medium (EGM-2 Bullekit, 
CC-3162) supplemented with a supplement kit, and cultured at 37°C in humidified 
air with 5% CO2. HUVEC cells between passages 1 and 2 were seeded into 96-well 
poly-L-lysine-coated culture plates at a density of 5 x 103 cells/well. After 24 h, the 
culture medium was removed, and 100 µl of fresh medium (without the supplement 
kit) were added and supplemented with 200 µl of transfected primary neuronal 
culture cells supernatant, containing VEGF secreted by transfected cells. HUVEC 
cells treated with secreted VEGF and non-treated control HUVEC cells were 
incubated for 72 h at 37°C in humidified air with 5% CO2. Cell proliferation was 
measured using a Cell Counting Kit-8 (CCK-8) according to the manufacturer’s 
instructions. 
2.10. Statistical analysis 
Statistical analyses were carried out using IBM SPSS Statistics software. Normal 
distribution of samples was assessed by the Kolmogorov–Smirnov test, and the 
homogeneity of the variance by the Levene test. Student's t-test was used to 




compare differences between groups. In all cases, P values < 0.05 were regarded 
as significant. Data were presented as mean ± SD, unless stated otherwise.  
3. RESULTS  
3.1. Nanoformulation characterization: size, zeta potential, PDI, morphology 
Physicochemical characterization of nanoparticles and nanoplexes is represented in 
Fig. 1a-c. The mean particle size of magnetic nanoparticles was 182.37 ± 0.29 nm 
and, when complexed to phVEGF165aIRESGFP plasmid DNA, mean size of 
magnetoplexes increased to 384.97 ± 21.57 nm. Mean particle size of cationic lipid 
based nanoformulations was 643.27 ± 125.26 nm, and lipoplexes exhibited mean 
particle size of 476.17 ± 98.65 nm. UOC based polymeric nanoformulations showed 
a mean particle size of 337.77 ± 68.35 nm, which increased to 546.3 ± 11.35 nm 
when they formed polyplexes (Fig. 1a, bars). Size distributions of nanoformulations 
ranged from narrow –magnetic nanoparticles with a PDI of 0.15- to large –cationic 
lipid nanoparticles with a PDI of 0.635- (Fig.1b, table). Zeta potential values of 
magnetic, cationic lipid and polymeric nanoparticles were 20.77 ± 2.00 mV, 18.57 ± 
5.19 mV and 4.49 ± 0.71 mV, respectively. Upon complexing to DNA, mean zeta 
potential values of magnetoplexes, lipoplexes and polyplexes decreased to -16 ± 
2.01 mV, -22.2 ± 1.51 mV and -2.05 ± 0.39, respectively (Fig. 1a, lines). When 
observed magnetic nanoparticles under transmission electron microscopy (TEM) 
and polymeric nanoparticles under cryogenic transmission electron microscopy 
(Cryo-TEM), both appeared spherical. Cationic lipid nanoparticles observed under 
TEM showed an irregular morphology (Fig. 1c).  





Figure 1. Physicochemical characterization of nanoparticles and nanoplexes. (a) Size (white 
and grey bars, which correspond to nanoparticles and nanoplexes, respectively) and zeta 
potential values (dotted and continuous lines, which correspond to nanoparticles and 
nanoplexes, respectively). Each value represents the mean ±SD, n=3. (b) PDI values. Each 
value represents the mean ±SD, n=3. (c) TEM images of cationic lipid (c1) and magnetic (c2) 
nanoparticles and Cryo-TEM images of polymeric (c3) nanoparticles. Original magnification 
140,000x for cationic lipid nanoparticles, 175,000x for magnetic nanoparticles and 25,000x for 
polymeric nanoparticles. (d) Binding, protection, and SDS-induced release of DNA from 
nanoparticles visualized by agarose electrophoresis. Lanes 1–3 correspond to free DNA; 
lanes 4–6, lipoplexes; lanes 7–9, magnetoplexes; lanes 10–12, polyplexes. Free DNA and 
nanoplexes were treated with SDS (lanes 2, 5, 8 and 11) and DNase I + SDS (lanes 3, 6, 9, 
and 12). OC: open circular form, SC: supercoiled form.   




3.2. phVEGF165aIRESGFP plasmid binding, releasing and protecting assay of 
nanoformulations 
Figure 1d shows the capacity of the three different nanoformulations to bind, release 
and protect the phVEGF165aIRESGFP plasmid against enzymatic degradation, 
evaluated by agarose gel electrophoresis. DNA was retained without migration in 
lanes 4, 7 and 10 (contrary to lane 1, where control naked DNA completely migrated). 
DNA partially migrated when SDS was added to the nanoplexes as indicated by the 
intense SC signal observed on lanes 5, 8 and 11 (similar to the control, on lane 2). 
Intensive SC bands observed in lanes 6, 9 and 12 indicate that DNA was not 
degraded by DNase I enzyme and was partially released after the addition of SDS.  
DNA signals observed in wells 6, 9 and 12 indicate that DNA was protected from 
enzymatic degradation and did not migrate upon SDS addition.  
3.3. Cell viability and transfection efficiency assays 
Figure 2 represents cell viability and transfection efficiency –in terms of GFP 
expression, MFI and VEGF expression- of nanoplexes in HEK293 and C6 cell lines. 
The percentages of live HEK293 and C6 cells were above 90% upon transfection 
with magnetoplexes and lipoplexes; this value was lower –around 85% – when using 
polpyplexes for transfection (Fig. 2a, dots). Regarding percentages of GFP 
expressing cells (Fig. 2a) and MFI (Fig. 2b), values in HEK293 cells (black bars) 
were higher than in C6 cells (light grey bars). GFP expressing HEK293 cell 
percentages were 28.43 ± 0.49% with magnetoplexes, 45.47 ± 0.07% with lipoplexes 
and 8.54 ± 0.55% with polyplexes. In C6 cells, percentages of GFP expressing cells 
were 6.87 ± 0.35% with magnetoplexes, 5.51 ± 0.38% with lipoplexes and 0.68 ± 
0.02% with polyplexes (Fig. 2a, bars). MFI values in HEK293 and C6 cells 
transfected with magnetoplexes, lipoplexes and polyplexes, respectively, were 
208.33 ± 5.51 and 93.23 ± 2.27; 260.00 ± 5.00 and 79.89 ± 2.25; and 157 ± 1.73 and 
61.77 ± 2.63 (Fig. 2b).  
VEGF expression levels (ng/ml) in transfected HEK293 and C6 cell lines are 
represented in Fig. 2c. After transfection with magnetoplexes, VEGF production in 
HEK293 cells was 16.32 ± 1.03 ng/ml and in C6 cells 23.11 ± 0.48 ng/ml. With 
lipoplexes, we obtained 20.15 ± 1.63 ng/ml VEGF in HEK293 cells and 20.21 ± 0.48 
ng/ml VEGF in C6 cells. When transfected with polyplexes, HEK293 produced 4.9 ± 
0.63 ng/ml VEGF and C6 cells produced 9.60 ± 0.24 ng/ml VEGF (Fig. 2c). Control 
non-transfected HEK293 cells produced 1.16 ± 0.13 ng/ml VEGF and C6 cells 7.19 
± 0.09 ng/ml VEGF.  




Statistical differences were found in all cases when comparing GFP expression 
levels, MFI values and VEGF expression levels of cells transfected with nanoplexes 
and non-transfected control cells.  
Figure 2. Cell viability and transfection 
efficiencies in HEK293 and C6 cells. (a) 
Cell viability (HEK293 cells, dark grey 
dots; C6 cells, light grey dots) 48h after 
transfection with magnetoplexes, 
lipoplexes and polyplexes. Control cells 
were not treated with nanoplexes. 
Percentages of GFP expressing cells 
(HEK293 cells, dark grey bars; C6 cells, 
light grey bars) 48 h after transfection 
with nanoplexes. Control cells were not 
treated with nanoplexes. Each value 
represents the mean ±SD, n=3. (b) 
Mean Fluorescent Intensity (MFI) values 
48h post-transfection with nanoplexes 
(HEK293 cells, dark grey bars; C6 cells, 
light grey bars). Each value represents 
the mean ±SD, n=3. (c) VEGF 
production (ng/ml) values 48h post-
transfection with nanoplexes (HEK293 
cells, dark grey bars; C6 cells, light grey 
bars). Control cells were not treated with 
nanoplexes. Each value represents the 
mean ±SD, n=3. Statistical significance: *p<0.05, **p<0.01, ***p<0.001 compared to control 
HEK293 cells; #p<0.05, ##p<0.01, ###p<0.001 compared to control C6 cells.  
3.4.Correlation between GFP expression, MFI and VEGF production values  
Figure 3a shows the correlation between the levels of VEGF production and the 
percentage of GFP expressing cells in HEK293 cells transfected with the three 
different nanoplexes. Lipoplexes (white dot) exhibited the highest values in both 
variables, followed by magnetoplexes (grey dot) and then polyplexes (black dot). At 
higher percentage of GFP positive cells, higher VEGF production levels were 
obtained (R2 = 0.9456). As shown in Figure 3b, a similar correlation pattern was 
found between VEGF production and MFI values (R2 = 0.9226). FL1 histograms in 




Fig. 3c illustrate HEK293 cells distribution 48h after transfection with the nanoplexes. 
FL1 positive cells represent cells expressing the GFP protein.  
 
 
Figure 3. Correlations between the transfection 
efficiency parameters in HEK293 cells. (a) 
Correlation between VEGF production (ng/ml) and 
percentage of GFP expressing live cells in HEK293 
cells 48h post-transfection with magnetoplexes (grey 
dot), lipoplexes (white dot) and polyplexes (black 
dot). Each value represents the mean ±SD, n=3. α 
represents the angle of the slope. (b) Correlation 
between VEGF production (ng/ml) and MFI values in 
HEK293 cells 48h post-transfection with nanoplexes. 
Each value represents the mean ±SD, n=3. α 
represents the angle of the slope. (c) GFP 
histograms of HEK293 cells 48h post-transfection 
with nanoplexes. M1 represents the threshold for 
GFP positive signal.  
 
 
Figure 4a shows the correlation the levels of VEGF production and the percentage 
of GFP expressing cells in C6 cells transfected with the three different nanoplexes. 
In this case, magnetoplexes (grey dot) exhibited the highest values in both variables, 
followed by lipoplexes (white dot) and then polyplexes (black dot). Again, a robust 
correlation was found between the production levels of VEGF and the percentage of 
GFP expressing cells (R2 = 0.999). Figure 4b illustrates an analogous correlation 
pattern between VEGF production and MFI values (R2 = 0.9474) (Fig. 4b). FL1 
histograms in Fig. 4c depict C6 cells distribution 48h after transfection with the 









Figure 4. Correlations between the transfection 
efficiency parameters in C6 cells. (a) Correlation 
between VEGF production (ng/ml) and 
percentage of GFP expressing live cells in C6 
cells 48h post-transfection with magnetoplexes 
(grey dot), lipoplexes (white dot) and polyplexes 
(black dot). Each value represents the mean 
±SD, n=3. α represents the angle of the slope. 
(b) Correlation between VEGF production 
(ng/ml) and MFI values in C6 cells 48h post-
transfection with nanoplexes. Each value 
represents the mean ±SD, n=3. α represents the 
angle of the slope. (c) GFP histograms of C6 
cells 48h post-transfection with nanoplexes. M1 
represents the threshold for GFP positive signal.   
 
3.5. Cell viability and VEGF production in primary neuronal culture cells 
Figure 5a-c shows cell viability and transfection efficiency of nanoplexes in primary 
neuronal culture cells. Upon transfection with nanoplexes, percentages of cell 
viability in primary neuronal culture were around 100% in all cases (Fig. 5a). In the 
immunocytochemistry images (Fig. 5b) a few disperse cells expressing GFP were 
observed upon transfection with magentoplexes. Regarding VEGF production 
levels, transfection with magnetoplexes obtained 5.06 ± 0.28 ng/ml, lipoplexes 3.94 
± 0.21 ng/ml and polyplexes 4.47 ± 0.47 ng/ml (Fig. 5c). Control non-transfected 
cells secreted 3.77 ± 0.12 ng/ml VEGF. Significant differences in VEGF secretion 
levels were found between magnetoplexes transfected cells and control cells 
(**p<0.01).  
3.6. Transfected primary neuronal culture cells released VEGF bioactivity assay 
Figure 5d shows HUVEC cell proliferation in response to VEGF secreted by the 
primary neuronal culture cells transfected with the nanoplexes. Proliferation of 
HUVEC cells in medium supplemented with VEGF from primary neuronal culture 
cells transfected with magentoplexes, polyplexes and lipoplexes was significantly 
higher than the one of HUVEC cells maintained in medium without supplements 
(***p<0.001).   




Figure 5. Primary neuronal culture cells viability, efficiencies of transfection with nanoplexes 
in those cells and bioactivity of VEGF protein secreted by the transfected cells. (a) Cell viability 
in primary neuronal culture cells 48h post-transfection with nanoplexes. Each value represents 
the mean ±SD, n=3. (b) Immunocitochemistry images of transfected primary neuronal culture 
cells. Green, Anti-GFP. Blue, Hoechst. Scale: 25 µm. (c) VEGF production (ng/ml) by primary 
neuronal culture cells 48h after transfection with nanoplexes. Control cells were not treated 
with nanoplexs. Each value represents the mean ±SD, n=3. (d) HUVEC cell proliferation in 
response to VEGF secreted by primary neuronal culture cells transfected with nanoplexes. 
Control HUVEC cells were not treated with VEGF. Each value represents the mean ±SD, n=6. 
Statistical significance: *p<0.05, **p<0.01, ***p<0.001 compared to control HUVEC cells.  
4. DISCUSSION 
Nucleic acid based therapies hold great promise but demand effective and safe 
carriers. Moreover, efficient transfection of CNS is still a challenge, which retards the 
development of therapeutic gene delivery strategies for the wide variety of 
neurodegenerative disorders. In recent years, biocompatible nanomaterials have 
emerged as potential candidates for that purpose. In fact, different nanosized non-
viral vectors have been recently reported to efficiently transfect CNS cells in vitro 
and in vivo, such as chitosans (Puras et al., 2013a; Puras et al., 2013b), cationic 
lipids (Ojeda et al., 2016) and magnetic nanoparticles (Soto-Sanchez et al., 2015). 
Besides, VEGF may be a potential therapeutic gene candidate for CNS disorders 
(Ruiz de Almodovar et al., 2009), due to the strong relationship between vascular 
alterations in brain and neurodegenerative diseases (Fournier et al., 2012) and its 
specific roles in brain angiogenesis and neuronal survival (Herran et al., 2013a; 
Carmeliet and Ruiz de Almodovar, 2013b).  




In this work we used non-viral nanocarriers for VEGF gene delivery into CNS cells. 
For that purpose, three different nanoparticles – magnetic, cationic lipid and 
polymeric - were complexed to the phVEGF165aIRESGFP plasmid to obtain the 
corresponding nanoplexes – magnetoplexes, lipoplexes and polyplexes-. 
Nanoformulations were fully characterized in terms of size, zeta potential, PDI, 
morphology and ability to bind, release and portect DNA. All formulations presented 
particle sizes in the nanoscale range (Fig. 1a, bars), which is related to higher cellular 
uptake values (Bivas-Benita et al., 2004), and exhibited positive surface charge 
values (Fig. 1a, lines), which is necessary to bind to the negatively charged DNA 
molecules by electrostatic interactions (Hosseinkhani and Tabata, 2006). Once 
complexed to DNA, surface charge switched to negative values in all cases. 
However, magnetoplexes and lipoplexes surface charge values changed from 
around +20 mV to around -20 mV, whereas polyplexes presented zeta potential 
values near the zero. It has been described that particles with surface charge values 
between -20mV and +20 mV form aggregates along the time (Caracciolo and 
Amenitsch, 2012). Therefore, to avoid aggregation, particularly in the case of 
polyplexes, all formulations employed in this work were used freshly prepared. PDI 
values were almost in all cases below 0.5, which is considered acceptable for 
comparative purposes of nanoparticles sizes measured by cumulative analysis 
(Reed et al., 2016). The exception was cationic lipids, where high PDI values could 
be attributed to the irregular morphology of these particles (Fig. 1c). In order to 
further analyze the ability of nanoparticles to bind, release and protect DNA, an 
agarose gel electrophoresis assay was performed (Fig.1d). Nanoparticles protected 
DNA from enzymatic degradation, but most of the plasmid was retained in the well, 
suggesting strong binding to DNA. However, all formulations showed a delicate 
balance between DNA binding and releasing abilities, necessary for efficient 
transfection mediated by non-viral vectors (Alatorre-Meda et al., 2011).  
Once nanoplexes were physicochemically characterized, in vitro studies were 
carried out in three cell lines: HEK293 –a general transfection model-, C6 cells –a 
CNS transfection model- and primary neuronal culture cells –the most relevant 
cellular model of CNS-. Before performing assays in primary neuronal culture cells, 
we analyzed cell viability and transfection efficiency of the nanoplexes in HEK293 
and in C6 cells, due to the challenge that represents primary neuronal culture cells 
transfection with non-viral vectors. Nanoplexes were well tolerated by both cell types, 
since cell viability was above 90% with magentoplexes and lipoplexes and above 
80% with polyplexes (Fig. 2a, dots).  The analysis of transfection efficiency was 
studied through three different parameters: percentage of GFP expressing cells (Fig. 




2a, bars), MFI of those transfected cells (Fig. 2b) and the amount of VEGF (ng/ml) 
secreted by transfected cells (Fig. 2c). The phVEGF165aIRESGFP plasmid codifies 
for both proteins, VEGF –which is extracellular and, therefore, secreted to the 
extracellular medium by transfected cells- and GFP –which is intracellular and 
remains in the cytoplasm of transfected cells-. Therefore, parameters related to GFP 
were analyzed by flow citometry, while the concentration of VEGF present in cellular 
supernatants was measured by ELISA. Regarding percentages of GFP expressing 
cells and MFI values, transfection efficiencies with all nanoplexes were higher in 
HEK293 cells compared to C6 cells. However, regarding expression of VEGF 
(ng/ml), comparable values were obtained in HEK293 and C6 cells 48 h after 
transfection with nanoplexes. Indeed, when transfecting with magnetoplexes, the 
amounts of secreted VEGF were higher in the supernatant of C6 cells compared to 
HEK293 cells. It has been reported that non-viral vector mediated transfection 
processes are cell-dependent, meaning that the transfection efficiency of the same 
non-viral vector can diverge depending on the transfected cell type (Ojeda et al., 
2015). Our results are consistent with this idea, since we found that in HEK293 cells 
highest transfection was achieved with lipoplexes, while in C6 cells magnetoplexes 
were more efficient. Polyplexes are in the third position in both cell lines, probably 
due to their surface charge values near zero, which may affect cellular uptake.  
Interestingly, a clear correlation is observed in both cell lines between the three 
parameters used to analyze transfection efficiencies. At higher percentages of GFP 
expressing cells, higher levels of secreted VEGF were detected (Fig. 3a and Fig. 
4a). Also, at higher MFI values, higher levels of secreted VEGF were observed (Fig. 
3b and Fig. 4b). However, when comparing the angles of the slope in those graphs, 
differences were detected between cell lines, since the gradients were more 
pronounced in C6 than in HEK293 cells in both correlations –in Figs. 3a and 4a, 
α=22.65° in HEK293 vs. α=65.42° in C6; in Figs. 3b and 4b, α=8.42° in HEK293 and 
α=23.67° in C6 . These data support the fact that although GFP expression and MFI 
values were lower in C6, VEGF expression levels were comparable in both cell lines 
transfected with nanoplexes. This effect could in part be explained by the higher 
basal expression of VEGF protein in C6 cells (Fig. 2c, control bars). Therefore, even 
at lower transfection efficiencies, transfected C6 cells could be able to secret as 
much VEGF protein as the more efficiently transfected HEK293 cells. Still, the big 
differences observed suggest that other factors may also be involved, specifically 
those related to the Internal Ribosome Entry Site (IRES) sequence of the plasmid. 
IRES sequences are translational enhancers that allow the co-expression of two 
genes of interest under the same promoter and with a constant ratio of the proteins 




(Fussenegger et al., 1998; Allera-Moreau et al., 2007). However, it has been 
described that cellular IRES often exhibit low efficiencies in transiently transfected 
cells, which has been attributed to the cell and tissue specificity of the cellular IRES 
activities (Ngoi et al., 2004; Renaud-Gabardos et al., 2015). In those cases, the 
expression of the gene downstream of the IRES element is usually lower, while the 
expression of the gene upstream the IRES sequence is not affected (Jopling and 
Willis, 2001). In our scenario, the VEGF gene is located upstream the IRES element 
in the phVEGF165aIRESGFP plasmid, and the GFP gene is located downstream 
that sequence. Therefore, we hypothesized that the IRES sequence of the 
phVEGF165aIRESGFP plasmid may be working less efficiently in neural cells such 
as the C6 cell line, and that consequently, the expression of the GFP gene could be 
affected in those cells, while the VEGF gene is normally expressed.  
Once the capacity of nanoplexes to transfect HEK293 and C6 cells was analyzed, 
we performed transfection assays in primary neuronal culture cells, which represent 
a more challenging scenario for non-viral gene delivery. Cell viabilities (Fig. 5a) were 
excellent in this case –near 100% with all nanoplexes-, but transfection efficiencies 
(Fig. 5a-b) were lower than in the previous cell lines, due to the difficulty of 
transfecting neuronal cells. GFP expression was only detectable by 
immunocitochemistry assay –Fig. 5b shows a few scattered fluorescent cells-. This 
supports the hypothesis of the tissue specificity of the IRES element in the 
phVEGF165aIRESGFP plasmid. Regarding VEGF expression, we found that these 
cells presented a high basal production of VEGF, probably due to the glial cells 
present in the primary culture, which secret angiogenic (Egervari et al., 2016) and 
neurotrophic (Du et al., 2014) factors to support the CNS cells. However, after 
transfection with nanoplexes, levels of secreted VEGF increased respect to the 
control in all cases, although statistically significant differences were only found in 
magnetoplexes transfected cells (Fig. 5c). Next, we analyzed the bioactivity of 
transfected cells secreted VEGF in HUVEC cells, since these cells are known to 
respond with increased proliferation to the effect of VEGF (Herran et al., 2013a; Bai 
et al., 2014). Compared to the proliferation control group –HUVEC cells not treated 
with VEGF-, HUVEC cells exposed to VEGF secreted by primary neuronal culture 
cells transfected with nanoplexes presented a statistically significant increase in 
proliferation, which validates that VEGF induced HUVEC cell proliferation. 
Furthermore, the increase of proliferation in HUVEC cells was proportional to the 
increase of VEGF production in primary neuronal culture cells, magnetoplexes 
obtaining the highest levels of VEGF expression in primary neuronal culture cells 
and their supernatants achieving the highest levels of proliferation in HUVEC cells, 




followed in both cases by polyplexes and, finally, lipoplexes. It is remarkable that 
magnetoplexes transfected CNS cell models more efficiently than their counterparts 
and that, unexpectedly, polyplexes were more efficient than lipoplexes in primary 
neuronal culture cells.  
Considering these results, non-viral vectors and, in particular, magnetoplexes might 
constitute a promising approach to deliver the VEGF gene into CNS cells in a safe 
and controlled way, which is consistent with previous reports (Soto-Sanchez et al., 
2015). Strong relationships described between vascular alterations and 
neurodegeneration (Ruiz de Almodovar et al., 2009), along with reported beneficial 
effects of VEGF protein in animal models of neurodegenerative diseases such as 
AD (Herran et al., 2013a; Herran et al., 2015) and Parkinson’s Disease (Herran et 
al., 2014; Herran et al., 2013b), suggest that VEGF may be a potential therapeutic 
candidate for CNS disorders. Besides, compared to drug delivery, VEGF gene 
delivery would demand fewer doses and would allow long-lasting effects. To date, 
administration of non-viral vectors to SNC is still a challenge for the scientific 
community, principally due to the invasive nature of the currently available 
approaches to target the brain, including craniotomy. A recent study has shown that 
intranasally administered plasmid DNA nanoparticles circumvented the BBB to 
target the CNS and have successfully transfected rat brain (Harmon et al., 2014). 
Therefore, the intranasal route, a safer and non-invasive alternative, merits special 
attention for non-viral gene delivery into the CNS.  
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Erretinako gene-terapiarako bektore ez-biralen arrakasta transgene espresio altuak eta 
iraunkorrak lortzearen menpe dago, batik bat hori lortzeko dosi bakarra ematea nahikoa 
izanda. Lan honetan, niosoma formulazioetako osagai diren tentsoaktibo ez-ionikoek 
transfekzio prozesuan eta eraginkortasunean duten eragina aztertu dugu arratoi-erretinan. 
Horretarako, hiru niosoma formulazio prestatu ditugu, soilik tentsoaktibo ez-ionikoa aldatuta 
kasu bakoitzean. Niosomen osagaiak izan ziren 1,2-di-O-oktadenilo-3-trimetilamonio propano 
(DOTMA) lipido kationikoa, eskualeno lipido laguntzailea eta Tween 20, 80 edo 85 
tentsoaktibo ez-ionikoa. Niosomak eta dagozkien nioplexoak fisiko-kimikoki karakterizatu 
ziren tamainari, zeta potentzialari, polidispertsio indizeari, morfologiari eta DNA babesteko eta 
askatzeko duten gaitasunaren arabera. In vitro esperimentuen bidez, formulazioen 
transfekzio gaitasuna eta bakoitzak jarraitutako zelula-barneko endozitosi-bideak aztertu 
ziren.  Tween 20 tentsoaktibo ez-ionikoz osatutako nioplexoekin lortu ziren transfekzio-maila 
altuenak in vitro. Gainera, erretina-azpiko eta bitreo-barneko injekzioak eginda arratoien 
erretinan transfekzio-maila altuak lortu ziren in vivo formulazio horrekin. Emaitza horiek 
erakusten dutenez, niosomen formulazioan Tween 20 tentsoaktibo ez-ionikoa erabiltzeak 
erretinako transfekzioa hobetzen du. Beraz, formulazio berri hau hautagai egokia izan daiteke 
gene terapeutikoak erretinara garraiatzeko ehun horri eragiten dioten gaixotasunei aurre 
egiteko tratamenduetan. 
 
El éxito de la liberación génica en retina mediante vectores no-virales basados en niosomas 
catiónicos depende de la habilidad de lograr niveles elevados y persistentes de expresión 
génica, idealmente tras una única administración. En este trabajo, estudiamos el efecto del 
tensioactivo no-iónico de las formulaciones de niosomas en su eficiencia de transfección en 
retina de rata. Para ello, se elaboraron tres formulaciones de niosomas que sólo diferían en 
el componente de tensioactivo no-iónico. Los niosomas contenían: el lípido catiónico 1,2-di-
O-octadecenil-3-trimetilamonio propano (DOTMA), el lípido helper escualeno y uno de los 
siguientes tensioactivos no-iónicos: polisorbato 20, 80 o 85. Los niosomas y correspondientes 
nioplexos se caracterizaron en términos de tamaño de partícula, índice de polidispersión 
(PDI), potencial zeta, morfología y habilidad para proteger y liberar el ADN. Se llevaron a 
cabo experimentos in vitro para evaluar la eficiencia de transfección, viabilidad celular y rutas 
de tráfico intracelular de las formulaciones. Los nioplexos que contenían polisorbato 20 fueron 
los más eficientes para transfectar células retinianas in vitro. Además, la administración 
intravítrea y subretiniana de esos nioplexos in vivo mostró elevados niveles de expresión 
génica en retina de rata. Estos resultados demuestran que la incorporación del polisorbato 
20 en niosomas catiónicos mejora la transferencia génica en retina. Por tanto, esta 
formulación constituye un candidato prometedor como vector no-viral para transferir genes 
terapéuticos específicos al ojo con fines biomédicos.   
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Abstract: The success of non-viral vectors based on cationic niosomes for retinal 
gene delivery applications depends on the ability to achieve persistent and high 
levels of transgene expression, ideally from a single administration. In this work, we 
studied the effect of the non-ionic surfactant component of niosomes in their 
transfection efficiency in rat retina. For that purpose, three niosome formulations that 
only differed in the non-ionic tensioactives were elaborated. Niosomes contained: 
cationic lipid 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), helper 
lipid squalene and polysorbate 20, polysorbate 80 or polysorbate 85. Niosomes and 
corresponding nioplexes were fully characterized in terms of size, polydispersity 
index, zeta potential, morphology and ability to protect and release DNA. In vitro 
experiments were carried out to evaluate transfection efficiency, cell viability and 
intracellular trafficking pathways of the formulations. Nioplexes based on polysorbate 
20 niosomes were the most efficient transfecting retinal cells in vitro. Moreover, 
subretinal and intravitreal administration of those nioplexes in vivo showed also high 
levels of transgene expression in rat retinas. Our results demonstrate that the 
incorporation of polysorbate 20 in cationic niosomes enhances retinal gene delivery. 
Thus, this formulation emerges as a potential non-viral candidate to efficiently 
transfer specific therapeutic genes into the eye for biomedical purposes.  
 
Keywords: non-viral vector, gene therapy, retina; non-ionic surfactants, niosomes.  




Several monogenic retinal disorders are well characterized, with identified mutations 
that most often affect to specific genes in retinal pigment epithelium (RPE) cells1. 
RPE cells perform pivotal functions required for the maintenance of the neural retina, 
such as protecting the photoreceptor cells and secreting growth factors2. In many 
retinal diseases, including Leber’s congenital amaurosis (LCA), retinitis pigmentosa 
(RP) and age-related macular degeneration (AMD) blindness occurs due to RPE 
degeneration, which results in photoreceptor loss or dysfunction1. Therefore, RPE 
cells constitute the main target of most ocular gene therapy strategies. Tight 
junctions between RPE cells form the blood retina barrier, which is responsible of 
the low ocular bioavailability of systemically administered drugs3. However, the same 
barriers that make ocular administration difficult also help the eye maintain its 
immune privilege, making intraocularly-delivered molecules less likely to induce 
severe immune responses than their systemically-delivered counterparts4. The 
success of retinal gene transfer strategies depends on the ability to achieve 
persistent and high levels of transgene expression in RPE cells, ideally from a single 
administration.  
Nucleic acids can be delivered into the retina both through viral or non-viral vectors. 
Some clinical trials using viral vectors have shown encouraging results5,6. However, 
some limitations of viral vectors such as safety concerns, expensive production 
costs7 and that many disease genes of the RPE and retina are too large to fit into 
viral vectors1 have motivated the development of non-viral vectors for ocular gene 
delivery. Non-viral vectors present low immunogenicity, high nucleic acid packing 
capacity, ease of fabrication, high reproducibility and acceptable costs compared to 
their counterparts8. Among the wide plethora of non-viral vectors, recently emerged 
niosomes are biocompatible, synthetic, non-ionic surfactant vesicles with a closed 
bilayer structure9,10 and they are based on three principal components: cationic 
lipids, helper lipids and non-ionic tensioactives11,12. The global chemical properties 
of these components influence on the physicochemical characteristics of niosomes, 
such as size, surface charge and morphology, which in turn determine their ability to 
enter the cells, follow a particular endocytic pathway and deliver the DNA cargo into 
the nucleus13,14. Our research group has previously evaluated the effect of cationic 
lipids15 and helper lipids16 in retinal transfection, and has reported transgene 
expression in retinal cells both in vitro16 and in vivo16,17. In order to optimize the 
design of niosome formulations for retinal gene delivery applications, in this work we 
evaluated the effect of the non-ionic surfactant of niosomes on the retinal 
transfection process and efficiency.  
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For that purpose, we elaborated three niosome formulations that only differed in the 
non-ionic surfactant component. Niosomes used in this work contained the cationic 
lipid 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), combined with 
the helper lipid squalene and one of the following non-ionic surfactants: polysorbate 
20, polysorbate 80 or polysorbate 85, differing in their chemical structure and 
hydrophile-lipophile balance (HLB) values (Figure 1). The cationic lipid DOTMA has 
been successfully used in niosome formulations for gene delivery to the retina18. 
Squalene is a natural lipid belonging to the terpenoid family19 that enhances the 
stability of niosome formulations20. Polysorbate 80 has been used combined with 
squalene obtaining effective transgene expression in rat retina in vivo17, but the 
effect of other non-ionic tensioactives such as polysorbate 20 and 85 combined with 
squalene and DOTMA has not been studied for retinal gene delivery. The three 
niosome formulations elaborated in this work were named DST20, DST80 and 
DST85, according to their composition. Niosomes were complexed to the pCMS-
EGFP reporter plasmid or to a fluorescein isothiocyanate (FITC) labeled pCMS-
EGFP plasmid to form nioplexes. Niosomes and nioplexes were characterized in 
terms of size, polydispersity index (PDI), zeta potential, morphology and ability to 
protect and release DNA. In vitro experiments were carried out in human embryonic 
kidney cells (HEK-293) and retinal pigment epithelial cells (ARPE-19) to evaluate 
cell viability and transfection efficiency. In order to examine the cell entry and 
intracellular trafficking process of the three formulations in ARPE-19 cells, co-
localization analysis were performed between the nioplexes (niosomes/FITC stained 
DNA) and the stained endocytic pathways. The pathways under study were the 
clathrin mediated endocytosis (CME), caveolae-mediated endocytosis (CvME) and 
late endosomal compartments (Lys). The best of those formulations was used to 
transfect primary cultures of rat retinal cells and was administered into rat eyes in 
order to evaluate the capacity of the formulation to deliver genetic material into the 
retina after subretinal and intravitreal injections.  




Figure 1. General scheme of niosomes and chemical structures of niosome components. 
2. Materials and Methods 
2.1. Preparation of niosomes and nioplexes 
Niosomes based on cationic lipid DOTMA (Avanti Polar Lipids, Inc., Alabama, USA), 
helper lipid squalene (Sigma-Aldrich, Madrid, Spain) and polysorbates 20, 80 and 
85 (Sigma-Aldrich, Madrid, Spain) were prepared using the o/w emulsification 
technique, as previously described12. Three different niosome formulations were 
prepared to a molar ratio of 2 mM cationic lipid – 8 mM helper lipid – 4 mM 
tensioactive. Briefly, 6.70 mg of the cationic lipid were gently ground with 19 µl of 
squalene. Then, 1 ml of dichloromethane (DCM) (Panreac, Barcelona, Spain) was 
added and emulsified with 5 ml of the non-ionic surfactant aqueous solution –at 
different w/v percentages to obtain the final molar relation- containing either 
polysorbate 20 (0.49% w/v), 80 (0.52% w/v) or 85 (0.17% w/v). The emulsion was 
obtained by sonication (Branson Sonifier 250, Danbury) for 30 s at 50 W. The organic 
solvent was removed from the emulsion by evaporation under magnetic agitation for 
3 h at room temperature, obtaining niosome solutions DST20, DST80 and DST85.  
The nioplexes were elaborated by mixing an appropriate volume of a stock solution 
of either a pCMS-EGFP plasmid (0.5 mg/ml) (Clontech Laboratories, Inc., USA) or a 
fluorescein isothiocyanate (FITC) labeled pCMS-EGFP plasmid (0.5 mg/ml) 
(DareBio, Elche, Spain), with different volumes of DST20, DST80 and DST85 
niosomes to obtain cationic lipid/DNA (w/w) mass ratios 2/1, 5/1 and 10/1. The 
mixture was left for 30 min at room temperature to enhance electrostatic interactions 
between the cationic lipid and the DNA.  
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2.2. Plasmid propagation  
The pCMS-EGFP plasmid was propagated in Escherichia coli DH5-α and purified 
using the Qiagen endotoxin-free plasmid purification Maxi-prep kit (Qiagen, Santa 
Clarita, CA, USA) according to manufacturer’s instructions. The concentration of 
pDNA was quantified by measuring the absorbance at 260 nm with a SimpliNanoTM 
device (GE Healthcare, Buckinghamshire, UK).  
2.3. Size, polydispersity index, zeta potential and morphology 
The intensity mean diameter (Z-average) and the zeta potential of niosomes and 
nioplexes were determined by dynamic light scattering and by lasser Doppler 
velocimetry, respectively, using a Zetasizer Nano ZS (Malvern Instrument, UK). 
Briefly, 50 µl of the formulations were resuspended into 950 µl of 0.1 mM NaCl 
solution. All measurements were carried out in triplicate. The particle size reported 
as hydrodynamic diameter was obtained by cumulative analysis. The Smoluchowski 
approximation was used to support the calculation of the zeta potential from the 
electrophoretic mobility. The morphology of niosomes was determined by 
transmission electron microscopy (TEM) as previously described17.  
2.4. Agarose gel electrophoresis assay 
Naked DNA and nioplexes at different mass ratios were subjected to a 0.8 % agarose 
(Sigma-Aldrich, Madrid, Spain) gel electrophoresis assay. For DNA protection and 
release assay, 3 μl of DNase I enzyme (Sigma-Aldrich, Madrid,Spain) were added 
and incubated at 37°C for 30 min. then, 12 μl of 7 % sodium dodecyl sulfate (SDS) 
(Sigma-Aldrich, Madrid, Spain) were added to the samples and incubated at room 
temperature for 10 minutes. Before running the gel, 4 µl of loading buffer (BioRad, 
USA) were added to all samples. The agarose gel was immersed in a Tris-acetate-
EDTA buffer and exposed for 45 min at 100 V. Once DNA bands were stained with 
GelRedTM (Biotium, Hayward, California, USA), they were observed with a 
ChemiDocTM MP Imaging System and analyzed with ImageLabTM Software (BioRad, 
USA). Naked DNA was used as control. The amount of DNA per well was 200 ng in 
all cases. 
2.5. Cell culture and transfection assays 
Human embryonic kidney cells 293 (HEK-293) (ATCC® CRL1573TM) were grown 
in Eagles’s Minimal Essential Medium (EMEM, ATCC 30-2003) supplemented with 
10 % of fetal bovine serum (FBS) (Sigma-Aldrich, Madrid, Spain) and with 1 % of 
antibiotic-antimycotic solution (Life Technologies, Paisley, UK). Human retinal 
pigment epithelium cells (ARPE-19) (ATCC® CRL2302TM) were grown in 
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Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (F-12K, ATCC 30-2006) 
supplemented with 10 % of FBS and 1 % of penicillin-streptomycin solution (Life 
Technologies, Paisley, UK). Cells were incubated at 37°C and 5 % CO2 atmosphere, 
and were split every 3-4 days to maintain monolayer coverage.  
For transfection efficiency in HEK-293 and ARPE-19 cell lines, cells were seeded in 
24 well plates at a density of 10 x 104 cells per well in a total volume of 250 µl per 
well, and incubated overnight to achieve 70 % of confluence at the time of 
transfection with nioplexes. Both cell types were transfected with DST20, DST80 and 
DST85 nioplexes at cationic lipid/DNA mass ratio 2/1. For that purpose, electrostatic 
interactions between the cationic lipid and the pCMS-EGFP plasmid were left to 
occur for 30 min at room temperature in OptiMEM (Gibco, San Diego, CA, USA) 
transfection medium. Once removing the growth medium from the plate, cells were 
exposed for 4 h to nioplexes for transfection. After the incubation, nioplexes were 
removed and fresh medium was added to the cells. Transfection efficiency was 
analyzed by fluorescence microscopy and flow cytometry 48 h after the exposure to 
nioplexes. Lipofectamine 2000TM (Invitrogen, Carlsbad, CA, USA) was used as 
positive control. Transfection negative control cells were not exposed to nioplexes, 
but were incubated in OptiMEM for 4 h. Each condition was performed in triplicate.  
2.6. Analysis of EGFP expression and cell viability 
Qualitative analysis of EGFP expression was conducted using an inverted 
microscope equipped with an attachment for fluorescent observation 
(EclipseTE2000-S, Nikon). For quantitative determination of EGFP expression and 
cell viability, flow cytometry analysis was conducted using a FACSCalibur system 
flow cytometer (Becton Dickinson Bioscience, San Jose, USA). DST20, DST80 and 
DST85 nioplex-transfected cells were washed twice with PBS (Sigma-Aldrich, 
Madrid, Spain) and detached with 200 μl of trypsin/EDTA (Gibco, San Diego, CA, 
USA) per well. 400 μl of complete growth medium were added and cells were 
transferred to specific flow cytometer tubes. Cell viability was evaluated using 
propidium iodide (Sigma-Aldrich, Madrid, Spain) at 1:10 dilution in each sample. The 
fluorescent signals corresponding to dead cells and to EGFP positive cells were 
measured at 650 nm (FL3) and 525 nm (FL1), respectively. Non-transfected cells, 
used as control samples, were displayed on a forward scatter (FSC) versus side 
scatter (SSC) dot plot to establish a collection gate and exclude cells debris. Positive 
control samples transfected with Lipofectamine 2000TM were used to establish 
cytometer settings and channel compensations. Cell viability data were normalized 
in relation to the value of non-treated control cells. Transfection data were 
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normalized in relation to the value of the positive control Lipofectamine 2000TM 
transfection. The experiments were carried out in triplicate for each condition. For 
each sample 10,000 events were collected. FlowJo software (Becton Dickinson, 
Mountain View, CA, USA) was employed to analyze the data. 
2.7. Endocytic trafficking 
For cellular internalization assays, ARPE-19 cells were seeded on coverslips on 24 
well plates and transfected with nioplexes containing the FITC-labeled pCMS-EGFP 
plasmid for 3 h. Then the following endocytic vesicle markers were added and 
incubated for 1 h with either AlexaFluor546-Transferrin (50 μg/mL), AlexaFluor555-
Cholera toxin B (10 μg/mL) or Lysotracker (140 nM), which are markers for CME, 
CvME and late endosomal compartment, respectively. Cells were fixed with 4 % 
formaldehyde and mounted with DAPI-Fluoromount-GTM (Fisher Scientific SL, 
Madrid, Spain) for examination by confocal laser scanning microscopy (CLSM) 
(Zeiss Axiobserver, Germany). Co-localization of the green and red signal was 
analyzed by ImageJ software and quantified by a cross-correlation analysis as 
previously described by van Steensel et al.21. Briefly, the green signal image was 
shifted in the x-direction pixel per pixel relative to the red signal image and the 
respective Pearson’s coefficient was calculated, which was then plotted as the 
function of the pixel shift (δx) obtaining a cross-correlation function (CCF). Co-
localizing structures peaked at δx = 0 and presented a bell-shaped curve. 3D plots 
to relate HLB, transfection efficiency and co-localization values were built using 
MATLAB® R2017b.  
2.8. Animals and anesthetics 
Adult male Sprague–Dawley rats were used as experimental animals in this study. 
All experimental procedures were carried out in accordance with the Spanish and 
European Union regulations for the use of animals in scientific research and the 
Association for Research in Vision and Ophthalmology (ARVO) statement for the 
use of animals in ophthalmic and vision research. Procedures were supervised by 
the Miguel Hernandez University Standing Committee for Animal Use in Laboratory. 
Rats were housed in temperature and light controlled rooms with a 12 h light/dark 
cycle and had food and water ad libitum. All the experimental manipulations were 
carried under general anesthesia induced with an intraperitoneal (i.p.) injection of a 
mixture of ketamine (70 mg/kg, Ketolar, Parke–Davies, S.L., Barcelona, Spain) and 
xylazine (10 mg/kg, Rompún, Bayer, S.A., Barcelona, Spain). 
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2.9. Transfection assays in rat primary retinal cell culture and 
immunocytochemistry 
Embrionary rat retinal retinal primary cells were extracted from E17.5 rat embryos 
from n = 4 Sprague Dawley rats. During the extraction of retina, the tissue was 
maintained in cold Hank´s Balanced Salt Solution (Gibco, California, USA). After 
enzymatic digestion with trypsin (Sigma), the retina was mechanically dissociated in 
Dulbecco´s modified Eagle medium (DMEM) (Thermo Fisher Scientific) and 
maintained in DMEM supplemented with 10 % FBS (Life Technologies, Paisley, UK), 
2 % of B27 (Thermo Fisher Scientific), 0.4 % of Glutamax (Thermo Fisher Scientific) 
and 0.4 % of penicillin-streptomycin solution (Life Technologies, Paisley, UK). Cells 
were incubated at 37°C under 5 % CO2 atmosphere.  
For transfection assays, cells were seeded on poly-D-lysine-coated coverslips in 12 
well plates at a density of 2x105 cells per well. The composition nioplexes and 
transfection conditions were the same as the previously mentioned for in vitro 
assays. Lipofectamine™ 2000 (Invitrogen, California, USA) was used as positive 
control.  
Transfection efficiency was analyzed qualitatively 96 h after the exposure to 
nioplexes by immunocytochemistry. Cellular phenotypes were assessed using 
specific antibody markers. For that, cells were washed twice with PBS, fixed with 4% 
paraformaldehyde for 30 min and permeabilized by 0.5% triton X-100 (Sigma-
Aldrich, St Louis, MO, USA), followed by 10% bovine serum albumin block to reduce 
non-specific bindings. Cover slips were incubated overnight with rabbit polyclonal 
anti-rabbit microtubule associated protein-2 (MAP2) (Millipore; 1:400 dilution) as a 
neuronal marker and with secondary antibody donkey anti-rabbit IgG Alexa Fluor 
555 (Thermo Fisher Scientific; 1:200 dilution) previous wash with PBS. Nuclei were 
stained with Hoechst 33342 (Thermo Fisher Scientific). Cover slips were mounted 
on glass slides and analyzed for fluorescence by a Zeiss AxioObserver Z1 (Carl 
Zeiss) microscope equipped with an ApoTome system and different fluorescence 
filters.      
2.10. Intravitreal and subretinal administration of nioplexes 
Adult male Sprague–Dawley rats of 6–7 weeks old and 150–200 g body weight (n = 
6) were employed as experimental animals in this study The injection solution 
consisted of 4 μl of nioplexes suspension containing 100 ng of the pCMS-EGFP 
plasmid. Nioplexes were injected in the left eyes of animals intravitreally (n = 3) or 
subretinally (n = 3) under an operating microscope (Zeiss OPMI® pico; Carl Zeiss 
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Meditec GmbH, Jena, Germany) with the aid of a Hamilton microsyringe (Hamilton 
Co., Reno, NV). A bent 34-gauge needle was used to inject nioplexes into the 
vitreous, immediately adjacent to the ora serrata without touching the lens. For 
subretinal administration of nioplexes, the needle was introduced through a 
sclerotomy 2 mm posterior to ora serrata and in a tangential direction toward the 
posterior retinal pole along the subretinal space. Successful administration was 
confirmed by the appearance of a partial retinal detachment by direct 
ophthalmoscopy of the eye fundus. The untreated right eyes served as negative 
control. Lipofectamine™ 2000 was used as positive control.  
2.11. Evaluation of EGFP expression in rat retinas 
EGFP expression was evaluated qualitatively 96 h after the injection of nioplexes in 
wholemount and sagital sections of the retina. For that, rats were sacrificed and 
perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1M phosphate 
buffer (pH 7.2-7.4) at 4ºC. Then, both eyes were enucleated and the anterior 
segments, including the lens, were removed. The eyes were washed with PBS and 
retinas were dissected out for flat mount. For cryoprotection of frozen sections, retina 
and eyecups were immersed in a graded series of 15%, 20% and 30% sucrose 
solutions in PBS overnight at 4 °C. Eyecups were embedded and oriented in optimal 
cutting temperature (O.C.T.™) compound (Tissue-Tek®, Sakura Finetek Europe 
B.V., Alphen and den Rijn, Netherlands) and frozen. Radial sections of 16 μm thick 
were cut with a cryostat (HM 550; Microm International GmbH, Walldorf, Germany) 
and mounted on SuperFrost® Plus microscope slides (VWR International BVBA, 
Leuven, Belgium). Nuclei were stained with Hoechst 33342 (Thermo Fisher 
Scientific) in frozen sections and wholemount retinas. Images of EGFP signal were 
acquired using a Leica TCS SPE spectral confocal microscope (Laica Microsystems 
GmbH, Wetzlar, Germany). Images were processed, montaged and composed 
digitally using ImageJ (NIH, Bethesda, MD) and Adobe® Photoshop® CS5.1 
software (Adobe Systems Inc., CA, USA). 
2.12. Statistical analysis 
To analyze the differences among the different formulations DST20, DST80 and 
DST85, a multiple comparison Kruskal-Wallis test followed by a Mann-Whitney U 
test was performed. Normal distribution was determined by a Shapiro-Wilks test and 
homogeneity of variance by the Levene test. Data were expressed as mean ± SD, 
unless stated otherwise. A P value <0.05 was considered statistically significant. The 
analysis was performed using the IBM SPSS Statistics 22.Ink statistical package. 




3.1. Size, polydispersity index, zeta potential and morphology of niosomes and 
nioplexes 
The physicochemical analysis of formulations revealed that the mean particle size of 
DST20, DST80 and DST85 niosomes were 159 ± 1 nm, 145 ± 1 nm and 173 ± 2 nm, 
respectively (Fig. 2A, bars). When complexed to plasmid DNA (pCMS-EGFP), the 
mean particle size of nioplexes remained similar, except for DST80 nioplexes, which 
increased to 217 ± 4 nm at cationic lipid/DNA ratio 2/1 and decreased to 128 ± 2 nm 
at cationic lipid/DNA ratio 10/1 (Fig. 2A, bars). All formulations showed low values of 
PDI (Fig. 2B). Zeta potential values of DST20, DST80 and DST85 niosomes were 
+48.0 ± 2.3 mV, +50.7 ± 2.2 mV and +52.8 ± 1.5 mV, respectively. When complexed 
to pCMS-EGFP, zeta potential values declined moderately, but with augmenting 
cationic lipid/DNA mass ratios, zeta potential values showed a clear tendency to rise 
again (Fig. 2A, lines). The three niosome formulations showed a clear spherical 
morphology when observed under TEM (Fig. 2C-E).   
3.2. Ability of nioplexes to protect and release DNA 
The capacity of DST20, DST80 and DST85 nioplexes to protect and release the 
pCMS-EGFP plasmid was determined by agarose gel electrophoresis (Fig. 2D). 
Lanes 1-2 correspond to control naked DNA; lanes 3-11 correspond to DST20, 
DST80 and DST85 nioplexes at cationic lipid/DNA (w/w) ratios 2/1, 5/1 and 10/1. 
The supercoiled (SC) DNA band on lane 1 indicated that the plasmid completely 
migrated, and the lack of DNA signals on lane 2 indicated total degradation of the 
plasmid. The SC DNA bands observed on lanes 3-11 indicated that DNA was 
protected against enzymatic degradation and effectively released in all conditions.  




Figure 2. Physicochemical characterization of DST20, DST80 and DST85 niosomes and their 
corresponding nioplexes at cationic lipid/DNA (w/w) ratios 2/1, 5/1 and 10/1. (A). Size values 
are represented with bars and zeta potential values with dots. Each value represents the mean 
± SD, n=3. (B). PDI values. Each value represents the mean ± SD, n=3. (C-E). TEM images 
of niosomes. Scale bars: 200.0 nm. (C) DST20 niosomes at 20,000x magnification, (D) DST80 
niosomes at 20,000x magnification and (E) DST85 niosomes at 40,000x magnification. (F). 
Agarose gel electrophoresis assay for analyzing the ability of DST20, DST80 and DST85 
nioplexes at different cationic lipid/DNA (w/w) ratios to protect the pCMS-EGFP plasmid. 
DNase I enzyme and SDS were added in lanes 2-11. Lanes 1-2 correspond to naked DNA. 
Lanes 3, 4 and 5 correspond to DST20 nioplexes at cationic lipid/DNA mass ratios 2/1, 5/1 
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and 10/1, respectively. Lanes 6, 7 and 8 correspond to DST80 nioplexes at cationic lipid/DNA 
mass ratios 2/1, 5/1 and 10/1, respectively. Lanes 9, 10 and 11 correspond to DST85 
nioplexes at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1, respectively. OC: open circular 
form, SC: supercoiled form. 
3.3. Cell viability and transfection efficiency of nioplexes in HEK-293 and ARPE-19 
cells 
Cell viability and transfection assays were performed with nioplexes at cationic 
lipid/DNA mass ratio 2/1. In HEK-293 cells, normalized cell viability percentages with 
DST20, DST80 and DST85 nioplexes were 100.16 ± 0.49%, 99.87 ± 0.56% and 
99.43 ± 0.31%, respectively. In HEK-293 cells transfected with Lipofectamine 
2000TM, the normalized cell viability value was 95.37 ± 0.56%. In ARPE-19 cells, 
normalized cell viability percentages with DST20, DST80 and DST85 nioplexes were 
87.99 ± 0.59%, 97.27 ± 1.17% and 96.68 ± 3.67%, respectively. In ARPE-19 cells 
transfected with Lipofectamine 2000TM, the normalized cell viability value was 54.49 
± 3.60%.  
Transfection efficiency data were normalized in each cell line in relation to the EGFP 
expression values obtained with the positive control Lipofectamine 2000TM. In HEK-
293, the percentage of EGFP expressing cells with the positive control Lipofectamine 
2000TM was 40.26 ± 1.95%. The normalized percentages of EGFP expressing cells 
obtained with nioplexes DST20, DST80 and DST85 were 18.62 ± 3.90%, 4.12 ± 
0.5% and 69.22 ± 2.64%, respectively (Figure 3A1). Differences in transfection 
efficiencies between the three nioplexes were statistically significant (p < 0.05). In 
ARPE-19 cells, the percentage of EGFP expressing cells with the positive control 
Lipofectamine 2000TM was 43.62 ± 5.79%. The normalized percentages of EGFP 
expressing cells obtained with nioplexes DST20, DST80 and DST85 were 24.57 ± 
3.83%, 14.19 ± 3.16% and 14.13 ± 1.09%, respectively (Figure 3B1). Statistical 
differences (p < 0.05) in transfection efficiency were found between DST20 and 
DST80 and between DST20 and DST85 nioplexes in ARPE-19 cells. Therefore, 
DST20 nioplexes were selected for further gene delivery assays in primary rat retinal 
cells and in vivo studies. Figures 3A2 and 3B2 show representative images of EGFP 
green fluorescent signal in HEK-293 cells transfected with DST85 nioplexes and in 
ARPE-19 cells transfected with DST20 nioplexes, respectively. 
 




Figure 3. Transfection efficiency and cell viability assay in HEK-293 and ARPE-19 cells 48 h 
post-addition of DST20, DST80 and DST85 nioplexes vectoring the pCMS-EGFP plasmid at 
cationic lipid/DNA mass ratio 2/1. (A1). Normalized percentages of EGFP expressing HEK-
293 cells evaluated by flow cytometry. Each value represents the mean ± SD, n = 3. Statistical 
significance: * p < 0.05, **p < 0.01, ***p < 0.001. (A2).  Representative fluorescence 
microscope image of EGFP expression in HEK-293 cells transfected with DST85 nioplexes 
captured at 20x magnification. Scale bar: 100 µm. (B1). Normalized percentages of EGFP 
expressing ARPE-19 cells evaluated by flow cytometry. Each value represents the mean ± 
SD, n = 3. Statistical significance: * p < 0.05, **p < 0.01, ***p < 0.001. (B2).  Representative 
fluorescence microscope image of EGFP expression in ARPE-19 cells transfected with 
DST20 nioplexes captured at 20x magnification. Scale bar: 100 µm.  
3.4. Cellular internalization and trafficking of nioplexes in ARPE-19 cells 
Figure 4 represents the cellular internalization and intracellular trafficking of DST20, 
DST80 and DST85 nioplexes at cationic lipid/DNA mass ratio 2/1 in ARPE-19 cells. 
DST20 nioplexes showed mean CCF peak values of 0.33 ± 0.04 with CME, 0.54 ± 
0.05 with CvME and no co-localization with the late endosome compartment. In the 
case of DST80 nioplexes, mean CCF peak values were near zero with all endocytic 
pathways. DST85 nioplexes presented mean CCF peak values of 0.58 ± 0.23, 0.29 
± 0.01 and 0.40 ± 0.09 with CME, CvME and late endosomes, respectively (Fig. 4B1-
3). Differences in mean CCF peak values between the three formulations were 
statistically significant (p < 0.05) in the case of CvME and late endosomes. 3D plots 
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in Figures 4C1-3 relate the HLB values of the polysorbates of each formulation with 
their corresponding transfection efficiency and co-localization values.  
 
Figure 4. Endocytic and intracellular trafficking pathways detection assay of DST20, DST80 
and DST85 nioplexes in ARPE-19 cells. (A1-3). Confocal microscopy merged images showing 
ARPE-19 cells co-incubated with nioplexes containing the FITC-labeled pCMS-EGFP plasmid 
(green) and with the endocytic vesicle marker (red): AlexaFluor546-Transferrin for CME, 
AlexaFluor555-Cholera toxin B for CvME and Lysotracker (Lys) for late endosomal 
compartment. (B1-3). Co-localization values of red and green signals determined by cross-
correlation analysis in each case. Data are represented as mean ± SEM, n=3. (C1-3). 3D plots 
relating HLB values and the corresponding transfection efficiency and co-localization with 
intracellular pathways CME (C1), CvME (C2) and late endosomes (C3). 
3.5. Transfection efficiency of DST20 nioplexes in primary culture of rat retinal cells 
Transfection assays with DST20 nioplexes at cationic lipid/DNA mass ratio2/1 
showed EGFP expression in retinal primary cells (Fig. 5A). Figure 5B shows 
transgene expression in cells exposed to the positive control Lipofectamine 2000TM. 
In both conditions, EGFP fluorescence signal was observed mainly in glial cells. 
Importantly, DST20 nioplexes were well tolerated by retinal primary cells whereas 
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cell damage was observed in their counterpart positive controls (Fig. 5B, white 
arrows).  
 
Figure 5. EGFP expression in embrionary rat retinal primary cells analyzed by fluorescence 
immunocytochemistry 96 h post-addition of DST20 nioplexes at cationic lipid/DNA mass ratio 
2/1. (A). EGFP expression in cells exposed to DST20 nioplexes. (B). EGFP expression in cells 
exposed to Lipofectamine 2000TM. Red: MAP2 neuronal dendrite marker; Blue: Hoechst 
33342 (cell nuclei); Green: EGFP. Scale bar: 20 µm. 
3.6. Transfection efficiency of DST20 nioplexes in rat retina in vivo 
DST20 nioplexes were administered to the rat eye through subretinal (SR) and 
intravitreal (IV) injections and transgene expression was found after 72h (Fig. 6). 
Sagital retinal sections for the analysis of SR administration of DST20 nioplexes 
allowed detecting fluorescence signal in different retinal cell layers. The highest 
EGFP expression was observed in the inner nuclear layer (INL), both in retinal cells 
transfected with DST20 nioplexes (Fig. 6B) and with the positive control (Fig. 6C). 
Some diffused fluorescence signal in the outer nuclear layer (ONL) and even in the 
RPE cells could also be observed in both conditions. Regarding IV administration of 
the formulations, the analysis of whole-mount preparations showed fluorescence 
signal in the ganglion cell layer (GCL) both in the case of DST20 nioplexes (Fig. 6D) 
and the positive control Lipofectamine 2000TM (Fig. 6E). Qualitative analysis of cell 
viability suggested that DST20 nioplexes were well tolerated in rat retina.  
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Figure 6. In vivo expression of EGFP 
after subretinal and intravitreal injection 
of DST20 nioplexes at cationic lipid/DNA 
mass ratio 2/1. (A). General schema of 
intravitreal and subretinal injections and 
complete structure of rat retina with 
identified layers visualized by 
hematoxylin and eosin staining of tissue 
sections. Scale bar: 50 µm. RPE (retinal 
pigment epithelium), ONL (outer nuclear 
layer), INL (inner nuclear layer), GCL 
(ganglion cell layer). (B). Confocal 
fluorescence micrographs of retinal 
cross sections showing EGFP signal 
after subretinal administration of DST20 
nioplexes. (C). Confocal fluorescence 
micrographs of retinal cross sections 
showing EGFP signal after subretinal 
administration of the positive control 
Lipofectamine 2000TM. (D). 
Fluorescence immunohistochemistry 
whole mount showing EGFP positive 
signal located in the ganglion cell layer 
after intravitreal administration of DST20 
nioplexes. (E). Fluorescence 
immunohistochemistry whole mount 
showing EGFP positive signal located in the ganglion cell layer after intravitreal administration 
of the positive control Lipofectamine 2000TM. Blue: Hoechst 33342 (cell nuclei); Green: EGFP. 
Scale bars: 20 µm. 
4. Discussion 
Chronic and degenerative diseases of the retina still lack curative treatments, and 
their blinding effect can seriously limit the quality of life3. Non-viral gene delivery 
offers reasonable hope to transfer specific therapeutic genes into the eye. Niosomes 
have been effectively used for gene delivery to retinal cells both in vitro and in vivo, 
and the effect of cationic lipids and helper lipids has been well studied in transfection 
processes mediated by those formulations16,17. To date, niosome formulations 
containing the cationic lipid DOTMA18 or the non-ionic surfactant polysorbate 80 
combined with the helper lipid squalene17 have shown effective gene delivery to the 
retina. However, the use of other non-ionic surfactants with different chemical 
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properties such as polysorbate 20 and polysorbate 85 for retinal gene transfer has 
not been explored. Therefore, in this work we elaborated and characterized, in terms 
of physicochemical properties and transfection efficiency into retinal cells, three 
niosome formulations that only differed in their non-ionic tensioactives. These 
niosomes named DST20, DST80 and DST85 were based on the cationic lipid 
DOTMA, combined with squalene as helper lipid and polysorbates 20, 80 or 85 as 
non-ionic surfactants.  
Non-ionic tensioactives in niosome formulations act as emulsifiers creating a steric 
barrier that avoids aggregation14. Polysorbates 20 and 85 share the same chemical 
root structure as polysorbate 80, but the three molecules differ in their hydrophyilic 
parts and number of hydroxyl groups, therefore presenting different (HLB) values 
(Figure 1). The HLB parameter determines the oil (HLB < 9) or water (HLB > 11) 
solubility of the non-ionic surfactants22. Among the three non-ionic surfactants 
tested, polysorbate 20 is the most hydrophilic, due to the presence of 2 hydroxyl 
groups and a lauric acid, with a HLB value of 16.7. Polysorbate 80 is next with HLB 
= 15 and polysorbate 85 is the less hydrophilic of the three non-ionic surfactants, 
due to the presence of three oleic acids in its chemical structure, with a HLB value 
of 11.  
The physicochemical parameters of formulations are key factors that determine 
transfection efficiency. DST20, DST80 and DST85 niosomes revealed mean particle 
sizes between 100 nm and 225 nm (Fig. 2A, bars), suitable for gene delivery 
purposes23. Little oscillations in particle sizes upon the addition of plasmid DNA at 
cationic lipid/DNA ratios 2/1, 5/1 and 10/1 were probably due to the balance between 
the larger space demanded by the lipid and the higher DNA condensation when 
increasing mass ratios17. In all conditions, formulations showed narrow size 
distributions as indicated by the low PDI values (Fig. 2B). The surface charge of the 
formulations has an impact on their stability, and zeta potential values under -30 mV 
and over +30 mV avoid particle aggregation24. In addition, positive zeta potential 
values promote electrostatic interactions with negatively charged DNA to form 
nioplexes25. The three niosome formulations presented suitable zeta potential values 
over +40 mV (Fig. 2A, dots). As expected, at low cationic lipid/DNA mass ratios 
surface charge values of nioplexes clearly declined, demonstrating that the amine 
groups of the niosomes electrostatically interacted with the phosphate groups of the 
DNA resulting in partial neutralization of surface charges26. In order to determine the 
morphology of our formulations, niosomes were examined under a TEM microscope 
at different magnifications, corroborating that all formulations presented a clear 
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spherical shape (Fig. 2C-E). The ability of nioplexes to protect and release plasmid 
DNA at different cationic lipid/DNA mass ratios was evaluated by a gel retardation 
assay. We found that all formulations were able to protect plasmid DNA even at the 
lowest cationic lipid/DNA mass ratio 2/1 (Fig. 2F). The exception were DST80 
nioplexes, which showed higher ability to protect DNA at higher cationic lipid/DNA 
mass ratios. However, since our purpose was to develop efficient niosome 
formulations for retinal gene delivery in vivo, in all formulations we selected the 
lowest cationic lipid/DNA mass ratio for posterior transfection assays, which allows 
increasing the amount of DNA to administer in vivo and reduces cellular toxicity 
associated to cationic lipids27.  
Once the formulations were fully characterized, we performed in vitro transfection 
studies at cationic lipid/DNA mass ratio 2/1 in the well-known transfection model 
HEK-293 cell line and with the retinal model ARPE-19 cell line in accordance to the 
aim of our study. In both cell lines, nioplexes showed excellent cell viabilities above 
95% in HEK-293 and above 85% in ARPE-19 cells, demonstrating that they were 
well tolerated by both types of cells. This was further confirmed by the healthy 
appearance of HEK-293 and ARPE-19 under the microscope 48 h after transfection 
(Fig. 3A2 and 3B2). In contrast, transfection positive control Lipofectamine 2000TM 
showed lower cell viability values than nioplexes in both cells, around 90% in HEK-
293 cells and around 55% in ARPE-19 cells, which in accordance with previous 
reports17, indicates that in retinal cells nioplexes are much better tolerated. In fact, 
Lipofectamine 2000TM is not considered suitable for retinal gene delivery due to its 
high toxicity to photoreceptor cells even at low concentrations28. Regarding 
transfection efficiency, we found that DST85 niosomes were the most efficient 
transfecting HEK-293 cells (Fig. 3A1), while DST20 nioplexes showed the highest 
transfection values in ARPE-19 cells (Fig. 3B1). It is generally accepted that non-
ionic surfactants with low HLB values and high liposolubility enhance the cellular 
uptake of the formulations29,30. This is consistent with results in HEK-293 cells, since 
polysorbate 85 presents the lowest HLB value among the three non-ionic surfactants 
tested. Interestingly, in ARPE-19 cells, polysorbate 20 containing niosomes seemed 
to be the most efficient for gene transfer. As previously mentioned, polysorbate 20 
has the highest HLB value and therefore, the lowest lipophilicity. All together 
suggests that other cell-dependent mechanisms such as the cell internalization 
mechanisms and endocytic pathways could explain the higher efficiency of DST20 
nioplexes to transfect retinal cells.  
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In this regard, in order to further understand the transfection process with DST20, 
DST80 and DST85 nioplexes in ARPE-19 cells, we analyzed the cell entry 
mechanisms and intracellular trafficking pathways followed by the formulations. Non-
viral vectors usually enter the cells via endocytosis, being CME and CvME the most 
common and well-studied endocytic pathways31. The CvME route has been 
generally considered a non-acidic and non-digestive endocytic pathway32, while the 
CME pathway is believed to integrate the endocyted vesicles into late endosomes, 
which then deliver their cargos to lysosomes33. However, controversial data exist in 
this regard, since it has also been described that caveosomes can join the classical 
endocytic pathway, eventually fusing with lysosomes34,35. In addition, the acid pH in 
lysosomes is believed to cause the dissociation of the DNA from the non-viral 
vector36 which, according to some authors, facilitates the cytosolic release of 
nanoparticles and enhances the nuclear entry of DNA37. Nevertheless, other studies 
reported that in absence of endosomal escape mechanisms, the acid environment 
and the enzymatic activity of lysosomes causes the degradation of nioplexes, 
impeding the access of DNA molecules into the nucleus38. In our study, we found 
that when nioplexes entered predominantly through CME, which was the case of 
DST85 nioplexes, they also co-localized with late endosome lysosomic 
compartments which apparently resulted in a lower transfection efficiency (Figure 4). 
In contrast, when nioplexes entered through CvME, as in the case of DST20 
nioplexes, they seemed to avoid late endosomes and transfection efficiency 
increased. Therefore, our results are in accordance with the lysosomal degradation 
hypothesis upon CME-mediated cell entry, which in turn would explain the higher 
transfection efficiency of DST20 nioplexes in ARPE-19 cells. DST80 nioplexes 
showed very low co-localization values in ARPE-19 cells with both CME and CvME 
pathways, which might be explained by the presence of other cellular internalization 
pathways. In fact, a recent study reported that niosomes based on polysorbate 80, 
squalene and 1-(2-dimethylaminoethyl)-3-[2,3-di(tetradecyloxy) propyl] urea showed 
higher tendency to enter the cells through macropinocytosis than through CME or 
CvME16.  
Based on these results, we selected the formulation DST20 for retinal gene delivery. 
Before moving on to in vivo assays, we performed a preliminary in vitro transfection 
assay in a primary culture of rat retinal cells with DST20 nioplexes, and we observed 
effective transgene expression (Figure 5). Encouraged by those findings, we carried 
out an in vivo study to assess whether the DST20 nioplexes were able to transfect 
the rat retinas after SR (Fig. 6B-C) and IV injections (Fig. 6D-E). In most cases, 
efficient transfection of ganglion cells of the retina can be achieved by IV injections, 
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whereas transfecting cells in the outer retina, such as photoreceptor and the RPE, 
requires the more invasive SR injection28,39. In accordance, our results show that IV 
administration of DST20 nioplexes was successful to transfect predominantly 
ganglion cells of the retina (Figure 6D), while with SR administration efficient 
transgene expression was observed in the inner layers of the retina, with clear 
diffusion to the outer layers including RPE cells (Figure 6B). Considering that many 
blinding diseases are associated to mutations in specific genes of the RPE, 
achieving transfection at this level is highly desirable for therapeutic purposes. 
Unfortunately, SR injection is one of the most invasive methods and implies 
significant risk of complications such as inflammation, damage to the lens and retinal 
detachment40. Although many efforts are conducted to increasing RPE transgene 
expression after IV injection, at present the SR administration remains more efficient 
for RPE cells transfection. Additionally, research is also being directed towards 
ocular topical instillation of drugs. In fact, efficient topical drug delivery to the RPE 
layer of the retina with microfluidizer produced small liposomes has been recently 
reported41. This method does not imply any risks of retinal damage and it would be 
the ideal administration method for non-viral vectors carrying nucleic acids. 
However, in the field of gene therapy more research is still needed to improve the 
efficiency of gene delivery through this approach and become clinically relevant for 
retinal diseases.  
Conclusions 
In summary, we have elaborated and characterized three niosome formulations that 
only differed in the non-ionic tensioactives. We found that the novel DST20 niosome 
formulation, based on polysorbate 20 combined with cationic lipid DOTMA and 
helper lipid squalene, efficiently transfected rat retina both in vitro and in vivo at the 
low cationic lipid/DNA mass ratio 2/1. Targeted cells strongly depended on the 
administration route. SR injection transfected the inner layers of the retina and 
showed clear diffusion to outer layers including the RPE, while IV injection 
transfected predominantly the ganglion cell layer. With the advancement of DNA 
compaction technology and vector engineering strategies, efficient transfection 
through less invasive administration routes and prolonged transgene expression 
may be achievable goals. 
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Non-viral vectors based on cationic niosomes 
and minicircle DNA technology enhance gene 
delivery efficiency for biomedical applications 
in retinal disorders 
 






Transfekzio-maila egokiak lortzea da bektore ez-biralek erabilera klinikora iristeko gainditu 
beharreko erronka nagusia. Gure helburua gene-terapia ez-biralaren eraginkortasuna 
areagotzeko estrategia berriak garatzea izan da, betiere erretinari eragiten dioten gaitzei aurre 
egiteko tratamenduak lortze aldera. Nioplexoak lortzeko, niosoma kationiko bakoitzari 
ondorengo hiru material genetiko ezberdinetako bat lotu genien: minicircle-a (2,3 kb), bere 
jatorrizko plasmidoa (3,5 kb) eta plasmido handiago bat (5,5 kb). Karakterizazio fisiko-kimiko 
osoa egin ondoren, in vitro entseguak egin genituen ARPE-19 erretinako zeluletan. Gure 
emaitzen arabera, minicircle material genetikoa zeramaten niosomekin lortutako transfekzio-
maila plasmidoak zeramatzatenekin lortutakoaren bikoitza izan zen, kasu guztietan zelulen 
biziraupen-maila egokiak mantenduz. Erretinako zelula primarioen kultiboetan zein in vivo 
arratoi erretinetan egindako transfekzio entseguek ere gauza bera erakutsi zuten, minicircle-
a zeramaten niosomen transfekzio-mailak altuenak ziren kasu guztietan. Beraz, niosoma 
kationikoz eta minicircle material genetikoz osatutako bektore ez-biralak aukera aparta izan 
daitezke erretinarako gaitzen aurkako aplikazio biomedikoetan erabiltzeko.  
 
Superar la baja eficiencia de transfección para llegar a la práctica clínica sigue siendo uno de 
los mayores retos de la terapia génica no-viral. Nuestro objetivo fue explora nuevas 
estrategias para obtener estrategias de transferencia de genes no-virales más eficientes que 
pudieran tener aplicaciones biomédicas en el tratamiento de enfermedades que afectan a la 
retina. Se combinaron niosomas catiónicos y tres tipos de material genético que codificaban 
la proteína verde fluorescente (GFP) que consistían en un minicircle (2,3 kb), su plásmido 
parental (3,5 kb) y un plásmido de mayor tamaño (5,5 kb) para formar los nioplexos. Una vez 
completamente caracterizados, se llevaron a cabo experimentos de transfección in vitro en la 
línea celular ARPE19 y se observó que la eficiencia de transfección de los nioplexos que 
contenían el minicircle doblaba la de los nioplexos que contenían los plásmidos, manteniendo 
excelentes porcentajes de viabilidad celular en todos los casos. Las transfecciones en células 
de cultivo primario de retina y las inyecciones de los nioplexos en retina de rata confirmaron 
la mayor capacidad de transfección de los nioplexos que vehiculizaban el minicircle frente a 
los que vehiculizaban plásmidos. Por lo tanto, los nioplexos basados en niosomas catiónicos 
y ADN minicircle representan una herramienta prometedora para el tratamiento de 
enfermedades retinianas genéticas.  
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Abstract  
Low transfection efficiency is a major challenge to overcome in non-viral approaches 
to reach clinical practice. Our aim was to explore new strategies to achieve more 
efficient non-viral gene therapies for clinical applications and in particular, for retinal 
diseases. Cationic niosomes and three GFP-encoding genetic materials consisting 
on minicircle (2.3 kb), its parental plasmid (3.5 kb) and a larger plasmid (5.5 kb) were 
combined to form nioplexes. Once fully physicochemically characterized, in vitro 
experiments in ARPE-19 retina epithelial cells showed that transfection efficiency of 
minicircle nioplexes doubled that of plasmids ones, maintaining good cell viability in 
all cases. Transfections in retinal primary cells and injections of nioplexes in rat 
retinas confirmed the higher capacity of cationic niosomes vectoring minicircle to 
deliver the genetic material into retina cells. Therefore, nioplexes based on cationic 
niosomes vectoring minicircle DNA represent a potential tool for the treatment of 
inherited retinal diseases. 
 
Keywords: Non-viral vector, niosomes, minicircle, transfection, gene therapy, retina.  




The pathogenesis of several blinding retinal disorders such as retinitis pigmentosa, 
Leber´s congenital amaurosis, macular dystrophies and age-related degeneration of 
the macula among others, have a genetic background 1, 2. Currently, there is no an 
effective treatment for these kind of disorders and, to date, gene therapy strategies 
seem to be one of the most promising field of research 3, 4. Non-viral gene delivery 
approaches have key safety advantages over viral vectors and their use in clinical 
trials has gained importance since 2004, meanwhile the viral vectors ones have 
significantly decreased 5 due to their risk of oncogenesis, immunogenicity, 
mutagenicity and even the persistence of viral vectors in the brain after intravitreal 
injection 6-8. Particularly, cationic lipids are actually among the most commonly used 
non-viral vectors 5, 9.  
Niosomes are drug delivery systems able to bind genetic material, forming 
complexes known as nioplexes, with the ability to protect the DNA from enzymatic 
digestion and to introduce it into the cell with controlled release kinetics. 
Furthermore, they present low toxicity due to their biocompatibility and 
biodegradability, are osmotically active, chemically stable formulations, and easy 
handling 10, 11, establishing as a better alternative than the common liposomes. 
Niosomes are composed by cationic lipids to form complexes with the negatively 
charged DNA by electrostatic interactions 12, helper lipids to promote the physico-
chemical and biological properties of the complex 13, 14, and non-ionic surfactants to 
enhance the stability 15. Recently, it has been reported their capacity to transfect in 
vivo brain and retinal cells in rats 16-19. Even though the low toxicity of nioplexes 
preserve cell viability when transfected, the major challenge to reach the clinical 
practice is the limited transfection efficiency 20. Therefore, more research efforts are 
required for the successful implementation of niosomes as optimal gene delivery 
carriers.   
Currently, minicircle (MC) DNA technology offers a potential solution to the reduced 
transfection efficiency translational barrier for gene therapy. MCs are small circular 
DNA vectors with no antibiotic resistant genes or bacterial backbone sequences, 
which make them superior to regular plasmids. MC-DNA has a reduced size 
compared with conventional plasmid DNA with the same expression cassette and 
the content of unmethylated CpG dinucleotides is considerably reduced. Thus, their 
use results in sustained transgene expression due to lower activation of nuclear 
transgene silencing mechanisms, and reduced immunogenic responses in vivo 21-26.   
Our goal is to provide as far as we are concerned, the first evidence that niosome 
based non-viral vectors combined with the MC technology is an effective technique 
for future clinical applications in the retinal gene therapy field. We employed DST20 
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formulation comprised of cationic lipid 1,2-di-O-octadecenyl-3-trimethylammonium 
propane (DOTMA), the helper lipid Squalene and the non-ionic surfactant 
polysorbate Tween 20 17-19. The resulting niosomes were combined with three 
different DNA materials consisting on MC-GFP of 2257 bp, pGFP of 3487 bp and 
pEGFP of 5541 bp, to form the corresponding nioplexes. Niosomes and nioplexes 
were characterized in terms of particle size, polydispersity index (PDI), zeta 
potential, morphology and stability. The capacity of niosomes to protect and release 
these DNA materials as well as the binding interactions between cationic niosomes 
and DNAs at molecular level was also analyzed. In vitro experiments were performed 
to evaluate both the efficiency and cell viability of transfection over time and at 
different temperatures with the three DNA materials complexed to DST20 niosomes 
in human ARPE-19 retinal pigment epithelium cells. Additionally, the transfection 
capacity of these nioplexes was assessed by ex vivo experiments in embrionary rat 
retinal primary cells and by in vivo administration of nioplexes to rat eyes via 
intravitreal (IV) and subretinal (SR) injections. 
 
2. Methods 
2.1. Production of cationic niosomes 
Niosomes based on cationic lipid DOTMA (Avanti Polar Lipids, Inc., Alabama, USA), 
helper lipid squalene (Sigma-Aldrich, Madrid, Spain) and the polysorbate Tween 20 
(Sigma-Aldrich, Madrid, Spain) were prepared using the o/w emulsification technique 
to a molar ratio of 2 mM cationic lipid/ 8 mM helper lipid/ 4 mM tensioactive. The 
emulsion was obtained by sonication (Branson Sonifier 250, Danbury) for 30 s at 50 
W. The dichloromethane organic solvent was removed from the emulsion by 
evaporation under magnetic agitation for 3 h at room temperature, obtaining the 
niosome DST20 solution.  
 
2.2 DNA material: plasmids and minicircle technology 
The 5541 bp pCMS-EGFP plasmid (Clontech laboratories, Inc, USA) (Figure 1), here 
named as pEGFP 5.5 kb, was propagated in Escherichia coli DH5-α and purified 
using the Qiagen endotoxin-free plasmid purification Maxi-prep kit (Qiagen, 
California, USA) according to manufacturer’s instructions. The concentration of the 
purified pDNA was quantified by measuring the absorbance at 260 nm in a 
SimpliNanoTM spectrophotometer device (GE Healthcare, Buckinghamshire, UK).  
The 3487 bp pCMV-GFP plasmid (PlasmidFactory, Bielefeld, Germany) was 
employed as the parental plasmid of the 2257 bp MC.CMV-GFP minicircle 
(PlasmidFactory, Bielefeld, Germany) (Figure 1), which was devoid of any selection 
markers such as antibiotic resistance genes and bacterial origin of replication (ori). 
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Figure 1: DNA material composition.  
(A) pEGFP 5.5 kb, (B) pGFP 3.5 kb, (C) MC-GFP 2.3 kb. MC: minicircle; GFP: green 
fluorescent protein; EGFP: enhanced green fluorescent protein; pCMS: plasmid containing 
Cytomegalovirus promoter, Multiple cloning site and SV40 promoter; pCMV: cytomegalovirus 
promoter plasmid; bp: base pairs. 
 
2.3. Preparation of nioplexes 
The nioplexes were prepared by mixing an appropriate volume of a stock solution of 
either MC-GFP (1 mg/ml), pGFP 3.5 kb (1 mg/ml) or pEGFP 5.5 kb (0.5 mg/ml), with 
a volume of the niosome DST20 suspension (1 mg DOTMA/ml) to obtain a 
DOTMA/DNA ratio (w/w) of 2/1. The mixture was incubated for 30 min at room 
temperature before use to enhance electrostatic interactions between the cationic 
lipid and the negatively charged DNAs.   
 
2.4. Physicochemical characterization of niosomes and nioplexes 
Z-average particle size and PDI were determined by dynamic light scattering, and 
zeta potential was measured by laser Doppler velocimetry in a Zetasizer Nano ZS 
(Malvern Instruments, UK) previous resuspension of the samples into NaCl 1 mM 
solution. The particle size, reported as hydrodynamic diameter, was achieved by 
cumulative analysis. The Smoluchowski approximation supported the calculation of 
the zeta potential from the electrophoretic mobility. All measurements were carried 
out in triplicate.  
The morphology of niosomes was assessed by transmission electron microscopy 
(TEM) as previously described 17. The capacity of niosomes to protect and release 
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the genetic material from enzymatic digestion was analyzed by a gel retardation 
assay as previously described 27. Naked DNA was used as control at each condition, 
being the amount of DNA per well 100 ng in all cases. 
Niosome-DNA interactions for nioplexes formation were analyzed by isothermal 
titration calorimetry (ITC) using a MicroCal PEAQ-ITC microcalorimeter (Malvern 
Instruments, UK). The assay was executed at 25°C by stepwise injection of DST20 
(0.25 mg/ml DOTMA) into the reaction cell loaded with an aqueous solution of the 
DNA material (0.0166 mg/ml). Typically, 1 × 0.4 μl injection followed by 13 x 3 μl 
injections was carried out automatically under 750 rpm stirring. In selected 
experiments, a second set of injections followed the first one after refilling the 
injection pipette with the same DST20 solution. The heat contributed by niosome 
dilution was measured in separate runs and subtracted from the total heat produced 
following each injection prior to the data analysis. The full set of experiments 
achieved at a given condition was carried out with the same dilution of niosomes in 
order to minimize errors.  
 
2.5. Stability assays 
DST20 niosomes were evaluated for stability at day 0 and after their storage for 30 
days at 4ºC and 25ºC. Stability test consisted of the analysis of niosomes and 
nioplexes at day 0 and after the aforementioned storage in terms of particle size, 
PDI, zeta potential, TEM, gel retardation assay and ITC, as previously mentioned. 
Additionally, biological stability of niosomes in terms of transfection efficiency and 
cell viability were assessed in vitro at the aforementioned storage conditions. 
 
2.6. Cell culture and in vitro transfection assays 
Human retinal pigment epithelium cells ARPE-19 (ATCC, CRL-2302™) were 
transfected with nioplexes at the day 0 of the DST20 niosomes preparation and after 
the storage of niosomes for 30 days at 4ºC and 25ºC. Cells were seeded without 
antibiotics in the medium in 24 well plates at 12 x 104 cells per well and incubated 
overnight to achieve 70 % of confluence at the time of transfection. The formation of 
DST20:DNA complexes composed of DST20 niosomes and 1.25 µg DNA of either 
MC-GFP, pGFP 3.5 kb or pEGFP 5.5 kb at 2/1 (w/w) DOTMA/DNA ratio, were left to 
occur through electrostatic interactions for 30 min at room temperature. Medium was 
removed and cells were washed with serum-free OptiMEM solution (Gibco, 
California, USA). Next, cells were exposed to nioplexes diluted in serum-free 
OptiMEM solution for 4 h at 37ºC for transfection. After incubation, the transfection 
medium was removed and fresh medium was added to the cells.   
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Transfection efficiency was analyzed qualitatively and quantitatively by fluorescence 
microscopy imaging (EclipseTE2000-S, Nikon) and by flow cytometry (FACSCalibur, 
BD Biosciences), respectively, 48 h after the exposure to nioplexes. To analyze cell 
viability, cells were stained with ethidium homodimer-1 (Life Technologies, Paisley, 
UK) prior to flow cytometry. A minimum of 10,000 events were collected and 
analyzed for each sample. Lipofectamine™ 2000 (Invitrogen, California, USA) was 
used as positive control, and corresponding lipoplexes were prepared according to 
the manufacturer’s protocol. Non-transfected cells but incubated with OptiMEM for 4 
h were employed as negative control. Each condition was performed in triplicate. 
 
2.7. Animal model 
Adult male Sprague–Dawley rats were used as experimental animal model. All 
experimental procedures were carried out in accordance with the Spanish and 
European Union regulations for the use of animals in scientific research and the 
Association for Research in Vision and Ophthalmology (ARVO) statement for the 
use of animals in ophthalmic and vision research. Procedures were supervised by 
the Miguel Hernández University Standing Committee for Animal Use in Laboratory.  
 
2.8. Transfection assays in rat primary retinal cell culture and 
immunocytochemistry 
Embrionary rat retinal primary cells were extracted from E17.5 rat embryos from n = 
4 Sprague Dawley rats. Transfection assays with nioplexes were performed at the 
day 0 of the DST20 niosomes preparation. Cells were seeded on poly-D-lysine-
coated coverslips in 12 well plates at 2x105 cells per well. The composition of 
DST20:DNA nioplexes and transfection conditions were the same as the previously 
mentioned ones for in vitro assays. Lipofectamine™ 2000 was used as positive 
control.  
Transfection efficiency was analyzed qualitatively 96 h after the exposure to 
nioplexes by immunocytochemistry. Cellular phenotypes were assessed using 
specific antibody markers. For that, coverslips were incubated overnight with rabbit 
polyclonal anti-rabbit microtubule associated protein-2 (MAP2) (1:400 dilution; 
Millipore) as neuronal marker and with secondary antibody donkey anti-rabbit IgG 
Alexa Fluor 555 (1:200 dilution; Thermo Fisher Scientific), previous wash with PBS. 
Nuclei were stained with Hoechst 33342 (Thermo Fisher Scientific). Fluorescence 
analysis was performed with a Zeiss AxioObserver Z1 (Carl Zeiss) microscope 
equipped with an ApoTome system and different fluorescence filters.      
 
2.9. Intravitreal and subretinal administration of nioplexes 
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The injection solution consisted of 4 μl of nioplexes suspension containing 100 ng of 
either the plasmids or MC. Nioplexes were injected in the left eyes of adult male 
Sprague–Dawley rats (6–7 weeks old and 150–200 g body weight) intravitreally (n = 
3) or subretinally (n = 3) under an operating microscope (Zeiss OPMI® pico; Carl 
Zeiss Meditec GmbH, Jena, Germany) with the aid of a Hamilton microsyringe 
(Hamilton Co., Reno, NV), as previously described 17. The untreated right eyes 
served as negative control. Lipofectamine™ 2000 was used as positive control of 
gene delivery.  
 
2.10. Evaluation of GFP expression in rat retina 
GFP expression was evaluated qualitatively 96 h after the injection of nioplexes in 
whole-mount and sagittal sections of the retina, as previously described 17. Images 
of GFP signal were acquired using a Leica TCS SPE spectral confocal microscope 
(Laica Microsystems GmbH, Wetzlar, Germany). Images were processed, montaged 
and composed digitally using ImageJ (NIH, Bethesda, MD) and Adobe® 
Photoshop® CS5.1 software (Adobe Systems Inc., CA, USA). GFP expression in 
the different layers of the retina was quantitatively evaluated in 7 to 10 retinal vertical 
sections from each group after subretinal injection. The percentage of the 
fluorescence in every layer was calculated with ImageJ software 
(http://imagej.nih.gov/ij/; provided in the public domain by the National Institutes of 
Health, Bethesda, MD, USA) using a self‐developed macro for analysis of acquired 
image. The same procedure was followed for retinal whole mounts fluorescent 
measurements after intravitreal injections. 
 
2.11. Statistical analysis 
Differences between groups were evaluated using a Student’s t test for unpaired 
data or a Mann–Whitney U test, as appropriate after evaluating normality (Shapiro–
Wilks test) and the homogeneity of the variance (Levene test). Data are expressed 
as mean ± SD. A P value < 0.05 was considered statistically significant. Analyses 
were performed with the IBM SPSS Statistics 22.Ink statistical package. 
 
3. Results  
3.1. Physicochemical characterization and stability of niosomes and nioplexes 
The physicochemical characteristics of niosomes and nioplexes at the day 0 of the 
formulation and after 30 days of storage at 4ºC and 25ºC are summarized in Figure 
2A. The mean diameter size of niosomes was around 125 nm and remained constant 
over time and temperature. PDI was lower than 0.20 and zeta potential values 
increased up to 63.4 mV after 30 days of incubation at 25°C. In nioplexes, as 
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expected, mean diameter sizes increased when complexing DST20 niosomes with 
the corresponding DNA material, reaching almost the double of its original diameter 
(from 123 nm to 239-255 nm), and zeta potential values diminished (from 63.4 mV 
to 22.7-5.1 mV). As all nioplexes were at the same 2/1 ratio, only slight differences 
in size were found among nioplexes, ranging from 228 nm to 255 nm. Furthermore, 
nioplexes maintained proper characteristics for gene therapy applications, with 
values under 0.3 for PDI and positive zeta potential after 30 days of incubation. 
Regarding stability of nioplexes, pEGFP 5.5 kb and specially MC-GFP nioplexes 
kept their size over time independently of the temperature of storage. In contrast, 
pGFP 3.5 kb nioplexes increased their size specially when stored at 25ºC, which 
consequently caused a more drastic reduction of its zeta potential value to 5 mV 28.  
TEM images (Figure 2B), revealed that DST20 niosomes at day 0 had clear spherical 
morphology and no aggregations were formed (Figure 2B, i), meanwhile a loss of 
the spherical shape was observed after 30 days of storage (Figure 2B, ii and iii) and, 
additionally, a high proportion of aggregates when stored at 25ºC (Figure 2B, iii).  
The gel retardation assay (Figure 2C) showed that DNA was properly protected from 
DNase I enzymatic digestion and released after the addition of sodium dodecyl 
sulfate (SDS) on lanes 3, 6 and 9 corresponding to MC-GFP, pGFP 3.5 kb and 
pEGFP 5.5 kb nioplexes, respectively. Of note, the signal of these bands was lower 
in the nioplexes formed with DST20 niosomes stored for 30 days at 4ºC and 25ºC 
(Figure 2C, ii and iii, respectively) compared with the ones formed with day 0 DST20 
niosomes (Figure 2C, i). The absence of bands on lanes 2, 5 and 8 demonstrated 
that free DNA was completely digested by the DNase I enzyme. In addition, in Figure 
2C, i, minicircle nioplexes (lane 3) showed better stability under enzymatic digestion, 
since intensity of lane 6 (pGFP 3.5 kb plasmid) is clearly inferior, and lane 9 (pEGFP 
5.5 kb plasmid) shows a long smear. This fact could account for better transfection 
efficiency of minicircle nioplexes. 
ITC data (Figure 2D) represents the heat evolved per injection (normalized per mg 
of DOTMA injected) as a function of the DOTMA/DNA ratio. At day 0 of niosome 
formulation (black circles), there was an abrupt change in the titration curves of 
pGFP 3.5 kb and pEGFP 5.5 kb at values of around 1.25 and 2.0, respectively. As 
more niosomes were added, the heat released during the injection decreased 
approaching to zero (Supplementary Figure S1). In addition, a slow process was 
observed in the raw injection peaks of pGFP 3.5 kb data at ratios 0.9−1.4, meanwhile 
the formation of MC-GFP and pGFP 5.5 kb nioplexes proceeded through fast 
kinetics (Supplementary Figure S2). Remarkably, both the abrupt change in the 
tendency of the titration profile and the slow process were sensitive to DST20 
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storage, as evidenced their shift toward lower DOTMA/DNA ratios when day 30 
niosomes were used.  
 
Figure 2: Physicochemical characterization and stability measurements of niosomes 
and nioplexes. (A) Physicochemical characterization of DST20 niosomes at day 0 and at day 
30 of storage at 4ºC and 25ºC, and corresponding nioplexes. Each value represents the mean 
± SD from three measurements. (B) TEM images of DST20 niosomes at day 0 (i), at day 30 
of storage at 4ºC (ii) and 25ºC (iii). Scale bars: 500 nm (outer images) and 200 nm (inner 
images). (C) Gel retardation assay to analyze the capacity of DST20 niosomes to protect and 
release the DNA material at day 0 (i), at day 30 of storage at 4ºC (ii) and 25ºC (iii). DNase I 
enzyme and SDS were added in lanes 3, 6 and 9 to evaluate both protection and release in 
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MC-GFP, pGFP 3.5 kb and pEGFP 5.5 kb nioplexes, respectively. As controls, lanes 1, 4 and 
7 correspond to control naked MC-GFP, pGFP 3.5 kb and pEGFP 5.5 kb, respectively, and 
lanes 2, 5 and 8 to those naked DNAs after adding DNase I enzyme, respectively. (D) ITC 
study of DNA titration with DST20 niosomes. Corresponding variation of heat evolved per mg 
of DOTMA injected vs. the ratio of DOTMA/DNA concentrations expressed in mg/ml. Symbols 
represent the experimental data whereas the discontinuous line illustrate the tendency of the 
ITC profiles. 
 
3.2. In vitro studies for transfection efficiency and cell viability over time and 
storage conditions 
The higher rate of transfection observed in vitro in ARPE-19 cell line was obtained 
with MC-GFP and pGFP 3.5 kb Lipofectamine positive controls, with a normalized 
value of 1 representing a 52% of GFP expression in live cells (Figure 3A, bars). All 
data were normalized in relation to this value. For DST20 formulation at day 0, there 
were no significant differences in GFP expression between MC-GFP nioplexes (0.8 
± 0.03) and its positive control (1.0 ± 0.15). In contrast, GFP expression of nioplexes 
carrying plasmid material was lower than their respective positive controls (P < 0.05). 
In addition, significant differences were found among nioplexes depending on the 
DNA material complexed to the niosome, thus, DST20 nioplexes containing MC 
presented higher transfection efficiency than those containing plasmids (MC-GFP: 
0.8 ± 0.03; pGFP 3.5 kb: 0.4 ± 0.02; pEGFP 5.5 kb: 0.1 ± 0.01; P < 0.05).  
Upon DST20 storage for 30 days, transfection efficiency of nioplexes was lower (P 
< 0.05) for every DNA material when compared to that at day 0, reaching the lowest 
values when stored at 25ºC except for pEGFP 5.5 kb where no differences were 
found between 4ºC and 25ºC storage (Figure 3B, bars). Of note, DST20 niosomes 
stored for 30 days at 4ºC vectoring MC remained exhibiting a higher gene delivery 
capacity compared with plasmid nioplexes (MC-GFP: 0.35 ± 0.02, pGFP 3.5 kb: 0.26 
± 0.01, pEGFP 5.5 kb: 0.05 ± 0.01; P < 0.05). Qualitative analysis of in vitro 
transfection efficiency is reflected in the fluorescence microscopy images shown in 
Supplementary Figure S3. 
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Regarding cell viability, DST20 at day 0 nioplexes presented higher rates (P < 0.05) 
of living cells compared with their counterpart positive controls in all cases, reaching 
values above 90% (Figure 3A, dots). This cell viability remained stable over time 
when DST20 was stored for 30 days at 4ºC and decreased to 80% values when 
stored at 25ºC (Figure 3B, dots).  
Figure 3: Transfection efficiency of nioplexes and cell viability in ARPE-19 cell line.  
Flow cytometry evaluation of GFP positive live cells (bars) and viability (dots) after transfection 
employing (A) DST20 niosomes at day 0 and (B) after 30 days of storage at 4ºC and 25ºC, 
bound to either MC-GFP, pGFP 3.5 kb or pEGFP 5.5 kb. Data are presented as mean ± SD, 
n = 3. *P < 0.05 for transfection efficiency groups, #P < 0.05 for cell viability relative to its 
respective Lipofectamine™ 2000; ns means no statistically significant differences. 
 
3.3. Immunofluorescence analysis of GFP expression in embrionary rat retinal 
primary cells  
Transfection assays showed GFP expression in retinal primary cells exposed to 
DST20 at day 0 nioplexes for every DNA material (Figure 4). In general terms, 
fluorescence signal emitted due to MC-GFP, pGFP 3.5 kb and pEGFP 5.5 kb 
transfections vectored by DTS20 niosomes was observed mainly in glial cells (Figure 
4A-C, respectively). Accordingly, glial morphology like cells too showed transgene 
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expression when vectored by their counterpart positive control (Figure 4D-F, 
respectively). Of note, many apoptotic cells could be observed in the 
LipofectamineTM  2000 positive controls (Figure 4, white arrows). 
 
 
Figure 4: GFP expression in embrionary rat retinal primary cells. 
Fluorescence immunocytochemistry showing GFP positive signal located mainly in glial cells 
after transfection with DST20 nioplexes, carrying either (A) MC-GFP, (B) pGFP 3.5 kb or (C) 
pEGFP 5.5 kb. (D-F) images of their counterpart positive controls exposed to Lipofectamine™ 
2000. Cell nuclei were counterstained with Hoechst 33342 (pseudocolored blue) and neuronal 
dendrites with MAP2 (red color). White arrows indicate apoptotic nuclei.  Scale bars: 20 µm. 
 
3.4. Analysis of GFP expression in vivo  
GFP expression was found in rat retinas 72 hours upon IV and SR administration of 
DST20 nioplexes vectoring any of the three DNA materials (Figures 5 and 6), 
whereas no fluorescence signal was detected in control retinas (data not shown).  
The analysis of whole-mount preparations after IV administration of DST20 
nioplexes showed in all cases GFP expression in the ganglion cell layer (GCL) 
(Figure 5). SR administration of DST20 nioplexes vectoring either MC-GFP, pGFP 
3.5 kb or pEGFP 5.5 kb (Figure 6 A-C, respectively) was analyzed in sagittal retinal 
sections, showing GFP expression located in different retinal cell layers. Some 
fluorescence signal was located in the inner nuclear layer (INL), especially for MC 
which showed also GFP expression in the ganglion cell layer (GCL). In all cases, 
GFP signal was mainly observed in the outer segments (OS) of the photoreceptors 
and, importantly, at the retinal pigment epithelium level (RPE). Qualitative analysis 
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after both IV and SR injections showed that MC-GFP nioplexes resulted in the higher 
rate of GFP expression, diminishing progressively with pGFP 3.5 kb and pEGFP 5.5 
kb nioplexes. 
 
Figure 5: In vivo expression of GFP after intravitreal injection of nioplexes. 
Fluorescence immunohistochemistry in a whole-mounted vitreous side-up retinal section 
showing GFP positive signal located in the ganglion cell layer after intravitreal administration 
of DST20 nioplexes carrying either (A) MC-GFP, (B) pGFP 3.5 kb or (C) pEGFP 5.5 kb. (D-F) 
images of their counterpart positive controls. Cell nuclei were counterstained with Hoechst 
33342 (pseudocolored blue). Scale bars: 20 µm. 




Figure 6: In vivo expression of GFP after subretinal injection of nioplexes. 
Confocal fluorescence micrographs of retinal cross sections showing GFP signal after 
subretinal administration of DST20 nioplexes carrying either (A) MC-GFP, (B) pGFP 3.5 kb or 
(C) pEGFP 5.5 kb. (D-F) images of their counterpart positive controls. RPE (retinal pigment 
epithelium), OS (outer segments), ONL (outer nuclear layer), INL (inner nuclear layer), GCL 
(ganglion cell layer). Cell nuclei were counterstained with Hoechst 33342 (pseudocolored 
blue). Scale bars: 20 µm. 
 
4. Discussion 
The main findings of this study are the following: (1) DST20 niosomes is a non-viral 
vector able to protect genetic material and release it with controlled kinetics; (2) the 
capacity of niosomes to protect and interact with DNA material is affected over time 
and temperature of storage; (3) DST20 niosomes complexed with different genetic 
material, varying in terms of size and composition, present similar size and zeta 
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potential but have different transfection efficiencies in vitro, meanwhile cell viability 
is not affected; (4) DST20 nioplexes containing MC-DNA present higher transfection 
efficiency than those containing plasmids in in vitro assays, even after DST20 
storage for 30 days; and (5) DST20 nioplexes are able to transfer the genetic 
material not only in ex vivo primary retinal cell cultures but also after in vivo injection 
in rat retinas regardless the via of administration, being those carrying MC-DNA the 
ones that present the higher rate of GFP signal. Therefore, DST20 niosomes 
vectoring MC technology seems to be an efficient and safe therapeutic tool for retinal 
disorders, overcoming the existing translational barrier of non-viral vectors 
complexed with plasmids due to their poor transfection efficiency.  
DST20 niosomes presented appropriate spherical morphology and size for gene 
therapy purposes, 123 nm, with low PDI and positive zeta potential pointing out not 
only a good homogeneity and stability of the suspensions, but also an easy 
interaction with the negatively charged phosphate groups of the DNA material to 
form nioplexes, respectively 29-31. It is worth mentioning that differences in the 
reported size of niosomes between dynamic light scattering and TEM techniques 
could be explained by the sample processing and treatment performed for both 
analyses 32. As expected, complexation of DST20 niosomes with the corresponding 
DNA almost doubled its original diameter and zeta potential values diminished due 
to the partial neutralization of the positive amine groups of niosomes by the DNA 
phosphate groups.  
The features observed regarding size, zeta potential and transfection efficiency 
when complexing niosomes to the three genetic materials, are in accordance with 
previous studies which confirm that the DNA size bound to niosomes does not affect 
such physicochemical properties of nioplexes 33 but have different transfection 
efficiencies in vitro 34. The explanation for the differences observed in transfection 
efficiencies might reside in two main factors. On the one hand, the magnitude of the 
increment in the particle-size of nioplexes with respect to the niosomes seems to 
rule out the possibility that the second phase seen in the ITC titration curves might 
be due to the binding of more niosomes onto DNA-coated nioplexes. Thus, niosome-
DNA binding events occurring at higher ratios than 2/1 would probably involve the 
reorganization of the previously bound genetic material, which would lead to a 
reduction in the number of DNA molecules bound per niosome and to the preferential 
occupation of the most favourable binding sites on the niosome surface. This could 
also affect the ability of the nioplexes to interact with the cell surface and, 
consequently, their transfection capacity. On the other hand, this study was 
developed with a constant DNA quantity of 1.25 µg per condition but it has to be 
taken into account that DNA length, and therefore weight and molarity, differs 
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between the three genetic materials under study, which consequently affects the 
number of DNA molecules bound to each niosome. This fact can be observed in the 
ITC assay where different calorimetry curves were obtained depending on the 
genetic material complexed to the DST20 formulation. Hence, niosomes would be 
incorporating more MC molecules than plasmids ones, which means a higher rate of 
expression cassettes per niosome, increasing the probability of efficient gene 
delivery into the cell and finally a higher transgene expression 25, 34.  
The differences found in GFP expression upon the storage of niosomes could be 
explained not by a single cause but by several cumulative reasons. In fact, effective 
gene delivery is affected by size range and zeta potential but many other relevant 
parameters such as a correct vector morphology and DNA binding affinity may 
impact on this effectiveness 35. In this regard, TEM images showed a loss of the 
spherical shape of niosomes and even the formation of some aggregates after 30 
days of storage, which in turn would difficult interactions with the DNA material. 
Actually, gel retardation and ITC assays confirm this reduction of DNA complexation 
capacity of niosomes over time. In agarose gels, the lower signal of bands 
corresponding to DNA protection and release after storage denoted a reduction of 
these capacities. Accordingly, ITC data would be indicative that the molecular 
features of the DST20-based nioplexes formed at 2.0 ratio (equivalent to 
DOTMA/DNA ratio 2/1) could depend on the previous history of the niosomes, 
explaining the differences mentioned before, such as the physicochemical features, 
the morphology of niosomes and their ability to protect and release the DNA. Even 
though DST20 niosomes stored for 30 days at 4ºC vectoring MC remained exhibiting 
a higher gene delivery capacity compared with plasmid nioplexes, additional efforts 
are required in order to achieve more stable formulations by either performing better 
characterization methods or by introducing modifications into formulations 
themselves. Regarding cell viability, the slightly lower values obtained with 
DST20/MC (2.3kb) nioplexes compared to both DST20/ pGFP(3.5kb) and DST20 
pEGFP (5.5kb) at day 0, could be explained by the higher transfection efficiencies 
obtained with this formulation, since the transfection process itself can cause cellular 
toxicity. Anyway, all DST20 nioplexes vectoring the three different genetic materials 
exhibited excellent cell viability values around 90% at day 0, significantly higher than 
those obtained with positive control  Lipofectamine™ 2000 (around 60%), indicating 
that they were well tolerated by cells. In embrionary rat retinal primary cell cultures, 
DST20 nioplexes showed clear transgene expression with high cell viability in all 
conditions, predominantly in glial cells probably due to their high phagocytic capacity.  
Since IV and SR routes are considered the most clinically viable options to deliver 
efficiently the genetic material to the back of the eye 36, nioplexes were injected at 
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these levels in vivo. In both cases, we did not observe any sign of toxicity or 
inflammation of the eye fundus upon administrations (data not shown). IV 
administration of DST20 nioplexes showed GFP expression in the GCL, in 
accordance with previous works employing non-viral vectors 17, 18. Effective gene 
transfer at this level could be clinically relevant for treatment of devastating inherited 
retinal disorders such as glaucoma, which is considered the first cause of blindness 
worldwide 37. After injection of those nioplexes at SR level, transgene expression 
diffused to the inner nuclear layer (INL) and, importantly, was localized close to the 
injection site in the retinal pigment epithelium (RPE). For therapeutic clinical practice, 
gene delivery reaching the outer layers of the retina is deeply desirable since many 
inherited retinal disorders with no curative treatment to date, such as retinitis 
pigmentosa, Stagardt´s disease or Leber´s congenital amaurosis, are associated 
with more than 200 mutations of genes expressed at the photoreceptors and RPE 
level 4. Qualitative analysis after both IV and SR injections showed a higher 
transgene expression the smaller the DNA was, pointing out that DST20 non-viral 
vector combined with MC-DNA offers a potential tool for retinal degenerative and 
inherited diseases. This qualitative analysis was further confirmed by the quantitative 
analysis (Supplementary Figure S4). In addition, it has been reported that MC 
technology offers not only a higher but also a sustained gene expression over time, 
offering key benefits for clinical translation 25, 34. Despite GFP expression was also 
observed employing Lipofectamine™ 2000, it has been shown that such formulation 
is not suitable for in vivo experiments due to its high toxicity mainly accused into 
photoreceptor cells even at low concentrations 38. In fact, our in vitro experiments 
clearly showed the toxicity of Lipofectamine™ 2000 in retinal cells. Finally, it is 
noteworthy the high transfection efficiency achieved with DST20/MC nioplexes at 
the low 2/1 ratio since it allows a higher gene content at small volumes of injection 
for clinical applications, where the volume to be injected represents an important 
handicap, and reduces cellular toxicity associated to cationic lipids 39. Furthermore, 
the lack of unmethylated CpG content in MC-DNA technology provides additional 
reduced immunogenic responses, reinforcing DST20/MC complexes as a potential 
efficient and safe tool for translational retinal gene therapy applications.   
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Bektore ez-biral idealik ez aurkitzeak beste estrategia batzuen garapena ekarri du, adibidez, 
gene-garraio sistemak eta hiru dimentsioko matrize-teknologiak uztartzea. Konbinaketa 
horien abantailen artean, sistemen egonkortasuna hobetzea eta toxikotasuna jaistea dira 
aipagarrienak. Lan honetan, konbinazio berri bat aztertu genuen niosoma eta azido 
hialuronikozko (HA) hidrogelen artean, biak ala biak ere oso sakonki ikertuak beren 
biobateragarritasuna eta molekula ezberdinak jasotzeko gaitasuna direla eta. Hiru niosoma 
formulazio ezberdin aztertu genituen (1, 2 eta 3 niosomak), lipido kationiko, lipido laguntzaile 
eta tentsoaktibo ez-ioniko ezberdinez osatuak. Niosoma eta dagozkien nioplexoen 
karakterizazio osoa egin zen partikulen tamainaren, zeta potentzialaren, polidispertsio 
indizearen eta sagu-zelula mesenkimalak (mMSC) 2D kultiboetan transfektatzeko 
gaitasunaren arabera. Jarraian, 1 niosoma hautatua izan zen HA hidrogelekin konbinatzeko, 
erakutsitako transfekzio-maila kontuan hartuta, eta formulazioaren kontzentrazioa bikoiztu 
zen DNA kantitate handiagoak sartu ahal izateko HA hidrogeletan. Nioplexoz betetako HA 
hidrogelen karakterizazio biomekanikoa egin zen eta partikulen distribuzioa, askapen zinetika 
eta hidrogeleko zelulak 3D kultiboan transfektatzeko gaitasuna aztertu ziren. Lortutako 
emaitzek erakutsi zutenez, HA hidrogeletan ez zegoen nioplexoren arteko agregaziorik, 
zelulak azalera guztian zehar hedatu ziren eta, gainera, transfekzio-maila altuak lortu ziren 
3D zelula kultiboetan zelula-biziraupen maila egokiak mantenduz. Gure ustez, in vitro eredu 
honen bidez ikasitakoa baliagarria izan daiteke in vivo aplikazioetarako gene-garraio sistema 
ez-biral, lokal eta eraginkorrak diseinatzeko.  
 
La falta de vectores no-virales ideales en terapia génica ha motivado la combinación entre 
sistemas de liberación génica y scaffolds de ingeniería tisular para incrementar la estabilidad 
y reducir la toxicidad. En este trabajo, evaluamos una nueva combinación entre vectores no-
virales basados en niosomas e hidrogeles de ácido hialurónico (HA), ambos ampliamente 
estudiados debido a su biocompatibilidad y capacidad de incorporar gran variedad de 
moléculas, incluyendo ácidos nucleicos. Evaluamos tres formulaciones de niosoma diferentes 
(niosomas 1, 2 y 3), que diferían en la composición de lípido catiónico, lípido helper y 
tensioactivo no-iónico. Los niosomas y nioplexos –obtenidos tras la adición del ADN- fueron 
caracterizados en términos de tamaño de partícula, índice de polidispersión (PDI), potencial 
zeta y capacidad de transfectar células mesenquimales de ratón (mMSC) en cultivos 2D. El 
niosoma 1 fue seleccionado para su incorporación en hidrogeles de HA debido a su mayor 
eficiencia de transfección, y la formulación fue concentrada para poder incorporar cantidades 
de ADN más relevantes en los hidrogeles. Los hidrogeles de HA con nioplexos incorporados 
fueron caracterizados según sus propiedades mecánicas, distribución de partículas, cinética 
de liberación de nioplexos y capacidad para transfectar células mMSC en cultivo 3D. Los 
resultados mostraron que los nioplexos no formaban agregados dentro de los hidrogeles de 
HA, que las células eran capaces de difundir libremente a través de los hidrogeles y que éstas 
fueron transfectadas con eficacia y manteniendo una excelente viabilidad celular. Por lo tanto, 
creemos que el conocimiento generado a través de este modelo in vitro puede ser utilizado 
para diseñar sistemas de liberación génica no-viral y local in vivo para aplicaciones 
biomédicas.  
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Abstract: The lack of ideal non-viral gene carriers has motivated the combination of 
delivery systems and tissue-engineered scaffolds, which may offer relevant 
advantages such as enhanced stability and reduced toxicity. In this work, we 
evaluated a new combination between niosome non-viral vectors and hyaluronic 
acid (HA) hydrogel scaffolds, both widely studied due to their biocompatibility as well 
as their ability to incorporate a wide variety of molecules. We evaluated three 
different niosome formulations (niosomes 1, 2 and 3) varying in composition of 
cationic lipid, helper lipid and non-ionic tensioactives. Niosomes and nioplexes 
obtained upon the addition of plasmid DNA were characterized in terms of size, 
polydispersity, zeta potential and ability to transfect mouse bone marrow cloned 
mesenchymal stem cells (mMSCs) in 2D culture. Niosome 1 was selected for 
encapsulation in HA hydrogels due to its higher transfection efficiency and the 
formulation was concentrated in order to be able to incorporate higher amounts of 
DNA within HA hydrogels. Nioplex-loaded HA hydrogels were characterized in terms 
of biomechanical properties, particle distribution, nioplex release kinetics and ability 
to transfect encapsulated mMSCs in 3D culture. Our results showed that nioplex-
loaded HA hydrogel scaffolds presented little or no particle aggregation, allowed for 
extensive cell spreading and were able to efficiently transfect encapsulated mMSCs 
with high cellular viability. We believe that the knowledge gained through this in vitro 
model can be utilized to design novel and effective platforms for in vivo local and 
non-viral gene delivery applications. 
Keywords: non-viral; gene delivery; biomaterials; niosomes; nioplexes. 




The biomedical applicability of gene therapy in tissue engineering is still limited by 
the lack of suitable local gene delivery platforms. The effective delivery of nucleic 
acids locally would enhance the applicability of gene therapy in many therapeutic 
fields, such as tissue regeneration and cancer1, 2. In this regard, the condensation of 
genetic material into different carriers (viral or non-viral) enhances the transfection 
efficiency. For applications in which transient gene expression is desired, such as 
tissue regeneration, non-viral vectors offer an attractive choice3. Additionally, non-
viral vectors are characterized by low immunogenicity, high nucleic acid packing 
capacity, ease of fabrication, high reproducibility and acceptable costs, compared to 
their viral counterparts4. The majority of nanosized non-viral vectors are based on 
cationic polymers, lipids or peptides. Among the wide variety of non-viral vectors, 
niosomes have gained interest in recent years due to their high biocompatibility and 
biodegradability, as well as because of the promising gene transfer results obtained 
in vivo5, 6. Niosomes are synthetic, non-ionic surfactant vesicles with a closed bilayer 
structure7. They are based on three principal components: (i) cationic lipids, which 
are responsible for the electrostatic interaction with the negatively charged DNA 
molecules8, (ii) helper lipids, to improve the physicochemical properties of the 
suspension9 and (iii) non-ionic surfactants, which enhance the stability of the 
formulation and prevent particle aggregation10. Complexes formed by niosomes and 
DNA (known as nioplexes) are usually in the range of 100 – 200 nm and positively 
charged, which make them suitable for gene delivery applications11. 
Complementing gene transfer with matrix design for targeted, local DNA delivery has 
also gained interest in recent years. Hyaluronic acid (HA), an anionic 
glycosaminoglycan, is one of the primary components of the natural extracellular 
matrix (ECM) and it is increasingly gaining popularity as a biomaterial in the field of 
tissue engineering12. HA hydrogel scaffolds have been widely studied for their 
biocompatibility as well as their ability to incorporate a wide variety of molecules, 
including nucleic acids13. Non-viral DNA nanoparticles based on cationic polymers 
such as poly(ethylene imine) (PEI) have been successfully encapsulated into fibrin14, 
15, enzymatically degradable PEG hydrogels16 and PEG-hyaluronic acid17 hydrogels. 
In addition, cationic nioplexes have also been successfully encapsulated in 
polysaccharide-based hydrogels made of κ-carrageenan and of a mixture of 
methylcellulose and κ-carrageenan18. However, despite the fast development of 
niosome formulations in the field of gene delivery, their applicability for encapsulation 
in HA hydrogel scaffolds has not yet been studied. 
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Therefore, the main objective of the present work was to develop an effective 
platform to deliver DNA locally using niosomes as non-viral vectors from HA hydrogel 
scaffolds. To our knowledge, this is the first example of niosome-based DNA 
nanoparticle delivery from HA hydrogels for non-viral gene expression. We explored 
three different niosome formulations varying in composition of cationic lipid, helper 
lipid and non-ionic tensioactives (Fig. 1) in complex with a reporter plasmid encoding 
for Gaussia luciferase (pGluc) to obtain the nioplexes. The selection of the 
components, their concentrations and the cationic lipid/DNA mass ratios (w/w) were 
based on previous studies developed in our laboratory. Niosomes and 
corresponding nioplexes were characterized in terms of size, PDI, zeta potential and 
ability to transfect mouse bone marrow cloned mesenchymal stem cells (mMSCs) in 
2D culture. HA hydrogels containing nioplexes were characterized in terms of 
biomechanical properties, particle distribution and nioplex release kinetics. 
Additionally, the biological activity of released nioplexes upon hydrogel degradation 
was also evaluated. mMSCs were efficiently transfected in nioplex encapsulated HA 
hydrogels and presented excellent cellular viability. These results demonstrate the 









Figure 1. General scheme of cationic niosomes and hydrogel scaffolds used in this work. A. 
Cationic lipid, helper lipid and non-ionic tensioactives components used to elaborate niosome 
formulations. B. Modification of HA to obtain HA hydrogels. C. Representative scheme of a 
HA hydrogel with entrapped nioplexes. 




Formation of niosomes and nioplexes 
Formulations based on niosomes 1, 2 and 3 (Fig. 1) were prepared by the oil-in-
water emulsion technique as previously described11. The organic phase of niosome 
1 contained 5 mg of cationic lipid 2,3-di(tetradecyloxy)propan-1-amine and 12.5 mg 
of Poloxamer 407 (Sigma-Aldrich, USA) and 12.5 mg of polysorbate 80 (Sigma-
Aldrich, USA) as non-ionic tensioactives, all dissolved in 1 ml of dichloromethane 
(DCM) (Panreac, USA). The water phase of niosome 1 contained 2.5 mg of helper 
lipid chloroquine diphosphate salt (Sigma-Aldrich, USA) dissolved in 5 ml of distilled 
water. In niosome 2, the organic phase contained 5 mg of cationic lipid 2,3-
di(tetradecyloxy)propan-1-amine and 20 µl of helper lipid squalene (Sigma-Aldrich, 
USA), dissolved in 1 ml of DCM; the aqueous phase contained 25 mg of polysorbate 
80 dissolved in 5 ml of distilled water. The organic phase of niosome 3 contained 5 
mg of cationic lipid DOTMA (Avanti Polar Lipids, Inc., Alabama, USA), 1.1 mg of 
helper lipid lycopene (Sigma-Aldrich, USA) and 26 mg of non-ionic tensioactives 
polysorbate 60 (Sigma-Aldrich, USA), dissolved in 1 ml of DCM, while the water 
phase consisted of 5 ml of distilled water. The organic phase and the water phase 
were emulsified by sonication (Branson Sonifier 250, Danbury) for 30 sec at 50 W. 
The organic solvent was removed from the emulsion by evaporation under magnetic 
agitation for 3 h at room temperature, obtaining niosome solutions 1, 2 and 3 at a 
concentration of 1 mg of cationic lipid/ml. Niosomes were concentrated using 
Absorbent Gel (Spectrum Labs, USA) and Slide-A-Lyzer MINI Dialysis Units of 
10,000 MWCO (Thermo Scientific, USA). Briefly, 500 µl of niosome formulation were 
introduced in the dialysis units and those were kept in the Absorbent Gel overnight 
at 4°C. Next, the final volume after dialysis was measured.  
The nioplexes were formed by mixing an appropriate volume of a stock solution of a 
gaussia luciferase expression vector (pGluc) (New England BioLabs, Ipswich, MA) 
with different volumes of niosomes 1, 2 and 3 to obtain, respectively, the following 
cationic lipid/DNA (w/w) mass ratios: 2/1, 15/1 and 18/1. Niosomes and DNA were 
incubated for 30 min at room temperature to enhance electrostatic interactions and 
allow the formation of nioplexes. The pGluc plasmid was expanded using an 
endotoxin-free Giga Prep kit from Qiagen following the manufacturer's instructions.  
Size, polydispersity index, zeta potential and morphology of niosomes and 
nioplexes 
The intensity mean diameter (Z-average) and the zeta potential of niosomes and 
nioplexes were determined by dynamic light scattering and by laser Doppler 
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velocimetry, respectively, using a Zetasizer Nano ZS (Malvern Instrument, UK). 
Briefly, 50 µl of the formulations were resuspended into 950 µl of 0.1 mM NaCl 
solution. All measurements were carried out in triplicate. Particle hydrodynamic 
diameter was obtained by cumulative analysis. The Smoluchowski approximation 
was used to support the calculation of the zeta potential from the electrophoretic 
mobility. The morphology of niosomes was determined by transmission electron 
microscopy (TEM) as previously described5. 
Cell culture and 2D transfection 
Mouse bone marrow cloned mesenchymal stem cells (mMSCs, D1, CRL12424) 
were purchased from ATCC (Manassas, VA) and cultured in Dulbecco's modified 
Eagle medium (DMEM, Invitrogen) supplemented with 10% bovine growth serum 
(BGS, Hyclone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen, Grand Island, 
NY) at 37 °C and 5% CO2. The cells were split using trypsin following standard 
protocols. 
For transfection in 2D cell culture, cells were seeded in 48 well plates at a density of 
25,000 cells per ml in a total volume of 250 µl per well, and incubated overnight to 
achieve 70% of confluence at the time of transfection with nioplexes. Nioplexes were 
suspended in OptiMEM (Gibco, San Diego, CA, USA) transfection medium. Then, 
growth medium was removed from the plate and cells were exposed for 4 h to 
nioplexes at 37 °C and 5% CO2. After the incubation, nioplexes were removed and 
fresh growth medium was added to the cells. Lipofectamine 2000TM (Fisher 
Scientific, USA) at cationic lipid/DNA mass ratio of 2/1 was used as a positive control 
of the transfection process. Non-treated cells were used as a negative control. 
Transfection efficiency was measured 48 h after exposure to nioplexes using the 
Gaussia Luciferase Assay Kit (New England BioLabs, Ipswich, MA) following 
manufacturer's protocol. Briefly, a 20 μl sample was mixed with a 50 μl 1x substrate 
solution, pipetted for 2-3 sec, and read for luminescence with a 5 sec integration. 
Background was determined with media that did not contain any DNA, and values 
were expressed as relative light units (RLU). 
HA-acrylate synthesis and formation of HA hydrogels loaded with nioplexes 
Acrylated hyaluronic acid (HA-AC) was prepared using a two-step synthesis as 
previously described19. HA hydrogels were formed by Michael-type addition of 
biscysteine-containing Ac-GCRDGPQGIWGQDRCG-NH2 peptides (MMP) 
(Genescript, Piscataway, NJ) onto HA-AC functionalized with cell adhesion Ac-
GCGWGRGDSPG-NH2 peptides (RGD) (Genescript). A lyophilized aliquot of RGD 
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peptides (0.1 mg) was dissolved in 15 μl of 0.3 M HEPES buffer (pH = 8.7), mixed 
with HA-AC, and allowed to react for 20 min at room temperature. The HA-RGD 
solution was kept in ice until used. A lyophilized aliquot of the cross-linker (0.91 mg) 
was then diluted in 18.2 μl of 0.3M HEPES buffer (pH = 8.2) immediately before 
mixing with nioplexes, HA-RGD (final concentration of 500 μM RGD), and the cell 
solution (250,000 cells per 100μl of final gel volume). Three different volumes of 
nioplexes were loaded into the hydrogels, obtaining final DNA concentrations of 
0.055 µg/µl, 0.12 µg/µl and 0.2 µg/µl in hydrogels 2, 3 and 4, respectively. Hydrogel 
1 did not contain nioplexes and was used as a control. Hydrogel 3 did not contain 
HEPES buffer since the whole volume was replaced by nioplexes. Hydrogel 4 did 
not contain HEPES and neither cell growth medium since both volumes were 
replaced by nioplexes.  
For rheology and particle distribution assays, gels were formed in the absence of 
cells. Gelation was achieved by placing a 40 µl drop of the precursor solution 
between Sigmacoted glass slides for 30 min at 37 °C. The final gel was placed inside 
48-well plates for culture. Thorough mixing was used to ensure the nioplexes were 
uniformly distributed throughout the hydrogel. The gel was then allowed to swell in 
phosphate-buffered saline (PBS) for 2 hours.  
YOYO-1 (Invitrogen, USA), a nucleic acid dye, was used to stain the gels to visualize 
the distribution of the nioplexes inside the HA hydrogels. The images were taken 
using the fluorescent (Observer Z1 Zeiss) microscope with 10x magnification. 
Characterization of HA hydrogel mechanical properties 
The storage and loss moduli were measured with a plate-to-plate rheometer 
(Physica MCR, Anton Paar, Ashland, VA) using an 8 mm plate under a constant 
strain of 0.01 and frequency ranging from 0.1 to 10 rad/s. Hydrogels were made as 
detailed above and cut to 8.0 mm in diameter to fit the plate. A humid hood was used 
to prevent the hydrogel from drying, and the temperature was maintained at 37 °C 
throughout the measurement.  
Radiolabeling DNA 
Plasmid DNA was radiolabeled with dCTP (100 μCi, MP Biomedicals, Santa Ana, 
CA) using a Nick translation kit (Roche, Indianapolis, IN) as per the manufacturer's 
protocol. Briefly, an equimolar mixture of dATP, dGTP, dTTP, and 32P-dCTP was 
prepared and added to the DNA (1 μg) solution. Once the enzyme solution was 
added to the mixture, the final solution (200 μl) was gently mixed by pipetting and 
incubated for 2 h at 15 °C. The reaction was stopped by addition of 10 μl of 0.2 M 
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ethylenediaminetetraacetic acid (EDTA, pH = 8.0) and heating to 65 °C for 10 min. 
The DNA was purified using the DNA concentrator kit (Zymo Research, Irvine, CA) 
following the manufacturer's instructions. The radiolabeled (“hot”) DNA 
concentration was 0.04 μg/μl. This “hot” DNA was then mixed with non-radiolabelled 
DNA to a concentration of 0.25% “hot” DNA.  
Nioplex release kinetics and activity 
To determine the extent of release of the encapsulated nioplexes and their activity 
post encapsulation, gels were formed as described above with 1% radiolabeled 
DNA. The gels were swelled in PBS for 2 h and the swelling solution was collected. 
The gels were then placed in 200 μl of release solution, either PBS only or 1 U/mL 
Collagenase I in PBS. At the indicated time points, 200 μl of the solution was 
removed, and replaced with fresh release solution. DNA concentrations of collected 
release solutions and from remaining hydrogels were measured using a scintillation 
counter. The readout was analyzed using a standard curve.  
To determine the activity of the encapsulated nioplexes, a HA gel was prepared and 
swelled as indicated above using the pGluc plasmid. After swelling in PBS, the gel 
was degraded through incubation with 100 μl of 0.25% trypsin at 37 °C for 10 min. 
The collected nioplexes from the degraded hydrogel sample were then used for a 
bolus transfection (0.625 μg of DNA/well for a 48 well-plate) and compared to freshly 
made nioplexes. The cell media was collected after 48 h, and transgene expression 
was measured using the Gaussia Luciferase Assay Kit (New England BioLabs, 
Ipswich, MA) as described.  
Gene transfer, cell viability and cell spreading in 3D culture 
Control hydrogel 1 without nioplexes and nioplex-loaded hydrogels 2 and 3 with 
mMSCs were made as described above, and transfection efficiency was measured 
at 48 h. Secreted Gluc levels in the media were quantified using a BioLux Gaussia 
Luciferase Assay Kit (New England BioLabs, Ipswich, MA) as described.  
Cell viability in hydrogels 1-3 was studied using a LIVE/DEAD kit (Molecular Probes, 
Eugene, OR). Briefly, 2 μl of ethidium homodimer-1 and 0.5 μl of calcein AM from 
the kit were diluted with 1 ml of DMEM. Each gel was stained with 150 μl of this 
staining solution for 30 min at 37 °C in the dark. Cell viability from hydrogels 2 and 3 
was normalized to the cell viability from control hydrogel 1 which contained no 
nioplexes. To better analyze cell spreading, separate gels were fixed for 30 min at 
room temperature using 4% paraformaldehyde, rinsed with PBS, treated with 0.1% 
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Triton-X for 10 min, and stained for 90 min in the dark with 4',6-diamidino-2-
phenylindole (DAPI) for cell nuclei (500x dilution from 5 mg/ml stock) and rhodamine-
phalloidin for actin filaments (5 μl per 200 μl final stain solution) in 1% bovine serum 
albumin solution. The samples were then washed with 0.05% Tween-20. For both 
cell viability and cell spreading, a Nikon confocal microscope was used to visualize 
samples. To better visualize the distribution throughout the hydrogel, z-stacks 1213 
μm thick were taken for each image, deconvoluted to minimize background, and 
presented either as maximum intensity projections or as an aerial view of a 3D render 
of the z-stack.  
Statistical analysis 
To analyze the differences, a multiple comparison Kruskal-Wallis test followed by a 
Mann-Whitney U test was performed. Normal distribution was determined using a 
Shapiro-Wilks test and homogeneity of variance by the Levene test. Data were 
expressed as mean ± SD, unless stated otherwise. A p value <0.05 was considered 
statistically significant. The analysis was performed using the IBM SPSS Statistics 
22.Ink statistical package.  
Results and discussion  
Since the emergence of non-viral gene delivery from hydrogel scaffolds, emphasis 
has been placed on optimizing non-viral vectors for combining gene transfer with 
matrix design and enhancing transfection efficiency. Yet while high concentrations 
of non-viral DNA complexes in hydrogels have been demonstrated to improve local 
gene delivery20, the physical incorporation of DNA complexes into hydrogels is 
challenging due to some limitations such as aggregation and inactivation of the 
complexes inside hydrogel scaffolds21. Among the wide variety of non-viral vectors, 
poly(ethylene imine) (PEI) has been successfully encapsulated in HA hydrogels and 
effective local transgene expression and ability to induce angiogenesis in vivo have 
been reported3. Although PEIderivatives present high gene carrying capacity and 
ability to achieve high transfection efficiencies, their biomedical application is often 
restricted due to immunogenicity and cytotoxicity issues22.  In this regard, niosomes 
offer several advantages, since they have high compatibility with biological systems 
and low toxicity because of their non-ionic nature and are biodegradable and non-
immunogenic23.  
The three different niosome formulations used in this work differed in the composition 
of cationic lipid, helper lipid and non-ionic tensioactives (Fig. 1). These niosome 
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components have previously demonstrated suitability for gene delivery applications. 
For instance, niosome formulations containing the non-ionic surfactant polysorbate 
80 combined with the helper lipid squalene have shown effective gene delivery5. In 
addition, it has been recently shown that the helper lipid lycopene, combined with 
cationic lipid DOTMA and polysorbate 60, enhances retinal transfection24 and 
Poloxamer 407 has been widely used in drug delivery applications25. The use of 
chloroquine has also been reported to enhance gene delivery both in vitro and in 
vivo26. Therefore, the selection of the components, and their concentrations used to 
prepare the niosome formulations, as well as the cationic lipid/DNA mass ratios (w/w) 
to form the corresponding nioplexes were based on available data and previous 
studies developed in our laboratory.  
The physicochemical analysis of formulations used in this work revealed that the 
mean particle sizes of niosomes 1, 2 and 3 were 118.1 ± 1.8 nm, 136.4 ± 0.9 nm and 
105.7 ± 2.3 nm, respectively (Fig. 2A). Niosomes 1 and 2 were relatively 
monodisperse (PDI < 0.2) while niosome 3 formed more polydisperse nanoparticle 
preparations (PDI = 0.4). All formulations formed highly positively charged 
nanoparticles with zeta potential values of +35.9 ± 2.2 mV, +48.5 ± 0.6 mV and +32.9 
± 1.7 mV, for niosomes 1, 2 and 3, respectively (Fig. 2B), necessary to bind to the 
negatively charged DNA molecules by electrostatic interactions27, 28. In addition, 
positive zeta potential values enhance cellular uptake29. Compared to non-treated 
cells, all formulations presented ability to transfect but nioplexes based on niosome 
1 showed significantly higher transgene expression than nioplexes based on 
niosomes 2 and 3 (Fig. 2C). Although transfection levels of niosomes were lower 
than the positive control Lipofectamine 2000TM, the latest is not considered suitable 
for in vivo gene delivery due to its high cytotoxicity even at low concentrations30. 
Therefore, we selected the nioplexes based on niosome 1 at 2/1 cationic lipid/DNA 
mass ratio (w/w) formulation to study its applicability for non-viral gene delivery in 
HA hydrogels.  
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Figure 2. Screening of niosome 
formulations. A. Size. B. Zeta 
Potential. C. Transfection 
efficiency 48 h post-exposure of 
mMSCs to nioplexes based on 
niosomes 1, 2 and 3 at cationic 
lipid/DNA mass ratios (w/w) 2/1, 
15/1 and 18/1, respectively. 
Positive (Lipofectamine 2000TM at 
a cationic lipid/DNA mass ratio of 
2/1) and negative (no DNA) 
controls are shown for reference. 
*p < 0.05 for transfection efficiency 
between niosome formulations, #p 
< 0.05 for transfection efficiency of 
all niosome formulations relative to 
the positive control. 
The use of nioplexes at low mass ratios presents several advantages, including the 
possibility of incrementing the dose of DNA as well as decreasing cellular toxicity31. 
Additionally, in order to be able to incorporate higher, more relevant amounts of DNA 
within HA hydrogels, the formulation based on niosome 1 was concentrated from 1 
mg/ml to 2 mg/ml. The TEM images of the concentrated formulation showed that 
concentration process did not affect morphology and, as expected, more particles 
were visible in the concentrated sample compared to the non-concentrated one (Fig. 
3A-B).  Size and PDI values were also maintained similar in the concentrated 
formulation. In contrast, zeta potential values declined from +35.9 ± 2.2 mV to +25.77 
± 1.1 mV, but since values remained above +20 mV, the concentrated formulation 
should not present an increased propensity to form aggregates along the time32. 
Additionally, the transfection ability of both concentrated and non-concentrated 
formulations was evaluated at cationic lipid/DNA mass ratio 2/1 and no statistically 
significant differences (p > 0.05) were found between the transfection efficiencies of 
both formulations (Fig. 3C), indicating that the concentrating process does not affect 
to the transfection capacity. In view of these results, we decided to use the 
concentrated formulation at the low cationic lipid/DNA mass ratio 2/1 for 
encapsulation in HA hydrogels.  
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Figure 3. Characterization of 
concentrated niosome formulations. 
A-B. TEM images of non-
concentrated (A) and concentrated 
(B) formulations based on niosome 
1 at 10,000x magnification. Scale 
bars: 500.0 nm. C. Transfection 
efficiency 48 h post-exposure of 
mMSCs to nioplexes based on 
concentrated and non-concentrated 
niosome 1 at 2/1 cationic lipid/DNA 
mass ratio (w/w). *p < 0.05 for 
transfection efficiency between 
niosome formulations, #p < 0.05 for 
transfection efficiency of all niosome 
formulations relative to the positive 
control. 
 
In order to achieve therapeutically relevant levels of DNA33, we evaluated three 
different amounts of nioplexes based on concentrated niosome 1 at 2/1 cationic 
lipid/DNA mass ratio, obtaining final DNA concentrations of 0.055 µg/µl, 0.12 µg/µl 
and 0.2 µg/µl in hydrogels 2, 3 and 4, respectively. Different DNA concentrations of 
hydrogels could cause differences in the mechanical properties, which are important 
factors determining cell proliferation, spreading and transgene expression in 
hydrogel scaffolds. High hydrogel stiffness (over 800 Pa) has been related to 
reduced cell spreading and transgene expression, while soft hydrogels (200 – 260 
Pa) resulted in enhanced transgene expression21. Therefore, we evaluated the 
mechanical properties of hydrogels as a function of DNA concentration in order to 
determine their grade of stiffness. Rheological characterization showed high 
variability in the mechanical properties of hydrogels ranging from an average 
modulus of ~380 Pa to ~1215 Pa over a frequency range of 0.1-10 rad/s at a constant 
strain of 0.01 (Fig. 4A-B). Hydrogel 3 presented the highest stiffness among the 
hydrogels tested, while hydrogel 4, with the highest DNA concentration, showed to 
be the softest. Such high values were not expected in hydrogel 3, however, that 
condition was not discarded and further studies were carried out in order to 
determine its transfection capacity despite its high stiffness. The evaluation of the 
distribution of the nioplexes inside the hydrogel scaffold showed that nioplexes were 
present uniformly throughout the hydrogels and, in hydrogels 3 and 4, those were 
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observed mostly as unaggregated particles (Fig. 4C-E). However, hydrogel 4 did not 
contain any cell growth medium because it was completely replaced by DNA in order 
to obtain higher amounts of genetic material. Therefore, it was not a possible 
candidate for 3D cell culture nor for in vitro transfection assays and only hydrogels 2 
and 3 were evaluated for gene delivery into encapsulated mMSCs. Yet, the high 
DNA concentration and absence of particle aggregation in hydrogel 4 suggested that 
it could be an attractive option for in vivo gene delivery. Taken together, these results 
demonstrate that nioplexes can be successfully encapsulated into HA hydrogels 
without significant particle aggregation, although high variability in mechanical 
properties was observed. 
Figure 4. Characterization of HA hydrogels loaded with nioplexes. The mechanical properties 
of the hydrogels were determined using plate-to-plate rheometry over a frequency range of 
0.1-10 rad/s at a constant strain of 0.01 (A). Average storage modulus (B). C-E. Particle 
distribution in hydrogels. Gel ID: 1, control hydrogel without nioplexes; 2, 0.055 µg DNA/µl; 3, 
0.12 µg DNA/µl and 4, 0.2 µg DNA/µl. Scale bars: 200 µm.  
In order to validate that nioplexes maintained the ability to transfect cells after 
encapsulation in HA hydrogels, we synthesized nioplex-loaded hydrogels, degraded 
them with trypsin and performed a transfection with the released nioplexes (Fig. 5). 
Not unexpectedly, nioplexes released from hydrogels degraded with trypsin were still 
able to efficiently transfect mMSCs in 2D culture, albeit to a somewhat lesser extent 
than fresh nioplexes (Fig. 5B). When exposing cells to fresh nioplexes + hydrogel + 
trypsin (Fig. 5C), transfection was similar to that obtained with nioplexes released 
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from degraded hydrogels (Fig. 5B). When exposing cells to fresh nioplexes + trypsin 
(Fig. 5D), the difference in transfection was less evident. Cells exposed to naked 
DNA + hydrogel + trypsin (Fig. 5E) and cells exposed to hydrogels without nioplexes 
+ trypsin (Fig. 5F) did not show luminescence signal. Statistical differences were 
found between all conditions (p < 0.05) except for between conditions “B” and “C” (p 
> 0.05). These results showed that the transfection capacity of the nioplexes was 
negatively affected by the presence of interfering hydrogel materials and trypsin in 
the 2D cell culture media, but not by the encapsulation process since there were no 
statistically significant differences in transfection values between released nioplexes 
from degraded hydrogels and fresh nioplexes supplemented with degraded hydrogel 
materials (Fig. 5B-C). 
Figure 5. Biological activity of nioplexes based on concentrated niosome 1 at 2/1 cationic 
lipid/DNA mass ratio (w/w). A. Fresh nioplexes. B. Nioplexes released from degraded HA 
hydrogels with trypsin. C. Fresh nioplexes supplemented with degraded hydrogels with 
trypsin. D. Fresh nioplexes supplemented with trypsin. E. Naked DNA supplemented with 
degraded hydrogels trypsin. F. Hydrogels without nioplexes degraded with trypsin. *p < 0.05 
for transfection efficiency between different conditions, #p < 0.05 for transfection efficiency of 
all conditions relative to condition “A” 
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Finally, gene delivery mediated by entrapped nioplexes was evaluated in hydrogels 
1 (no nioplexes), 2 (0.055 µg DNA/ µl hydrogel) and 3 (0.12 µg DNA/ µl hydrogel). 
Two main mechanisms are postulated to contribute to the gene transfer process from 
hydrogel scaffolds: DNA/nanoparticle release kinetics and rate of cellular 
infiltration34. Nioplexes released after hydrogel degradation could transfect 
surrounding cells, while infiltrating cells would encounter entrapped nioplexes and 
become transfected leading to transgene expression inside the hydrogel area35, 36. 
As expected, in the present work the release kinetics of nioplexes were faster in the 
presence of Collagenase I (Col I), with almost 100% of nioplexes being released by 
day in presence of Col I, compared to ~80% release by day 7 in PBS alone (Fig. 6A). 
This progressive release of nioplexes potentially allows for sustained transgene 
expression, which is essential for therapeutic applicability. Regarding cellular 
infiltration, for cells cultured in three dimensions, the migration rate of cells through 
the hydrogel has previously been related to successful non-viral gene transfer34. 
Therefore, we would expect that softer hydrogel scaffolds that allowed for extensive 
cell spreading would result in enhanced gene transfer. Interestingly, in the present 
work all hydrogels allowed for extensive cell spreading (Fig. 6C) and, despite its high 
stiffness, the 3D transfection efficiency was significantly (p < 0.05) higher in hydrogel 
3 compared to its softer counterparts (Fig. 6B, bars). Therefore, these results 
suggest that increasing amounts of DNA can be used to overcome limitations of 
stiffer hydrogels. Moreover, cell viability was excellent in all conditions (Fig. 6B, dots), 
which indicated that the presence of nioplexes in the HA hydrogels was well tolerated 
by the cells. 
 
Figure 6. A. Nioplex release kinetics from HA hydrogels in PBS and in PBS supplemented 
with Collagenase I (1 U/ml). B. Transfection efficiency and cell viability of nioplex-loaded 
hydrogels 1-3 at 48 h. C. Representative images of cell spreading in hydrogels 1, 2 and 3. 
Blue = cell nuclei (DAPI) and red = F-actin (rhodamine-phalloidin). Scale bars: 200 µm. *p < 
0.05 for transfection efficiency. 




We successfully developed a process to load concentrated nioplexes into HA 
hydrogels without aggregation. To our knowledge, this is the first time that niosome 
formulations composed of 2,3-di(tetradecyloxy)propan-1-amine, Poloxamer 407, 
polysorbate 80 and chloroquine diphosphate salt are incorporated to HA hydrogels 
for non-viral gene delivery. In general, HA hydrogel scaffolds loaded with nioplexes 
presented suitable mechanical properties, little or no particle aggregation, allowed 
for extensive cell spreading and were able to efficiently transfect encapsulated 
mMSCs in 3D cultures. We believe that the knowledge gained through this in vitro 
model can be utilized to design novel and effective platforms for in vivo local and 
non-viral gene delivery applications.  
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Gene therapy can be broadly defined as the introduction of genetic material into 
target cells in order to modify and control protein expression for therapeutic or 
experimental purposes 1. The culmination of the Human Genome Project along with 
recent advances on molecular biology have provided a better understanding of 
cellular and pathogenic processes, and several genes have been identified as 
targets for therapeutic approaches. However, even if gene therapy holds great 
promise for conceiving new treatments for several diseases, nucleic acid based 
strategies demand effective and safe carriers, which is the main limitation nowadays. 
In fact, one of the main reasons why gene therapy clinical trials are still few in number 
is the lack of suitable and safe approaches to deliver the genetic material to target 
cells. The success of gene therapy critically depends on suitable transfection 
vectors, which should be able to: (i) protect nucleic acids against degradation by 
blood and interstitial nucleases, (ii) promote internalization of the genetic material 
into target cells and (iii) release the nucleic acids once inside the cell to the correct 
site1. Furthermore, an ideal gene delivery system should be effective, specific, long 
lasting, safe, easy to use and as inexpensive as possible2.  
Broadly, gene delivery vectors are mainly classified into two categories: viral vectors 
and non-viral vectors. According to data updated to June 2014 and presented by 
The Journal of Gene Medicine3, among the over 2,000 clinical trials for gene therapy 
approved globally, 70% correspond to trials using viral vectors. Moreover, to date 
only four gene-therapy products have been commercialized, all of them based on 
viral vectors. In 2003, China approved the first gene therapy product, Gendicine™, 
based on an adenoviral (Ad) vector and indicated for the treatment of head and neck 
squamous cell carcinoma4. China approved the second gene therapy product, 
Oncorine™, in 2005, which is also based on an Ad vector and is indicated for the 
treatment of late stage refractory nasopharyngeal cancer5. In Europe, the first 
approved gene therapy product was Glybera® in 2012, based on an adeno-
associated viral (AAV) vector and indicated for the treatment of severe lipoprotein 
lipase deficiency6. In 2015, the gene therapy product IMLYGIC™ was approved in 
the USA, which is based on a herpes simplex virus (HSV) vector and is indicated for 
the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in 
patients with melanoma recurrent after initial surgery7. However, according to data 
updated in 20178, this tendency is inverted when focusing on studies involving 
delivery strategies for gene editing. Unlike traditional gene therapy methods mainly 
based in gene addition, in investigations involving gene-editing therapies non-viral 
vector-based studies are clearly predominant (70%) over viral vector-based studies. 




(39%), followed by methods based on lipids (17%) and polymers (8%)8. Therefore, 
it seems that the use of non-viral vector-based delivery systems are gaining 
importance over viral delivery systems in new gene therapy strategies based on 
gene edition or correction.  
In fact, viruses are powerful tools to deliver genetic material into target cells, but they 
also present many impediments such as low carrying capacity, expensive and 
complex production and, most importantly, safety issues, since they usually induce 
immunogenic responses and they can induce oncogenesis when randomly 
integrated in the host genome. In this regard, nanotechnology-based non-viral 
vectors have emerged as promising alternatives due to their potential to overcome 
many of the limitations of viral vectors. Non-viral vectors present lower 
immunogenicity, higher nucleic acid packing capacity and ease of fabrication 
compared to their viral counterparts9. Additionally, non-viral formulations can be 
produced on a large scale with high reproducibility and acceptable costs, and they 
are relatively stable to storage1. Therefore, continuous advances in the fields of 
material science and nano-engineering have motivated the synthesis, 
characterization, and functionalization of biocompatible nanomaterials for gene 
delivery purposes10. In addition, the diversity of available nanosized material allows 
the design of multifunctional vectors specifically tailored for different applications11. 
To date, a wide variety of nanosized non-viral gene delivery vectors have been 
developed, including cationic lipids12-14, polymers15,16 and magnetic nanoparticles17. 
These molecules can be nanoengineered to transport therapeutic genes into specific 
organs or cell types and to pass over several extracellular and intracellular barriers. 
Among the wide plethora of non-viral vectors, recently emerged niosomes are 
biocompatible, synthetic, non-ionic surfactant vesicles with a closed bilayer 
structure18,19. They are based on three principal components: (i) cationic lipids, which 
are responsible for the electrostatic interaction with the negatively charged DNA 
molecules, forming nioplexes20, (ii) helper lipids, to improve the physicochemical 
properties of the suspension21 and (iii) non-ionic surfactants, which enhance the 
stability of the formulation and prevent particle aggregation22. The global chemical 
properties of these components influence on the physicochemical characteristics of 
niosomes, such as size, surface charge and morphology, which in turn determine 
their ability to enter the cells, follow a particular endocytic pathway, deliver the DNA 
cargo into the nucleus and, therefore, their transfection efficiency21,22. Recently, the 
potential of niosomes for gene therapy purposes has been demonstrated since it has 




Not only the carrier is important, but also the vectored genetic material. Until recently, 
most efforts have focused on improving nucleic acid delivery strategies either by 
modifying non-viral vectors or by employing physical methods such as 
electroporation. Nevertheless, the enhancement of transfection efficiency can also 
be achieved by modifying the composition and conformation of the genetic material 
in order to improve its bioavailability, biocompatibility, durability and safety27. In this 
regard, recently a number of groups have produced minicircle DNA by removing the 
bacterial backbone from plasmid DNA in order to enhance the transfection 
efficiency28. Prokaryotic sequences present in plasmid DNA, such as CpG 
dinucleotide motifs, origins of replication, and antibiotic selectable markers are 
necessary to maintain and amplify these plasmids in bacterial hosts, but they 
decrease their biocompatibility and safety. In fact, several clinical studies have 
shown that unmethylated CpG motifs induce inflammatory responses29,30 and 
necrosis- or apoptosis-mediated cell death in target cells, which in turn results in 
short-lived and compromised transgene expression31,32. Additionally, the sequences 
of plasmid DNA can also become inaccessible to transcription factors when bacterial 
sequences associated with histone indicators are close to the gene of interest. These 
indicators –which are rapidly recognized inside the cells-, induce the packing of the 
sequences into a dense heterochromatin structure, resulting in poor transgene 
expression or silencing of the gene of interest33. Therefore, minimized expression 
units that only contain the gene of interest and regulatory sequences such as 
minicircle (MC) DNA vectors emerge as an attractive alternative to conventional 
plasmid DNA vectors. Several in vitro and in vivo studies demonstrated a significant 
improvement of transfection efficiency with sustained and high transgene expression 
levels28 as well as enhanced immunocompatibility and safety profiles. Furthermore, 
mini DNA vectors have also the potential to overcome many intracellular barriers, 
presenting higher bioavailability than their larger parent plasmid DNA counterparts34.  
In addition to the optimization of the carrier and the genetic material, a new trend in 
non-viral gene therapy is to explore novel complementary synergies between 
delivery systems and tissue-engineered scaffolds in order to improve the transfection 
efficiency. In fact, these combined approaches may offer relevant advantages such 
as enhanced stability and reduced toxicity. Moreover, complementing gene transfer 
with matrix design would allow an effective, targeted and local DNA delivery, which 
would enhance the applicability of gene therapy in many therapeutic fields, such as 




Therefore, this doctoral thesis focuses on the development of effective non-viral 
gene delivery platforms and, for that purpose, the scope of the project includes the 
following aspects: (i) preparation, characterization and comparative evaluation of the 
transfection efficiency of three different non-viral vectors based on cationic lipids, 
polymers and magnetic nanoparticles to deliver a therapeutic plasmid coding for the 
vascular endothelial growth factor (VEGF) to central nervous system (CNS) cells; (ii) 
preparation, characterization and evaluation of the transfection process and 
efficiency of three niosome formulations that only differed on the non-ionic 
tensioactives component, in order to determine the its role in the gene transfer 
process; (iii) preparation and characterization of niosome formulation and 
comparative evaluation of the transfection efficiency and cell viability of nioplexes 
bound to two different genetic materials, a plasmid DNA and a minicircle (MC) DNA; 
and (iv) exploration of complementary synergies for non-viral gene therapy between 
niosome formulations and hyaluronic acid (HA) hydrogel scaffolds. In the following 
sections, each of those studies will be discussed in detail.  
1. The influence of the components of the non-viral vector in the 
transfection efficiency of a therapeutic plasmid encoding for the 
vascular endothelial growth factor in cells of the central nervous 
system.  
Nucleic acid based therapies hold great promise but demand effective and safe 
carriers. Moreover, efficient transfection of CNS is still a challenge, which retards the 
development of therapeutic gene delivery strategies for the wide variety of 
neurodegenerative disorders. In recent years, biocompatible nanomaterials have 
emerged as potential candidates for that purpose. In fact, different nanosized non-
viral vectors have been recently reported to efficiently transfect CNS cells in vitro 
and in vivo, such as chitosans37,38, cationic lipids39 and magnetic nanoparticles17. 
Besides, VEGF may be a potential therapeutic gene candidate for CNS disorders40, 
due to the strong relationship between vascular alterations in brain and 
neurodegenerative diseases41 and its specific roles in brain angiogenesis and 
neuronal survival42,43.  
Based on these considerations, we present a nanoformulation based approach for 
VEGF gene delivery into CNS cells. For that purpose, three different 
nanoformulations –ultrapure oligochitosan (UOC), Lipofectamine cationic lipid and 
NeuroMag magnetic nanoparticles– were complexed to the phVEGF165aIRESGFP 




fluorescent protein (GFP).  Nanoformulations and resulting nanoplexes –
nanoformulations complexed to DNA– were physicochemically characterized in 
terms of size, superficial charge, polydispersity index (PDI), morphology and 
capacity to condense, release and protect DNA. In vitro transfection studies were 
carried out in C6 glial cells and in primary neuronal culture cells as CNS cell models, 
and in HEK293 cells, as a general transfection model. Transfection efficiencies were 
evaluated in terms of percentage of GFP expressing cells, mean fluorescent intensity 
(MFI) and VEGF protein expression. Cell viability upon exposition to nanoplexes was 
also evaluated. Bioactivity of the VEGF protein secreted by transfected primary 
neuronal culture cells was assessed by a proliferation assay in human umbilical vein 
endothelial cells (HUVEC). 
All nanoformulations and corresponding nanoplexes –magnetoplexes, lipoplexes 
and polyplexes- presented particle sizes in the nanoscale range (Fig. 1.1.a, bars), 
which is related to higher cellular uptake values44, and exhibited positive surface 
charge values (Fig. 1.1.a, lines), which is necessary to bind to the negatively charged 
DNA molecules by electrostatic interactions45. Once complexed to DNA, surface 
charge switched to negative values in all cases. However, magnetoplexes and 
lipoplexes surface charge values changed from around +20 mV to around -20 mV, 
whereas polyplexes presented zeta potential values near the zero. It has been 
described that particles with surface charge values between -20mV and +20 mV 
form aggregates along the time46. Therefore, to avoid aggregation, particularly in the 
case of polyplexes, all formulations employed in this work were used freshly 
prepared. PDI values were almost in all cases below 0.5, which is considered 
acceptable for comparative purposes of nanoparticles sizes measured by cumulative 
analysis47. The exception was cationic lipids, where high PDI values could be 
attributed to the irregular morphology of these particles (Fig. 1.1.c). In order to further 
analyze the ability of nanoparticles to bind, release and protect DNA, an agarose gel 
electrophoresis assay was performed (Fig.1.1.d). Nanoparticles protected DNA from 
enzymatic degradation, but most of the plasmid was retained in the well, suggesting 
strong binding to DNA. However, all formulations showed a delicate balance 
between DNA binding and releasing abilities, necessary for efficient transfection 




Figure 1.1. Physicochemical characterization of nanoparticles and nanoplexes. (a) Size 
(white and grey bars, which correspond to nanoparticles and nanoplexes, respectively) and 
zeta potential values (dotted and continuous lines, which correspond to nanoparticles and 
nanoplexes, respectively). Each value represents the mean ±SD, n=3. (b) PDI values. Each 
value represents the mean ±SD, n=3. (c) TEM images of cationic lipid (c1) and magnetic (c2) 
nanoparticles and Cryo-TEM images of polymeric (c3) nanoparticles. Original magnification 
140,000x for cationic lipid nanoparticles, 175,000x for magnetic nanoparticles and 25,000x for 
polymeric nanoparticles. (d) Binding, protection, and SDS-induced release of DNA from 
nanoparticles visualized by agarose electrophoresis. Lanes 1–3 correspond to free DNA; 
lanes 4–6, lipoplexes; lanes 7–9, magnetoplexes; lanes 10–12, polyplexes. Free DNA and 
nanoplexes were treated with SDS (lanes 2, 5, 8 and 11) and DNase I + SDS (lanes 3, 6, 9, 




Once nanoplexes were physicochemically characterized, in vitro studies were 
carried out in three cell lines: HEK293 –a general transfection model-, C6 cells –a 
CNS transfection model- and primary neuronal culture cells –the most relevant 
cellular model of CNS-. Before performing assays in primary neuronal culture cells, 
we analyzed cell viability and transfection efficiency of the nanoplexes in HEK293 
and in C6 cells, due to the challenge that represents primary neuronal culture cells 
transfection with non-viral vectors. Nanoplexes were well tolerated by both cell types, 
since cell viability was above 90% with magentoplexes and lipoplexes and above 
80% with polyplexes (Fig. 1.2.a, dots).  The analysis of transfection efficiency was 
studied through three different parameters: percentage of GFP expressing cells (Fig. 
2a, bars), MFI of those transfected cells (Fig. 1.2b) and the amount of VEGF (ng/ml) 
secreted by transfected cells (Fig. 1.2.c). The phVEGF165aIRESGFP plasmid 
codifies for both proteins, VEGF –which is extracellular and, therefore, secreted to 
the extracellular medium by transfected cells- and GFP –which is intracellular and 
remains in the cytoplasm of transfected cells-. Therefore, parameters related to GFP 
were analyzed by flow citometry, while the concentration of VEGF present in cellular 
supernatants was measured by ELISA. Regarding percentages of GFP expressing 
cells and MFI values, transfection efficiencies with all nanoplexes were higher in 
HEK293 cells compared to C6 cells. However, regarding expression of VEGF 
(ng/ml), comparable values were obtained in HEK293 and C6 cells 48 h after 
transfection with nanoplexes. Indeed, when transfecting with magnetoplexes, the 
amounts of secreted VEGF were higher in the supernatant of C6 cells compared to 
HEK293 cells. It has been reported that non-viral vector mediated transfection 
processes are cell-dependent, meaning that the transfection efficiency of the same 
non-viral vector can diverge depending on the transfected cell type49. Our results are 
consistent with this idea, since we found that in HEK293 cells highest transfection 
was achieved with lipoplexes, while in C6 cells magnetoplexes were more efficient. 
Polyplexes are in the third position in both cell lines, probably due to their surface 




Figure 1.2. Cell viability and 
transfection efficiencies in 
HEK293 and C6 cells. (a) Cell 
viability (HEK293 cells, dark 
grey dots; C6 cells, light grey 
dots) 48h after transfection 
with magnetoplexes, 
lipoplexes and polyplexes. 
Control cells were not treated 
with nanoplexes. Percentages 
of GFP expressing cells 
(HEK293 cells, dark grey bars; 
C6 cells, light grey bars) 48 h 
after transfection with 
nanoplexes. Control cells were 
not treated with nanoplexes. 
Each value represents the 
mean ±SD, n=3. (b) Mean 
Fluorescent Intensity (MFI) 
values 48h post-transfection 
with nanoplexes (HEK293 
cells, dark grey bars; C6 cells, 
light grey bars). Each value 
represents the mean ±SD, 
n=3. (c) VEGF production 
(ng/ml) values 48h post-
transfection with nanoplexes (HEK293 cells, dark grey bars; C6 cells, light grey bars). Control 
cells were not treated with nanoplexes. Each value represents the mean ±SD, n=3. Statistical 
significance: *p<0.05, **p<0.01, ***p<0.001 compared to control HEK293 cells; #p<0.05, 
##p<0.01, ###p<0.001 compared to control C6 cells.  
Interestingly, a clear correlation was observed in both cell lines between the three 
parameters used to analyze transfection efficiencies. At higher percentages of GFP 
expressing cells, higher levels of secreted VEGF were detected (Fig. 1.3.a and Fig. 
1.4.a). Also, at higher MFI values, higher levels of secreted VEGF were observed 
(Fig. 1.3.b and Fig. 1.4.b). However, when comparing the angles of the slope in those 
graphs, differences were detected between cell lines, since the gradients were more 
pronounced in C6 than in HEK293 cells in both correlations –in Figs. 1.3.a and 1.4.a, 
α=22.65° in HEK293 vs. α=65.42° in C6; in Figs. 1.3.b and 1.4.b, α=8.42° in HEK293 
and α=23.67° in C6 . These data support the fact that although GFP expression and 




lines transfected with nanoplexes. This effect could in part be explained by the higher 
basal expression of VEGF protein in C6 cells (Fig. 1.2.c, control bars). Therefore, 
even at lower transfection efficiencies, transfected C6 cells could be able to secret 
as much VEGF protein as the more efficiently transfected HEK293 cells. Still, the big 
differences observed suggest that other factors may also be involved, specifically 
those related to the Internal Ribosome Entry Site (IRES) sequence of the plasmid. 
IRES sequences are translational enhancers that allow the co-expression of two 
genes of interest under the same promoter and with a constant ratio of the 
proteins50,51. However, it has been described that cellular IRES often exhibit low 
efficiencies in transiently transfected cells, which has been attributed to the cell and 
tissue specificity of the cellular IRES activities52,53. In those cases, the expression of 
the gene downstream of the IRES element is usually lower, while the expression of 
the gene upstream the IRES sequence is not affected54. In our scenario, the VEGF 
gene is located upstream the IRES element in the phVEGF165aIRESGFP plasmid, 
and the GFP gene is located downstream that sequence. Therefore, we 
hypothesized that the IRES sequence of the phVEGF165aIRESGFP plasmid may 
be working less efficiently in neural cells such as the C6 cell line, and that 
consequently, the expression of the GFP gene could be affected in those cells, while 
the VEGF gene is normally expressed.  
Figure 1.3. Correlations between the transfection 
efficiency parameters in HEK293 cells. (a) 
Correlation between VEGF production (ng/ml) and 
percentage of GFP expressing live cells in 
HEK293 cells 48h post-transfection with 
magnetoplexes (grey dot), lipoplexes (white dot) 
and polyplexes (black dot). Each value represents 
the mean ±SD, n=3. α represents the angle of the 
slope. (b) Correlation between VEGF production 
(ng/ml) and MFI values in HEK293 cells 48h post-
transfection with nanoplexes. Each value 
represents the mean ±SD, n=3. α represents the 
angle of the slope. (c) GFP histograms of HEK293 
cells 48h post-transfection with nanoplexes. M1 







Figure 1.4. Correlations between the transfection 
efficiency parameters in C6 cells. (a) Correlation 
between VEGF production (ng/ml) and 
percentage of GFP expressing live cells in C6 
cells 48h post-transfection with magnetoplexes 
(grey dot), lipoplexes (white dot) and polyplexes 
(black dot). Each value represents the mean ±SD, 
n=3. α represents the angle of the slope. (b) 
Correlation between VEGF production (ng/ml) 
and MFI values in C6 cells 48h post-transfection 
with nanoplexes. Each value represents the mean 
±SD, n=3. α represents the angle of the slope. (c) 
GFP histograms of C6 cells 48h post-transfection 
with nanoplexes. M1 represents the threshold for 
GFP positive signal.   
 
Once the capacity of nanoplexes to transfect HEK293 and C6 cells was analyzed, 
we performed transfection assays in primary neuronal culture cells, which represent 
a more challenging scenario for non-viral gene delivery. Cell viabilities (Fig. 1.5.a.) 
were excellent in this case –near 100% with all nanoplexes-, but transfection 
efficiencies (Fig. 1.5.a-b) were lower than in the previous cell lines, due to the 
difficulty of transfecting neuronal cells. GFP expression was only detectable by 
immunocitochemistry assay –Fig. 1.5.b shows a few scattered fluorescent cells-. 
This supports the hypothesis of the tissue specificity of the IRES element in the 
phVEGF165aIRESGFP plasmid. Regarding VEGF expression, we found that these 
cells presented a high basal production of VEGF, probably due to the glial cells 
present in the primary culture, which secret angiogenic55 and neurotrophic56 factors 
to support the CNS cells. However, after transfection with nanoplexes, levels of 
secreted VEGF increased respect to the control in all cases, although statistically 
significant differences were only found in magnetoplexes transfected cells (Fig. 
1.5.c). Next, we analyzed the bioactivity of transfected cells secreted VEGF in 
HUVEC cells, since these cells are known to respond with increased proliferation to 
the effect of VEGF57,58. Compared to the proliferation control group –HUVEC cells 
not treated with VEGF-, HUVEC cells exposed to VEGF secreted by primary 
neuronal culture cells transfected with nanoplexes presented a statistically 




proliferation. Furthermore, the increase of proliferation in HUVEC cells was 
proportional to the increase of VEGF production in primary neuronal culture cells, 
magnetoplexes obtaining the highest levels of VEGF expression in primary neuronal 
culture cells and their supernatants achieving the highest levels of proliferation in 
HUVEC cells, followed in both cases by polyplexes and, finally, lipoplexes. It is 
remarkable that magnetoplexes transfected CNS cell models more efficiently than 
their counterparts and that, unexpectedly, polyplexes were more efficient than 
lipoplexes in primary neuronal culture cells. 
 
 
Figure 1.5. Primary neuronal culture cells viability, efficiencies of transfection with nanoplexes 
in those cells and bioactivity of VEGF protein secreted by the transfected cells. (a) Cell viability 
in primary neuronal culture cells 48h post-transfection with nanoplexes. Each value represents 
the mean ±SD, n=3. (b) Immunocitochemistry images of transfected primary neuronal culture 
cells. Green, Anti-GFP. Blue, Hoechst. Scale: 25 µm. (c) VEGF production (ng/ml) by primary 
neuronal culture cells 48h after transfection with nanoplexes. Control cells were not treated 
with nanoplexs. Each value represents the mean ±SD, n=3. (d) HUVEC cell proliferation in 
response to VEGF secreted by primary neuronal culture cells transfected with nanoplexes. 
Control HUVEC cells were not treated with VEGF. Each value represents the mean ±SD, n=6. 




Considering these results, non-viral vectors and, in particular, magnetoplexes might 
constitute a promising approach to deliver the VEGF gene into CNS cells in a safe 
and controlled way, which is consistent with previous reports17. Strong relationships 
described between vascular alterations and neurodegeneration40, along with 
reported beneficial effects of VEGF protein in animal models of neurodegenerative 
diseases such as AD59 and Parkinson’s Disease57, suggest that VEGF may be a 
potential therapeutic candidate for CNS disorders. Besides, compared to drug 
delivery, VEGF gene delivery would demand fewer doses and would allow long-
lasting effects. To date, administration of non-viral vectors to SNC is still a challenge 
for the scientific community, principally due to the invasive nature of the currently 
available approaches to target the brain, including craniotomy. A recent study has 
shown that intranasally administered plasmid DNA nanoparticles circumvented the 
BBB to target the CNS and have successfully transfected rat brain60. Therefore, the 
intranasal route, a safer and non-invasive alternative, merits special attention for 
non-viral gene delivery into the CNS. 
 
2. The role of the non-ionic tensioactive component of niosome 
formulations in the transfection process and efficiency in rat retina 
Several monogenic retinal disorders are well characterized, with identified mutations 
that most often affect to specific genes in retinal pigment epithelium (RPE) cells61. 
RPE cells perform pivotal functions required for the maintenance of the neural retina, 
such as protecting the photoreceptor cells and secreting growth factors62. In many 
retinal diseases, including Leber’s congenital amaurosis (LCA), retinitis pigmentosa 
(RP) and age-related macular degeneration (AMD) blindness occurs due to RPE 
degeneration, which results in photoreceptor loss or dysfunction61. Therefore, RPE 
cells constitute the main target of most ocular gene therapy strategies, and the 
success of retinal gene transfer strategies depends on the ability to achieve 
persistent and high levels of transgene expression in RPE cells, ideally from a single 
administration. 
Non-viral gene delivery offers reasonable hope to transfer specific therapeutic genes 
into the eye. Niosomes have been effectively used for gene delivery to retinal cells 
both in vitro and in vivo, and the effect of cationic lipids and helper lipids has been 
well studied in transfection processes mediated by those formulations26,63. To date, 
niosome formulations containing the cationic lipid DOTMA18 or the non-ionic 




effective gene delivery to the retina. However, the use of other non-ionic surfactants 
with different chemical properties such as polysorbate 20 and polysorbate 85 for 
retinal gene transfer has not been explored. Therefore, in this work we elaborated 
and characterized, in terms of physicochemical properties and transfection efficiency 
into retinal cells, three niosome formulations that only differed in their non-ionic 
tensioactives. These niosomes named DST20, DST80 and DST85 were based on 
the cationic lipid DOTMA, combined with squalene as helper lipid and polysorbates 
20, 80 or 85 as non-ionic surfactants.  
Non-ionic tensioactives in niosome formulations act as emulsifiers creating a steric 
barrier that avoids aggregation22. Polysorbates 20 and 85 share the same chemical 
root structure as polysorbate 80, but the three molecules differ in their hydrophyilic 
parts and number of hydroxyl groups, therefore presenting different (HLB) values 
(Figure 2.1.). The HLB parameter determines the oil (HLB < 9) or water (HLB > 11) 
solubility of the non-ionic surfactants64. Among the three non-ionic surfactants 
tested, polysorbate 20 is the most hydrophilic, due to the presence of 2 hydroxyl 
groups and a lauric acid, with a HLB value of 16.7. Polysorbate 80 is next with HLB 
= 15 and polysorbate 85 is the less hydrophilic of the three non-ionic surfactants, 
due to the presence of three oleic acids in its chemical structure, with a HLB value 








The physicochemical parameters of formulations are key factors that determine 
transfection efficiency. DST20, DST80 and DST85 niosomes revealed mean particle 
sizes between 100 nm and 225 nm (Fig. 2.2.A, bars), suitable for gene delivery 
purposes65. Little oscillations in particle sizes upon the addition of plasmid DNA at 
cationic lipid/DNA ratios 2/1, 5/1 and 10/1 were probably due to the balance between 
the larger space demanded by the lipid and the higher DNA condensation when 
increasing mass ratios26. In all conditions, formulations showed narrow size 
distributions as indicated by the low PDI values (Fig. 2.2.B). The surface charge of 
the formulations has an impact on their stability, and zeta potential values under -30 
mV and over +30 mV avoid particle aggregation46. In addition, positive zeta potential 
values promote electrostatic interactions with negatively charged DNA to form 
nioplexes45. The three niosome formulations presented suitable zeta potential values 
over +40 mV (Fig. 2.2.A, dots). As expected, at low cationic lipid/DNA mass ratios 
surface charge values of nioplexes clearly declined, demonstrating that the amine 
groups of the niosomes electrostatically interacted with the phosphate groups of the 
DNA resulting in partial neutralization of surface charges66. In order to determine the 
morphology of our formulations, niosomes were examined under a TEM microscope 
at different magnifications, corroborating that all formulations presented a clear 
spherical shape (Fig. 2.2.C-E). The ability of nioplexes to protect and release 
plasmid DNA at different cationic lipid/DNA mass ratios was evaluated by a gel 
retardation assay. We found that all formulations were able to protect plasmid DNA 
even at the lowest cationic lipid/DNA mass ratio 2/1 (Fig. 2.2.F). The exception were 
DST80 nioplexes, which showed higher ability to protect DNA at higher cationic 
lipid/DNA mass ratios. However, since our purpose was to develop efficient niosome 
formulations for retinal gene delivery in vivo, in all formulations we selected the 
lowest cationic lipid/DNA mass ratio for posterior transfection assays, which allows 
increasing the amount of DNA to administer in vivo and reduces cellular toxicity 





Figure 2.2. Physicochemical characterization of DST20, DST80 and DST85 niosomes and 
their corresponding nioplexes at cationic lipid/DNA (w/w) ratios 2/1, 5/1 and 10/1. (A). Size 
values are represented with bars and zeta potential values with dots. Each value represents 
the mean ± SD, n=3. (B). PDI values. Each value represents the mean ± SD, n=3. (C-E). TEM 
images of niosomes. Scale bars: 200.0 nm. (C) DST20 niosomes at 20,000x magnification, 
(D) DST80 niosomes at 20,000x magnification and (E) DST85 niosomes at 40,000x 
magnification. (F). Agarose gel electrophoresis assay for analyzing the ability of DST20, 
DST80 and DST85 nioplexes at different cationic lipid/DNA (w/w) ratios to protect the pCMS-
EGFP plasmid. DNase I enzyme and SDS were added in lanes 2-11. Lanes 1-2 correspond 
to naked DNA. Lanes 3, 4 and 5 correspond to DST20 nioplexes at cationic lipid/DNA mass 




cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1, respectively. Lanes 9, 10 and 11 correspond 
to DST85 nioplexes at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1, respectively. OC: open 
circular form, SC: supercoiled form.  
Once the formulations were fully characterized, we performed in vitro transfection 
studies at cationic lipid/DNA mass ratio 2/1 in the well-known transfection model 
HEK-293 cell line and with the retinal model ARPE-19 cell line in accordance to the 
aim of our study. In both cell lines, nioplexes showed excellent cell viabilities above 
95% in HEK-293 and above 85% in ARPE-19, demonstrating that they were well 
tolerated by both types of cells. This was further confirmed by the healthy 
appearance of HEK-293 and ARPE-19 under the microscope 48 h after transfection 
(Fig. 2.3.A2 and 3B2). In contrast, transfection positive control Lipofectamine 2000TM 
showed lower cell viability values than nioplexes in both cells, around 90% in HEK-
293 cells and around 55% in ARPE-19 cells, which in accordance with previous 
reports26, indicates that in retinal cells nioplexes are much better tolerated. In fact, 
Lipofectamine 2000TM is not considered suitable for retinal gene delivery due to its 
high toxicity to photoreceptor cells even at low concentrations68. Regarding 
transfection efficiency, we found that DST85 niosomes were the most efficient 
transfecting HEK-293 cells (Fig. 2.3.A1), while DST20 nioplexes showed the highest 
transfection values in ARPE-19 cells (Fig. 2.3.B1). It is generally accepted that non-
ionic surfactants with low HLB values and high liposolubility enhance the cellular 
uptake of the formulations69,70. This is consistent with results in HEK-293 cells, since 
polysorbate 85 presents the lowest HLB value among the three non-ionic surfactants 
tested. Interestingly, in ARPE-19 cells, polysorbate 20 containing niosomes seemed 
to be the most efficient for gene transfer. As previously mentioned, polysorbate 20 
has the highest HLB value and therefore, the lowest lipophilicity. All together 
suggests that other cell-dependent mechanisms such as the cell internalization 
mechanisms and endocytic pathways could explain the higher efficiency of DST20 




Figure 2.3. Transfection efficiency and cell viability assay in HEK-293 and ARPE-19 cells 48 
h post-addition of DST20, DST80 and DST85 nioplexes vectoring the pCMS-EGFP plasmid 
at cationic lipid/DNA mass ratio 2/1. (A1). Normalized percentages of EGFP expressing HEK-
293 cells evaluated by flow cytometry. Each value represents the mean ± SD, n = 3. Statistical 
significance: * p < 0.05, **p < 0.01, ***p < 0.001. (A2).  Representative fluorescence 
microscope image of EGFP expression in HEK-293 cells transfected with DST85 nioplexes 
captured at 20x magnification. Scale bar: 100 µm. (B1). Normalized percentages of EGFP 
expressing ARPE-19 cells evaluated by flow cytometry. Each value represents the mean ± 
SD, n = 3. Statistical significance: * p < 0.05, **p < 0.01, ***p < 0.001. (B2).  Representative 
fluorescence microscope image of EGFP expression in ARPE-19 cells transfected with 
DST20 nioplexes captured at 20x magnification. Scale bar: 100 µm.  
In this regard, in order to further understand the transfection process with DST20, 
DST80 and DST85 nioplexes in ARPE-19 cells, we analyzed the cell entry 
mechanisms and intracellular trafficking pathways followed by the formulations. Non-
viral vectors usually enter the cells via endocytosis, being CME and CvME the most 
common and well-studied endocytic pathways71. The CvME route has been 
generally considered a non-acidic and non-digestive endocytic pathway72, while the 
CME pathway is believed to integrate the endocyted vesicles into late endosomes, 
which then deliver their cargos to lysosomes73. However, controversial data exist in 
this regard, since it has also been described that caveosomes can join the classical 
endocytic pathway, eventually fusing with lysosomes74,75. In addition, the acid pH in 
lysosomes is believed to cause the dissociation of the DNA from the non-viral 
vector76 which, according to some authors, facilitates the cytosolic release of 




reported that in absence of endosomal escape mechanisms, the acid environment 
and the enzymatic activity of lysosomes causes the degradation of nioplexes, 
impeding the access of DNA molecules into the nucleus78. In our study, we found 
that when nioplexes entered predominantly through CME, which was the case of 
DST85 nioplexes, they also co-localized with late endosome lysosomic 
compartments which apparently resulted in a lower transfection efficiency (Figure 
2.4.). In contrast, when nioplexes entered through CvME, as in the case of DST20 
nioplexes, they seemed to avoid late endosomes and transfection efficiency 
increased. Therefore, our results are in accordance with the lysosomal degradation 
hypothesis upon CME-mediated cell entry, which in turn would explain the higher 
transfection efficiency of DST20 nioplexes in ARPE-19 cells. DST80 nioplexes 
showed very low co-localization values in ARPE-19 cells with both CME and CvME 
pathways, which might be explained by the presence of other cellular internalization 
pathways. In fact, a recent study reported that niosomes based on polysorbate 80, 
squalene and 1-(2-dimethylaminoethyl)-3-[2,3-di(tetradecyloxy) propyl] urea showed 
higher tendency to enter the cells through macropinocytosis than through CME or 
CvME13.  
Figure 2.4. Endocytic and intracellular trafficking pathways detection assay of DST20, DST80 
and DST85 nioplexes in ARPE-19 cells. (A1-3). Confocal microscopy merged images showing 
ARPE-19 cells co-incubated with nioplexes containing the FITC-labeled pCMS-EGFP plasmid 
(green) and with the endocytic vesicle marker (red): AlexaFluor546-Transferrin for CME, 
AlexaFluor555-Cholera toxin B for CvME and Lysotracker (Lys) for late endosomal 




correlation analysis in each case. Data are represented as mean ± SEM, n=3. (C1-3). 3D plots 
relating HLB values and the corresponding transfection efficiency and co-localization with 
intracellular pathways CME (C1), CvME (C2) and late endosomes (C3). 
Based on these results, we selected the formulation DST20 for retinal gene delivery. 
Before moving on to in vivo assays, we performed a preliminary in vitro transfection 
assay in a primary culture of rat retinal cells with DST20 nioplexes, and we observed 
effective transgene expression (Figure 2.5.). Encouraged by those findings, we 
carried out an in vivo study to assess whether the DST20 nioplexes were able to 
transfect the rat retinas after SR (Fig. 2.6.B-C) and IV injections (Fig. 2.6.D-E). In 
most cases, efficient transfection of ganglion cells of the retina can be achieved by 
IV injections, whereas transfecting cells in the outer retina, such as photoreceptor 
and the RPE, requires the more invasive SR injection68,79. In accordance, our results 
show that IV administration of DST20 nioplexes was successful to transfect 
predominantly ganglion cells of the retina (Figure 2.6.D), while with SR 
administration efficient transgene expression was observed in the inner layers of the 
retina, with clear diffusion to the outer layers including RPE cells (Figure 2.6.B). 
Considering that many blinding diseases are associated to mutations in specific 
genes of the RPE, achieving transfection at this level is highly desirable for 
therapeutic purposes. Unfortunately, SR injection is one of the most invasive 
methods and implies significant risk of complications such as inflammation, damage 
to the lens and retinal detachment80. Although many efforts are conducted to 
increasing RPE transgene expression after IV injection, at present the SR 
administration remains more efficient for RPE cells transfection. Additionally, 
research is also being directed towards ocular topical instillation of drugs. In fact, 
efficient topical drug delivery to the RPE layer of the retina with microfluidizer 
produced small liposomes has been recently reported81. This method does not imply 
any risks of retinal damage and it would be the ideal administration method for non-
viral vectors carrying nucleic acids. However, in the field of gene therapy more 
research is still needed to improve the efficiency of gene delivery through this 




Figure 2.5.. EGFP expression in embrionary rat retinal primary cells analyzed by fluorescence 
immunocytochemistry 96 h post-addition of DST20 nioplexes at cationic lipid/DNA mass ratio 
2/1. (A). EGFP expression in cells exposed to DST20 nioplexes. (B). EGFP expression in 
cells exposed to Lipofectamine 2000TM. Red: MAP2 neuronal dendrite marker; Blue: Hoechst 
33342 (cell nuclei); Green: EGFP. Scale bar: 20 µm. 
 
Figure 2.6. In vivo expression of EGFP after 
subretinal and intravitreal injection of DST20 
nioplexes at cationic lipid/DNA mass ratio 2/1. 
(A). Confocal fluorescence micrographs of 
retinal cross sections showing EGFP signal 
after subretinal administration of DST20 
nioplexes. (B). Confocal fluorescence 
micrographs of retinal cross sections showing 
EGFP signal after subretinal administration of 
the positive control Lipofectamine 2000TM. (C). 
Fluorescence immunohistochemistry showing 
EGFP positive signal located in the ganglion 
cell layer after intravitreal administration of 
DST20 nioplexes. (D). Fluorescence 
immunohistochemistry showing EGFP positive 
signal located in the ganglion cell layer after 
intravitreal administration of the positive 
control Lipofectamine 2000TM. Blue: Hoechst 
33342 (cell nuclei); Green: EGFP. Scale bars: 
20 µm. RPE (retinal pigment epithelium), ONL 
(outer nuclear layer), INL (inner nuclear layer), 





In summary, we elaborated and characterized three niosome formulations that only 
differed in the non-ionic tensioactives. We found that the novel DST20 niosome 
formulation, based on polysorbate 20 combined with cationic lipid DOTMA and 
helper lipid squalene, efficiently transfected rat retina both in vitro and in vivo at the 
low cationic lipid/DNA mass ratio 2/1. Targeted cells strongly depended on the 
administration route. SR injection transfected the inner layers of the retina and 
showed clear diffusion to outer layers including the RPE, while IV injection 
transfected predominantly the ganglion cell layer. With the advancement of DNA 
compaction technology and vector engineering strategies, efficient transfection 
through less invasive administration routes and prolonged transgene expression 
may be achievable goals. 
3. The influence of the genetic material in niosome formulations in their 
transfection efficiency in rat retina 
In addition to improving the delivery formulation as discussed in the previous section, 
we were now interested in the optimization of the DNA payload itself. Various 
elements of plasmid DNA vectors have been studied and optimized so far in order 
to increase or prolong transgene expression, including the promoter sequence, 
enhancer sequences, polyadenylation signals and the removal of CpG motifs to 
decrease inflammatory responses82-86. Nevertheless, plasmid DNA vectors also 
contain a bacterial backbone, which consists of prokaryotic replication origin 
sequences and antibiotic resistance genes. This bacterial backbone allows for the 
propagation of plasmid DNA in bacterial hosts, but it has recently been related to 
decreased transgene expression and lower biocompatibility and safety profile of the 
gene delivery complex. Therefore, minimized expression units that only contain the 
gene of interest and regulatory sequences such as minicircle (MC) DNA vectors 
emerge as an attractive alternative to conventional, larger plasmid DNA vectors. 
MCs are small circular DNA vectors with no antibiotic resistant genes or bacterial 
backbone sequences, which make them superior to regular plasmids. MC-DNA has 
a reduced size compared with conventional plasmid DNA with the same expression 
cassette and the content of unmethylated CpG dinucleotides is considerably reduced 
(Fig. 3.1.). Thus, their use results in sustained transgene expression because of a 
lower activation of nuclear transgene silencing mechanisms, and reduced 
immunogenic responses in vivo87-92.  Due to its minimal size and lack of bacterial 
backbone sequences, minicircle DNA presents a promising alternative to plasmid 
DNA for non-viral gene delivery in terms of biosafety and improved gene transfer. 




transgene expression in a variety of organ systems in vivo including the liver93-95, 
heart96,97 and skeletal muscle97, but minicircles have not yet been assessed for 
retinal gene delivery in complex with niosome formulations. 
 
Figure 3.1.: DNA material composition.  
(A) pEGFP 5.5 kb, (B) pGFP 3.5 kb, (C) MC-GFP 2.3 kb. MC: minicircle; GFP: green 
fluorescent protein; EGFP: enhanced green fluorescent protein; pCMS: plasmid containing 
Cytomegalovirus promoter, Multiple cloning site and SV40 promoter; pCMV: cytomegalovirus 
promoter plasmid; bp: base pairs. 
Therefore, our goal was to provide as far as we were concerned, the first evidence 
that niosome based non-viral vectors combined with the MC technology is an 
effective technique for future clinical applications in the retinal gene therapy field. We 
employed DST20 formulation comprised of cationic lipid 1,2-di-O-octadecenyl-3-
trimethylammonium propane (DOTMA), the helper lipid Squalene and the non-ionic 
surfactant polysorbate Tween 2024-26. The resulting niosomes were combined with 
three different DNA materials consisting on MC-GFP of 2257 bp, pGFP of 3487 bp 
and pEGFP of 5541 bp, to form the corresponding nioplexes. Niosomes and 
nioplexes were characterized in terms of particle size, polydispersity index (PDI), 
zeta potential, morphology and stability. The capacity of niosomes to protect and 
release these DNA materials as well as the binding interactions between cationic 
niosomes and DNAs at molecular level was also analyzed. In vitro experiments were 
performed to evaluate both the efficiency and cell viability of transfection over time 
and at different temperatures with the three DNA materials complexed to DST20 
niosomes in human ARPE-19 retinal pigment epithelium cells. Additionally, the 




embrionary rat retinal primary cells and by in vivo administration of nioplexes to rat 
eyes via intravitreal (IV) and subretinal (SR) injections. 
DST20 niosomes presented appropriate spherical morphology and size for gene 
therapy purposes, 123 nm, with low PDI and positive zeta potential pointing out not 
only a good homogeneity and stability of the suspensions, but also an easy 
interaction with the negatively charged phosphate groups of the DNA material to 
form nioplexes, respectively45,98,99. It is worth mentioning that differences in the 
reported size of niosomes between dynamic light scattering and TEM techniques 
could be explained by the sample processing and treatment performed for both 
analyses13. As expected, complexation of DST20 niosomes with the corresponding 
DNA almost doubled its original diameter and zeta potential values diminished due 
to the partial neutralization of the positive amine groups of niosomes by the DNA 
phosphate groups (Figure 3.2.A-B).  
The features observed regarding size, zeta potential and transfection efficiency 
when complexing niosomes to the three genetic materials, are in accordance with 
previous studies which confirm that the DNA size bound to niosomes does not affect 
such physicochemical properties of nioplexes100 but have different transfection 
efficiencies in vitro101. The explanation for the differences observed in transfection 
efficiencies might reside in two main factors. On the one hand, the magnitude of the 
increment in the particle-size of nioplexes with respect to the niosomes seems to 
rule out the possibility that the second phase seen in the ITC titration curves might 
be due to the binding of more niosomes onto DNA-coated nioplexes. Thus, niosome-
DNA binding events occurring at higher ratios than 2/1 would probably involve the 
reorganization of the previously bound genetic material, which would lead to a 
reduction in the number of DNA molecules bound per niosome and to the preferential 
occupation of the most favourable binding sites on the niosome surface. This could 
also affect the ability of the nioplexes to interact with the cell surface and, 
consequently, their transfection capacity. On the other hand, this study was 
developed with a constant DNA quantity of 1.25 µg per condition but it has to be 
taken into account that DNA length, and therefore weight and molarity, differs 
between the three genetic materials under study, which consequently affects the 
number of DNA molecules bound to each niosome. This fact can be observed in the 
ITC assay where different calorimetry curves were obtained depending on the 
genetic material complexed to the DST20 formulation (Figure 3.2.D). Hence, 




means a higher rate of expression cassettes per niosome, increasing the probability 
of efficient gene delivery into the cell and finally a higher transgene expression92,101.  
 
Figure 3.2.: Physicochemical characterization and stability measurements of niosomes 
and nioplexes. (A) Physicochemical characterization of DST20 niosomes at day 0 and at day 
30 of storage at 4ºC and 25ºC, and corresponding nioplexes. Each value represents the mean 
± SD from three measurements. (B) TEM images of DST20 niosomes at day 0 (i), at day 30 
of storage at 4ºC (ii) and 25ºC (iii). Scale bars: 500 nm (outer images) and 200 nm (inner 




release the DNA material at day 0 (i), at day 30 of storage at 4ºC (ii) and 25ºC (iii). DNase I 
enzyme and SDS were added in lanes 3, 6 and 9 to evaluate both protection and release in 
MC-GFP, pGFP 3.5 kb and pEGFP 5.5 kb nioplexes, respectively. As controls, lanes 1, 4 and 
7 correspond to control naked MC-GFP, pGFP 3.5 kb and pEGFP 5.5 kb, respectively, and 
lanes 2, 5 and 8 to those naked DNAs after adding DNase I enzyme, respectively. (D) ITC 
study of DNA titration with DST20 niosomes. Corresponding variation of heat evolved per mg 
of DOTMA injected vs. the ratio of DOTMA/DNA concentrations expressed in mg/ml. Symbols 
represent the experimental data whereas the discontinuous line illustrate the tendency of the 
ITC profiles. 
The differences found in GFP expression upon the storage of niosomes (Fig. 3.3.) 
could be explained not by a single cause but by several cumulative reasons. In fact, 
effective gene delivery is affected by size range and zeta potential but many other 
relevant parameters such as a correct vector morphology and DNA binding affinity 
may have an impact on this effectiveness102. In this regard, TEM images showed a 
loss of the spherical shape of niosomes and even the formation of some aggregates 
after 30 days of storage, which in turn would difficult interactions with the DNA 
material. Actually, gel retardation and ITC assays confirm this reduction of DNA 
complexation capacity of niosomes over time. In agarose gels, the lower signal of 
bands corresponding to DNA protection and release after storage denoted a 
reduction of these capacities (Fig. 3.2.C). Accordingly, ITC data would be indicative 
that the molecular features of the DST20-based nioplexes formed at 2.0 ratio 
(equivalent to DOTMA/DNA ratio 2/1) could depend on the previous history of the 
niosomes, explaining the differences mentioned before, such as the 
physicochemical features, the morphology of niosomes and their ability to protect 
and release the DNA. Even though DST20 niosomes stored for 30 days at 4ºC 
vectoring MC remained exhibiting a higher gene delivery capacity compared with 
plasmid nioplexes (Fig. 3.3.), additional efforts are required in order to achieve more 
stable formulations by either performing better characterization methods or by 




Figure 3.3.: Transfection efficiency of nioplexes and cell viability in ARPE-19 cell line. 
Flow cytometry evaluation of GFP positive live cells (bars) and viability (dots) after transfection 
employing (A) DST20 niosomes at day 0 and (B) after 30 days of storage at 4ºC and 25ºC, 
bound to either MC-GFP, pGFP 3.5 kb or pEGFP 5.5 kb. Data are presented as mean ± SD, 
n = 3. *P < 0.05 for transfection efficiency groups, #P < 0.05 for cell viability relative to its 
respective Lipofectamine™ 2000; ns means no statistically significant differences. 
Since IV and SR routes are considered the most clinically viable options to deliver 
efficiently the genetic material to the back of the eye103, nioplexes were injected at 
these levels in vivo. IV administration of DST20 nioplexes showed GFP expression 
in the GCL, in accordance with previous works employing non-viral vectors24,25. 
Effective gene transfer at this level could be clinically relevant for treatment of 
devastating inherited retinal disorders such as glaucoma, which is considered the 
first cause of blindness worldwide104. After injection of those nioplexes at SR level, 
transgene expression diffused to the inner nuclear layer (INL) and, importantly, was 
localized close to the injection site in the retinal pigment epithelium (RPE). For 




deeply desirable since many inherited retinal disorders with no curative treatment to 
date, such as retinitis pigmentosa, Stagardt´s disease or Leber´s congenital 
amaurosis, are associated with more than 200 mutations of genes expressed at the 
photoreceptors and RPE level 4. Qualitative analysis after both IV (Fig. 3.5.) and SR 
(Fig. 3.6.) injections showed a higher transgene expression the smaller the DNA 
was, pointing out that DST20 non-viral vector combined with MC-DNA offers a 
potential tool for retinal degenerative and inherited diseases. In addition, it has been 
reported that MC technology offers not only a higher but also a sustained gene 
expression over time, offering key benefits for clinical translation92,101. Despite GFP 
expression was also observed employing Lipofectamine™ 2000, it has been shown 
that such formulation is not suitable for in vivo experiments due to its high toxicity 
mainly accused into photoreceptor cells even at low concentrations68. In fact, our in 
vitro experiments clearly showed the toxicity of Lipofectamine™ 2000 in retinal cells 
(Fig. 3.3., Fig. 3.4.). Finally, it is noteworthy the high transfection efficiency achieved 
with DST20:MC nioplexes at the low 2/1 ratio since it allows a higher gene content 
at small volumes of injection for clinical applications, where the volume to be injected 
represents an important handicap, and reduces cellular toxicity associated to 
cationic lipids67. Furthermore, the lack of unmethylated CpG content in MC-DNA 
technology provides additional reduced immunogenic responses, reinforcing 
DST20:MC complexes as a potential efficient and safe tool for translational retinal 
gene therapy applications.  
 
Figure 3.4.: GFP expression in embrionary rat retinal primary cells. Fluorescence 
immunocytochemistry showing GFP positive signal located mainly in glial cells after 
transfection with DST20 nioplexes, carrying either (A) MC-GFP, (B) pGFP 3.5 kb or (C) 




2000. Cell nuclei were counterstained with Hoechst 33342 (pseudocolored blue) and neuronal 
dendrites with MAP2 (red color). White arrows indicate apoptotic nuclei.  Scale bars: 20 µm. 
 
Figure 3.5.: In vivo expression of GFP after intravitreal injection of nioplexes. Confocal 
fluorescence micrographs of retinal cross sections showing GFP signal after intravitreal 
administration of DST20 nioplexes carrying either (A) MC-GFP, (B) pGFP 3.5 kb or (C) pEGFP 
5.5 kb. (D-F) images of their counterpart positive controls. RPE (retinal pigment epithelium), 
OS (outer segments), ONL (outer nuclear layer), INL (inner nuclear layer), GCL (ganglion cell 









Figure 3.6.: In vivo expression of GFP after subretinal injection of nioplexes. Confocal 
fluorescence micrographs of retinal cross sections showing GFP signal after subretinal 
administration of DST20 nioplexes carrying either (A) MC-GFP, (B) pGFP 3.5 kb or (C) pEGFP 
5.5 kb. (D-F) images of their counterpart positive controls. RPE (retinal pigment epithelium), 
OS (outer segments), ONL (outer nuclear layer), INL (inner nuclear layer), GCL (ganglion cell 
layer). Cell nuclei were counterstained with Hoechst 33342 (pseudocolored blue). Scale bars: 
20 µm. 
Therefore, the main findings of this study are the following: (1) DST20 niosomes is 
a non-viral vector able to protect genetic material and release it with controlled 
kinetics; (2) the capacity of niosomes to protect and interact with DNA material is 
affected over time and temperature of storage; (3) DST20 niosomes complexed with 
different genetic material, varying in terms of size and composition, present similar 




cell viability is not affected; (4) DST20 nioplexes containing MC-DNA present higher 
transfection efficiency than those containing plasmids in in vitro assays, even after 
DST20 storage for 30 days; and (5) DST20 nioplexes are able to transfer the genetic 
material not only in ex vivo primary retinal cell cultures but also after in vivo injection 
in rat retinas regardless the via of administration, being those carrying MC-DNA the 
ones that present the higher rate of GFP signal. Therefore, DST20 niosomes 
vectoring MC technology seems to be an efficient and safe therapeutic tool for retinal 
disorders, overcoming the existing translational barrier of non-viral vectors 
complexed with plasmids due to their poor transfection efficiency.  
4. Tridimesional aspects of non-viral gene delivery systems: exploring 
complementary synergies between niosomes and hyaluronic acid 
hydrogel scaffolds 
In addition to the optimization of the carrier and the genetic material, a new trend in 
non-viral gene therapy is to explore novel complementary synergies between 
delivery systems and tissue-engineered scaffolds in order to improve the transfection 
efficiency. In fact, these combined approaches may offer relevant advantages such 
as enhanced stability and reduced toxicity. Moreover, complementing gene transfer 
with matrix design would allow an effective, targeted and local DNA delivery, which 
would enhance the applicability of gene therapy in many therapeutic fields, such as 
tissue regeneration and cancer35,36. Hyaluronic acid (HA), an anionic 
glycosaminoglycan, is one of the primary components of the natural extracellular 
matrix (ECM) and it is increasingly gaining popularity as a biomaterial in the field of 
tissue engineering105. HA hydrogels have been widely studied for their 
biocompatibility as well as their ability to incorporate a wide variety of molecules, 
including nucleic acids106.  
Therefore, the main objective of the present work was to develop an effective 
platform to deliver DNA locally using niosomes as non-viral vectors from HA hydrogel 
scaffolds. To our knowledge, this is the first example of niosome-based DNA 
nanoparticle delivery from HA hydrogels for non-viral gene expression. We explored 
three different niosome formulations (niosomes 1, 2 and 3) varying in composition of 
cationic lipid, helper lipid and non-ionic tensioactives (Fig. 4.1.) in complex with a 
reporter plasmid encoding for Gaussia luciferase (pGluc) to obtain the nioplexes. 
The selection of the components, their concentrations and the cationic lipid/DNA 
mass ratios (w/w) were based on previous studies developed in our laboratory. 




zeta potential and ability to transfect mouse bone marrow cloned mesenchymal stem 
cells (mMSCs) in 2D culture. HA hydrogels containing nioplexes were characterized 
in terms of biomechanical properties, particle distribution and nioplex release 
kinetics. Additionally, the biological activity of released nioplexes upon hydrogel 
degradation was also evaluated. mMSCs were efficiently transfected in nioplex 
encapsulated HA hydrogels and presented excellent cellular viability. These results 
demonstrate the potential for nioplex loaded HA hydrogels for sustained gene 
delivery. 
 
Figure 4.1. General scheme of cationic niosomes and hydrogel scaffolds used in this work. 




niosome formulations. B. Modification of HA to obtain HA hydrogels. C. Representative 
scheme of a HA hydrogel with entrapped nioplexes.  
Yet while high concentrations of non-viral DNA complexes in hydrogels have been 
demonstrated to improve local gene delivery107, the physical incorporation of DNA 
complexes into hydrogels is challenging due to some limitations such as aggregation 
and inactivation of the complexes inside hydrogel scaffolds108. Among the wide 
variety of non-viral vectors, poly(ethylene imine) (PEI) has been successfully 
encapsulated in HA hydrogels and effective local transgene expression and ability 
to induce angiogenesis in vivo have been reported109. Although PEI derivatives 
present high gene carrying capacity and ability to achieve high transfection 
efficiencies, their biomedical application is often restricted due to immunogenicity 
and cytotoxicity issues110.  In this regard, niosomes offer several advantages, since 
they have high compatibility with biological systems and low toxicity because of their 
non-ionic nature and are biodegradable and non-immunogenic64. In this work, in vitro 
transfection efficiencies obtained with nioplex encapsulated HA hydrogels 48 hours 
after exposure were comparable to those reported with PEI/DNA encapsulated HA 
hydrogels111. Therefore, reasonable hope suggests that nioplex encapsulated HA 
hydrogels could also be able to transfect cells in vivo and further studies in this 
direction would be of remarkable interest in order to explore this possibility.  
The three different niosome formulations differed in the composition of cationic lipid, 
helper lipid and non-ionic tensioactives (Fig. 4.1.). The niosome components used 
in this work have previously demonstrated suitability for gene delivery applications. 
For instance, niosome formulations containing the non-ionic surfactant polysorbate 
80 combined with the helper lipid squalene have shown effective gene delivery26. In 
addition, it has been recently shown that the helper lipid lycopene, combined with 
cationic lipid DOTMA and polysorbate 60, enhances retinal transfection24 and 
Poloxamer 407 has been widely used in drug delivery applications112. The use of 
chloroquine has also been reported to enhance gene delivery both in vitro and in 
vivo113. Therefore, the selection of the components, and their concentrations used to 
prepare the niosome formulations, as well as the cationic lipid/DNA mass ratios (w/w) 
to form the corresponding nioplexes were based on available data and previous 
studies developed in our laboratory.  
Niosomes and nioplexes were fully characterized in terms of size, PDI and zeta 




three niosome formulations presented positive zeta potential values (Fig. 4.2.B), 
necessary to bind to the negatively charged DNA molecules by electrostatic 
interactions45,66. In addition, positive zeta potential values enhance cellular uptake44. 
Compared to non-treated cells, all formulations showed ability to transfect, with 
nioplexes based on niosome 1 resulting in the highest transfection efficiency (Fig. 
4.2.C). Therefore, we selected the nioplexes based on niosome 1 at 2/1 cationic 
lipid/DNA mass ratio (w/w) formulation to study its applicability for non-viral gene 
delivery in HA hydrogels.  
Figure 4.2. Screening of niosome formulations. A. 
Size. B. Zeta Potential. C. Transfection efficiency 48 h 
post-exposure of mMSCs to nioplexes based on 
niosomes 1, 2 and 3 at cationic lipid/DNA mass ratios 
(w/w) 2/1, 15/1 and 18/1, respectively. Positive 
(Lipofectamine 2000TM at a cationic lipid/DNA mass 
ratio of 2/1) and negative (no DNA) controls are shown 
for reference.  
The use of nioplexes at low mass ratios presents several advantages, including the 
possibility of incrementing the dose of DNA as well as decreasing cellular toxicity13. 
Additionally, in order to be able to incorporate higher, more relevant amounts of DNA 
within HA hydrogels, the formulation based on niosome 1 was first concentrated from 
1 mg/ml to 2 mg/ml. The TEM images of the concentrated formulation showed that 
concentration did not affect morphology and, as expected, more particles were 
visible in the concentrated sample (Fig. 4.3.A-B).  Size and PDI values were also 
maintained similar in the concentrated formulation. Although the zeta potential 
values clearly declined in the concentrated niosome, values remained above +20 
mV, meaning that the stability of the formulation should not be affected. In fact, 
particles with surface charge values between -20 mV and +20 mV present more 
propensity to form aggregates along the time46. Additionally, the transfection ability 
of both concentrated and non-concentrated formulations was evaluated at cationic 
lipid/DNA mass ratio 2/1 and no statistically significant differences were found 
between the transfection efficiencies of both formulations (Fig. 4.3.C), indicating that 




results, we decided to use the concentrated formulation at the low cationic lipid/DNA 
mass ratio 2/1 for encapsulation in HA hydrogels.  
Figure 4.3. Characterization of concentrated 
niosome formulations. A-B. TEM images of 
non-concentrated (A) and concentrated (B) 
formulations based on niosome 1 at 10,000x 
magnification. Scale bars: 200.0 nm. C. 
Transfection efficiency 48 h post-exposure of 
mMSCs to nioplexes based on concentrated 
and non-concentrated niosome 1 at 2/1 
cationic lipid/DNA mass ratio (w/w).  
 
In order to achieve therapeutically relevant levels of DNA114, we evaluated three 
different amounts of concentrated nioplexes, obtaining final DNA concentrations of 
0.055 µg/µl, 0.12 µg/µl and 0.2 µg/µl in hydrogels 2, 3 and 4, respectively. Different 
DNA concentrations of hydrogels could cause differences in the mechanical 
properties, which are important factors determining cell proliferation, spreading and 
transgene expression in hydrogel scaffolds. High hydrogel stiffness (over 800 Pa) 
has been related to reduced cell spreading and transgene expression, while soft 
hydrogels (200 – 260 Pa) resulted in enhanced transgene expression108. Therefore, 
we evaluated the mechanical properties of hydrogels as a function of DNA 
concentration in order to determine their grade of stiffness. Rheological 
characterization showed high variability in the mechanical properties of hydrogels 
(Fig. 4.4.A-B). Hydrogel 3 presented the highest stiffness among the hydrogels 
tested, while hydrogel 4, with the highest DNA concentration, showed to be the 
softest. Such high values were not expected in hydrogel 3, however, that condition 
was not discarded and further studies were carried out in order to determine its 
transfection capacity despite its high stiffness. The evaluation of the distribution of 
the nioplexes inside the hydrogel scaffold showed larger DNA clusters in hydrogel 
2, which could be attributed to the presence of higher amounts of cell growth medium 
containing peptides and proteins that could interact with the nioplexes resulting in 
particle aggregation. Hydrogels 3 and 4, despite their higher DNA concentrations, 
presented a homogeneous distribution of nioplexes with no aggregates (Fig. 4.4.C-
E). However, since hydrogel 4 did not contain any cell growth medium, it was not a 
possible candidate for 3D cell culture nor for transfection assays and only hydrogels 




concentration and absence of particle aggregation in hydrogel 4 suggested that it 
could be an attractive option for in vivo gene delivery. Taken together, these results 
demonstrate that nioplexes can be successfully encapsulated into HA hydrogels 
without significant particle aggregation, although high variability in mechanical 
properties was observed.  
Figure 4.4. Characterization of HA hydrogels loaded with nioplexes. The mechanical 
properties of the hydrogels were determined using plate-to-plate rheometry over a frequency 
range of 0.1-10 rad/s at a constant strain of 0.01 (A). Average storage modulus (B). C-E. 
Particle distribution in hydrogels. Gel ID: 1, control hydrogel without nioplexes; 2, 0.055 µg 
DNA/µl; 3, 0.12 µg DNA/µl and 4, 0.2 µg DNA/µl. Scale bars: 200 µm. 
In order to validate that nioplexes maintained the ability to transfect cells after 
encapsulation in HA hydrogels, we synthesized nioplex-loaded hydrogels, degraded 
them with trypsin and performed a transfection with the released nioplexes (Fig. 
4.5.). Results showed that the transfection capacity of the nioplexes was negatively 
affected by the presence of interfering hydrogel materials and trypsin in the 2D cell 
culture media, but not by the encapsulation process since there were no statistically 
significant differences in transfection values between released nioplexes from 
degraded hydrogels and fresh nioplexes supplemented with degraded hydrogel 
materials (Fig. 4.5.B-C). In addition to the hydrogel components, the negative effect 





Figure 4.5. Biological activity of nioplexes based on concentrated niosome 1 at 2/1 cationic 
lipid/DNA mass ratio (w/w). A. Fresh nioplexes. B. Nioplexes released from degraded HA 
hydrogels with trypsin. C. Fresh nioplexes supplemented with degraded hydrogels with 
trypsin. D. Fresh nioplexes supplemented with trypsin. E. Naked DNA supplemented with 
degraded hydrogels trypsin. F. Hydrogels without nioplexes degraded with trypsin. *p < 0.05 
for transfection efficiency between different conditions, #p < 0.05 for transfection efficiency of 
all conditions relative to condition “A”. 
Two main mechanisms are postulated to contribute to the gene transfer process from 
hydrogel scaffolds: DNA/nanoparticle release kinetics and rate of cellular 
infiltration115. Nioplexes released after hydrogel degradation could transfect 
surrounding cells, while infiltrating cells would encounter entrapped nioplexes and 
become transfected leading to transgene expression inside the hydrogel area116,117. 
In this regard, for cells cultured in three dimensions, the migration rate of cells 
through the hydrogel has previously been related to successful non-viral gene 
transfer115. Therefore, we would expect that softer hydrogel scaffolds that allowed 
for extensive cell spreading would result in enhanced gene transfer. In the present 
work, nioplexes were released from the gels within 7 days in the presence of Col I 
and the process was slightly slower in the absence of enzymatic degradation (Fig. 
4.6.A). This progressive release of nioplexes potentially allows for sustained 
transgene expression, which is essential for therapeutic applicability.. Regarding cell 




including hydrogel 3 allowed for extensive cell spreading (Fig. 4.6.C-E) and, despite 
its high stiffness, the highest transfection values were obtained in hydrogel 3 (Fig. 
6B, bars). Therefore, these results suggest that increasing amounts of DNA can be 
used to overcome limitations of stiffer hydrogels. Moreover, cell viability was 
excellent in all conditions (Fig. 4.6.B, dots), which indicated that the presence of 
nioplexes in the HA hydrogels was well tolerated by the cells.  
 
Figure 4.6. A. Nioplex release kinetics from HA hydrogels in PBS and in PBS supplemented 
with Collagenase I (1 U/ml). B. Transfection efficiency and cell viability of nioplex-loaded 
hydrogels 1-3 at 48 h. C. Representative images of cell spreading in hydrogels 1, 2 and 3. 
Blue = cell nuclei (DAPI) and red = F-actin (rhodamine-phalloidin). Scale bars: 200 µm. *p < 
0.05 for transfection efficiency.  
To sum up, we successfully developed a process to load concentrated nioplexes into 
HA hydrogels without aggregation. To our knowledge, this is the first time that 
niosome formulations composed of 2,3-di(tetradecyloxy)propan-1-amine, 
Poloxamer 407, polysorbate 80 and chloroquine diphosphate salt are incorporated 
to HA hydrogels for non-viral gene delivery. In general, HA hydrogel scaffolds loaded 
with nioplexes presented suitable mechanical properties, little or no particle 
aggregation, allowed for extensive cell spreading and were able to efficiently 
transfect encapsulated mMSCs in 3D cultures. We believe that the knowledge 
gained through this in vitro model can be utilized to design novel and effective 




As a whole, this doctoral thesis describes and explores key factors that determine 
the transfection efficiency of non-viral vectors and that need to be taken into account 
when developing efficient non-viral gene delivery systems. Those key aspects 
include the composition and physicochemical properties of non-viral vectors, the 
composition and conformation of the genetic material and the combination of delivery 
systems with other technologies such as matrix design. We believe that the concept 
of a unique universal non-viral vector is nowadays obsolete, and that future non-viral 
gene delivery platforms will be based on multifunctional vectors specifically tailored 
for different applications. Although non-viral vectors are still far from clinical practice, 
reasonable hope suggests that next generation delivery systems for gene addition 
and, most importantly, gene editing strategies may be based non-viral vector 
systems, which, ideally, would be suitable for administration via non-invasive routes.  
 







Gene-terapiaren helburua da material genetiko arrotza zeluletan txertatzea horien 
proteina-espresioa aldatzeko edota kontrolatzeko, eta aplikazio terapeutikoak zein 
esperimentalak izan ditzake1. Giza Genomaren Proiektuak eta azken urteetan 
biologia molekularraren arloan egindako aurrerapenek prozesu zelularrak eta 
patologikoak hobeto ulertzea ahalbidetu dute. Aldi berean, aurrerapauso horiek 
gene-terapiarako jomuga izan litezkeen hainbat gene identifikatzen lagundu dute 
gaixotasun genetiko ezberdinei dagokienean. Halere, nahiz eta gene-terapiak 
potentzial handia erakutsi duen batez ere gaixotasun monogenikoen 
tratamendurako, bektore seguru eta eraginkorrak garatzea ezinbesteko baldintza da 
gene-transferentzian oinarritutako estrategia terapeutikoak erabilera klinikora 
iristeko. Izan ere, gene-terapiaren arrakasta bektoreen eraginkortasunaren menpe 
dago erabat. Gaur egun uste da honako hauek direla bektoreek bete beharreko 
baldintza nagusiak gene-garraioa modu efizientean eman dadin: (i) material 
genetikoa nukleasen erasotik babesteko gai izan behar dira, (ii) azido nukleikoak 
zelulan barneratzeko gai izan behar dira eta (iii) material genetikoa zelula barruko 
konpartimentu egokian askatzeko gaitasuna izan behar dute. Gainera, gene-garraio 
sistema idealak espezifikoak, iraunkorrak, seguruak, erabilerrazak eta ahalik eta 
ahalik eta kosturik baxuenekoak izan behar dira2.  
Orohar, gene-garraiorako bektoreak bi multzotan sailkatzen dira: bektore biralak eta 
ez-biralak. The Journal of Gene Medicine aldizkariak 2014an argitaratutako datuen 
arabera, mundu-mailan gene-terapiako 2000 entsegu kliniko inguru daude abian eta, 
horietatik, %70ek bektore biralak erabiltzen dituzte geneak garraiatzeko3. Gainera, 
gaur egun soilik lau gene-terapia produktu iritsi dira merkatura eta laurak bektore 
biraletan oinarrituta daude. Lehen gene-terapia produktu medizinala GendicineTM 
izan zen eta Txinan onartu zen 2003 urtean. Bektore gisa adenobirus (Ad) eraldatu 
bat darama eta lepoko zein buruko kartzinomen tratamendurako balio du4. Bigarren 
gene-terapia produktua ere, OncorineTM izenekoa, Txinan onartu zen 2005ean eta 
Ad eraldatu batean oinarritutako bektore birala darama. Beste sendagairik onartzen 
ez duen minbizi nasofaringeoaren tratamenduan gomendatuta dago5. Europa-
mailan, lehen gene-terapia produktua 2012. urtean merkaturatu zen, Glybera® 
izenez. Medikamentu horrek birus adenoasoziatua (AAV) darama gene-garraiatzaile 
gisa eta lipoproteina lipasa entzimaren defizitaren tratamenduan erabiltzen da6. 
Azkenik, 2015ean IMLYGICTM gene-terapia produktua merkaturatu zen Estatu 
Batuetan, herpes simplex (HSV) birusean oinarrituta eta melanoma errepikakorra 
duten pazienteei zuzenduta7. Dena dela, 2017an eguneratutako datuen arabera, 
gene-terapia konbentzionalean bektore biralak nagusi diren arren, gene-edizio 




%70ek metodo ez-biralak erabiltzen ditu, elektroporazioa lehen estrategia izanik 
(%39) eta atzetik lipofekzioan (%17) eta polimeroetan (%8) oinarritutako metodoak 
egonik8. Beraz, ematen du bektore ez-biraletan oinarritutako gene-garraio sistemek 
birusei lekua hartu dietela gene-edizio eta genoma-zuzentze estrategia berrietan.  
Izan ere, birusak garraio-sistema sendoak diren arren, desabantaila ugari dituzte, 
besteak beste, karga-gaitasun txikia, ekoizpen konplexua eta garestia edota 
immune-erantzunei eta mutagenesiari lotutako segurtasun arazoak. Zentzu 
horretan, nanoteknologian oinarritzen diren bektore ez-biralak etorkizun oparoko 
alternatiba gisa jaio dira birusek dituzten mugak gainditzeko gai direlako. Birusak ez 
bezala, bektore ez-biralak gai dira tamaina handiko material genetikoa garraiatzeko, 
ekoizpen erraza eta kostu baxukoa dute, erabilerrazak dira, ez dute segurtasun 
arazorik ematen eta ez dute erantzun immunerik pizten9. Gainera, formulazio ez-
biralak eskala handian ekoiztu daitezke eta biltegiratzean beren propietateak 
egonkor mantentzen dira epe luzez1. Beraz, abantaila horiek guztiek eta nano-
ingeniaritzan zein materialen zientzian egindako aurrerapenek gene-garraiorako 
mota guztietako bektore ez-biral biobateragarrien sintesia, karakterizazioa eta 
funtzionalizazioa bultzatu dituzte11. Gaur egun, nano-eskalako bektore ez-biralak 
material ezberdinez osatuta egon daitezke, eta batez ere lipido kationikoz12-14, 
polimeroz15, 16 edota partikula magnetikoz17 osatutakoak erabiltzen dira. Molekula 
horiek era ezberdinetan egokitu daitezke gene terapeutikoak ehun edo zelula 
espezifikoetara garraiatzeko eta zelulaz kanpoko zein barneko hesiak gainditu ahal 
izateko. Bektore ez-biralen aukera zabalaren artean, niosoma izenekoak lipido 
kationikoz eta tentsoaktibo ez-ionikoz osatutako besikula sintetiko eta 
biobateragarriak dira18, 19. Hiru osagai nagusi dituzte: (i) lipido kationikoa, karga 
positiboa du eta beraz karga negatibodun DNA molekulekin elkarrekintza 
elektrostatikoak ahalbidetzen ditu20, (ii) lipido laguntzailea, formulazioaren ezaugarri 
fisiko-kimikoak hobetzen laguntzen duena21 eta (iii) tentsoaktibo ez-ionikoa, 
formulazioaren egonkortasuna bermatzeko eta partikulen agregazioa ekiditeko22. 
Osagai horien ezaugarriek niosoma formulazioaren propietate fisiko-kimikoak –
tamaina, karga, polidispertsioa, morfologia, etab.- baldintzatuko dituzte eta, aldi 
berean, horiek niosomek zeluletan sartzeko, material genetikoa nukleoraino 
helarazteko eta transfekzio prozesua eraginkortasunez bideratzeko duten gaitasuna 
baldintzatuko dute21, 22. Duela gutxiko ikerketek erakutsi dute niosomak gai direla 
arratoien erretinako zein garuneko zelulak in vivo transfektatzeko23-26.  
Bektoreaz gain, horrek garraiatzen duen material genetikoaren ezaugarriak ere oso 




eraginkortasuna handitzeko estrategia ia guztiak bektoreen egokitzapenetan edota 
elekroporazioa bezalako prozesu fisikoen erabileran oinarritzen ziren. Hala ere, 
transfekzio-efizientziaren hobekuntza material genetikoaren konposizioan eta 
konformazioan aldaketak eginez ere lortu daiteke, adibidez, bere 
bioerabilgarritasuna, biobateragarritasuna, iraunkortasuna eta segurtasuna 
areagotuz27. Zentzu horretan, azken aldian ikerketa-talde batzuk minicircle (MC) 
teknologia garatu dute, hau da, DNA plasmidoei bakteria-sekuentziak ezabatu 
dizkiete eta soilik gene terapeutikoa eta sekuentzia erregulatzaileak mantendu 
dituzte28. Plasmidoetako sekuentzia prokariotikoak, besteak beste CpG motiboak, 
erreplikazio jatorria eta antibiotikoekiko erresistentzia, beharrezkoak dira 
plasmidoak bakterioetan hedatzeko, baina material genetikoaren 
bioerabilgarritasuna eta segurtasuna gutxitzen dituzte. Izan ere, hainbat ikerketa 
klinikoren arabera, CpG sekuentzia ez-metilatuek hantura erantzuna pizten dute29, 
30 eta baita nekrosi- edo apoptosi-bidezko zelula heriotza ere, transgene-espresioa 
modu esanguratsuan murriztuz31, 32. Gainera, kasu batzuetan zeluletako 
transkripzio-faktoreek ez dute modurik izaten plasmidoen sekuentzietara iristeko, 
adibidez, histona-markatzaileekin lotutako bakterio-sekuentziak transgenetik gertu 
kokatuta daudenean. Markatzaile horiek berehala ezagutzen ditu ostatu-zelulak eta 
plasmido-sekuentziak heterokromatina konpaktu bilakatzea eragiten du, 
transgenearen espresioa oztopatuz eta, askotan, erabat isilaraziz33. Beraz, 
espresio-unitate minimizatuak, minicircle-ak kasu, plasmidoen ordez erabili daitezke 
horien mugak gainditu eta transfekzio eraginkorragoak lortze aldera. In vitro zein in 
vivo ikerketa ugarik erakutsi dute minicircle teknologia erabilita transfekzio-
efizientzia igo egiten dela, espresio iraunkorrak lortzen direla eta segurtasun zein 
immuno-bateragarritasun profil hobeak lortzen direla28. Horrez gain, miniDNA 
bektoreek erraztasun handiagoa dute zelulaz kanpoko zein barneko hesiak gainditu 
eta zelulen nukleoraino iristeko, plasmidoena baino bioerabilgarritasun handiagoa 
lortuz34.  
Azkenik, bektoreak eta material genetikoa aztertzeaz eta hobetzeaz gain, gene-
garraio sistema ez-biral eraginkorrak lortzeko, horiek beste teknologia batzuekin 
uztartzea da gaur egungo joera nagusietako bat. Adibidez, gene-garraio sistemak 
eta ehun-ingeniaritza konbinatu daitezke sinergia berriak lortzeko. Izan ere, 
konbinaketa horiek ekar ditzaketen abantailen artean, garraio-sistemen 
egonkortasun handiagoa eta toxikotasun baxuagoa dira aipagarrienak. Gainera, 
bektore ez-biralak, esaterako, hiru dimentsioko matrize edo hidrogeletan txertatuta, 




aplikazio klinikoa erraztuko luke hainbat gaixotasunetan, besteak beste, minbizian 
edota ehunen birsorkuntzan35, 36.  
Aurreko guztia kontutan hartuta, doktoretza-tesi honen helburua gene-garraiorako 
sistema ez-biral eraginkorren garapenean sakontzea izan da, horretarako 
ondorengo aspektu nagusien inguruko ikerketan oinarrituta: (i) material ezberdinez 
–lipido kationikoz, polimeroz eta nanopartikula magnetikoz- osatutako hiru bektore 
ez-biralen arteko konparaketa ezaugarri fisiko-kimikoei eta endotelio baskularraren 
hazkuntza faktorearen genea daraman plasmidoa nerbio sistema zentraleko 
zeluletara garraiatzeko gaitasunari dagokienez; (ii) niosomen tentsoaktibo ez-
ionikoak transfekzio-prozesuan eta eraginkortasunean duen garrantziaren 
azterketa, (iii) material genetikoaren ezaugarriek niosomek bideratutako transfekzio-
efizientzian duten garrantziaren azterketa hiru DNA molekula ezberdinen 
konparaketaren bitartez eta (iv) niosomen eta azido hialuronikoz osatutako 
hidrogelen arteko konbinaketaren ikerketa transfekzio lokalizatua eta eraginkorra 
lortze aldera. Ondorengo ataletan, doktoretza-tesian ikertutako aspektu horiek 
guztien eztabaida sakona egingo da.  
1. Bektore ez-biralen osagaien eragina endotelio baskularraren 
hazkuntza-faktorearen genea daraman plasmidoa nerbio sistema 
zentraleko zeluletara garraiatzeko eta horien transfekzioa burutzeko 
gaitasunean.  
Azido nukleikoen erabileran oinarritzen diren terapiek itxaropen handia piztu dute, 
baina bektore eraginkor eta seguruen beharra dute. Gainera, nerbio sistema 
zentraleko (NSZ) zelulak transfektatzea erronka handia da oraindik eta hori oztopo 
da neuroendekapenezko gaitzei aurre egiteko gene terapeutikoen garraioan 
oinarritzen diren estrategien garapenarentzat. Azken urteetan, nanomaterial 
biobateragarriek bide berriak zabaldu dituzte erronka horri aurre egiteko. Izan ere, 
zenbait ikerketaren arabera, nanopartikulaz osatutako bektore ez-biralak gai dira 
NSZko zelulak transfektatzeko, besteak beste, kitosanoz osatutako partikulak37, 38, 
lipido kationikoak39 edota nanopartikula magnetikoak17. Bestalde, endotelio 
baskularraren hazkuntza-faktorea (VEGF) hautagai egokia izan daiteke gene 
terapeutiko gisa NSZri eragiten dioten gaitzei aurre egiteko40, garuneko asaldura 
baskularren eta neuroendekapenezko gaitzen artean dagoen lotura estuagatik41 eta 
baita proteina horrek garuneko angiogenesian zein neuronen biziraupenean 




Aurrekoa kontuan hartuta, nanoformulazioetan oinarritutako estrategia terapeutiko 
bat proposatu dugu ikerketa honetan, VEGF genea NSZko zeluletara garraiatu eta 
horiek transfektatzeko asmoz. Horretarako, hiru nanoformulazio ezberdin erabili 
ditugu, hiru material ezberdinez osatuta daudenak: oligokitosano ultrapuruz (UOC) 
osatutako bektore polimerikoa, Lipofectamine 2000TM bektore lipidikoa eta 
Neuromag partikula magnetikoak. Formulazio horiei phVEGF165aIRESGFP 
plasmidoa gehitu zitzaien, giza VEGF165a proteinaren eta GFP proteina berde 
fluoreszentearen sekuentziak daramatzana. Nanoformulazioak eta DNA molekulak 
elkartuta nanoplexoak osatu genituen, alegia, poliplexoak, lipoplexoak eta 
magnetoplexoak, hurrenez hurren. Nanoformulazioak eta dagozkien nanoplexoak 
fisiko-kimikoki karakterizatu genituen tamainari, zeta potentzialari, polidispertsio 
indizeari (PDI), morfologiari eta DNA eusteko, babesteko eta askatzeko duten 
gaitasunari dagokionez. In vitro transfekzio entseguak egin genituen C6 glia-
zeluletan eta neurona kultibo primarioetan NSZko zelula-eredu gisa, eta HEK-293 
zeluletan transfekzio-eredu orokor gisa. Transfekzio-efizientzien ebaluazioa GFP 
proteinaren espresioa, bataz besteko fluoreszentzia intentsitatea (MFI) eta VEGF 
proteinaren produkzioa neurtuta egin zen. Zelulen biziraupena ere aztertu zen 
nanoplexoen eraginpean egon ostean. VEGF proteinaren bioaktibitatea neurtzeko 
proteina horren efektuarekiko sentiberak diren HUVEC edo zilborresteko giza 
endotelio-zelulak erabili ziren.  
Nanoformulazio eta nanoplexo –magnetoplexo, lipoplexo eta poliplexo- guztiek 
nanometro-eskalako tamaina zuten (1.1.a irudia, barrak), eta hori egokia da 
formulazioek zelulan sartzeko duten gaitasuna hobetzeko44. Gainera, 
nanoformulazioek gainazaleko karga positiboak zituzten denek (1.1.a irudia, 
lerroak), ezinbesteko ezaugarria karga negatibodun DNA molekulekin elkarrekintza 
elektrostatikoak eratzeko45. Espero bezala, behin DNA molekulekin lotuta, 
nanoplexoen zeta potentzialak balio negatiboak hartu zituen kasu guztietan. 
Magnetoplexoen eta lipoplexoen zeta potentzialak -20 mV ingurukoak izan ziren 
neurketetan, poliplexoenak berriz zerotik gertu agertu ziren. Literaturaren arabera, -
20 mV baino gutxiagoko eta +20 mV baino gehiagoko zeta potentziala duten 
partikulek joera txikiagoa dute agregatuak sortzeko, aldiz, bi balio horien arteko zeta 
potentzial balioak dituzten partikulek joera handiagoa izango lukete euren artean 
agregazioa sortzeko46. Beraz, batez ere poliplexoen kasuan, agregazioa ekiditeko, 
formulazioak prestatu berritan erabili ziren lan honetan. PDI balioak 0,5 baino 
baxuagoak izan ziren kasu guztietan, orokorrean onargarritzat jotzen den balioa aldi 
berean eta metatze-analisien bidez neurtutako partikulen arteko konparaketak 




eta horretarako arrazoia nanoformulazio horien tamaina irregularra izan daiteke 
(1.1.c irudia). Nanopartikulek DNA molekulak eusteko, babesteko eta askatzeko 
zuten gaitasuna aztertzeko, elektroforesia egin genuen agarosa geletan (1.1.d 
irudia). Emaitzen arabera, nanoformulazioak gai izan ziren DNA molekulak 
degradaziotik babesteko eta gogor eutsi zioten DNAri, geleko putzuetan itsatsita 
geratu baitzen hau. Hala ere, DNA askatzeko gaitasuna ere erakutsi zuten 
nanoformulazioek, eta euste- eta askatze-gaitasunaren arteko erlazio orekatua 
ezinbestekoa da transfekzioa eraginkortasunez bideratu ahal izateko48.  
1.1. Irudia. Nanopartikulen eta nanoplexoen karakterizazio fisiko-kimikoa. (a) Tamaina (barra 
txuriak eta grisak, nanopartikulei eta nanoplexoei dagozkienak hurrenez hurren) eta zeta 
potentziala (lerro puntukatuak eta jarraiak, nanopartikulei eta nanoplexoei dagozkienak 
hurrenez hurren). Balio bakoitzak bataz besteko ±SD adierazten du, n = 3. (b) PDI balioak. 
Balio bakoitzak bataz besteko ±SD adierazten du, n = 3. (c) TEM bidezko nanopartikula 




polimerikoen (c3) irudiak. Jatorrizko magnifikazioa: x140.000 lipido kationikoen kasuan, 
x175.000 nanopartikula magnetikoen kasuan eta x25.000 UOC nanopartikula polimerikoen 
kasuan. (d) Nanopartikulek duten gaitasuna DNA molekulak eusteko, babesteko eta 
askatzeko agarosa geleko elektroforesian. 1-3 zutabeak: bektorerik gabeko DNA askea; 4-6 
zutabeak: lipoplexoak; 7-9 zutabeak: magnetoplexoak; 10-12 zutabeak: poliplexoak. DNA 
askea eta nanoplexoei SDS (2, 5, 8 eta 11 zutabeetan) eta DNase I + SDS (3, 6, 9 eta 12 
zutabeetan) gehitu zitzaien. OC: DNAren forma zirkular irekia. SC: DNAren forma super-
kiribildua.  
Nanoplexoak fisiko-kimikoki karakterizatu ostean, in vitro entseguak egin genituen 
hiru zelula-lerrotan: HEK-293 –transfekzio-eredu orokorra-, C6 glia-zelulak –NSZko 
transfekzio eredua- eta neurona kultibo primarioetan –NSZko zelula-eredu 
aipagarriena-. Lehenik eta behin, nanoformulazioen transfekzio-efizientzia eta 
horiek zelulen biziraupenean duten eragina HEK-293 eta C6 zeluletan aztertu 
genituen. Nanoplexoen onarpena biziraupen aldetik egokia izan zen bi zelula-
lerroetan, zelulen %80 inguruk biziraun baitzuen nanoplexoen eraginpean egon 
ondoren (1.2.a irudia, puntuak). Transfekzio-efizientziaren analisia egiteko hiru 
parametro hartu genituen kontuan: GFP proteinaren espresioa izan zuen zelulen 
ehunekoa 1.2.a irudia, barrak), zelula transfektatatuen MFI balioak (1.2.b irudia) eta 
zelula transfektatuek ekoiztutako VEGF proteinaren kontzentrazioa ng/ml-tan (1.2.c 
irudia). Erabilitako plasmidoak bi proteinen gene-sekuentzia dauka, VEGF –zelulaz 
kanpoko proteina eta, beraz, zelulaz kanpoko mediora jariatzen dena- eta GFP –
zelulaz barnekoa eta, beraz, zitoplasman geratzen dena-. Hori dela eta, GFP 
proteinarekin lotutako parametroak fluxu-zitometriaren bidez neurtu ziren eta VEGF 
proteinari dagozkionak, berriz, ELISA teknikaren bitartez. GFP proteinaren 
espresioa zuten zelula-ehunekoari eta MFI balioei dagokienez, transfekzio-
efizientziak altuagoak izan ziren HEK-293 zeluletan C6 zeluletan baino nanoplexo 
guztiekin. Aldiz, VEGF proteinaren ekoizpena antzekoa izan zen bi zelula-lerroetan 
eta, magnetoplexoen kasuan, balio hori altuagoa izan zen C6 zeluletan HEK-293 
zeluletan baino. Literaturaren arabera, bektore ez-biralen bidezko transfekzio-
efizientziak zelula-motaren araberakoak dira eta, beraz, horiek zelula-mota batetik 
bestera ezberdinak izan daitezke49. Gure emaitzak bat datoz ideia horrekin, zeren 
eta HEK-293 zelula-lerroan transfekzio-maila altuena lipoplexoekin lortu genuen eta 
C6 zeluletan, aldiz, magnetoplexoekin. Poliplexoak izan ziren transfekzio-maila 
baxuenak lortu zituztenak bi zelula-lerroetan, ziurrenik euren zeta potentzial balioa 





1.2. Irudia. Zelulen biziraupena eta 
nanoplexoen transfekzio-efizientzia 
HEK-293 eta C6 zelula-lerroetan. (a) 
Zelulen biziraupena (HEK-293 zelulak, 
puntu gris ilunak eta C6 zelulak, puntu 
gris argiak) eta transfekzio-efizientzia 
(HEK-293 zelulak, barra gris ilunak eta 
C6 zelulak, barra gris argiak) 
nanoplexoekin transfekzioa egin eta 48 
ordura. Zelula-kontrolak ez ziren 
nanoplexoen eraginpean egon. Balio 
bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (b) MFI balioak 
(HEK-293 zelulak, barra gris ilunak eta 
C6 zelulak, barra gris argiak) 
nanoplexoekin transfekzioa egin eta 48 
ordura. Zelula-kontrolak ez ziren 
nanoplexoen eraginpean egon. Balio 
bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (c) VEGF 
ekoizpena (ng/ml-tan) (HEK-293 
zelulak, barra gris ilunak eta C6 zelulak, 
barra gris argiak) nanoplexoekin 
transfekzioa egin eta 48 ordura. Zelula-
kontrolak ez ziren nanoplexoen 
eraginpean egon. Balio bakoitzak bataz besteko ±SD adierazten du, n = 3. Esangura 
estatistiko maila: *p < 0,05, **p < 0,01, ***p < 0,001 HEK-293 zelula-kontrolekiko; #p < 
0,05, ##p < 0,01, ###p < 0,001 C6 zelula-kontrolekiko.  
Aipagarria da korrelazio argia zegoela bi zelula-lerroetan transfekzio-efizientzia 
neurtzeko erabilitako hiru parametroen artean. GFP proteinaren espresioa zuten 
zelula-ehunekoa zenbat eta altuagoa izan, orduan eta VEGF ekoizpen altuagoa 
antzeman genuen (1.3.a eta 1.4.a irudiak). Era berean, zenbat eta MFI balio 
altuagoak izan, orduan eta VEGF ekoizpen altuagoa antzeman genuen (1.3.b eta 
1.4.b irudiak). Hala ere, malda-angeluak konparatuta, ezberdintasunak topatu 
genituen bi zelula-lerroen artean. Izan ere, malda nabarmenagoa zen C6 zeluletan 
HEK-293 zeluletan baino bi korrelazioei dagokienez –1.3.a eta 1.4.a irudietan, α = 
22,65° HEK-293 zeluletan eta α = 65,42° C6 zeluletan; 1.3.b eta 1.4.b irudietan, α = 
8,42° HEK-293 zeluletan eta α = 23,67° C6 zeluletan-. Emaitza horiek bat datoz 




ezberdintasunak dauden nanoplexoekin tansfektatutako bi zelula-lerroen artean, 
VEGFren ekoizpena antzekoa dela bi kasuetan. Fenomeno horren arrazoietako bat 
izan daiteke C6 zelulek modu basalean HEK-293 zelulek baino VEGF gehiago 
ekoizten dutela berez (1.2.c irudia, kontrol-barrak). Beraz, nahiz eta transfekzio-
maila baxuagoa izan, VEGF ekoizpena HEK-293 zelulen mailara iritsi daiteke. Hala 
ere, beste faktoreren batek ere parte hartu behar du fenomeno hori guztiz azaldu 
ahal izateko. Zentzu horretan, uste dugu plasmidoaren IRES (Internal Ribosome 
Entry Site) sekuentziak, VEGF eta GFP geneak bereizten dituenak, eragina izan 
dezakeela. IRES sekuentziak translazioa abiarazten duten faktoreak dira eta bi 
generen aldi bereko espresio bereiztua ahalbidetzen dute, alegia, kasu honetan, 
VEGF eta GFP geneak promotore beraren gidaritzapean egongo lirateke baina bi 
proteina ezberdin sortzen dituzte proportzio berean IRES sekuentziari esker50, 51. 
Halere, jakina da IRES sekuentziak ez direla beti gai bi proteinen arteko proportzioa 
konstante mantentzeko eta, askotan, efizientzia baxua dutela behin-behinean 
transfektatutako zeluletan ehun- edota zelula-motaren arabera52, 53. Kasu horietan, 
IRESaren ondoren datorren genearen espresioa kaltetzen da, IRESaren aurretik 
doan genearen espresioan aldaketarik egon gabe54. Gure kasuan, VEGF genea 
IRES sekuentziaren aurretik doa eta GFP genea, berriz, atzetik. Beraz, uste dugu 
IRESa dela eta, GFP proteinaren espresioa kaltetuta egon daitekeela NSZko 
zeluletan, alegia, C6 zeluletan. Horrek azalduko luke VEGF ekoizpenean ia 
diferentziarik egon ez arren GFPren espresioa baxuagoa izatea C6 zeluletan HEK-





1.3. Irudia. Transfekzio-efizientzia neurtzeko 
erabilitako parametroen arteko korrelazioa HEK-
293 zeluletan. (a) VEGF ekoizpenaren (ng/ml) eta 
GFP espresatzen dute zelula-ehunekoaren arteko 
korrelazioa magnetoplexoekin (puntu grisa), 
lipoplexoekin (puntu zuria) eta poliplexoekin 
(puntu beltza) transfekzioa egin eta 48 ordura. 
Balio bakoitzak bataz besteko ±SD adierazten du, 
n = 3. α sinboloak maldaren angelua adierazten 
du. (b) VEGF ekoizpenaren (ng/ml) eta MFI 
balioen arteko korrelazioa nanoplexoekin 
transfekzioa egin eta 48 ordura. Balio bakoitzak 
bataz besteko ±SD adierazten du, n = 3. α 
sinboloak maldaren angelua adierazten du. (c) 
GFP espresioaren araberako histogramak HEK-
293 zeluletan nanoplexoekin transfekzioa egin eta 
48 ordura. M1 da GFP seinale positiboaren 
atalasea. 
 
1.4. Irudia. Transfekzio-efizientzia neurtzeko 
erabilitako parametroen arteko korrelazioa C6 
zeluletan. (a) VEGF ekoizpenaren (ng/ml) eta GFP 
espresatzen dute zelula-ehunekoaren arteko 
korrelazioa magnetoplexoekin (puntu grisa), 
lipoplexoekin (puntu zuria) eta poliplexoekin 
(puntu beltza) transfekzioa egin eta 48 ordura. 
Balio bakoitzak bataz besteko ±SD adierazten du, 
n = 3. α sinboloak maldaren angelua adierazten 
du. (b) VEGF ekoizpenaren (ng/ml) eta MFI 
balioen arteko korrelazioa nanoplexoekin 
transfekzioa egin eta 48 ordura. Balio bakoitzak 
bataz besteko ±SD adierazten du, n = 3. α 
sinboloak maldaren angelua adierazten du. (c) 
GFP espresioaren araberako histogramak C6 
zeluletan nanoplexoekin transfekzioa egin eta 48 





Behin nanoplexoek HEK-239 eta C6 lerro zelularrak transfektatzeko zuten gaitasuna 
aztertuta, gene-transferentzia entseguak egin genituen neurona kultibo 
primarioetan, horiek NSZko eredu gisa esanguratsuagoak direlako. Zelula-
biziraupena (1.5.a irudia) bikaina izan zen kasu guztietan –%100 inguru nanoplexo 
guztiekin-, baina transfekzio-efizientziak (1.5.a-b irudia) aurreko zelula-lerroetan 
baino baxuagoak izan ziren, neurona-zelulak baitira transfektatzen zailenetakoak. 
GFP proteinaren espresioa kasu honetan immunozitokimika bidez aztertu zen (1.5.b 
irudian fluoreszentzia berdedun zelula bakan batzuk ikus daitezke). Horrek berriro 
ere erabilitako plasmidoaren IRES sekuentziaren ehun-espezifikotasunaren 
hipotesia babesten du. VEGF proteinaren espresioari dagokionez, emaitzen arabera 
neurona kultibo primarioetako zelulek modu basalean VEGF endogeno kantitate 
handiak ekoizten dituzte eta, ziurrenik glia-zelulak dira horren erantzule, jakina baita 
faktore angiogenikoak55 eta neurotrofikoak56 askatzea dela euren funtzio 
nagusietako bat NSZko beste zelulei babesa emateko. Modu guztietan, 
nanoplexoekin transfektatutako zelulen VEGF ekoizpena zelula-kontrolena baino 
altuagoa izan zen kasu guztietan, baina diferentzia estatistikoki esanguratsua 
kontrolekiko soilik magnetplexoekin lortu zen (1.5.c irudia). Jarraian, zelula 
transfektatuek ekoiztutako VEGF proteinaren aktibitate biologikoa ikertu genuen 
HUVEC zelula-lerroan, proteina horren efektuari bikoizketa azkarraz erantzuten 
diona57, 58. Kontrolarekin konparatuta –VEGFren eraginpean jarri gabeko zelulak- 
nanoplexoekin transfektatutako zelulek askatutako VEGF proteinaren eraginpean 
egondako zelulek bikoizte-tasa altuagoa erakutsi zuten. Horrek baieztatzen du 
VEGF gai dela zelula-lerro horretan bikoizketa abiarazteko eta, gainera, bikoizte-
tasaren igoera VEGF kontzentrazioarekiko proportzionala izan zen. Aipagarria da, 
beraz, magnetoplexoak izan zirela eraginkorrenak NSZko zelulak transfektatzen, 
atzetik poliplexoak eta, azkenik, lipoplexoak zituztela.  
1.5. Irudia. Zelula-biziraupena, 
transfekzio-efizientzia eta VEGF 
proteinaren aktibitate biologikoa 
neurona kultibo primarioetan 
nanoplexoen eraginpean egon eta 48 
ordura. (a) Zelula-biziraupena. Balio 
bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (b) 






Berdez, anti-GFP. Urdienz, Hoescht. Eskala-barra: 25 µm. (c) VEGF ekoizpena 
(ng/ml-tan) nanoplexoekin transfektatutako neurona kultibo primarioetan. Kontrol-
zelulak ez ziren nanoplexoen eraginpean egon. Balio bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (d) HUVEC zelula-lerroaren bikoizketa-erantzuna VEGF 
proteinaren eraginpean egon ondoren. Kontrol-zelulak ez ziren VEGF proteinaren 
eraginpean egon. Balio bakoitzak bataz besteko ±SD adierazten du, n = 6. Esangura 
estatistiko maila: *p < 0,05, **p < 0,01, ***p < 0,001 HUVEC zelula-kontrolekiko.  
Emaitza horiek kontuan hartuta, esan genezake bektore ez-biralak eta, batez ere, 
nanopartikula magnetikoak, VEGF genea NSZko zeluletara modu seguru eta 
eraginkorrean garraiatzeko aukera egokia izan daitezkeela, beste ikerketa batzuek 
bat datozen emaitzak izanik17.  Alterazio baskularren eta neuroendekapen 
prozesuen arteko erlazioa40 aintzat hartuta eta baita VEGF proteina Alzheimer 
gaixotasun ereduko59 zein Parkinson gaixotasun ereduko57 animalietan izan dituen 
efektu onuragarriak ere, uste dugu VEGF gene terapeutikoa hautagai ona izan 
daitekeela NSZko gaitzei aurre egiteko. Bestalde, farmako-garraioarekin 
konparatuta, VEGF gene-garraioari esker dosiak gutxitzea eta denboran iraunkorrak 
diren efektu terapeutikoak lortzea posible izango litzateke. Gaur egun, bektore ez-
biralak NSZra helaraztea erronka handia da oraindik ere eta, askotan, eman-bide 
inbaditzaileak erabili behar izaten dira, adibidez, garuneko ebakuntza. Hala ere, 
aurrerapauso handiak ari dira egiten zentzu horretan eta duela gutxiko ikerketa 
batek erakutsi du posible dela bektore ez-biralak garunera sudur-barneko eman-bide 
ez-inbaditzailea erabilita iristea60. Beraz, komenigarria litzateke arreta berezia 
jartzea sudur-barneko eman-bidearen ikerketan, alternatiba seguru eta ez-
inbaditzailea baita NSZko zeluletara ailegatzeko.  
2. Niosoma formulazioetako tentsoaktibo ez-ionikoaren rola arratoi-
erretinako zelulen transfekzio-prozesuan eta eraginkortasunean 
Erretinako gaitz monogeniko asko ondo karakterizatuta daude eta horien erantzule 
diren geneak eta inplikatutako mutazioak ondo ezagutzen dira. Kasu gehienetan, 
mutazioek erretinako epitelio pigmentarioko (RPE) zelulei eragiten diete61 eta zelula-
mota horren funtzio nagusia erretina neurala mantentzea izaten da, adibidez, foto-
errezeptore gisa jarduten duten zelulak babestuz eta hazkuntza-faktoreak askatuz62. 
Erretinako gaixotasun askotan, besteak beste Leberren amaurosi kongenitoa (LCA), 
erretinitis pigmentosoa (RP) edota adinari lotutako endekapen makularra (AMD), 
RPEko zelulen endekapenak itsu geratzea eragin dezake. Izan ere, RPEko zelulen 




RPEko zelulak jomuga dira erretinako gaitz genetikoei aurre egiteko gene-terapia 
bidezko estrategia gehienetan. Erretinako gene-transferentziaren arrakasta 
transgene-espresio altu eta iraunkorrak lortzearen menpe dago kasu gehienetan.  
Bektore ez-biralen bidezko gene-garraioak aukera aparta eskaintzen du gene 
terapeutikoak modu seguru eta eraginkorrean erretinara bideratzeko. Niosoma 
izeneko bektore ez-biralak arrakasta handiz erabili dira zentzu horretan in vitro zein 
in vivo entseguetan. Formulazio horiek hiru osagai nagusi dituzte eta horietako biren 
–lipido kationikoaren eta lipido laguntzailearen- eragina transfekzio prozesuan eta 
eraginkortasunean ondo aztertuta daude26, 63. Bestalde, DOTMA lipido kationikoaz18 
edota Tween 80 tentsoaktibo ez-ionikoaz eta eskualeno lipido laguntzaileaz26 
osatutako niosoma formulazioen eraginkortasuna frogatuta dago erretinako zelulen 
transfekzioan. Hala eta guztiz ere, beste tentsoaktibo ez-ioniko batzuen erabilera, 
esaterako Tween 20 edo Tween 80, ez da oraindik ikertu gene-transferentzia 
prozesuetan. Beraz, lan honetan hiru niosoma formulazio prestatu eta aztertu 
genituen, soilik tentsoaktibo ez-ionikoan ezberdintzen zirenak. Hiru niosoma 
formulazioen osagaiak ondokoak izan ziren: DOTMA lipido kationikoa, eskualenoa 
lipido laguntzaile gisa eta Tween 20, 80 edo 85 tentsoaktibo ez-ionikoetako bat. 
Horrela, DST20, DST80 eta DST85 izeneko niosoma formulazioak osatu genituen. 
Horiek fisiko-kimikoki karakterizatu ostean, transfekzio- eta zelula-barneko trafiko-
entseguak egin genituen in vitro eta, jarraian, arratoi-erretinako zelulak transfektatu 
genituen in vivo.  
Niosoma formulazioetan, tentsoaktibo ez-ionikoek emultsionatzaile gisa jarduten 
dute, hesi esteriko bat sortuz partikulen agregazioa ekiditeko22. Lan honetan 
erabilitako hiru tentsoaktiboek oinarrizko egitura kimiko bera dute, baina beren atal 
hidrofilikoak eta daukaten hidrozilo-talde kopurua ezberdinak dira (2.1. irudia). 
Ezberdintasun kimiko horiek direla eta, Tween 20, 80 eta 85 tentsoaktiboek hidrofilo-
lipofilo balantze (HLB) balio desberdinak dituzte. HLB balioak molekularen olio- (HLB 
< 9) edo ur-disolbagarritasuna (HLB > 11) adierazten du64, eta lan honetan 
erabilitako tentsoaktiboen artean, Tween 20 da hidrofilikoena azido laurikoaren eta 
2 hidroxilo-talderen eraginez (HLB = 16,7). Aldiz, Tween 85 lipofilikoena da (HLB = 





2.1. Irudia. Niosomen eskema orokorra eta niosomen osagaien egitura kimikoak.  
Formulazioen parametro fisiko-kimikoek transfekzio-efizientzia baldintzatu 
dezakete. DST20, DST80 eta DST85 partikulek 100 eta 225 nm arteko tamainak 
zituzten (2.2.A irudia, barrak) eta horiek egokiak dira gene-garraioan erabiltzeko65. 
Partikulen tamainan oszilazio txikiak topatu genituen nioplexoak lortzeko niosmei 
DNA molekulak 2/1, 5/1 eta 10/1 lipido kationikoa/DNA masa ratioetan gehitu 
ondoren. Aldaera horiek DNA molekulek hartzen duten espazioaren eta ratio 
altuetan gertatzen den DNAren kondentsazio handiagoaren balantzearen 
araberakoak izaten dira26. Egoera guztietan, PDI balioek erakusten dutenez, 
formulazioen tamainen distribuzioa estua izan zen, beraz, partikulek tamaina 
homogeneoak zituztela ondorioztatu dezakegu (2.2.B irudia). Formulazioen 
gainazaleko kargari dagokionez, horrek formulazioaren egonkortasuna 
baldintzatzen du eta -30 mV eta +30 mV arteko zeta potentzial balioek partikulen 
agregazioa eragiten dutela uste da46 eta, beraz, hobe da balio horiek baino 
negatiboagoak edo positiboagoak diren partikulak sortzea. Gainera, zeta potentzial 
balio positiboak zelulan barneratzeko gaitasun handiagoarein erlazionatuta daude, 
mintz plasmatikoak karga negatiboa duenez, elkarrekintza elektrostatikoak sortzen 
direlako karga positibodun nanopartikulekin45. Lan honetako hiru niosoma 
formulazioek zeta potentzial balio egokiak agertu zituzten, +40 mV-etik gorakoak 
(2.2.A irudia, puntuak). Espero bezala, DNA molekulak gehitzean, gainazaleko 
kargen balioak jaitsi egin ziren, niosomen amina taldeek DNAren fosfato taldeekin 
elkarrekintzak osatu zituztelako eta, beraz, kargak partzialki neutralizatu zirelako66. 
Gure partikulen morfologia aztertzeko, TEM bidezko mikroskopio irudiak atera 
genituen eta denek itxura esferikoa zutela baieztatu genuen (2.2.C-E irudiak). 




elektroforesi-entseguak egin genituen agarosa geletan. Gure emaitzen arabera, 
formulazio guztiak gai izan ziren DNA molekulak babesteko, baita lipido 
kationikoa/DNA masa ratio baxuenetan ere. Beharbada, DST80 nioplexoak izan 
ziren salbuespena, ratio baxuetan DNA babesteko gaitasun baxuagoa erakutsi 
zuten eta. Modu guztietan, kontuan hartuta ratio baxuak erabiltzeak gene-terapian 
abantaila handiak dakartzala, aipagarriena DNA dosi handiagoak erabili ahal izatea 
lipido gutxirekin –oso egokia in vivo entseguetarako-, ondorengo entseguetarako 2/1 
ratio baxua aukeratu genuen formulazio guztietan.  
2.2. Irudia. DST20, DST80 eta DST85 niosoma eta nioplexoen karakterizazio fisiko-kimikoa, 
ondoko lipido kationikoa/DNA masa ratioak erabilita: 2/1, 5/1 eta 10/1. (A). Tamaina balioak 
barren bidez adierazita daude eta zeta potentzialak, puntuen bidez. Balio bakoitzak bataz 
besteko ±SD adierazten du, n = 3. (B) PDI balioak. Balio bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (C-E) Niosomen TEM irudiak. Eskala-barrak: 200,0 nm. (C) DST20 
niosomak x20.000 magnifikazioan, (D) DST80 niosomak x20.000 magnifikazioan eta (E) 
DST85 niosomak x40.000 magnifikazioan. (F) Elektroforesi-entsegua agarosa geletan, 




aztertzeko lipido kationikoa/DNA masa ratio ezberdinetan. DNase I entzima gehitu zen 2-11 
zutabeetan. 1-2 zutabeetan DNA askea dago. 3, 4 eta 5 zutabeetan DST20 nioplexoak ageri 
dira 2/1, 5/1 eta 10/1 ratioetan, hurrenez hurren. 6, 7 eta 8 zutabeetan DST20 nioplexoak 
ageri dira 2/1, 5/1 eta 10/1 ratioetan, hurrenez hurren. 9, 10 eta 11 zutabeetan DST20 
nioplexoak ageri dira 2/1, 5/1 eta 10/1 ratioetan, hurrenez hurren. OC: DNAren forma zirkular 
irekia. SC: DNAren forma super-kiribildua.  
Behin formulazioak erabat karakterizatu ostean, in vitro transfekzio-entseguak egin 
genituen lipido kationikoa/DNA 2/1 masa ratioa erabilita bi zelula-lerrotan: HEK-293, 
transfekzio-eredu orokor gisa, eta ARPE-19, erretinako zelula-eredu gisa. Zelulen 
biziraupen-maila bikaina izan zen nioplexoen eraginpean egon ondoren, %95eko 
biziraupenetik gora HEK-293 zelula-lerroan eta %85etik gora ARPE-19 zelula-
lerroan. Beraz, formulazioak biobateragarriak direla esan dezakegu zelula-lerro 
horietan. Gainera, zelulak mikroskopio bidez aztertuta ikusi genuen itxura 
osasuntsua zutela bi zelula-lerroek 2.3.A1 eta 2.3.B1 irudietan antzeman daitekeen 
moduan. Aldiz, Lipofectamine 2000TM kontrol positiboa erabilita, zelulen biziraupena 
asko kaltetu zen, batez ere ARPE-19 zelula ereduan, %55eraino jaitsi baitzen. Datu 
horiek bat datoz beste ikerketa batzuen emaitzekin, izan ere, Lipofectamine 2000TM 
konposatua ez da egokia erretinako gene-garraiorako bertako zelulentzat oso 
toxikoa delako baita kontzentrazio baxuetan ere68. Transkezio-efizientziari 
dagokionez, HEK-293 zelula-lerroan DST85 nioplexoak erabilita lortu genituen 
emaitza onenak (2.3.A1 irudia). Aldiz, ARPE-19 zelula-lerroan, DST20 nioplexoak 
izan ziren transfekzio-maila altuena lortu zutenak (2.3.B1 irudia). Orokorrean, uste 
da HLB balio baxuak dituzten eta, beraz, liposolubilitate handiagoa dute tentsoaktibo 
ez-ionikoek zelulan barneratzea errazten dutela69, 70. Ideia hori bat dator HEK-293 
zeluletan ikusi dugunarekin, Tween 85 baita HLB balio baxuena duen tentsoaktiboa 
lan honetan ikertutakoen artean. Harrigarria bada ere, ARPE-19 zelula-lerroan 
tentsoaktibo hidrofilikoena duen niosoma formulazioa izan da transfekzioan 
eraginkorrena, alegia, DST20 formulazioa. Horrek guztiak iradokitzen du zelula-
motaren araberako beste mekanismo batzuk ere abian direla , esate baterako, 
zeluletan barneratzeko bide endozitikoak, eta horiek ere paper garrantzitsua joka 





2.3. Irudia. Transfekzio-efizientzia DST20, DST80 eta DST85 nioplexoekin transfektatutako 
HEK-293 eta ARPE-19 zelula-lerroetan, 2/1 lipido kationikoa/DNA masa ratioa eta pCMS-
EGFP plasmidoa erabilita. (A1) Transfekzio-efizientzia HEK-293 zelula-lerroan. (A2) EGFP 
espresioa DST85 nioplexoekin transfektatutako HEK-293 zeluletan erakusten duen 
fluoreszentzia-mikroskopio bidezko irudia,  x20 magnifikazioan. (B1) Transfekzio-efizientzia 
ARPE-19 zelula-lerroan. (B2) EGFP espresioa DST20 nioplexoekin transfektatutako ARPE-
19 zeluletan erakusten duen fluoreszentzia-mikroskopio bidezko irudia,  x20 magnifikazioan. 
Balio bakoitzak bataz besteko ±SD adierazten du, n = 3. Esanahi estatistiko maila: *p < 0,05, 
**p < 0,01, ***p < 0,001. Eskala-barrak: 100 nm.  
Nioplexoen bidezko transfekzio prozesua hobeto ulertze aldera, zelulan 
barneratzeko mekanismoak eta formulazio bakoitzak jarraitutako bide endozitikoak 
aztertu genituen. Bektore ez-biralak normalean endozitosi bidez sartzen dira 
zeluletan eta katrina bidezko endozitosia (CME) eta kabeola bidezkoa (CvME) izaten 
dira ohikoenak71. CvME bide orohar ez-azidiko eta ez-degradatzaile gisa ulertzen 
da72 eta CME bidea, berriz, lisosomekin fusionatzen dela uste da73. Halere, 
eztabaida handia dago oraindik ere zentzu horretan eta, zenbait ikertzaileren 
arabera, kabeolak ere lisosomekin fusionatzen dira74, 75. Gainera, lisosometako pH 
azidoaren inguruan ere zalantzak daude. Ikertzaile batzuen ustez, pH azidoa 
transfekziorako onuragarria da lisosometako pH azidoa, DNA bektore ez-biraletik 




77. Aldiz, beste batzuen esanetan, lisosometako pH azidoak transfekzioa oztopatzen 
du, bektore ez-biralen zein horiek garraiatzen duten DNAren degradazioa eragiten 
duelako78. Gure ikerketaren arabera, nioplexoak CME bide endozitikoaren bitartez 
barneratzen baziren ARPE-19 zeluletan, lisosomekin besteek baino gehiago ko-
lokalizatzen zuten eta transfekzio-maila baxuagoak lortzen zituzten. Hori izan zen 
DST85 nioplexoen kasua (2.4. irudia). Aldiz, nioplexoek CvME bide erabiltzen 
zutenean, gutxiago ko-lokalizatzen zuten lisosomekin eta transfekzio-maila 
altuagoak lortzen zituzten. Beraz, gure emaitzak bat datoz lisosometan DNA 
molekulen degradazioa gertatzen dela dioten hipotesiekin, eta horrek azalduko luke 
DST20 nioplexoek nahiz eta HLB balio altuko tentsoaktibo ez-ionikoa izan, beste 
nioplexoek baino transfekzio-maila altuagoak lortzea ARPE-19 zeluletan. DST80 
nioplexoei dagokienez, oso ko-lokalizazio baxua erakutsi zuten CME zein CvME 
bide endozitikoekin, beharbada beste sarbide batzuk erabili zutelako. Izan ere, duela 
gutxiko ikerketa baten arabera, Tween 80, 1-(2-dimetilaminoetil)-3-[2,3-
di(tetradeziloxi) propil] urea eta eskualnoz osatutako nioplexoak makropinozitosi 
bidez barneratzen dira zeluletan13.  
2.4. Irudia. Bide endozitikoak eta zelula-barneko trafikoa aztertzeko entsegua DST20, DST80 
eta DST85 nioplexoekin ARPE-19 zeluletan. (A1-3) mikroskopio konfokal irudiak, ARPE-19 
zelulak eta FITC markatzailea daraman pCMS-EGFP plasmidoa (berdez) garraiatzen duten 
nioplexoak ikusgai. Gorriz: CME (AlexaFluor546-Transferrina), CvME (AlexaFluor555-Kolera 
toxina) edo lisosoma (Lysotracker). (B1-3) Kolore gorri eta berdearen arteko ko-lokalizazio 




du, n = 3. (C1-3) 3D grafikoak, HLB balioen, transfekzio-efizientziaren eta bide endozitiko 
bakoitzaren arteko erlazioa aztertzeko.  
Aurreko guztia kontuan hartuta, DST20 formulazioa hautatu genuen erretinarako 
gene-garraioa bideratzeko. In vivo entseguak egin baino lehen, erretinako kultibo 
primarioetan egin genituen gene-transferentzia saioak DST20 nioplexoekin eta GFP 
espresio-maila egokiak antzeman genituen (2.5. irudia). Emaitza horiek indartuta, in 
vivo entseguak egin genituen arratoi-erretinan, DST20 formulazioa erretinako 
zelulak transfektatzeko gai ote zen jakiteko bitreo-barneko (IV) (2.6.D-E irudia) eta 
erretina-azpiko (SR) (2.6.B-C irudia) injekzioen ondoren. Normalean, IV injekzioen 
bitartez erretinako ganglio-geruzako zelulak transfekatzea lortu daiteke eta SR 
injekzioen bidez, berriz, erretinaren geruza sakonagoetara iristea posible izan 
daiteke68, 79.  Kontzeptu horrekin bat datoz gure emaitzak ere. Izan ere, IV 
injekzioaren bidez batez ere ganglio-geruzako zelulak transfektatu genituen DST20 
nioplexoekin (2.6.D irudia) eta SR injekzioaren bitartez RPE geruzako zeluletaraino 
iristea lortu genuen DST20 nioplexoekin (2.6.B irudia). Kontuan hartuta itsu geratzea 
eragiten duten erretinako gaitz gehienak RPE geruzako zeluletan gertatzen diren 
mutazioek eragiten dituztela, geruza horretan transfekzioa lortzea oso garrantzitsua 
da aplikazio terapeutikoetarako. Tamalez, SR injekzioak oso inbaditzaileak dira eta 
arrisku larriak ditu, adibidez, inflamazioa, lentea kaltetzea edota erretina-askatzea80. 
Nahiz eta saiakera ugari egin diren RPE geruzara iristeko IV injekzioen bidez, ez da 
oraindik lortu eta SR injekzioek eraginkorrenak izaten jarraitzen dute RPE geruza 
transfektatzeko. Bestalde, ikerketa-lerro berriak eman-bide okular topiko 
eraginkorrak lortzera zuzenduta daude. Izan ere, eman-bide ez-inbaditzailea 
litzateke eta erabilera klinikora iristeko oso egokia. Duela gutxi, farmakoak 
garraiatzen dituzten mikrofluidika bidez eratutako liposomak begian topikoki 
aplikatuta RPE geruzara iristea lortu da81, baina geneekin ez da oraindik antzekorik 
lortu. Beraz, oso interesgarria litzateke bide hori aztertzea gene-terapia ez-biralaren 
bidez gene terapeutikoak RPE geruzaraino bideratzeko eta, zentzu horretan, lan 
honetan garatutako DST20 niosoma formulazioa egokia izan daiteke ikerketa-lerro 




2.5. Irudia. EGFP espresioa arratoien erretinako zelulen kultibo primarioetan. (A) EGFP 
espresioa DST20 nioplexoekin transfekzioa egin eta 96 ordura. (B) EGFP espresioa 
Lipofectamine 2000TM kontrol positiboarekin transfekzioa egin eta 96 ordura. Gorriz: MAP2 
neuronen dendrita markatzailea. Urdinez: Hoescht (zelulen nukleoak). Berdez: EGFP. 
Eskala-barra: 20 µm.  
 
2.6. Irudia. (A) Arratoi-erretinaren egitura osoa 
eta in vivo bitreo-barneko (IV) eta erretina-
azpiko (SR) injekzioen eskema orokorra. SR 
injekzioaren bidez lortutako EGFP espresioa 
DST20 nioplexoekin (B) eta Lipofectamine 
2000TM kontrol positiboarekin (C).  IV 
injekzioaren bidez lortutako EGFP espresioa 
DST20 nioplexoekin (D) eta Lipofectamine 
2000TM kontrol positiboarekin. Urdinez: Hoescht 
(zelulen nukleoak). Berdez: EGFP. Eskala-
barrak: 20 µm. RPE (erretinako epitelio 
pigmentarioa), ONL (kanpoko nukleo geruza), 
INL (barneko nukleo geruza), GCL (ganglio-
zelulen geruza).  
 
 
Laburbilduz, soilik tentsoaktibo ez-ionikoan ezberdintzen ziren hiru niosoma 
formulazio garatu eta karakterizatu ditugu. Gure emaitzen arabera, DST20 
formulazioa –Tween 20, DOTMA eta eskualenoz osatua- izan da eraginkorrena 
arratoi-erretinako zeluletan gene-transferentzia bideratzeko, lipido kationiokoa/DNA 
masa ratio baxua (2/1) erabilita. In vivo, iritsitako zelula-geruzak eman-bidearen 




dugu, aldiz, IV injekzioen bidez ganglio-zelulen geruza transfektatu dugu. Bektore-
ingeniaritzan zein eman-bide ez-inbaditzaileen ikerketan aurrera egin ahala, posible 
izan daiteke begian topikoki emandako formulazioak RPE geruzaraino iristea eta 
bertako zelulak gene terapeutikoekin transfekatztea.  
3. Material genetikoaren eragina niosomen bidezko erretinako gene-
transferentziaren eraginkortasunean 
Aurreko ataletan egin bezala formulazioaren ezaugarriak hobetzeaz gain, gene-
transferentzia eraginkortasunez gauzatzeko ezinbestekoa da material genetikoaren 
propietateak ere ondo ezagutzea eta beharrezko aldaketak egitea. Orain arte, DNA 
plasmidoetan hainbat egokitzapen egin dira transfekzio-efizientzia hobetze aldera, 
besteak beste, promotore-sekuentzia hobetuz, sekuentzia indartzaileak gehituz, 
poliadenilazio seinaleekin jokatuz edota CpG motiboak kenduz hantura-erantzunak 
ekiditeko82-86. Halere, DNA plasmidoek oinarri bakterianoa dute, alegia, erreplikazio-
jatorriaren sekuentzia eta antibiotikoen erresistentziarako geneak. Oinarri 
prokariotiko hori ezinbestekoa da plasmidoak laborategian bikoiztu eta mantendu 
ahal izateko, baina transgene-espresioa gutxitu dezake eta, gainera, gene-garraio 
sistemaren bioerabilgarritasuna eta segurtasun profila kaltetzen dituzte. Beraz, 
espresio-unitate minimoak, bakarrik intereseko transgenea eta beharrezko 
sekuentzia erregulatzailez osatuak, adibidez, minicircle (MC) egiturak, plasmido 
konbentzionalen ordezko alternatiba erakargarriak dira. MC egiturak DNA molekula 
zirkular itxiak dira eta ez daukate ez antibiotikoekiko erresistentziarako generik eta 
ezta sekuentzia bakterianorik ere. MC egiturek plasmido tradizionalek baino tamaina 
txikiagoa dute nahiz eta espresio-kasete bera mantendu (3.1. irudia). Egitura berri 
horien ezaugarriak direla eta, MC material genetikoak ez du erantzun immunerik ez 
eta transgenea isilarazteko mekanismorik pizten zelula-ostatuetan. Beraz, 
transgenearen espresio-maila altuagoak eta denboran iraunkorragoak lortu daitezke 
in vivo teknologia berri horri esker87-92. Beraz, tamaina txikiari eta sekuentzia 
baketerianorik ez izateari esker, MC egiturak plasmidoak baino egokiagoak izan 
daitezke gene-terapia ez-biralean biosegurtasunari eta eraginkortasunari 
dagokionez. Ikerketa askok erakutsi dute MC DNA molekulek transgene-espresioa 
hobetzen dutela hainbat organotan in vivo, gibela93-95, bihotza96, 97 eta muskulu 
eskeletikoa97 barne. Halabaina, MC teknologiaren eraginkortasuna ez da oraindik 
ikertu erretinako zelulen transfekzioan eta niosoma formulazioak bektore ez-biral 




3.1. Irudia. DNA material genetikoaren ezaugarriak. (A) pEGFP 5,5 kb, (B) pGFP 3,5 kb, (C) 
MC-GFP 2,3 kb. MC: minicircle; GFP: proteina berde fluoreszentea; EGFP: proteina berde 
fluoreszente indartua; pCMS: plasmidoa, zitomegalobirusaren promotorea, klonazio eremu 
anitza eta SV40 promotorea dituena; pCMV: zitomegalobirusaren promotorea daraman 
plasmidoa; bp: base-pareak.  
Beraz, aurrekoa kontuan hartuta, lan honen helburua da MC teknologia niosoma 
formulazioekin konbinatuz, gene-garraio sistema berri horren erretinako zelulen 
transfekziorako eraginkortasunaren inguruko lehen ebidentziak ematea. 
Horretarako, MC teknologia plasmido konbentzionalekin konparatu dugu eta aurreko 
lanean garatutako DST20 niosoma formulazioa –Tween 20, DOTMA eta eskualenoz 
osatua- erabili dugu gene-transferentzia bideratzeko, erretinako zelulak 
transfektatzeko egokiena zela erakutsi genuen eta. Beraz, nioplexoak eratzeko, 
DST20 niosomak ondorengo hiru material genetikoetako batekin elkartu genituen: 
MC-GFP (2257 bp), pGFP (3487 bp) edo pEGFP (5541 bp). Niosomak eta 
nioplexoak fisiko-kimikoki karakterizatu genituen tamaina, zeta potentziala, 
polidispertsio indizea, morfologia eta egonkortasunaren arabera. Gainera, DST20 
niosomek material genetiko ezberdinak degradaziotik babesteko eta askatzeko 
zuten gaitasuna ere ikertu genuen, baita niosoma eta DNA molekulen arteko 
elkarrekintza molekularraren nondik norakoak ere. In vitro esperimentuen bidez, 
formulazioen transfekzio-efizientzia eta horien eraginpean egon ondoren zelulek 
agertutako biziraupen-maila ikertu genituen. Horretarako, erretinako epitelio 
pigmentarioko ARPE-19 zelulak erabili genituen eta formulazio ezberdinak aztertu 
genituen: DST20 niosomak material genetiko ezberdinei lotuta, prestatu berritan, 
4°C-tan hilabetez biltegiratu ostean eta 25°C-tan hilabetez biltegiratu ostean. 
Horrela, material genetikoaren eragina aztertzeaz gain, formulazioen egonkortasuna 




in vivo arratoi-erretinan transfekzio-entseguak bideratu genituen, hiru material 
genetikoen artean eraginkorrena zein zen erabaki ahal izateko.  
DST20 niosomek morfologia esferikoa eta gene-garraiorako tamaina egokia erakutsi 
zuten, 123 nm-ko diametroko partikulak. Gainera, PDI balio baxuek tamainen 
distribuzio homogeneoa adierazi zuten eta zeta potentzialaren balio positiboak 
egokiak ziren karga negatibodun DNA molekuletako fosfato taldeekin elkarrekintza 
elektrostatikoen bidez lotzeko45, 98, 99. Aipatzekoa da TEM bidez lortutako irudietan 
ikusten diren partikula-tamainen eta DLS teknikaren bidez neurtutako partikula-
tamainen arteko ezberdintasuna laginen prozesaketa ezberdinagatik dela13. Espero 
bezala, niosoma formulazioei DNA molekulak gehitzean, partikulen diametroa ia 
bikoiztu egin zen eta zeta potentziala, berriz, jaitsi, niosomen amina taldeak DNA 
molekulen fosfato taldeekin partzialki neutralizatu zirelako (3.2.A-B irudia).  
DST20 niosomak hiru material genetiko ezberdinekin elkartu ostean lortutako 
nioplexoen tamaina, zeta potentziala eta transfekzio-efizientziari dagozkion datuak 
bat datoz beste ikerketa batzuekin, non material genetiko ezberdinek ez dituzten ia 
formulazioen parametro fisiko-kimikoetan eraginik100 baina bai transfekzio-
efizientzian in vitro101. Gene-transferentziaren eraginkortasunean antzemandako 
desberdintasunak azaltzeko bi arrazoi nagusi egon daitezke. Batetik, partikulen 
tamainan DNA gehitzean ikusten den igoerak alde batera uzten du ITC kurbei 
begiratuta litekeena zen nioplexoen arteko agregazioa. Beraz, lipido kationikoa/DNA 
ratioaren arabera, molekulen antolaera aldatu daiteke eta DNA molekulak niosoma 
formulazioaren gainazaleko leku mesedegarrienetan lotuko dira, ratioak igotzeak 
niosoma bakoitzeko DNA molekula gutxiago lotzea ekarriko lukeelarik. Horrek 
niosomek zelulen gainazalarekin interakzioak osatzeko gaitasuna baldintzatuko luke 
eta, beraz, baita horien transfekzio-gaitasuna ere. Bestetik, ikerketa honetan DNA 
kantitate konstanteak erabili ziren –1,25 µg kondizio bakoitzeko- baina kontuan 
hartzekoa da DNA molekulen tamainak eta, beraz, baita horien masa eta molaritatea 
ere, ezberdina izango dela material genetiko mota bakoitzarentzat. Horrek niosoma 
bakoitzari lotutako DNA molekula-kopurua baldintzatuko du, eta ITC entseguan 
erraz antzeman daiteke daiteke fenomeno hor, DNA mota bakoitzarentzat 
formulazioen kalorimetria-kurbak ezberdinak baitira (3.2.D irudia). Beraz, ematen du 
niosoma formulazioek MC molekula gehiago jaso zituztela plasmido molekulak 
baino eta, horrek, MC daramaten formulazioen transfekzio-probabilitatea jaso egiten 




3.2. Irudia. Niosoma eta nioplexoen karakterizazio fisiko-kimikoa eta egonortasun neurketa. 
(A) DST20 nioplexoen karakterizazio fisiko-kimikoa prestatu berritan (0 eguna) eta hilabetera 
(30 eguna) 4°C-tan edo 25°C-tan biltegiratu ondoren. Balio bakoitzak bataz besteko ±SD 
adierazten du, n = 3. (B) DST20 niosomen TEM irudiak (i) 0 egunean, (ii) 30 egunean 4°C-
tan biltegiratuta eta (iii) 30 egunean 25°C-tan biltegiratuta. Eskala-barrak: 500 nm (irudi 
nagusiak) eta 200 nm (txertatutako irudiak). (C) Elektroforesi-entsegua agarosa geletan 
DST20 niosomek material genetiko ezberdinak babesteko eta askatzeko zuten gaitasuna 
ikertzeko, (i) 0 egunean, (ii) 30 egunean 4°C-tan biltegiratuta eta (iii) 30 egunean 25°C-tan 
biltegiratuta. DNase I entzima eta SDS gehitu ziren 3, 6 eta 9 zutabeetan MC-GFP, pGFP eta 




4 eta 5 zutabeetan MC-GFP, pGFP eta pEGFP material genetiko biluziak ipini ziren hurrenez 
hurren eta 2, 5 eta 8 zutabeetan horiek berak + DNase I entzima. (D) ITC entsegua DNA 
molekulen eta DST20 niosomen arteko elkarrekintza ikertzeko. Bero-bariazioaren eboluzioa 
gehitutako DOTMA kantitatearen (mg) eta DOTMA/DNA kontzentrazioen (mg/ml) araberakoa 
izan zen. Grafiketako ikurrek datu esperimentalak adierazten dituzte eta ikurrak lotzen 
dituzten lerroek, berriz, ITC perfilen joera adierazten dute.  
Formulazioak biltegiratu aurretik eta ondoren transgene-espresioan ikusitako 
ezberdintasunak (3.3. irudia) azaltzeko faktore-metaketak hartu behar dira kontuan. 
Izan ere, gene-garraioa aspektu askok baldintzatzen dute, partikulen tamaina, 
gainazaleko karga, morfologia eta DNArekin lotzeko gaitasuna barne102. Zentzu 
horretan, TEM irudietan itxura esferikoaren galera eta baita agregazioen sorrera ere 
antzeman daitezke 30 egunez biltegiratuta egon ostean eta, horrek, DNA 
molekulekin elkarrekintzak modu egokian sortzea oztopatu dezake. Halaber, 
elektroforesi eta ITC entseguetan garbi ikus daiteke niosomek DNA molekulei 
eusteko gaitasuna jaitsi egiten dela denboran zehar. Agarosa-geletan, DNA banden 
seinale ahulagoak formulazioaren babes eskasagoa adierazten dute (3.2.C irudia). 
Era berean, ITC entseguetako datuek adierazten dute DST20 nioplexoen 
ezaugarriak niosomen araberakoak direla eta, horiek 30 egunez biltegiratu badira, 
propietate fisiko-kimikoak kaltetuta egongo direla. Nahiz eta MC material genetikoa 
daramaten DST20 nioplexoen transfekzio-maila 30 egunera plasmidoak 
daramatzaten DST20 nioplexoek 0 egunean lortzen dutena baino altuagoa izan (3.3. 
irudia), ikerketa-esfortzu handiagoak zuzendu behar dira formulazio egonkorragoak 




3.3. Irudia. Nioplexoen transfekzio-efizientzia eta zelulen biziraupena ARPE-19 zelula-
lerroan. Fluxu zitometria bidez neurtutako EGFP positiboak diren zelula biziak (barrak) eta 
zelula-populazioaren biziraupena (puntuak) transfekzioaren ondoren, (A) DST20 niosomak 
prestatu berritan erabilita (0 eguna) eta (B) 30 egunez 4°C-tan edo 25°C-tan biltegiratuta egon 
ondoren, eta MC-GFP, pGFP edo pEGFP material genetikoak garraiatzen dituztela. Balio 
bakoitzak bataz besteko ±SD adierazten du, n = 3. *p < 0,05 transfekzio-efizientziari 
dagokionez eta #p < 0,05 zelula-biziraupenari dagokionez, Lipofectamine 2000TM kontrol 
positiboarekin alderatuta, ns siglek ez dagoela diferentzia estatistikorik adierazten dute.  
Gaur egun, bitreo-barneko (IV) eta erretina-azpiko (SR) injekzioak dira klinikan 
erabilgarriak diren eman-bide bakarrak, nahiz eta oso inbaditzaileak izan103. Beraz, 
eman-bide horien bitartez injektatu ziren material genetiko ezberdindun DST20 
nioplexoak in vivo arratoi-erretinetan. Aurreko ikerketetan bezala, IV injekzioen bidez 
erretinako ganglio-zelula geruzara iristea lortu zen24, 25. Maila honetako gene-
transferentzia eraginkorra erabilgarria izan daiteke glaukoma bezalako 
gaixotasunetan104. Bestalde, SR injekzioen bidez RPE geruzaraino iristea lortu zen. 




zeluletan gertatzen diren mutazioek eragiten baitituzte erretinako gaitz hereditario 
gehienak, eta horien erantzule diren 200 mutazio baino gehiago ezagutzen dira gaur 
egun. Immunohistokimika irudien analisi kualitatiboaren bidez antzeman genuen 
transgene handiagoa MC zeramaten DST20 nioplexoekin transfektatutako 
erretinetan, bai IV (3.5. irudia) zein SR (3.6. irudia) injekzioen ostean. Beraz, DST20 
bektore ez-biralaren eta MC DNA molekulen arteko konbinaketa egokia izan liteke 
erretinako gaitzei aurre egiteko gene-terapia estrategietan erabiltzeko. Gainera, 
literaturaren arabera, MC teknologiak ez du bakarrik gene-transferentzia hobetzen, 
baizik eta denboran irauten duen transgene-espresioa ahalbidetzen du, klinikan 
aplikagarria izateko faktore gakoa dena92, 101. Nahiz eta GFP espresioa 
Lipofectamine 2000TM kontrol positiboa erabilita ere antzeman genuen, formulazio 
hori ez da egokia in vivo entseguetarako erretinan, bertako zeluletan toxikotasun 
handia eragiten duelako baita kontzentrazio baxuetan ere68. Izan ere, gure in vitro 
entseguek ARPE-19 zeluletan garbi erakutsi zuten Lipofectamine 2000TM 
bektorearen toxikotasun handia (3.3. eta 3.4. irudiak). Azkenik, aipatzekoa da 
DST20/MC nioplexoak 2/1 lipido kationikoa/DNA masa ratioan erabiltzeak abantaila 
garrantzitsuak dituela, besteak beste, DNA dosia handitu ahal izatea efektu 
terapeutiko nabarmenagoa lortzeko eta niosoma kantitate txikiagoak erabiltzea 
lipido kationikoei lotutako toxikotasun arazoak ekiditeko67. Gainera, MC molekulek 
ez dutenez ez CpG motiborik ez beste oinarri prokariotikorik, euren 
bioerabilgarritasuna eta segurtasun profila plasmido konbentzionalena baino 
egokagoak dira.  
3.4. Irudia. GFP espresioa erretinako 
zelulen kultibo primarioan. Fluores-
zentzia immuno-histokimika irudiak, non 
GFP seinalea batez ere glia-zeluletan 
antzeman daitekeen, DST20 nioplexoak 
erabilita ondoko material genetikoetako 
bati lotuta: (A) MC-GFP, (B) pGFP eta 
(C) pEGFP. (D-F) bakoitzari dagokion 
kontrol positiboa Lipofectamine 2000TM 
bektore gisa erabilita. Zelula-nukleoak 
Hoescht 33342 markatzailearekin 
tindatu ziren (urdinez) eta neuronen 
dendritak MAP2 markatzailearekin (gorriz). Gezi zuriek nukleo apoptotikoak adierazten 





3.5. Irudia. In vivo GFP espresioa IV injekzioaren ondoren. Erretinako mikroskopio 
fluoreszente irudiak, GFP seinalea erakusten dutenak transfekzioa egiteko DST20 nioplexoak 
ondorengo material genetikoetako bati lotuta erabilita: (A) MC-GFP, (B) pGFP eta (C) pEGFP. 
(D-F) bakoitzari dagokion kontrol positiboa Lipofectamine 2000TM bektore gisa erabilita. RPE 
(erretinako epitelio pigmentarioa), OS (kanpo-segmentuak), ONL (kanpoko nukleo geruza), 
INL (barneko nukleo geruza), GCL (ganglio-zelulen geruza). Zelula-nukleoak Hoescht 33342 




3.6. Irudia. In vivo GFP espresioa SR injekzioaren ondoren. Erretinako mikroskopio 
fluoreszente irudiak, GFP seinalea erakusten dutenak transfekzioa egiteko DST20 nioplexoak 
ondorengo material genetikoetako bati lotuta erabilita: (A) MC-GFP, (B) pGFP eta (C) pEGFP. 
(D-F) bakoitzari dagokion kontrol positiboa Lipofectamine 2000TM bektore gisa erabilita. RPE 
(erretinako epitelio pigmentarioa), OS (kanpo-segmentuak), ONL (kanpoko nukleo geruza), 
INL (barneko nukleo geruza), GCL (ganglio-zelulen geruza). Zelula-nukleoak Hoescht 33342 
markatzailearekin tindatu ziren (urdinez). Eskala-barrak: 20 µm.  
Laburbilduz, lan honetako aurkikuntza nagusiak ondorengoak dira: (1) DST20 
niosomak material genetikoa babesteko eta era kontrolatuan askatzeko gai diren 
bektore ez-biralak dira; (2) niosomek material genetikoa babesteko eta horrekin 
elkarrekintzak osatzeko gaitasuna kaltetu egiten dira biltegiratze denboraren eta 




formulazioen parametro fisiko-kimikoak antzekoak dira, baina in vitro transfekzio-
gaitasun ezberdinak dituzte nahiz eta denek zelula-biziraupen maila egokiak 
erakutsi; (4) MC daramaten DST20 nioplexoek plasmidoak daramatzatenek baino 
transfekzio-efizientzia altuagoa dute in vitro, baita 30 egunez biltegiratuta egon 
ondoren ere; eta (5) DST20 nioplexoak gai dira erretinako zelulen kultibo primarioak 
transfektatzeko eta baita in vivo ere erretinako zelulak transfektatzeko IV eta SR 
injekzioen bidez, eta kasu honetan ere MC daramaten DST20 nioplexoak dira 
transfekzio-gaitasun handiena erakutsi dutenak. Beraz, DST20/MC nioplexoak 
sistema ez-biral egokia izan daitezke gene terapeutikoak modu seguru eta 
eraginkorrean erretinara garraiatzeko eta bertako zeluletan gene terapeutikoen 
espresio iraunkorra lortzeko.  
4. Gene-garraio sistema ez-biralen aspektu tridimentsionalak: niosomen 
eta azido hialuronikozko hidrogelen arteko sinergia bateragarrien bila 
Bektorea eta garraiatutako material genetikoa hobetzeaz gain, gene-terapia ez-
biralean gaur egungo joera da beste teknologia batzuekin konbinaketa berriak 
bilatzea transfekzio-efizientzia hobetze aldera. Izan ere, estrategia konbinatu horiek 
abantaila handiak izan ditzakete, aipagarrienak egonkortasun hobea eta toxikotasun 
baxuagoa lortzea direlarik. Gainera, gene-transferentzia matrizeen diseinuarekin 
uztartuta, DNA garraio lokala, eraginkorra eta ehun zehatzetara zuzendua posible 
litzateke eta, horrek, gene-terapiaren aplikazio klinikoa erraztuko luke, besteak 
beste, minbiziaren tratamenduan edota ehunen birsortzean35, 36. Azido hialuronikoa 
(HA) glikosamino anionikoa da eta zelulaz kanpoko matrizearen osagai natural 
nagusietako bat da. Azken aldian, bere erabilerak biomaterial gisa arreta erakarri du 
ehun-ingeniaritzan, biobateragarria delako eta molekula ezberdinak barneratzeko 
gai delako, azido nukleikoak barne105, 106.  
Hori dela eta, lan honen helburua da DNA-garraioa modu lokalean egin ahal izateko 
niosoma eta HA hidrogelen arteko konbinaketaren bidez, plataforma ez-biral seguru 
eta eraginkorra garatzeko lehen urratsak ematea. Guk dakigula, lehen aldia da 
niosoma eta HA hidrogelen teknologiak uztartzen direna gene-garraio ez-biralaren 
baitan. Hiru niosoma formulazio ezberdin prestatu eta aztertu genituen (1, 2 eta 3 
niosomak), lipido kationiko, lipido laguntzaile eta tentsoaktibo ez-ioniko ezberdinez 
osatutakoak (4.1. irudia). Nioplexoak eratzeko, niosoma horiei luziferasa genearen 
sekuentzia daraman DNA plasmidoa (pGluc) gehitu genien. Niosomen osagaien, 
lipido kationikoen kontzentrazioaren eta lipido kationikoa/DNA masa ratioen 




nioplexoak fisiko-kimikoki zein biologikoki karakterizatu genituen tamaina, PDI, zeta 
potentziala eta sagu-hezurmuinetik klonatutako ama-zelula mesenkimalak (mMSC) 
2D kultiboetan transfektatzeko gaitasunari dagokionez. Jarraian, nioplexodun HA 
hidrogelen propietate biomekanikoak ikertu genituen, eta baita partikulen hidrogel 
barruan zuten distribuzioa ere. Horrez gain, nioplexoen askapen-zinetika HA 
hidrogeletatik ere aztertu genuen. Azkenin, mMSC zelulak hiru-dimentsiotan hazi 
genituen nioplexodun HA hidrogeletan eta nioplexoen transfekzio-efizientzia 
ebaluatu genuen 3D kultibo horietako zeluletan.  
4.1. Irudia. Niosoma kationikoen eta hidrogelen eskema orokorra. A. Niosoma formulazioak 
prestatzeko erabilitako lipido kationiko, lipido laguntzaile eta tentsoaktibo ez-ionikoen egitura 
kimikoak. B. HA molekuletan eginiko moldaketa kimikoak HA hidrogelak osatzeko. C. 




Nahiz eta DNA kontzentrazio altuek gene-garraio lokala hobetzen duten 
hidrogeletan107, DNA kantitate handiak hidrogeletan txertatzea erronka handia da, 
azido nukleikoen agregazioa edota inaktibazioa ekidin behar dira eta108. Bektore ez-
biralen aukera zabalaren artean, poli(etileno imina) edo PEI polimeroz osatutako 
partikulak, DNA molekulei lotuta poliplexoak osatuz, arrakasta handiz txertatu dira 
hidrogeletan eta transgene-espresio maila altuak lortzea zein in vivo angiogenesia 
abiaraztea posible izan dira109. Hala eta guztiz ere, nahiz eta PEI molekulen 
eratorriak oso eraginkorrak diren gene-garraiorako, toxikoak dira eta erantzun 
immunea pizten dute eta, beraz, ez dira egokiak erabilera klinikorako110. Zentzu 
horretan, niosomak alternatiba aparta izan daitezke sistema biologikoekin duten 
bateragarritasuna dela eta. Gainera, niosomak biodegradagarriak dira, toxikotasun 
oso baxua dute eta ez dute erantzun immunerik sortzen64. Lan honetan, nioplexodun 
HA hidrogeletan lortutako transfekzio-efizientziak in vitro beste lan batzuetan PEI 
poliplexodun HA hidrogeletan lortutakoen antzekoak dira111. Beraz, espero izatekoa 
litzateke in vivo entseguetan ere nioplexodun HA hidrogelak gene-transferentzia 
eraginkorra bideratzeko gai izatea eta interesgarria litzateke ikerketa-lerro horretan 
sakontzea etorkizunera begira.  
Lan honetan erabilitako hiru niosoma formulazioek osagai ezberdinak zituzten (4.1. 
irudia), denak aurretik ikertuak beste gene-garraio ez-biral aplikazio batzuetarako. 
Esate baterako, Tween 80 daramaten formulazioak eskualeno lipido 
laguntzailearekin batera, gene-transferentziarako egokiak direla erakutsi da26. 
Bestalde, lycopene lipido laguntzailea DOTMA lipido kationikoarekin eta Tween 60 
tentsoaktibo ez-ionikoarekin konbinatuta, formulazio horiek gai izan ziren erretinako 
zelulak transfektatzeko aurreko ikerketetan24 eta Poloxamer 407 ere oso erabilia 
izan da gene-garraiorako bektore ez-biralen prestaketan112. Gainera, klorokinaren 
erabilerak formulazioen gene-transferentzia gaitasuna indartzen duela uste da, bai 
in vitro eta baita in vivo ere113. Beraz, niosomak prestatzeko erabilitako osagaiak, 
kontzentrazioak eta lipido kationikoa/DNA masa ratioak aurreko ikerketetako 
emaitzetan oinarrituta aukeratu genituen.  
Hasteko, niosomak eta nioplexoak fisiko-kimikoki zein biologikoki karakterizatu 
genituen tamaina, PDI, zeta potentziala eta mMSC zelulan 2D kultiboetan 
transfektatzeko gaitasuna kontuan hartuta (4.2. irudia). Hiru formulazioek zeta 
potentzial positiboak zituzten (4.2.B irudia), ezinbestekoa karga negatibodun DNA 
molekulekin elkarrekintza elektrostatikoen bidez lotzeko45, 66. Gainera, partikulen 
gainazaleko karga positiboek zeluletan barneratzea errazten dute44. Formulazioen 




zuten zelulak transfektatzeko gaitasuna, baina 1 nioplexoak izan ziren transfekzio-
efizientzia handiena erakutsi zutenak, Lipofectamine 2000TM kontrol positiboaren 
atzetik (4.2.C irudia). Lipofectamine 2000TM kontrol positibo gisa erabiltzen da, baina 
ez da egokia in vivo entseguetarako eta ezta aplikazio klinikorako ere toxikotasun 
handia eragiten duelako. Beraz, HA hidrogelekin konbinatzeko 1 nioplexoak 
aukeratu genituen entsegu horien ondoren.  
4.2. Irudia. Niosoma formulazioen karakterizazioa. 
A. Tamaina (nm). B. Zeta potentziala (mV). C. 
Transfekzio-efizientzia mMSC zelulen 2D kultiboan, 
nioplexoen eraginpean ipini eta 48 ordura neurtuta. 
1, 2 eta 3 nioplexoen lipido kationikoa/DNA masa 
ratioak 2/1, 15/1 eta 18/1 izan ziren, hurrenez 
hurren. Kontrol negatiboa (C-) tratamendurik 
gabeko zelulek osatzen dute eta kontrol positiboa 
(C+), berriz, Lipofectamine 2000TM bektorearekin 
transfektatutako zelulek osatzen dute. RLU: 
Relative Light Units, alegia, luziferasa 
transgenearen espresio-mailaren adierazle diren 
seinale lumuniko unitateak.  
Nioplexoak masa ratio baxuetan erabiltzeak abantailen artean, garrantzitsuenak 
DNA kantitate handiagoak erabili ahal izatea formulazio-bolumen txikiagoak erabilita 
eta lipido kationikoei lotutako toxikotasuna gutxitzea dira13. Horrez gain, DNA 
kantitate are handiagoak txertatu ahal izateko HA hidrogelek onartzen dituzten 
niosoma bolumen baxuetan, 1 niosoma formulazioaren kontzentrazioa bikoiztu 
genuen (1 mg/ml-tik 2 mg/ml-ra). Kontzentratutako niosoma formulazioa TEM bidez 
aztertu genuen eta irudietan ikus daiteke partikulen morfologia ez zela aldatu 
kontzentrazio-prozesuan zehar eta, espero bezala, partikula gehiago ikusten dira 
formulazio kontzentratuaren irudietan ez-kontzentratuarekin alderatuta (4.3.A-B 
irudiak). Bestalde, partikulen tamaina eta PDI balioak ere antzera mantendu ziren. 
Zeta potentzial balioek behera egin bazuten ere, +20 mV-en gainetik mantendu 
ziren, balio egokia beraz partikulen agregazioa ekiditeko46. Gainera, ez genuen 
ezberdintasunik aurkitu niosoma kontzentratuen eta ez-kontzentratuen transfekzio-
efizientzian (4.3.C irudia), beraz, gene-transferentzia gaitasuna ere ez zen kaltetu 
kontzentrazio-prozesuan zehar. Emaitza horiek kontuan hartuta, formulazio 




4.3. Irudia. Niosoma kontzentratuen 
karakterizazioa. A-B. Niosoma ez-
kontzentratuen (A) eta kontzentratuen (B) TEM 
irudiak x10.000 magnifikazioan. Eskala-barra: 
200 nm. C. Transfekzio-efizientzia mMSC 
zelulen 2D kultiboetan formulazioen eraginpean 




Terapeutikoki egokiak izan daitezkeen DNA kantitateak lortze aldera114, HA 
hidrogeletan hiru nioplexo kantitate ezberdin txertatu genituen hiru hidrogeletan, 
honako amaierako DNA kontzentrazioak lortuz 2, 3 eta 4 hidrogeletan, hurrenez 
hurren: 0,055 µg/ml, 0,12 µg/ml eta 0,2 µg/ml. Kontrol gisa, nioplexorik gabeko eta, 
beraz, DNArik gabeko hidrogelak erabili ziren (1 hidrogela). Material genetiko 
kontzentrazio ezberdinek hidrogelen ezaugarri biomekanikoetan eragin dezakete, 
eta horiek zelulen hidrogel barneko hedapena eta gene-transferentzia baldintzatzen 
dituzten faktore garrantzitsua dira. Hidrogel zurrunak (800 Pa baino gehiagokoak) 
zelulen hedape baxuarekin erlazionatuta daude eta hidrogel bigunak (200 eta 260 
Pa artean), berriz, transgene-espresio indartuarekin daude erlazionatuta108. Beraz, 
1, 2, 3 eta 4 hidrogelen propietate mekanikoak aztertu genituen beren zurruntasun-
maila ezagutzeko. Erreologia bidezko karakterizazioaren arabera, hidrogelek oso 
zurruntasun-maila ezberdinak erakutsi zituzten, 3 hidrogela zurrunena izanik eta 4 
hidrogela bigunena (4.4.A-B irudia). Nioplexoen distribuzioa hidrogelen barruan 
nahiko homogeneoa izan zen eta 3 eta 4 hidrogeletan, partikulek ez zuten batere 
agregaziorik sortu. Zelula-hazkuntzarako mediorik ez zuen 4 hidrogela ezin zen 3D 
kultiboak egiteko erabili, baina in vivo entseguetarako hautagai egokia izan daiteke 
bere propietate biomekanikoei esker. Transfekzio-entseguan 3D kultiboetan, beraz, 
2 eta 3 hidrogeletan egin ziren, 1 hidrogela kontrol negatibo gisa erabilita. Orohar, 
emaitza horiek erakusten dute nioplexoak, baita DNA kantitate handiak garraiatuta 
ere, agregaziorik sortu gabe eta ezaugarri mekaniko egokiak mantenduz txertatu 







4.4 Irudia. Nioplexodun HA hidrogelen 
karakterizazioa. A. Hidrogelen 
propietate mekanikoak erreologia 
bidez neurtu ziren 0,1 eta 10 rad/s-ko 
frekuentzian eta 0,01-eko tentsio 
konstantea aplikatuta. B. Batez 
besteko zurruntasuna. C-E. Partikulen 
distribuzioa hidrogeletan. Gel ID: 1 
nioplexorik gabeko hidrogel kontrola; 2: 
0,055 µg/ml DNA; 3: 0,12 µg/ml DNA 
eta 4: 0,2 µg/ml DNA.  
 
Behin hidrogeletik askatuta nioplexoek transfekzio-gaitasuna mantentzen zutela 
ziurtatzeko, nioplexo-aktibitate entsegu bat egin genuen (4.5. irudia). Nioplexoak 
hidrogeletan txertatu ondoren, horiek tripsinaren bidez degradatu genituen eta 
nioplexodun produktu horrekin transfekzioa egin genuen mMSC zelulen 2D 
kultiboetan. Emaitzen arabera, nioplexoak gai izan ziren transfekzioa bideratzeko 
hidrogeletatik askatuak izan ondoren, baina prestatu berritan baino efizientzia 
baxuagoa erakutsi zuten. Hala ere, aipatzekoa da transfekzioa egiteko, nioplexoez 
gain hidrogel degradatua eta tripsina ere bazituen nahasketa erabili genituela eta, 
ziurrenik, produktu horiek izan ziren transfekzio-prozesua oztopatu zutenak109. 
4.5 Irudia. Nioplexoen 
aktibitate biologikoa HA 
hidrogeletatik askatu eta 
gero. A. nioplexo prestatu 
berriak. B. Tripsinarekin 
degradatutako HA 
hidrogeletatik askatutako 
nioplexoak. C. Nioplexo 
prestatu berriak + 
tripsinarekin degradatutako 
hidrogelak. D. Nioplexo 
prestatu berriak + tripsina. 
E. DNA askea (niosomei 
lotu gabea) + tripsinarekin degradatutako HA hidrogelak. F. Nioplexorik gabeko hidrogelak 




Bi mekanismo nagusik baldintzatzen dute gene-transferentzia hidrogeletan: 
DNA/nanopartikula konplexuen askapen-zinetikak eta zelula-infiltrazio tasak115. 
Hidrogelaren degradazioaren ondorioz askatutako nioplexoek inguruko zelulak 
transfektatuko lituzkete eta, era berean, hidrogelean zehar infiltratu eta hedatzen 
diren zelulek nioplexoekin topo egingo lukete eta barneratu egingo lituzkete, 
transfekzioa gauzatuz116, 117. Zentzu horretan, 3D kultiboetako gene-transferentzia 
baxuagoa da hidrogeleko zelulak ez badira gai azalera guztian zehar hedatzeko eta, 
beraz, hidrogel zurrunegiak ez dira komenigarriak115. Lan honetan, nioplexoek 7 
egun behar dituzte hidrogeletik ia erabat askatzeko kolagenasa I entzimaren 
presentzian, eta zertxobait motelago askatzen dira entzima hori ez badago (4.6.A 
irudia). Nioplexoen askatze progresibo hori komenigarria aplikazio 
terapeutikoetarako, transgene-espresio iraunkorra ahalbidetzen duelako. 
Hidrogeletako 3D transfekzio-entseguei eta zelula-hedapenari dagokionez, esan 
dezakegu zelulak hidrogel guztietan hedatzeko gai izan zirela, baita 3 hidrogelean 
ere bere zurruntasuna kontuan hartuta harrigarria bada ere (4.6.C-E irudia). 
Gainera, transfekzio-maila altuagoa izan zen 3 hidrogelean –DNA kantitate 
handiagoa ere bazuen- 2 hidrogelean baino (4.6.B irudia, barrak) eta horrek 
adierazten du, beharbada, DNA kantitate handiek hidrogelen zurruntasuna nolabait 
konpentsatzen dutela. Horrez gain, kasu guztietan eta nioplexorik gabeko 1 
hidrogelekin alderatuta, zelulen biziraupena bikaina izan zen, nioplexoen 
presentziak hidrogeletako 3D kultiboetako zelulak kaltetzen ez dituela erakutsiz (6.B 
irudia, puntuak).  
 
 
4.6. Irudia. (A) Nioplexoen askapen-zinetika HA hidrogeletatik kolagenasa I entzimarekin (1 
U/ml) eta entzimarik gabe. (B) Transfekzio-efizientzi eta, zelulen biziraupena nioplexodun HA 
hidrogeletako 3D zelula kultiboetan. (C-E) Zelula-hedapenaren adierazgarri diren mikroskopio 
konfokal bidezko irudiak 1, 2 eta 3 hidrogeletan. Urdinez: DAPI (zelula-nukleoak) eta gorriz: 




Laburbilduz, kontzentratutako nioplexoak agregaziorik sortu gabe HA hidrogeletan 
txertatzeko prozesua garatu dugu lan honetan. Guk dakigula lehen aldia da 2,3-
di(tetradeziloxil)propan-1-amina, Poloxamer 407, Tween 80 eta klorokinaz 
osatutako niosoma formulazioen eta HA hidrogelen arteko konbinaketa egiten dela 
gene-garraio ez-biralaren baitan. Orohar, nioplexodun HA hidrogelek propietate 
mekaniko egokiak erakutsi zituzten, partikulek ez zuten agregaziorik sortu 
hidrogelen barruan eta zelulak modu egokian hedatu ziren hidrogeletan, gene-
transferentzia arrakastatsua lortuz mMSC zelulen 3D kultiboetan. Gure ustez, in vitro 
eredu honetan ikasitako baliagarria izan daiteke niosoma eta HA hidrogelen 
teknologiak uztartuz gene-garraio sistema ez-biral seguru eta eraginkorrak 
garatzeko in vivo aplikazioetarako.  
Dena batuz, doktoretza-tesi honek bektore ez-biralen transfekzio-gaitasunean 
eragiten duten eta gene-garraio sistema eraginkorren diseinuan kontuan hartu 
beharreko faktore gakoak aztertu ditu. Aspektu horiek honakoak biltzen dituzte: 
bektore ez-biralen konposizioa eta ezaugarri fisiko-kimikoak, garraiatutako material 
genetikoaren konposizioa eta egitura eta garrio-sistemen eta hiru-dimentsioko 
matrizeen teknologiak uztartzea. Gure ustez, bektore ez-biral unibertsal eta 
bakarraren kontzeptua atzean utzi beharra dago eta etorkizuneko gene-garraio ez-
birala aplikazio bakoitzera egokitutako bektoreen diseinuan oinarritu beharra dago. 
Nahiz eta bektore ez-biralak ez diren oraindik erabilera klinikora iritsi, egin diren 
aurrerapenek itxaropena pizten dute eta lortutako ebidentziek iradokitzen dute 
etorkizun hurbilean material genetikoa bektore ez-biralen eta eman-bide ez-
inbaditzaileetan barrena burutuko dela. 
 








En términos generales, la terapia génica se define como la introducción de material 
genético en células diana con el fin de modificar o controlar su expresión génica, 
pudiendo tener objetivos terapéuticos o experimentales1. La culminación del 
Proyecto del Genoma Humano, junto con los avances recientes en el campo de la 
biología molecular, han facilitado comprender procesos patológicos y celulares que, 
a su vez, ha permitido identificar genes diana para distintas estrategias terapéuticas. 
De todos modos, a pesar de que la terapia génica posee gran potencial para el 
tratamiento de distintas enfermedades, las estrategias basadas en el uso de ácidos 
nucleicos exigen el uso de vectores capaces de vehiculizar el ADN a las células 
diana de forma segura y efectiva, lo cual hoy en día sigue siendo uno de los mayores 
retos de las terapias basadas en transferencia genética. De hecho, la falta de 
vectores eficaces es la principal razón que limita el número de ensayos clínicos 
basados en terapia génica. El éxito de la transferencia génica depende en gran 
medida de la idoneidad del vector utilizado y éstos deberían ser capaces de: (i) 
proteger los ácidos nucleicos frente a la degradación enzimática, (ii) promover la 
internalización celular del material genético y (iii) liberar los ácidos nucleicos en el 
correcto compartimento intracelular1. Además, un vector ideal debe ser eficaz, 
seguro, específico, duradero, fácil de manejar y tener el mínimo coste posible2.  
En general, los vectores se clasifican en dos grandes grupos: los virales y los no-
virales. Según datos publicados por The Journal of Gene Medicine en 20143, existen 
alrededor de 2.000 ensayos clínicos basados en terapia génica aprobados a nivel 
mundial y, de ellos, el 70% usan vectores virales. Además, hoy en día sólo cuatro 
medicamentos basados en la terapia génica han sido comercializados y todos ellos 
se basan en el uso de vectores virales. En 2003, China aprobó por primera vez un 
medicamento de terapia génica, GendicineTM, basado en un vector adenoviral (Ad) 
e indicado para el tratamiento del carcinoma de células escamosas de cabeza y 
cuello4. En segundo medicamento de terapia génica también fue aprobado en 
China, en el año 2005, y fue denominado OncorineTM. Este segundo producto 
contiene un vector basado en un virus adenoasociado (AAV) y está indicado en el 
tratamiento de cáncer nasofaríngeo de estadío avanzado y refractario5. En Europa, 
el primer producto comercializado basado en terapia génica fue Glybera® y se 
aprobó en 2012. Este medicamento contiene también un vector viral AAV y está 
indicado para combatir el déficit severo de la lipoproteína lipasa6. En 2015, fue 
Estados Unidos quien aprobó su primer medicamento de terapia génica, 
denominado IMLYGICTM y que contiene como vector viral el virus del herpes simplex 
(HSV). Está indicado para tratar lesiones cutáneas, subcutáneas y nodales en 




actualizados en el año 2017, en las nuevas estrategias de edición genómica existe 
una tendencia cada vez mayor en el uso de sistemas no-virales. Al contrario que los 
métodos convencionales de terapia génica basados en la adición de un gen 
funcional, las nuevas estrategias basadas en la edición o corrección de la secuencia 
del genoma prefieren el uso de sistemas no-virales frente a los virales, siendo el 
70% de los estudios realizados en este sentido de carácter no-viral8. Entre las 
estrategias no-virales, la principal consiste en el uso del método físico de la 
electroporación (39%), seguido por los vectores no-virales lipídicos (17%) y los 
poliméricos (8%)8. Por lo tanto, parece que el uso de vectores no-virales está 
ganando terreno a los vectores virales para el transporte de material genético en las 
recién surgidas estrategias de edición genética.  
De hecho, a pesar de que los virus son herramientas altamente eficaces para el 
transporte génico, presentan también muchos inconvenientes como una baja 
capacidad de carga, producción compleja y costosa y problemas de seguridad 
relacionados con la respuesta inmune y la mutagénesis insercional. En este sentido, 
los vectores no-virales basados en nanotecnología, a pesar de su menor eficiencia 
de transfección, ofrecen innumerables ventajas incluyendo una baja 
inmunogenicidad, alta capacidad de carga y facilidad de fabricación a un coste 
asequible9. Además, las formulaciones no-virales pueden ser producidas a gran 
escala con alta reproductibilidad y son relativamente estables durante el 
almacenamiento1. Por lo tanto, los avances constantes en el campo de los 
biomateriales y la nano-ingeniería han motivado la síntesis, caracterización y 
funcionalización de nanomateriales biocompatibles para transportar material 
genético10. Asimismo, la gran variedad de nanomateriales disponibles ha permitido 
el diseño de vectores multifuncionales específicamente adaptados para distintas 
aplicaciones11. Hasta la fecha, se han desarrollado vectores no-virales compuestos 
de distintos materiales, siendo los más comunes los que se basan en lípidos 
catiónicos12-14, polímeros15-16 y nanopartículas magnéticas17. Estas moléculas se 
pueden modificar a través de la nanoingeniería para que distribuyan el material 
genético en órganos y células diana de forma específica o para que puedan 
atravesar distintas barreras tanto extra- como intracelulares. Entre la amplia gama 
de vectores no-virales disponibles, los denominados niosomas constituyen uno de 
los ejemplos más recientes y se trata de vesículas de surfactante no-iónico 
sintéticas y biocompatibles que forman una bicapa lipídica cerrada18, 19. Se basan 
en tres componentes principales: (i) el lípido catiónico –responsable de la 
interacción electrostática con las moléculas de ADN de carga negativa-, el lípido 




iónico –capaz de aumentar la estabilidad de la formulación y evitar la formación de 
agregados22. Las propiedades físico-químicas globales de estos componentes 
tienen gran influencia sobre las características de los niosomas como, por ejemplo, 
el tamaño de las partículas, la carga superficial o la morfología. A su vez, esas 
propiedades determinarán la habilidad de los niosomas para penetrar en las células, 
seguir una ruta endocítica en particular, liberar la carga de ADN en el núcleo y, por 
tanto, su eficiencia de transfección22-23. Es importante recalcar, además, que 
estudios recientes han demostrado que los vectores no-virales basados en 
niosomas son capaces de transfectar células de retina y sistema nervioso central 
(SNC) tanto in vitro como in vivo en ratas23-26.  
En cualquier caso, no sólo el vector utilizado es importante a la hora de determinar 
la eficiencia de transfección, sino que las propiedades del material genético 
transportado también influyen en el proceso. Hasta hace poco, la mayoría de 
estrategias destinadas a incrementar la eficiencia de transfección en terapia génica 
no-viral se han centrado en mejorar la vehiculización del material genético, ya sea 
mediante la introducción de modificaciones en el vector o a través del uso de 
métodos físicos como la electroporación. Sin embargo, la potenciación de la 
transferencia génica se puede conseguir mediante la optimización del material 
genético en cuanto a su composición y conformación, ya que esto permite tanto 
mejorar la biodisponibilidad y biocompatibilidad del ADN como obtener una mayor 
duración de la expresión génica27. En este sentido, varios grupos de investigación 
han desarrollado recientemente la denominada tecnología minicircle (minicírculo en 
inglés, abreviado MC), que consiste en la deleción de las secuencias bacterianas 
de los plásmidos convencionales, manteniendo únicamente el gen de interés y las 
secuencias reguladoras28. Las secuencias procariotas de los plásmidos 
convencionales incluyen motivos CpG, orígenes de replicación y genes de 
resistencia a antibióticos. A pesar de que esas secuencias son necesarias para 
poder propagar y mantener los plásmidos en huéspedes bacterianos en el 
laboratorio, obstaculizan su aplicabilidad clínica, ya que pueden inducir respuestas 
inflamatorias y muerte celular por apoptosis o necrosis. Ello, además de suponer un 
problema de seguridad, reduce la expresión del transgen de manera notoria31, 32. 
Además, las secuencias de ADN de los plásmidos convencionales pueden resultar 
en muchas ocasiones inaccesibles a la maquinaria de transcripción de la célula 
diana, sobre todo si las secuencias bacterianas asociadas a los indicadores de 
histonas se encuentran adyacentes al gen de interés. Estos indicadores –que son 
rápidamente reconocidos por la célula diana- producen el empaquetamiento de las 




reducción de la expresión del transgen o en su silenciamiento33. Por lo tanto, las 
unidades de expresión minimizadas como el MC constituyen una alternativa 
prometedora a los plásmidos convencionales para incrementar la eficacia de la 
transfección y la duración de la expresión del gen de interés. Varios estudios in vitro 
e in vivo han demostrado una mejora significativa en los niveles y duración de la 
expresión génica mediante el uso de la tecnología MC, así como mejores perfiles 
de seguridad e inmunocompatibilidad18. Por otro lado, las estructuras de ADN “mini” 
también poseen mayor capacidad para atravesar barrera extra- e intracelulares, 
aumentando su biodisponibilidad en los tejidos diana34.  
Además de la optimización del vector y del material genético, una nueva tendencia 
en terapia génica no-viral es la exploración de sinergias complementarias con otras 
tecnologías, por ejemplo, con el diseño de matrices tridimensionales o hidrogeles. 
Estas estrategias combinadas pueden proporcionar ventajas significativas a los 
sistemas de terapia génica no-viral como, por ejemplo, mayor estabilidad y menor 
toxicidad. Asimismo, el hecho de complementar la transferencia génica con el 
diseño de matrices tridimensionales permitiría distribuir el ADN terapéutico de 
manera local y efectiva, lo cual acercaría estas estrategias a su aplicación clínica 
en el tratamiento del cáncer o la regeneración tisular35, 36.  
Tomando en cuenta todo lo anterior, esta tesis doctoral se centra en el desarrollo 
de sistemas efectivos de liberación génica no-virales y, para ello, lleva a cabo los 
siguientes estudios: (i) preparación, caracterización y evaluación comparada de la 
eficiencia de transfección de tres vectores comerciales basados en lípidos 
catiónicos, polímeros y nanopartículas magnéticas que transportan un plásmido que 
codifica el factor de crecimiento vascular (VEGF) a las células del SNC; (ii) 
preparación, caracterización y evaluación del proceso y eficiencia de transfección 
de tres formulaciones de niosomas que únicamente difieren en el tensioactivo no-
iónico para dilucidar el rol que desempeña ese componente en la transfección 
mediada por niosomas; (iii) preparación y caracterización de niosomas unidos a tres 
tipos de material genético –MC y plásmidos de distinto tamaño- y evaluación 
comparada de su eficiencia de transfección; y (iv) exploración de sinergias 
complementarias para terapia génica no-viral entre niosomas e hidrogeles de ácido 






1. La influencia de la composición de los vectores no-virales en su 
eficiencia de transfección con un plásmido terapéutico que codifica el 
gen de crecimiento del endotelio vascular en células del sistema 
nervioso central  
Las terapias basadas en ácidos nucleicos son esperanzadoras pero requieren el 
uso de vectores eficaces y seguros. Además, la transfección de células del SNC 
constituye todavía un gran reto, lo cual retrasa el desarrollo de estrategias 
terapéuticas basadas en la liberación génica para enfermedades que afectan al 
SNC. En los últimos años, los nanomateriales biocompatibles han surgido como 
candidatos prometedores para desempeñar esa función, y ya se han conseguido 
los primeros resultados de transfección en el SNC tanto in vitro como in vivo 
utilizando quitosanos37, 38, lípidos catiónicos39 o nanopartículas magnéticas17. Por 
otro lado, el gen del VEGF podría ser adecuado como gen terapéutico para el SNC40 
dada la estrecha relación descrita entre las alteraciones vasculares en cerebro y los 
procesos neurodegenerativos41 y por sus roles específicos en angiogénesis cerebral 
y supervivencia neuronal42, 43.  
Basándonos en esas consideraciones, presentamos un estudio basado en la 
liberación del gen VEGF en células del SNC a través de distintos vectores no-virales. 
Para ello, utilizamos tres nanoformulaciones diferentes –oligoquitosano ultrapuro 
(UOC) en una formulación polimérica, Lipofectamina en la formulación lipídica y 
NeuroMag en la magnética- y los unimos al plásmido phVEGF165aIRESGFP –que 
contiene el gen de la proteína VEGF y de la proteína verde fluorescente (GFP)- para 
obtener los nanoplexos correspondientes. Las nanoformulaciones y los nanoplexos 
fueron caracterizados en términos de tamaño, carga, índice de polidispersión (PDI), 
morfología y habilidad para condensar, proteger y liberar el ADN. Se llevaron a cabo 
estudios de transfección in vitro para determinar la eficiencia de transfección en 
líneas celulares del SNC –C6 y cultivo primario de neuronas- y en la línea celular 
HEK293 –utilizada como modelo general de transfección-. La eficiencia de 
transfección fue evaluada atendiendo a tres parámetros: porcentaje de células que 
expresa GFP, la intensidad de fluorescencia media (MFI) y la expresión de VEGF. 
También se analizó la viabilidad celular tras la exposición a los nanoplexos. La 
bioactividad de la proteína VEGF secretada por las células de cultivo primario de 
neurona transfectadas se evaluó en células endoteliales de la vena umbilical 




Todas las nanoformulaciones y nanoplexos –magnetoplexos, lipoplexos, poliplexos- 
presentaron partículas del rango nanométrico (Figura 1.1.a, barras), lo cual se ha 
relacionado con una mayor captación celular44 y exhibieron potenciales zeta 
positivos (Figura 1.1.a, líneas), lo cual es necesario para establecer interacciones 
electroestáticas con las moléculas de ADN de carga negativa45. Una vez unidos al 
ADN, la carga superficial de los nanoplexos descendió notablemente, alcanzando 
valores de alrededor de – 20 mV en el caso de los  magnetoplexos y lipoplexos, y 
valores cercanos al cero en el caso de los poliplexos. Teniendo en cuenta que se 
ha descrito que las partículas con valores de potencial zeta situados entre – 20 mV 
y + 20 mV son más propensos a formar agregados46, en este trabajo utilizamos 
siempre formulaciones recién preparadas para evitar la agregación sobre todo en el 
caso de los poliplexos. Los valores de PDI fueron inferiores a 0,5 en prácticamente 
todos los casos, lo cual se considera aceptable para fines comparativos entre 
tamaños de partículas medidos por análisis cumulativo47. La excepción fueron los 
lipoplexos, donde los valores de PDI elevados fueron atribuidos a su irregular 
morfología (Fig. 1.1.c). Con el fin de estudiar la capacidad de las nanoformulaciones 
de condensar, proteger y liberar el ADN, se llevó a cabo un ensayo de electroforesis 
en gel de agarosa (Figura 1.1.d). Las nanopartículas fueron capaces de proteger el 
ADN frente a la degradación enzimática y la retención de la mayoría del ADN en el 
pocillo superior del gel sugiere una fuerte interacción entre las nanopartículas y el 
material genético. Sin embargo, al añadir el SDS, las nanoformulaciones fueron 
capaces de liberar el ADN, lo cual indica un equilibrio entre capacidad de 





Figura 1.1. Caracterización físico-química de nanopartículas y nanoplexos. (a) Tamaño 
(barras blancas y grises, que corresponden a nanopartículas y nanoplexos, respectivamente) 
y potencial zeta (líneas discontinuas y continuas, que corresponden a nanopartículas y 
nanoplexos, respectivamente). Cada valor representa el promedio ± SD, n = 3. (b) Valores 
de PDI. Cada valor representa el promedio ± SD, n = 3. (c) Imágenes de TEM de 
nanopartículas magnéticas (c1) y lípido catiónico (c2), e imágenes de cryo-TEM de las 
partículas poliméricas (c3). Magnificación original: x140.000 en lípido catiónico, x175.000 en 
partículas magnéticas y x25.000 en partículas poliméricas. (d) Unión, protección y liberación 
de ADN visualizado en electroforesis en gel de agarosa. Columnas: 1-3, ADN libre; 4-6, 
lipoplexos; 7-9, magnetoplexos. Se añadió SDS en las columnas 2, 5, 8 y 11 y se añadió 
DNase I + SDS en las columnas 3, 6, 9 y 12. OC: forma circular abierta del ADN. SC: forma 




Una vez los nanoplexos fueron caracterizados, se llevaron a cabo estudios de 
transfección in vitro en tres líneas celulares: HEK-293 –modelo de transfección 
general-, C6 –modelo de SNC-, y cultivo primario de neuronas –modelo de SNC 
más relevante desde el punto de vista terapéutico-. Antes de pasar a los cultivos 
primarios de neurona, la viabilidad celular y la eficiencia de transfección de los 
nanoplexos se estudió en HEK293 y C6. Los nanoplexos fueron bien tolerados por 
ambas líneas celulares, con viabilidades celulares superiores al 90% con los 
magnetoplexos y lipoplexos y superiores al 80% con los poliplexos (Figura 1.2.a, 
puntos). El análisis de la eficiencia de transfección se estudió a través de tres 
parámetros: porcentaje de células que expresan GFP (Fig. 1.2.a, barras), MFI (Fig. 
1.2.b) y expresión de VEGF (ng/ml) (Fig. 1.2.c). El plásmido utilizado codifica para 
VEGF –extracelular- y para GFP –intracelular- y, por lo tanto, la evaluación de la 
expresión de VEGF se realizó mediante la técnica ELISA, mientras que la de GFP 
se realizó a través de la citometría de flujo. En cuanto al porcentaje de células que 
expresan GFP y al MFI, las eficiencias de transfección de todas las formulaciones 
fueron superiores en HEK193 en comparación con la línea C6. Sin embargo, en 
cuanto a la producción de VEGF, en ambas líneas celulares se obtuvieron niveles 
parecidos tras la transfección. Se ha descrito que la eficiencia de transfección con 
vectores no-virales depende del tipo celular49, lo cual coincide con nuestros 
resultados ya que en HEK293 los lipoplexos fueron los más eficientes, mientras que 
en C6 lo fueron los magnetoplexos. Los poliplexos no alcanzaron niveles elevados 
en ningún tipo celular, probablemente debido a su carga superficial cercana al cero, 





Figura 1.2. Viabilidad celular y eficiencia 
de transfección en células HEK293 y C6 
48 h después de la transfección con 
nanoplexos. (a) Viabilidad celular 
(HEK293, puntos gris oscuro; C6, puntos 
gris claro) y porcentajes de células que 
expresan GFP (HEK293, barras gris 
oscuro; C6, barras gris claro). Las 
células control un fueron tratadas con 
ninguna formulación. Cada valor 
representa el promedio ± SD, n = 3. (b) 
Valores de MFI. (HEK293, barras gris 
oscuro; C6, barras gris claro). Cada valor 
representa el promedio ± SD, n = 3. (c) 
Producción de VEGF (ng/ml). (HEK293, 
barras gris oscuro; C6, barras gris claro). 
Cada valor representa el promedio ± SD, 
n = 3. Significancia estadística: *p < 0,05, 
**p < 0,01, ***p < 0,001 respecto a las 
células HEK293 control; #p < 0,05, ##p < 
0,01, ###p < 0,001 respecto a células C6 
control.  
 
Se observó una clara correlación en ambas líneas celulares entre los tres 
parámetros utilizados para evaluar la eficiencia de transfección. Cuanto mayor era 
el porcentaje de células que expresa GFP, mayor era también el valor de MFI (Fig. 
1.3.a y 1.4.a). Asimismo, cuanto mayor era el porcentaje de células que expresa 
GFP, mayor era también la expresión de VEGF (Fig. 1.3.b y 1.4.b). Sin embargo, al 
comparar los ángulos de la pendiente de las correlaciones, se observó que estas 
eran más pronunciadas en las células C6 en comparación con HEK293. Es decir, la 
producción de VEGF alcanzó valores similares en ambos casos, pero la expresión 
de GFP fue inferior en C6. Estos datos pueden deberse a dos factores. Por un lado, 
las células C6 expresan un nivel basal de VEGF superior al de las células HEK293, 
por lo tanto, a pesar de presentar menor grado de transfección, se puede llegar más 
rápido a niveles elevados de VEGF. Por otro lado, la explicación puede residir en la 
naturaleza órgano-específica de la secuencia IRES del plásmido empleado. Esta 
secuencia se encarga de mantener a ambos genes bajo el mismo promotor, de 




independiente50,51. La secuencia IRES también debe garantizar que las dos 
proteínas se expresen en la misma proporción, pero eso es algo que no siempre 
ocurre. De hecho, algunas secuencias IRES funcionan mejor en unos órganos que 
en otros y es frecuente que no puedan garantizar una expresión equilibrada de 
ambas proteínas en células del SNC52, 53. Por lo tanto, teniendo en cuenta los datos 
obtenidos en este estudio, podemos deducir que la secuencia IRES no ha 
funcionado correctamente en las células C6 del SNC, viéndose afectada la 
expresión del gen que se encuentra después del elemento IRES en la secuencia del 
plásmido54. La expresión del VEGF, situada por delante del IRES en la secuencia 
del plásmido, no se vería afectada y eso explicaría la obtención de valores similares 
de VEGF en ambas líneas celulares.  
Figura 1.3. Correlaciones entre los tres parámetros 
utilizados para evaluar la eficiencia de transfección en 
células HEK293. (a) Correlación entre producción de VEGF 
y porcentaje de células transfectadas. Cada valor representa 
el promedio ± SD, n = 3. (b) Correlación entre producción de 
VEGF y valores de MFI. Cada valor representa el promedio 
± SD, n = 3. (c) Histogramas de GFP en células HEK293 48 
h después de la transfección. M1 indica el umbral de señal 
positiva de GFP. 
 
 
Figura 1.4. Correlaciones entre los tres parámetros 
utilizados para evaluar la eficiencia de transfección en 
células C6. (a) Correlación entre producción de VEGF y 
porcentaje de células transfectadas. Cada valor representa 
el promedio ± SD, n = 3. (b) Correlación entre producción de 
VEGF y valores de MFI. Cada valor representa el promedio 
± SD, n = 3. (c) Histogramas de GFP en células C6 48 h 
después de la transfección. M1 indica el umbral de señal 
positiva de GFP.  
 
Una vez analizada la capacidad de transfección de los nanoplexos en células 
HEK293 y C6, llevamos a cabo estudios de transfección en células de cultivo 




vista terapéutico. Las viabilidades celulares fueron excelentes (Fig. 1.5.a) en todos 
los casos, pero las eficiencias de transfección resultaron más bajas que en las 
anteriores líneas celulares, probablemente debido a la gran dificultad que supone la 
transfección en neuronas. La expresión de GFP se estudió mediante 
inunohistoquímica (Fig. 1.5.b) y se observaron algunas células dispersas que 
expresaban señal verde fluorescente. Esta baja señal de GFP refuerza la idea de la 
especificidad de tejido de la secuencia IRES del plásmido. En cuanto a la expresión 
de VEGF, observamos que había una producción basal de VEGF elevada en 
cultivos primarios de neuronas, probablemente atribuible a la presencia de células 
gliales encargadas de secretar factores angiogénicos y neurotróficos para mantener 
las células del SNC55, 56. A pesar de que los niveles de VEGF se vieron 
incrementados tras la transfección en todos los casos, sólo se pudieron detectar 
diferencias estadísticamente significativas respecto al control en el caso de los 
magnetoplexos (Fig. 1.5.c). A continuación, evaluamos la bioactividad de la proteína 
VEGF secretada por células transfectadas en células HUVEC, que responden con 
gran proliferación al efecto de esa proteína57, 58. Observamos que, en comparación 
con células control no tratadas con VEGF, las tratadas con VEGF secretado por 
células transfecadas con nanoplexos respondieron con elevada proliferación a su 
efecto. Además, este incremento en la proliferación fue proporcional a la cantidad 
de VEGF presente en el sobrenadante celular (Fig. 1.5.c).  
Figura 1.5. Viabilidad celular y 
eficiencia de transfección en células 
de cultivo primario de neurona y 
bioactividad de la proteína VEGF 
secretada por células 
transfectadas. (a) Viabilidad celular 
48 h después de la transfección. 
Cada valor representa el promedio 
± SD, n = 3. (b) Imágenes de 
inmunohistoquímica donde se 
observa señal de GFP (verde). Azul: 
Hoescht (núcleos celulares). 
Escala: 25 µm. (c) Producción de 
VEGF (ng/ml) por células de cultivos primario de neurona 48 h después de la transfección. 
Las células control no fueron tratadas con nanoplexos. Cada valor representa el promedio ± 
SD, n = 3. (d) Proliferación de células HUVEC en respuesta a la proteína VEGF secretada 
por células transfectadas. Las células control no fueron tratadas con VEGF. Cada valor 
representa el promedio ± SD, n = 3. Significancia estadística: *p < 0,05, **p < 0,01, ***p < 




Tomando en cuenta los resultados de este trabajo, podemos decir que los vectores 
no-virales estudiados y, en particular, los magnetoplexos pueden ser adecuados 
para transportar el gen terapéutico VEGF a células del SNC de forma segura y 
eficaz, lo cual coincide con trabajos anteriores17. La estrecha relación descrita entre 
alteraciones vasculares en SNC y procesos neurodegenerativos40, junto con efectos 
beneficiosos descritos en modelos animales de Alzheimer y Parkinson tras la 
administración del factor VEGF57, 59, sugieren que el gen de VEGF puede ser un 
candidato terapéutico apropiado para tratar alteraciones del SNC. Además, en 
comparación con la liberación de fármacos, la liberación de genes presenta varias 
ventajas, como la posibilidad de administrar menos dosis y conseguir un efecto 
terapéutico duradero. La administración de vectores no-virales al SNC in vivo 
supone un gran reto todavía, ya que la mayoría de las veces es necesario recurrir a 
vías de administración muy invasivas que no tendrían cabida en la aplicación clínica. 
Sin embargo, se han hecho algunos avances en la búsqueda de vías no-invasivas 
para vehiculizar genes al SNC, y uno de los más prometedores es el uso de la vía 
intranasal. Un estudio reciente ha demostrado que se pueden transfectar células del 
SNC de rata a través de la administración intranasal de vectores no-virales60. Por lo 
tanto, creemos que sería interesante explorar esta vía no-invasiva en el campo de 
la terapia génica no-viral del SNC.  
2. El rol del tensioactivo no-iónico de las formulaciones de niosomas en 
su eficiencia y proceso de transfección en retina de rata 
Existen varias enfermedades retinianas monogénicas bien caracterizadas, con 
mutaciones identificadas que en la mayoría de los casos afectan a genes 
específicos en las células del epitelio pigmentario (RPE) de la retina61. Las células 
RPE desempeñan funciones esenciales para el mantenimiento y correcto 
funcionamiento de retina neural, entre otras, protegen las células fotorreceptoras 
mediante la secreción de factores de crecimiento62. En varias enfermedades 
retinianas como, por ejemplo, la amaurosis congénita de Leber (LCA), la retinitis 
pigmentosa (RP) y la degeneración macular relacionada con la edad (AMD), la 
ceguera ocurre debido a la degeneración de las células RPE, lo cual lleva a pérdida 
o disfunción de las células fotorreceptoras61. Por lo tanto, las células RPE 
constituyen la principal diana en la mayoría de estrategias de terapia génica en ojo, 
y el éxito de estas estrategias depende de la capacidad de alcanzar niveles 





Los vectores no-virales poseen gran potencial para transferir genes terapéuticos 
específicos a células de la retina. Los denominados niosomas ya se han utilizado 
de manera eficaz para transfectar células retinianas tanto in vitro como in vivo, y la 
influencia de dos de sus componentes –el lípido catiónico y el lípido helper- ha sido 
estudiado en profundidad26, 63. Sin embargo, aún queda un importante margen de 
mejora para la transferencia génica en retina mediante el uso de niosomas y, para 
ello, es necesario investigar el rol que desempeña en la eficiencia de transfección 
su tercer componente, es decir, el tensioactivo no-iónico. Hasta la fecha, la mayoría 
de niosomas utilizados para transferir genes al ojo contenían el polisorbato 80 como 
tensioactivo no-iónico, pero no se han explorado otras opciones como el polisorbato 
20 o el 85. Por tanto, en este trabajo elaboramos y caracterizamos, en cuanto a las 
propiedades físico-químicas y capacidad de transfección en células de la retina- tres 
formulaciones de niosomas que sólo diferían en el componente del tensioactivo no-
iónico. Los niosomas utilizados contenían en su composición el lípido catiónico 
DOTMA, el lípido helper escualeno y uno de los siguientes tensioactivos no-iónicos: 
polisorbato 20, 80 o 85. Los niosomas se denominaron, según su composición, 
DST20, DST80 y DST85 (Figura 2.1.).  
Los tensioactivos no-iónicoa actúan como agentes emulsificadores en los niosomas, 
creando una barrera estérica que evita la agregación de las partículas22. Los tres 
polisorbatos utilizados comparten la misma estructura química básica, pero difieren 
en sus partes hidrófilas y en el número de grupos hidroxilo, difiriendo por tanto 
también en su balance hidrófilo-lipófilo (HLB) (Figura 2.1.). El parámetro HLB 
determina la liposolubilidad (HLB < 9) o hidrosolubilidad (HLB > 11) de los 
compuestos64. Entre los tres polisorbatos estudiados en este trabajo, el polisorbato 
20 es el más hidrófilo, debido a la presencia de dos grupos hidroxilo y un ácido 
láurico, con un valor de HLB de 16,7. Le sigue en polisorbato 80 (HLB = 15), y el 
polisorbato 85 es el menos hidrófilo debido a la presencia de tres ácidos oleicos en 





Figura 2.1. Esquema general de los niosomas y estructura química de sus componentes.  
Los parámetros físico-químicos de las formulaciones son factores clave que 
determinan la eficiencia de trasnfección de los niosomas. Las formulaciones DST20, 
DST80 y DST85 presentaron un tamaño medio de partículas entre 100 y 225 nm 
(Fig. 2.2.A, barras), lo cual es apropiado para la liberación génica65. Las pequeñas 
oscilaciones en el tamaño de las partículas tras la adición del plásmido en ratios 
peso/peso de lípido catiónico/ ADN 2/1, 5/1 y 10/1 se debieron probablemente a un 
balance entre el mayor espacio requerido por el lípido y la mayor condensación de 
ADN a mayores ratios26. En todas las condiciones, las partículas mostraros 
distribuciones de tamaño estrechas tal y como indican los bajos valores de PDI (Fig. 
2.2.B). La carga superficial de las partículas tiene un impacto en la estabilidad de 
las formulaciones, y valores de potencial zeta entre – 30 mV y + 30 mV se han 
relacionado con una mayor propensidad para formar agregados46. Por otro lado, las 
cargas superficiales positivas facilitan la captación celular y permiten la formación 
de complejos con las moléculas de ADN de carga negativa a través de interacciones 
electrostáticas45. Los tres niosomas presentarion valores de potencial zeta 
superiores a + 40 mV (Fig. 2.2.A, líneas). Como era de esperar, al añadir el ADN 
estos valores descendieron, lo cual demuestra la interacción entre los grupos amina 
del lípido catiónico y los grupos fosfato del ADN, que neutraliza parcialmente la 
carga superficial66. Para determinar la morfología de las partículas, los niosomas se 
examinaron bajo el microscopio TEM y se pudo observar que todas presentaron 
forma esférica (Fig. 2.2.C-E). la habilidad de los nioplexos para proteger y liberar el 
plásmido se analizó mediante electroforesis en gel de agarosa (Fig. 2.2.F). Las 




proteger el ADN frente a la degradación enzimática, incluso al ratio más bajo (2/1). 
La excepción fue quizá el DST80, que no pudo proteger en su totalidad al ADN 
frente a la acción de la DNase I. sin embargo, teniendo en cuenta que el objetivo de 
este trabajo era encontrar formulaciones más eficientes para la transfección en 
retina in vivo, seleccionamos el ratio 2/1 en todas las formulaciones, ya que permite 
incrementar la dosis de ADN a administrar sin aumentar el volumen total de la 
formulación. Esto puede incrementar la eficiencia de transfección y, además, reduce 
notablemente la toxicidad celular asociada a los lípidos catiónicos67.  
Figura 2.2. Caracterización físico-química de los niosomas DST20, DST80, DST85 y sus 
correspondientes nioplexos utilizando ratios peso/peso de lípido catiónico/ ADN 2/1, 5/1 y 
10/1. (A) Los valores de tamaño se representan con barras y el potencial zeta con puntos. 




promedio ± SD, n = 3. (C-E) Imágenes de TEM de las partículas. Escala: 200 nm. (C) DST20, 
magnificación x20.000; (D) DST80, magnificación x20.0000 y (E) DST85, magnificación 
x40.000. (F) Electroforesis en gel de agarosa para analizar la habilidad de los nioplexos de 
proteger y liberar el plásmido pCMS-EGFP. La enzima DNase I y el SDS se añadieron en las 
columnas 2-11. Columnas: 1-2, ADN desnudo; 3-5, nioplexos DST20, ratios 2/1, 5/1 y 10/1; 
6-8, DST80, ratios 2/1, 5/1 y 10/1; 9-11, DST85, ratios 2/1, 5/1 y 10/1. OC: forma circular 
abierta del ADN. SC: forma supercompacta del ADN.  
Una vez las formulaciones totalmente caracterizadas, se llevaron a cabo estudios 
de transfección in vitro –utilizando el ratio 2/1 en todos los casos- en las líneas 
celulares HEK293 –como modelo de transfección general- y ARPE19 –como 
modelo celular de la retina-. En ambos tipos celulares los nioplexos mostraron 
viabilidades celulares excelentes, superiores a 95% en HEK293 (Fig. 2.A1) y 
superiores a 85% en ARPE19 (Fig. 2B1), lo cual demuestra que fueron bien 
tolerados por las células. Esto también se corroboró por la sana apariencia de las 
células transfectadas en ambas líneas, 48 h después de la transfección (Fig. 2.3.A2 
y B2). Por el contrario, las células ARPE19 transfectadas con el control positivo 
Lipofectamine 2000TM exhibieron una baja viabilidad celular de alrededor del 55%, 
lo cual es consistente con estudios anteriores que afirman que este compuesto 
produce gran citotoxicidad en células de retina incluso a bajas concentraciones68. 
En cuanto a la eficiencia de transfección, la formulación DST85 fue la más eficaz en 
las células HEK293 (Fig. 2.A1), mientras que en ARPE19 la formulación con mayor 
eficiencia de trasnfección fue DST20 (Fig. 2.B1). En general, se considera que las 
formulaciones con valores bajos de HLB y mayor liposolubilidad suelen captarse de 
manera más fácil por las células69, 70. Esto concuerda con los datos obtenidos en 
HEK293, ya que el polisorbato 85 es el que presenta un HLB más bajo entre los 
tensioactivos testados. Sin embargo, en ARPE19 ocurre lo contrario, puesto el 
polisorbato 20 es el más hidófilo entre los tres, lo cual nos llevó a pensar que otros 
mecanismos dependientes del tipo celular podría desempeñar un papel importante 
a la hora de determinar la eficiencia de transfección de los nioplexos, por ejemplo, 




Figura 2.3. Eficiencia de transfección en HEK293 y ARPE19, 48 h después de la transfección 
con los nioplexos DST20, DST80 y DST85. (A1) Eficiencia de transfección en la línea celular 
HEK293. (A2) Imagen representativa de microscopio de fluorescencia donde se observa señal 
de EGFP en células HEK293 transfectadas con los nioplexos DST85. Magnificación x20. (B1) 
Eficiencia de transfección en la línea celular ARPE19. (B2) Imagen representativa de 
microscopio de fluorescencia donde se observa señal de EGFP en células ARPE19 
transfectadas con los nioplexos DST20. Magnificación x20. Escala: 100 nm. Cada valor 
representa el promedio ± SD, n = 3. Significancia estadística: *p < 0,05, **p < 0,01, ***p < 
0,001.  
En ese sentido, con el fin de entender el proceso de transfección con los nioplexos 
DST20, DST80 y DST85 en células ARPE19, analizamos los mecanismos de 
internalización celular y las rutas endocíticas que tomaron las formulaciones. Los 
vectores no-virales suelen internalizarse en las células a través de la endocitosis, 
siendo la endocitosis mediada por clatrinas o CME y la mediada por caveolas o 
CvME las más utilizadas71. La ruta CvME es considerada no-acídica y no-dogestiva, 
mientras que las vesículas endocíticas formadas en la ruta CME suelen fusionarse 
con los lisosomas72, 73. Sin embargo, existe cierta controversia en este sentido ya 
que algunos autores afirman que las vesículas de la ruta CvME o caveosomas 
también se fusionan con los lisosomas en ciertos casos74, 75. Además, tampoco está 
claro si la fusión con el lisosoma favorece o no la transfección. Según algunos 
investigadores, la fusión con el lisosoma permite que el ADN se libere del vector, 
facilitando así su llegada al núcleo y, por tanto, favoreciendo la eficiencia de 
transfección76, 77. Por el contrario, otros autores sostienen que la fusión con el 




transferencia génica78. En nuestro estudio, observamos que los nioplexos que 
entraban predominantemente por la vía CvME co-localizaban menos con el 
lisosoma y su eficiencia de transfección era mayor, como es el caso de la 
formulación DST20 (Figura 2.4.). En cambio, las formulaciones que entraban 
predominantemente a través de la ruta CME en las células, co-localizaban más con 
el lisosoma y la eficiencia de transfección era menor, como es el caso de los 
nioplexos DST85. Por lo tanto, nuestro estudio coincide con la hipótesis de 
degradación en el lisosoma, ya que parece que las formulaciones que evitan el 
compartimento lisosomal son las que mayor eficiencia de transfección obtienen. En 
cuanto a la formulación DST80, no observamos co-localización con ninguna de las 
dos rutas estudiadas, lo cual indicaría que puede usar otras vías como la 
macropinocitosis para entrar en las células. De hecho, un estudio reciente de 
liberación génica en células de la retina concluyó que los vectores no-virales 
lipídicos que contenían polisorbato 80 entraban predominantemente vía 
macropinocitosis en las células13.  
 
Figura 2.4. Rutas endocíticas y de tráfico intracelular de los nioplexos DST20, DST80 y 
DST85 en células ARPE19. (A1-3) Imágenes de microscopía confocal donde se observa co-
localización entre los nioplexos que contienen el plásmido marcado con FITC (verde) y las 
rutas endocíticas (rojo). AlexaFluor546-Transferrin (CME), AlexaFluor555-CholeraToxin 
(CvME) y Lysotracker (lisosomas). (B1-3) Valores de co-localización entre la señal verde y 




= 3. (C1-3) Representaciones 3D que relacionan el valor de HLB, la eficiencia de transfección 
y la co-localización con los compartimentos intracelulares.  
Basándonos en esos resultados, seleccionamos la formulación DST20 para realizar 
ensayos de transfección en retina in vivo. En primer lugar, llevamos a cabo un 
ensayo de transfección en cultivo primario de retina para validar la funcionalidad de 
los nioplexos y observamos una elevada señal de EGFP y células de apariencia 
sana (Figura 2.5.). Animados por estos resultados, administramos los nioplexos 
DST20 en retina de rata a través de inyecciones intravítreas (IV) (Figura 2.6.D-E) y 
subretinianas (SR) (Figura 2.6.B-C). En la mayoría de casos, la inyección IV permite 
transfectar células de la capa ganglionar de la retina, mientras que con las 
inyecciones SR, a pesar de ser más invasivas, es posible llegar a la capa de células 
RPE, las más interesantes desde el punto de vista terapéutico68, 79. En 
concordancia, nuestro estudió demostró que fuimos capaces de transfectar células 
de la capa ganglionar a través de las inyecciones IV, mientras que con las 
inyecciones SR conseguimos ver transfección también en la capa RPE. 
Desafortunadamente, la inyección SR es altamente invasiva y conlleva riesgo de 
inflamación, daño en las lentes e incluso desprendimiento de la retina80. Por lo tanto, 
no es aplicable en la práctica clínica y sería conveniente explorar nuevas de 
administración no-invasivas para transfectar células de la retina. En este sentido, se 
han hecho grandes avances en la liberación de fármacos, ya que recientemente se 
ha conseguido que un medicamento administrado de manera tópica en el ojo llegara 
a la parte posterior de la retina81. Este tipo de administración no implicaría riesgo 
alguno para el paciente y sería el ideal también para las formulaciones no-virales de 
terapia génica.  
Figura 2.5. Expresión de la proteína 
EGFP en cultivo primario de células 
embrionarias de retina, analizada a 
través de inmunocitoquímica 96 h 
después de la transfección. (A) 
Expresión de EGFP tras transfectar 
con nioplexos DST20. (B) Expresión 
de EGFP tras transfectar con el 
control positivo Lipofectamine 
2000TM. Rojo: MAP2 (marcador de dendritas neuronales); azul: Hoescht (núcelos celulares); 




Figura 2.6. Expresión de EGFP en 
retina de rata in vivo tras inyecciones 
IV y SR. (A) Esquema general de las 
inyecciones IV y SR. (B) Micrografías 
de microscopía confocal de 
secciones de retina en la que se 
observa señal de EGFP tras la 
administración SR de nioplexos 
DST20. (C) Micrografías de 
microscopía confocal de secciones 
de retina en la que se observa señal 
de EGFP tras la administración SR 
de Lipofectamine 2000TM. (D) 
Inmunohistoquímica de 
fluorescencia en la que se observa 
señal de EGFP tras la administración 
IV de nioplexos DST20. (E) 
Inmunohistoquímica de 
fluorescencia en la que se observa 
señal de EGFP tras la administración 
IV de Lipofectamine 2000TM. Azul: 
Hoescht (núcelos celulares); verde: 
EGFP. Escala: 20 µm. RPE (epitelio 
pigmentario de la retina), ONL 
(capas nucleares exteriores de la 
retina); INL (capas nucleares 
interiores de la retina); GCL (capa de 
células ganglionares de la retina).  
 
En conclusión, hemos elaborado y caracterizado tres formulaciones de niosomas 
que únicamente diferían en su componente de tensioactivo no-iónico. Descubrimos 
que la formulación DST20, compuesta por DOTMA, escualeno y polisorbato 20, 
presentó alta eficiencia de transfección en células de la retina tanto in vitro como in 
vivo. Las células trasfectadas in vivo dependieron claramente de la vía de 
administración, ya que se llegó a la capa ganglionar a través de las inyecciones IV 
y a hasta la capa RPE a través de inyecciones SR. Gracias s los avances en 
ingeniería de vectores y de ADN, esperamos que en un futuro próximo estas 
formulaciones puedan ser administradas a través de vías no invasivas para la 




3. La influencia del material genético de las formulaciones de niosomas 
en su eficiencia de transfección en retina de rata 
Además de la optimización de la formulación discutida en la sección anterior, la 
optimización del propio material genético es también necesaria en terapia génica 
no-viral. Hasta la fecha se han investigado varios elementos de los plásmidos para 
incrementar o prolongar la expresión génica como, por ejemplo, la secuencia del 
promotor, los motivos CpG, las señales de poliadenilación o las secuencias 
potenciadoras82-86. Sin embargo, los plásmidos también contienen una base 
bacteriana que consiste en las secuencias procariotas de origen de replicación y los 
genes de resistencia a antibióticos. Esas secuencias son esenciales para poder 
propagar los plásmidos de ADN en huéspedes bacterianos en el laboratorio, pero 
se han relacionado recientemente con respuestas inflamatorias, baja 
biocompatibilidad y reducción de la expresión génica. Por lo tanto, unidades 
mínimas de expresión génica como la estructura MC han surgido como alternativas 
prometedoras a los plásmidos convencionales. Los MC son secuencias de ADN 
circulares mínimas que a las que se les han eliminado las secuencias bacterianas y 
que únicamente contienen el gen de interés y las secuencias reguladoras. Por lo 
tanto, los MC pueden contener el mismo casete de expresión que sus plásmidos 
parentales, pero presentan un tamaño menor (Figura 3.1.). Gracias a su mayor 
biocompatibilidad, su uso permite una expresión génica más elevada y duradera, 
así como un mejor perfil de seguridad in vivo87-92. Distintos estudios han demostrado 
una mejora de la expresión génica utilizando la tecnología MC en diversos órganos, 
incluyendo el hígado93-95, el corazón96, 97 y el músculo esquelético97, pero su 
aplicación en transferencia génica en retina y mediada por niosomas no ha sido aún 
estudiada.  
 
Figura 3.1. Composición del material genético. (A) pEGFP 5,5 kb, (B) pGFP 3,3 kb, (C) MC-
GFP 2,3 kb. MC: minicircle: GFP: proteína verde fluorescente; EGFP: proteína verde 
fluorescente potenciada; pCMS: plásmido que contiene el promotor del citomegalovirus, una 
región de clonaje múltiple y el promotor SV40; pCMV: plásmido con promotor de 




Por lo tanto, el objetivo de este estudio fue proporcionar la primera evidencia de la 
eficiencia de transfección en retina con la tecnología MC combinada con los 
niosomas y compararla con la eficiencia de transfección de los plásmidos 
convencionales. Para ello, empleamos la formulación DST20, ya estudiada en el 
capítulo anterior, debido a su alta eficiencia de transfección en retina. Para formar 
los distintos nioplexos, unimos la formulación DST20 a tres tipos de material 
genético, dos plásmidos de distinto tamaño (pEGFP y pGFP) y un MC. Los 
niosomas y nioplexos fueron caracterizados en términos de tamaño de partícula, 
potencial zeta, PDI, morfología, estabilidad y habilidad de interacción con los 
distintos materiales genéticos. La capacidad de las formulaciones de proteger y 
liberar el material genético se estudió mediante electroforesis en geles de agarosa. 
Se llevaron a cabo estudios in vitro para evaluar la eficiencia de transfección y la 
viabilidad celular en la línea celular ARPE19. También se evaluó y comparó la 
eficiencia de transfección de las distintas formulaciones en cultivo primario de retina 
y en ensayos in vivo tras administraciones IV y SR.  
Los niosomas DST20 presentaron morfología esférica y tamaños de partículas en 
el rango nanométrico, ambos apropiados para la terapia génica. Además, exhibieron 
valores bajos de PDI que indican gran homogeneidad en el tamaño, y potenciales 
zeta positivos, necesarios para la interacción electrostática con las moléculas de 
ADN de carga negativa45, 98, 99. Como era de esperar, al añadir el material genético 
el diámetro original de las partículas se vio incrementado, mientras que el potencial 
zeta se redujo debido a la parcial neutralización de las cargas por la interacción de 
los grupos amina del lípido catiónico y los grupos fosfato de las moléculas de ADN 
(Figura 3.2.A-B).  
Los distintos materiales genéticos no alteraron las propiedades físico-químicas de 
las formulaciones, ya que los tres nioplexos presentaron características similares en 
cuanto al tamaño, la carga o el PDI, lo cual coincide con otros estudios100. Sin 
embargo, la eficiencia de transfección sí que varía de un material genético a otro, 
cuya explicación puede deberse a dos factores. Por un lado, la magnitud del 
incremento del incremento del tamaño de las partículas al añadir el ADN descarta 
la posibilidad de la agregación entre nioplexos. Por tanto, los eventos de unión entre 
niosoma y ADN a ratios peso/peso de lípido catiónico/ADN superiores conlleva 
probablemente la reorganización del material genético previamente unido, lo que 
resultaría en menos moléculas de ADN unidas por cada partícula de niosoma. Esto 
también afectaría a la capacidad de los niosomas de interaccionar con la membrana 




este estudio se llevó a cabo con una cantidad constante de ADN de 1,25 µg por 
condición, pero también deben considerarse otros factores como la longitud, el peso 
y la molaridad de cada tipo de material genético estudiado, ya que esos factores 
también afectaría a la cantidad de moléculas de ADN unidas a cada partícula de 
niosoma. Este hecho se observó en el ensayo ITC donde se obtuvieron diferentes 
curvas calorimétricas con cada nioplexo (Figura 3.2.D). Por tanto, las partículas de 
niosomas incorporarían mayor cantidad de moléculas MC que de plásmidos, lo que 
significa una mayor tasa de casetes de expresión por niosoma, incrementando así 
la probabilidad de transfección de los niosomas que vectorizan moléculas MC92, 101.  
Figura 3.2. Caracterización físico-química y estudios de estabilidad de niosomas y nioplexos. 
(A) caracterización físico-química de niosomas y nioplexos a día 0 y a día 30 tras ser 
almacenados a 4°C y a 25°C. Cada valor representa el promedio ± SD, n = 3. (B) Imágenes 
de niosomas DST20 a día 0 (i), día 30 almacenados a 4°C (ii) y día 30 almacenados a 25°C. 




electroforesis en gel de agarosa para analizar la capacidad de proteger y liberar el ADN de 
los niosomas a día 0 (i), día 30 almacenado a 4°C (ii) y día 30 almacenado a 25°C (iii). Se 
añadió DNase I y SDS en las columnas 3, 6 y para evaluar la protección y liberación de MC-
GFP, pGFP y pEGFP, respectivamente. Las columnas 1, 4 y 7 corresponden al control no 
unido a niosomas de cada material genético. Las columnas 2, 5 8 continen cada material 
genético no unido a niosomas a los que se les ha añadido el enzima DNase I. (D) Estudio 
ITC con niosomas DST20 y los tres tipos de material genético. Variación de calor evoluciona 
por mg de DOTMA inyectado vs. el ratio de DOTMA/ADN expresado en mg/ml. Los símbolos 
representan los datos experimentales, mientras que las líneas discontinuas representan la 
tendencia de los perfiles ITC.  
Las diferencias observadas en la expresión de GFP tras el almacenamiento durante 
30 días a 4°C y a 25°C (Figura 3.3.) pueden explicarse por un cúmulo de factores. 
De hecho, la eficiencia de transfección de los niosomas puede verse afectada por 
variaciones en distintos parámetros como el tamaño de las partículas, su potencial 
zeta, su morfología o su afinidad por el ADN102. En este sentido, las imágenes de 
TEM demostraron una pérdida de la morfología esférica transcurridos 30 días e 
incluso cierta agregación de partículas (Figura 3.2.C), lo cual dificultaría las 
interacciones con el ADN. En realidad, esto fue confirmado por los ensayos de ITC 
y de electroforesis, ya que tanto la capacidad de interacción con las moléculas de 
ADN como la habilidad de protección frente a la degradación enzimática se vieron 
afectadas por el transcurso del tiempo. A pesar de que los nioplexos que contenían 
MC a día 30 presentaron eficiencias de transfección superiores que los nioplexos 
que contenían plásmido a día 0 (Figura 3.3.), se requieren mayores esfuerzos para 
desarrollar formulaciones más estables, ya sea mediante la utilización de métodos 









Figura 3.3. Eficiencia de transfección 
y viabilidad celular en ARPE19. 
Evaluación por citometría de flujo de 
células vivas que expresan la 
proteína GFP (barras) y del 
porcentaje de viabilidad celular 
puntos) utilizando nioplexos unidos a 
cada tipo de material genético (A) a 
día 0 y (B) a día 30 almacenados a 
4°C y a 25°C. Los datos se presentan 
como promedio ± SD, n = 3. *P < 0,05 
para grupos de eficiencia de 
transfección y #P < 0,05 para grupos 
de viabilidad celular, respecto a su 
correspondiente control positivo con 
Lipofectamine 2000TM; ns: ausencia 
de diferencias estadísticamente 
significativas.  
Dado que las vías de administración IV y SR son hoy en día las más viables para 
liberar genes terapéuticos en retina103, los nioplexos unidos a los distintos tipos de 
material genético fueron inyectados a través de esas vías en rata in vivo. En 
concordancia con estudios anteriores, la inyección IV alcanzó predominantemente 
células de la capa ganglionar, mientras que a través de las inyecciones SR fue 
posible observar cierto nivel de transfección en la capa RPE. La transfección a ese 
nivel es la más relevante clínicamente, ya que la mayoría de enfermedades 
monogénicas retinianas que cursan con ceguera son causadas por mutaciones 
específicas de los genes de las células de esa capa104. El análisis cualitativo de la 
expresión de GFP in vivo demostró que, tanto en la inyección IV como en la SR, la 
mayor eficiencia de transfección se consiguió con los nioplexos que vectorizaban el 
MC (Figuras 3.5. y 3.6.), sugiriendo que esta tecnología podría tener gran potencial 
para transferir genes terapéuticos en retina. Es importante mencionar también que 
la ausencia de motivos CpG y secuencias bacterianas en la tecnología MC los hace 
más biocompatible, lo que facilitaría su uso en aplicaciones clínicas. Por otro lado, 
también se observó alta eficiencia de transfección con la formulación Lipofectamine 
2000TM utilizada como control positivo, pero su aplicación está limitada por su 
elevada citotoxicidad en células de la retina, incluso a bajas concentraciones. De 
hecho, en nuestro trabajo también hemos encontrado núcleos apoptóticos en 




Figura 3.4. Expresión de la proteína GFP 
en células de cultivo primario de retina 
transfectadas con nioplexos DST20 que 
vectorizan (A) MC-GFP, (B) pGFP o (C) 
pEGFP. Las imágenes (D-F) 
corresponden al control positivo de cada 
tipo de material genético utilizando 
Lipofectamine 2000TM. Azul: Hoescht 
(núcleos celulares), rojo: MAP2 (dendritas 
neuronales) y verde: GFP. Las fechas 
blancas indican núcleos apoptóticos. 
Escala: 20 µm.  
 
Figura 3.5. Expresión de la proteína GFP in vivo tras la administración IV de los nioplexos 
que vectorizan (A) MC-GFP, (B) pGFP o (C) pEGFP. Las imágenes (D-F) corresponden al 
control positivo de cada tipo de material genético utilizando Lipofectamine 2000TM. Azul: 




blancas indican núcleos apoptóticos. Escala: 20 µm. RPE (epitelio pigmentario de la retina); 
OS (segmentos externos); ONL (capas nucleares exteriores de la retina); INL (capas 




Figura 3.6. Expresión de la proteína GFP in vivo tras la administración SR de los nioplexos 
que vectorizan (A) MC-GFP, (B) pGFP o (C) pEGFP. Las imágenes (D-F) corresponden al 
control positivo de cada tipo de material genético utilizando Lipofectamine 2000TM. Azul: 
Hoescht (núcleos celulares), rojo: MAP2 (dendritas neuronales) y verde: GFP. Las fechas 
blancas indican núcleos apoptóticos. Escala: 20 µm. RPE (epitelio pigmentario de la retina); 
OS (segmentos externos); ONL (capas nucleares exteriores de la retina); INL (capas 




En conclusión, los principales hallazgos de este estudio son los siguientes: (i) los 
niosomas DST20 son capaces de proteger y liberar de forma adecuada los diferente 
tipos de material genético; (ii) la capacidad de los niosomas de proteger, liberar e 
interaccionar con el ADN se ve afectada con el transcurso del tiempo y la 
temperatura de almacenaje; (iii) los parámetros físico-químicos de los niosomas 
DST20 unidos a distintos materiales genéticos no varían, mientras que sí se 
observan diferencias en su eficiencia de transfección; (iv) los nioplexos DST20 que 
contienen MC presentan mayor eficiencia de tansfección que los que contienen 
plásmidos, in vitro, incluso después de 30 días de almacenaje; (v) los nioplexos son 
capaces de transferir material genético de forma eficaz tanto ex vivo en cultivo 
primario de retina como in vivo tras inyecciones IV y SR, y los que contienen MC 
presentan mayor eficiencia de transfección en todos los casos. Por lo tanto, 
consideramos que los niosomas DST20 unidos a MC representan un método 
eficiente y seguro para vehiculizar genes a la retina, y podría tener cabida en la 
aplicación clínica para transportar genes terapéuticos en distintas enfermedades 
retinianas.  
4. Aspectos tridimensionales de los sistemas no-virales de liberación 
génica: búsqueda de nuevas sinergias complementarias entre 
niosomas e hidrogeles de ácido hialurónico 
Además de la optimización del vector no-viral y del material genético discutidos en 
secciones anteriores, una nueva tendencia hoy en día es buscar nuevas sinergias 
entre sistemas de liberación génica no-viral e ingeniería tisular para mejorar la 
eficiencia de transfección. De hecho, estas estrategias combinadas pueden ofrecer 
varias ventajas, como una mayor estabilidad de los sistemas de liberación y una 
menor toxicidad. Además, el hecho de complementar la transferencia génica con el 
diseño de matrices tridimensionales permite llevar a cabo una liberación local y 
efectiva del ADN, lo que facilitaría su aplicabilidad clínica en el tratamiento de 
enfermedades como el cáncer o en la regeneración tisular35, 36. El ácido hialurónico 
(HA) es un glicosaminoglicano aniónico y constituye uno de los componentes 
principales de la matriz extracelular105. Su uso y estudio se ha incrementado en los 
últimos años debido a su biocompatibilidad y su capacidad de incorporar una amplia 
variedad de moléculas, incluyendo los ácidos nucleicos106.  
Por lo tanto, el objetivo principal de este trabajo fue desarrollar un sistema de 
liberación génica eficiente basado en la combinación de niosomas e hidrogeles de 




1, 2 y 3), con distinta composición de lípido catiónico, lípido helper y tensioactivo no-
iónico (Figura 4.1.). Unimos los niosomas al plásmido que codifica el gen de la 
luciferasa para obtener los correspondientes nioplexos. Los niosomas y nioplexos 
fueron caracterizados en cuanto al tamaño, potencial zeta, PDI y eficiencia de 
transfección de células mesenquimales de ratón (mMSC) en cultivos 2D. Los 
hidrogeles de HA que contenían los nioplexos fueron caracterizados atendiendo a 
sus propiedades biomecánicas, distribución de partículas y cinética de liberación de 
los nioplexos. También se evaluó la actividad de los nioplexos una vez liberados de 
los hidrogeles y su capacidad de transfectar células mMSC encapsuladas en 
hidrogeles en cultivos 3D.  
Figura 4.1. Esquema general de los niosomas catiónicos e hidrogeles de HA utilizados en 
este trabajo. (A) Lípidos catiónicos, lípidos helper y tensioactivos no-iónicos utilizados en este 
trabajo. (B) Modificación del HA para obtener hidrogeles de HA. (C) Esquema representativo 




A pesar de que altas concentraciones de complejos de ADN/vectores no-virales en 
hidrogeles han demostrado mayores eficiencias de transfección107, la introducción 
física de grandes cantidades de ADN no es tarea fácil dada su tendencia a formar 
agregados en los hidrogeles108. Entre la gran variedad de vectores no-virales, los 
formados por derivados del polímero poli(etileno imina) o PEI han demostrado alta 
eficiencia de transfección en hidrogeles tanto in vitro como in vivo109. Si embargo, 
su aplicabilidad clínica está limitada por la elevada citotoxicidad de los compuestos 
derivados del PEI110. En este sentido, los niosomas podrían ser una alternativa 
apropiada dada su alta compatibilidad con sistemas biológicos y su demostrada 
capacidad de transfección64. En este trabajo, además, las eficiencias de 
transfección obtenidas con los niosomas encapsulados fueron similares a las 
obtenidas con PEI en trabajos anteriores111, lo que indica que los niosomas pueden 
ser buenos candidatos para sustituir al PEI y evitar los problemas de toxicidad 
manteniendo la alta capacidad de transfección.  
Los tres niosomas utilizados en este trabajo diferían en su composición (Figura 4.1.) 
y los componentes fueron escogidos en base a los resultados de trabajos anteriores. 
Por ejemplo, las formulaciones con polisorbato 80 combinado con escualeno han 
demostrado ser eficaces en otros estudios26. También se ha demostrado 
recientemente que la incorporación de licopeno en formulaciones que contienen 
DOTMA y polisorbato 60 mejora su eficiencia de transfección24, y el Poloxamer 407 
es ampliamente utilizado para liberación de fármacos112. Por su parte, la cloroquina 
mejora la eficiencia de transfección in vitro e in vivo113. Por lo tanto, la selección de 
los componentes, su concentración y los ratios peso/peso de lípido catiónico/ADN 
utilizados en este trabajo se basó en estudios anteriores.  
Los tres niosomas presentaron valores de potencial zeta positivos (Figura 4.2.B), 
necesario para la interacción con las moléculas de ADN de carga negativa45, 66. 
Además, la carga superficial positiva facilita la captación celular de las partículas44. 
En comparación con las células control no tratadas, todas las formulaciones fueron 
capaces de transfectar células mMSC en cultivo 2D, pero las basadas en el niosoma 
1 fueron las que exhibieron mayor eficiencia de transfección (Figura 4.2.C). A pesar 
de que la formulación usada como control positivo –Lipofectamine 2000TM- fue la 
más eficaz, su aplicabilidad está limitada debido su citotoxicidad, por lo que 





Figura 4.2. Caracterización de los 
niosomas. (A) Tamaño (nm). (B) 
Potencial zeta. (C) Eficiencia de 
transfección a las 48 h en células 
mMSC utilzando niosomas 1, 2 y 3. 
C+: control positivo, células tratadas 
con Lipofectamine 2000TM. C-: control 
negativo, células no tratadas. Cada 
valor representa el promedio ± SD, n = 
3. RLU: Relative light units (expresión 
del transgen luciferasa). 
 
 
El uso de nioplexos a ratios bajos permite incrementar la dosis de ADN y reducir la 
toxicidad celular asociada a los lípidos catiónicos13. Además de usar los niosomas 
1 al ratio peso/peso lípido catiónico/ADN 2/1, para conseguir introducir cantidades 
terapéuticamente más relevantes en los hidrogeles, concentramos la formulación 
del niosoma de 1 mg/ml a 2 mg/ml. Las imágenes de TEM de la formulación 
concentrada muestran que ni el tamaño ni la morfología se vieron afectadas por el 
proceso de concentración y, como era de esperar, se observa mayor número de 
partículas en la muestra concentrada (Figura 4.3.B). Asimismo, la capacidad de 
transfección de células mMSC en cultivo 2D tampoco se vio afectada (Fig. 4.3.C), 
por lo que se decidió utilizar la formulación concentrada para los estudios en 
hidrogeles de HA.  
Figura 4.3. Caracterización de la formulación 
concentrada y no concentrada. (A-B) Imágenes de 
TEM de la formulación no concentrada (A) y 
concentrada (B). Magnificación: x10.000. Escala: 
500 nm. (C) Eficiencia de transfección a las 48 h en 
células mMSC. Cada valor representa el promedio ± 
SD, n = 3. RLU: Relative light units (expresión del 





Para obtener cantidades de ADN terapéuticamente relevantes114, evaluamos tres 
cantidades diferentes de nioplexos en los hidrogeles, obteniendo concentraciones 
finales de 0,055 µg/ml, 0,12 µg/ml y 0,2 µg/ml de ADN en los hidrogeles 2, 3 y 4, 
respectivamente. El hidrogel 1 no contenía nioplexos y fue utilizado como control 
negativo. Las distintas concentraciones de ADN en los hidrogeles pueden ocasionar 
diferencias en sus propiedades mecánicas, las cuales determinan en gran medida 
la eficiencia de transfección en los hidrogeles. Se ha descrito que los hidrogeles 
más rígidos (> 800 Pa) impiden la difusión celular, dificultando así que ocurra la 
transfección, mientras que los hidrogeles más blandos (200 – 260 Pa) facilitarían la 
difusión celular y, por tanto, la transfección108. La evaluación reológica de los 
hidrogeles reveló gran variabilidad en las propiedades mecánicas de los hidrogeles, 
siendo el hidrogel 3 el más rígido y el hidrogel 4 el más blando (Figura 4.4.A-B). en 
cuanto a la distribución de los nioplexos dentro de los hidrogeles, estos mostraron 
en su mayoría una distribución homogénea y sin agregados (Fig. 4.4.C-E). Aunque 
no se pudo utilizar para cultivar células en 3D debido a que no contenía medio 
celular en su composición, el hidrogel 4 presentó características muy favorables 
para aplicaciones in vivo, debido a su alta concentración de ADN, ausencia de 
excesiva rigidez y distribución homogénea de los nioplexos. Para aplicaciones de 
transfección celular en cultivos 3D de células mMSC, utilizamos los hidrogeles 2 y 
3. En general, estos resultados demuestran que los nioplexos pueden ser 
incorporados en hidrogeles de HA manteniendo sus propiedades mecánicas y sin 
crear agregados.  
Figura 4.4. Caracterización de los 
hidrogeles de HA con nioplexos. (A) 
Las propiedades mecánicas de los 
hidrogeles se evaluaron utilizando 
reometría en un rango de frecuencia 
de 0,1-10 rad/s y a una tensión 
constante de 0,1. (B) Promedio de 
medidas reológicas. (C-E) 
Distribución de los nioplexos en los 
hidrogeles 2, 3 y 4. Gel ID: 1, hidrogel 
control sin nioplexos; 2, 0,055 µg/ml 
ADN; 3, 0,12 µg/ml ADN; 4, 0,2 µg/ml 





Para determinar si los nioplexos mantenían su bioactividad una vez liberados del 
hidrogel, realizamos una transfección en cultivo 2D con nioplexos liberados de 
hidrogeles degradados con tripsina. Tal y como se observa en la Figura 4.5., a pesar 
de que la eficiencia de transfección se vio ligeramente reducida, los nioplexos 
seguían manteniendo su actividad y su capacidad de transfección. La disminución 
en la eficiencia era, de todos modos, de esperar, ya que la presencia de tripsina y 
otros productos procedentes de la degradación de los hidrogeles pueden interferir 
en el proceso de transfección109. 
 
Figura 4.5. Actividad biológica de los nioplexos liberados de hidrogeles de HA. 
Se postula que existen dos mecanismos principales que determinan la eficiencia de 
transfección en los hidrogeles: la cinética de liberación de los nioplexos y la tasa de 
infiltración celular en el hidrogel115. Los nioplexos liberados tras la degradación del 
hidrogel transfectarían las células de su alrededor, mientras que a medida que las 
células se infiltran en el hidrogel encontrarían nioplexos en su camino, que 
fagocitarían iniciando el proceso de transfección116, 117. En este sentido, se espera 
que los hidrogeles más blandos permitan una mayor infiltración celular y, por tanto, 
proporcionen una mayor eficiencia de transfección que los hidrogeles más 
rígidos115. Volviendo a la cinética de liberación, para su aplicación terapéutica 




permitan prolongar el efecto terapéutico. Precisamente, eso es lo que observamos 
en este trabajo, ya que la totalidad de los nioplexos es liberada del hidrogel en 7 
días en presencia de la enzima colagenasa y la cinética de liberación es algo más 
lenta en ausencia de esa enzima (Figura 4.6.A). Finalmente, estudiamos la 
capacidad de transfección de los nioplexos incorporados, junto con células mMSC, 
en hidrogeles de ácido hialurónico. Los resultados demostraron que las células 
difundieron en todos lo hidrogeles y, a pesar de ser el más rígido, la mayor eficiencia 
de transfección se obtuvo en el hidrogel 3, que también poseía mayor cantidad de 
ADN (Figura 4.6.B). Por lo tanto, esto sugiere que las cantidades elevadas de ADN 
compensan la excesiva rigidez del hidrogel en el proceso de transfección. Además, 
las viabilidades celulares fueron excelentes en todos los casos, lo cual indica que la 
presencia de los nioplexos en los hidrogeles no resulta tóxica para las células.  
Figura 4.6. (A) Cinética de liberación de los nioplexos de los hidrogeles de HA en presencia 
y ausencia de colagenasa I (Col I). (B) Eficiencia de transfección (barras) y viabilidad celular 
(puntos) en cultivos 3D en los hidrogeles 1, 2 y 3. Cada valor representa el promedio ± SD, n 
= 3. (C-E) Imágenes representativas de difusión celular en los hidrogeles 1, 2 y 3. Azul: DAPI 
(núcleos celulares), rojo: F-actina (citoplasma). Escala: 200 µm.  
En conclusión, desarrollamos con éxito un método para incorporar formulaciones 
concentradas de niosomas en hidrogeles de HA. En general, los hidrogeles de HA 
que contenían nioplexos presentaron propiedades mecánicas adecuadas, una 
distribución de partículas homogénea y sin agregados, cinéticas de liberación de 
nioplexos adecuadas, permitieron gran difusión celular y fueron capaces de 




que el conocimiento adquirido a través de este modelo in vitro puede ser utilizado 
para diseñar sistemas de liberación génica no-viral, local y eficiente para 
aplicaciones in vivo.  
Para terminar, esta tesis doctoral, en su totalidad, describe y explora los factores 
clave que determinan la eficiencia de transfección y que se deben tener en cuenta 
a la hora de diseñar sistemas no-virales de liberación génica. Estos aspectos clave 
incluyen la composición y las propiedades físico-químicas de los vectores no-virales, 
la composición y conformación del material genético y la búsqueda de sinergias 
complementarias con otras tecnologías como la ingeniería tisular. En nuestra 
opinión, el concepto del vector no-viral único y universal ha quedado obsoleto, y 
debemos trabajar en el diseño de partículas multifuncionales específicamente 
adaptadas para cada aplicación. Gracias a los continuos avances para prolongar e 
incrementar la expresión de genes terapéuticos en sistemas de liberación génica 
no-viral, junto con los estudios realizados sobre la administración a través de vías 
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1. The three different commercial non-viral vectors based on cationic lipids, 
polymers and magnetic nanoparticles presented similar physicochemical 
characteristics and ability to condense and protect plasmid DNA. Although the 
three were able to transfect central nervous system cells and the VEGF 
produced by transfected cells was active in all cases, magnetoplexes presented 
the highest transfection efficiencies in terms of both EGFP expression and VEGF 
production.  
 
2. The evaluation of niosome formulations that only differed in the non-ionic 
tensioactive component showed that the incorporation of polysorbate 20 
enhanced retinal gene delivery both in vitro and in vivo at the low cationic 
lipid/DNA mass ratio 2/1. The different chemical structures and HLB values of 
polysorbates 20, 80 and 85 seem to determine the ability of nioplexes to enter 
the cells, follow a particular endocytic pathway and deliver the DNA cargo into 
the nucleus. In vivo, targeted cells strongly depended on the administration 
route. Subretinal injection transfected the inner layers of the retina and showed 
clear diffusion to outer layers including the retinal pigment epithelium, while 
intravitreal injection transfected predominantly the ganglion cell layer.  
 
3. The comparative study between different genetic material in nioplexes, varying 
in terms of size and composition, revealed that formulations containing different 
types of DNA molecules maintained similar physicochemical characteristics but 
differed in transfection efficiency. Niosomes carrying minicircle DNA were more 
efficient than the ones carrying DNA plasmids for retinal transfection both in vitro 
and in vivo, regardless of the administration route.  
 
4. The investigation of new combinations between delivery systems and tissue-
engineered scaffolds demonstrated that niosome formulations composed of 2,3-
di(tetradecyloxy)propan-1-amine, Poloxamer 407, polysorbate 80 and 
chloroquine diphosphate salt can be successfully incorporated into hyaluronic 
acid hydrogels for non-viral gene delivery. Hyaluronic acid hydrogel scaffolds 
loaded with nioplexes presented suitable mechanical properties, little or no 
particle aggregation, allowed for extensive cell spreading and were able to 








1. Hiru bektore ez-biral komertzialek –lipoplexoak, poliplexoak eta 
magnetoplexoak- ezaugarri fisiko-kimiko antzekoak eta DNA eusteko, 
babesteko eta askatzeko pareko gaitasuna erakutsi zituzten. Gainera, hiru 
formulazioak gai izan ziren nerbio sistema zentraleko zeluletara VEGF genea 
garraiatzeko eta genea jasotako zelulek ekoiztutako VEGF proteinak aktibitate 
biologikoa zuela baieztatu zen. Hala ere, magnetoplexoak izan ziren transfekzio-
maila altuenak lortu zituzten bektore ez-biralak, bai EGFP espresioari eta baita 
VEGF proteinaren ekoizpenari dagokionean ere.  
 
2. Niosoma formulazioetako tentsoaktibo ez-ionikoek transfekzio prozesuan 
jokatzen duten paperaren ebaluazioan ikusi zenez, Tween 20 zeramaten 
formulazioekin lortu ziren transfekzio-mailarik altuenak erretinako zeluletan in 
vitro zein in vivo. Dirudienez, surfaktante ez-ionikoen ezaugarri kimiko eta HLB 
balio ezberdinek nioplexoen zelulan sartzeko eta zelulaz barneko bide bat edo 
bestea jarraitzeko gaitasunean eragiten dute eta horrek guztiak, aldi berean, 
formulazioaren transfekzio efizientzian eragiten du. In vivo entseguetan ikusi 
zenez, eman-bidearen arabera erretinako zelula-geruza ezberdinetara iristea 
lortzen da. Erretina-azpiko injekzioaren bitartez, epitelio pigmentarioko zelulak 
transfektatzea lortu zen. Aldiz, bitreo-barneko injekzioaren bitartez, batez ere 
zelula ganglionarren geruzaraino iritsi ziren nioplexoak.   
 
3. Tamaina eta konposizio ezberdineko material genetikoa zeramaten niosomek 
ezaugarri fisiko-kimiko antzekoak baina transfekzio-efizientzia ezberdinak 
aurkeztu zituzten. Minicircle DNA molekulak zeramatzaten niosoma 
formulazioen transfekzio-maila plasmidoak zeramatzatenen bikoitza izan zen 
erretinako zeluletan bai in vitro eta baita in vivo ere. Beraz, tamaina txikiko eta 
bakteria-sekuentziarik gabeko material genetikoa erabiltzeak transfekzio 
eraginkortasuna hobetzen du.   
 
4. Gene-garraiorako sistema ez-biralen eta ehun-injeniaritzaren arteko 
konbinaketa berrien bilaketari dagokionez, niosoma formulazioak eta azido  
hialuroniko hidrogelak bateragarriak direla erakutsi dugu. Lortutako emaitzetan 
ikusi zenez, azido hialuroniko hidrogeletan ez zegoen nioplexoren arteko 
agregaziorik, zelulak azalera guztian zehar hedatu ziren eta, gainera, 








1. Los tres vectores no-virales comerciales basados en lípidos catiónicos,
polímeros y nanopartículas magnéticas presentaron características físico-
químicas y habilidades para condensar y proteger ADN similares. A pesar de
que los tres fueron capaces de transfectar células del sistema nervioso central
y de que la proteína VEGF producida por las células transfectadas mantenía su
actividad biológica en todos los casos, la mayor eficiencia de transfección se
obtuvo con los magnetoplexos tanto en cuanto a expresión de la proteína GFP
como de la proteína VEGF.
2. La evaluación de las formulaciones de niosomas que sólo diferían en su
tensioactivo no-iónico reveló que la incorporación del polisorbato 20 mejora la
transferencia génica en retina tanto in vitro como in vivo. Las diferencias en la
estructura y valores de HLB del tensioactivo parecen determinar la habilidad de
los niosomas para penetrar en las células, seguir una ruta endocítica particular
y liberar el ADN en el núcleo. In vivo, el tipo de células transfectadas dependió
de la ruta de administración, ya que a través de inyecciones intravítreas se
transfectaron predominantemente células de la capa ganglionar de la retina,
mientras que con las inyecciones subretinianas se pudo llegar hasta el epitelio
pigmentario de la retina.
3. El estudio comparativo de los distintos tipos de material genético demostró que
las características físico-químicas no variaban entre los nioplexos unidos a
distintos tipos de ADN, mientras que sí se observaron diferencias significativas
en cuanto a la capacidad de transfección. Las formulaciones de nioplexos que
vehiculizaban material genético en forma de minicircle demostraron obtener
mayor eficiencia de transfección que los que vehiculizaban plásmidos tanto in
vitro como in vivo en células de la retina.
4. La investigación de nuevas combinaciones entre vectores no-virales e
hidrogeles de ácido hialurónico concluyeron que los niosomas pueden ser
incorporados de forma eficaz y sin formar agregados en geles de ácido
hialurónico, y fueron liberados de manera progresiva. Además, las células
fueron capaces de difundir libremente en los hidrogeles cargados con nioplexos
y se obtuvo alta eficacia de transfección en cultivos 3D con excelente viabilidad
celular.

